<table>
<thead>
<tr>
<th>Source</th>
<th>Projects</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Federal</td>
<td>386</td>
<td>$132,218,707</td>
</tr>
<tr>
<td>Corporate</td>
<td>291</td>
<td>23,001,642</td>
</tr>
<tr>
<td>Foundation</td>
<td>106</td>
<td>8,504,844</td>
</tr>
<tr>
<td>Other Support</td>
<td>114</td>
<td>6,903,219</td>
</tr>
<tr>
<td>State of SC</td>
<td>46</td>
<td>4,400,304</td>
</tr>
<tr>
<td><strong>GRAND TOTAL:</strong></td>
<td><strong>943</strong></td>
<td><strong>$175,028,716</strong></td>
</tr>
</tbody>
</table>
The Medical University of South Carolina faculty are highly successful in competing for discretionary grants and contracts. The Chronicle of Higher Education ranks MUSC as the ninth fastest growing medical institution in terms of NIH grant funding. During the last decade, faculty submitted 9,951 proposals for $1.82 billion dollars and received 7,358 awards for $1.01 billion.

Chart 1 Ten Year Summary of Research funding with NIH breakout.

Extramural research climbed by $23.8 million for a 15.7% increase over FY03. Faculty generated 1,262 proposals for $281.6 million and 407 principal investigators received 943 awards for $175.0 million. Of the $23.8 million total increase in funding, federal support accounted for 97.9% of the increase. Federal funding increased from $108.9 million to $132.2 million and now federal grants and contracts constitute 75% of MUSC’s research portfolio.
Table 1 NIH Funding by Activity Type

<table>
<thead>
<tr>
<th>NIH Awards</th>
<th>Number</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>219</td>
<td>$50,494,262</td>
</tr>
<tr>
<td>Program Projects &amp; Centers</td>
<td>26</td>
<td>26,528,233</td>
</tr>
<tr>
<td>Training</td>
<td>13</td>
<td>2,810,803</td>
</tr>
<tr>
<td>Fellowships</td>
<td>8</td>
<td>224,349</td>
</tr>
<tr>
<td>Cooperative Agreements</td>
<td>11</td>
<td>3,985,854</td>
</tr>
<tr>
<td>Construction</td>
<td>2</td>
<td>3,485,698</td>
</tr>
<tr>
<td>Contracts</td>
<td>6</td>
<td>2,908,995</td>
</tr>
</tbody>
</table>

285  $ 90,438,194

NIH support increased by $11.9 million to $90.4 million, and NIH represents 51.6% of MUSC’s total funding. MUSC continued to follow the national federal trend of multidisciplinary and collaborative research endeavors represented by program project grants, center grants, cooperative agreements and contracts. The totals in these categories increased by 3 to 43 for a total of $33.4 million.

Chart 2 Awards from the National Institutes of Health by Institute

NIH AWARDS BY INSTITUTE

...
Chart 3 Federal Award percentages by Agency
The combined non-federal Sources of funding managed a net gain of $600,000. Federal funding increased from 72% to 75% of the total sources for research. State funding increased 1%; Foundations declined by 2%; Corporate funding dropped 1% despite total dollar gains, and Other Support decreased 1% with a decrease in funding.

Corporate funding increased by $2.3 million to $23 million in FY04 and continued its third consecutive increase after the market fall in 2000-2001. Foundation support continued it alternate year up cycling and down cycling with FY04 being a down year and funding dropping from $9.8 million to $8.5 million. The State showed an increase for the first time in three years. Project numbers increased from 39 to 46 and the major difference is a construction grant for the shutter/flood retrofit for wind damage prevention for the Institute of Psychiatry.
### Grant and Contract Sponsors

#### Corporate

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Grants</th>
<th>Contract</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aaris Pharma, Inc.</td>
<td>1</td>
<td>1,159,144</td>
</tr>
<tr>
<td>Abbott Labs</td>
<td>4</td>
<td>371,048</td>
</tr>
<tr>
<td>Actelion Pharmaceuticals</td>
<td>3</td>
<td>108,874</td>
</tr>
<tr>
<td>Alcon, Inc.</td>
<td>4</td>
<td>124,805</td>
</tr>
<tr>
<td>Altana Pharma</td>
<td>1</td>
<td>90,291</td>
</tr>
<tr>
<td>Alza Corp.</td>
<td>1</td>
<td>14,018</td>
</tr>
<tr>
<td>Alzheimer's Disease Cooperative Study</td>
<td>1</td>
<td>75,737</td>
</tr>
<tr>
<td>AmeriSamm Health</td>
<td>2</td>
<td>490,470</td>
</tr>
<tr>
<td>Angen</td>
<td>6</td>
<td>224,810</td>
</tr>
<tr>
<td>Amylin Pharmaceuticals</td>
<td>1</td>
<td>48,700</td>
</tr>
<tr>
<td>Argolyn Bioscience, Inc.</td>
<td>2</td>
<td>124,960</td>
</tr>
<tr>
<td>Astra Pharmaceuticals, L.P.</td>
<td>4</td>
<td>4,065</td>
</tr>
<tr>
<td>Astrazeneca</td>
<td>11</td>
<td>851,167</td>
</tr>
<tr>
<td>Aventis Pasteur, Inc.</td>
<td>1</td>
<td>2,400</td>
</tr>
<tr>
<td>Aventis Pharmaceutical, Inc.</td>
<td>5</td>
<td>314,576</td>
</tr>
<tr>
<td>Axonv Corp.</td>
<td>1</td>
<td>135,000</td>
</tr>
<tr>
<td>Berhinger Laboratories</td>
<td>2</td>
<td>257,922</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>2</td>
<td>54,200</td>
</tr>
<tr>
<td>Boeing Coastal Corp.</td>
<td>2</td>
<td>78,600</td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
<td>5</td>
<td>429,258</td>
</tr>
<tr>
<td>Cardiovascular Clinical Studies</td>
<td>1</td>
<td>39,178</td>
</tr>
<tr>
<td>Carolinas Healthcare</td>
<td>1</td>
<td>38,144</td>
</tr>
<tr>
<td>Celgene Corp.</td>
<td>1</td>
<td>18,470</td>
</tr>
<tr>
<td>Centocor, Inc.</td>
<td>2</td>
<td>103,000</td>
</tr>
<tr>
<td>Cephalon, Inc.</td>
<td>3</td>
<td>110,835</td>
</tr>
<tr>
<td>Cephos Corp.</td>
<td>1</td>
<td>152,451</td>
</tr>
<tr>
<td>Clinical Innovations</td>
<td>1</td>
<td>33,700</td>
</tr>
<tr>
<td>Codia, Inc.</td>
<td>1</td>
<td>17,123</td>
</tr>
<tr>
<td>Cook, Inc.</td>
<td>1</td>
<td>55,350</td>
</tr>
<tr>
<td>Cortex Pharmaceuticals</td>
<td>1</td>
<td>146,320</td>
</tr>
<tr>
<td>Covance, Inc.</td>
<td>2</td>
<td>43,250</td>
</tr>
<tr>
<td>Cyberonics, Inc.</td>
<td>1</td>
<td>42,378</td>
</tr>
<tr>
<td>Cycle Solutions</td>
<td>4</td>
<td>313,760</td>
</tr>
<tr>
<td>DCL Medical Laboratories</td>
<td>1</td>
<td>988</td>
</tr>
<tr>
<td>Dialysis, Inc.</td>
<td>3</td>
<td>541,565</td>
</tr>
<tr>
<td>Digene Corp.</td>
<td>4</td>
<td>179,008</td>
</tr>
<tr>
<td>Digestive Care, Inc.</td>
<td>1</td>
<td>75,420</td>
</tr>
<tr>
<td>Elan Pharmaceuticals</td>
<td>1</td>
<td>42,982</td>
</tr>
<tr>
<td>Eli Lilly</td>
<td>8</td>
<td>573,002</td>
</tr>
<tr>
<td>Emphasys Medical, Inc.</td>
<td>1</td>
<td>332,000</td>
</tr>
<tr>
<td>Encysive, LP</td>
<td>1</td>
<td>101,192</td>
</tr>
<tr>
<td>Etez Corp.</td>
<td>1</td>
<td>30,361</td>
</tr>
<tr>
<td>Ethicon</td>
<td>1</td>
<td>12,256</td>
</tr>
<tr>
<td>Ezem, Inc.</td>
<td>1</td>
<td>1,540</td>
</tr>
<tr>
<td>Forest Labs, Inc.</td>
<td>3</td>
<td>61,938</td>
</tr>
<tr>
<td>Forest Research Inst.</td>
<td>3</td>
<td>151,249</td>
</tr>
<tr>
<td>Fujiwasa Healthcare, Inc.</td>
<td>4</td>
<td>180,700</td>
</tr>
<tr>
<td>Galen Holdings PLC</td>
<td>1</td>
<td>9,000</td>
</tr>
<tr>
<td>Gambro Renal Products, Inc.</td>
<td>1</td>
<td>16,008</td>
</tr>
<tr>
<td>Genentech, Inc.</td>
<td>1</td>
<td>45,455</td>
</tr>
<tr>
<td>Genphar, Inc.</td>
<td>3</td>
<td>329,778</td>
</tr>
<tr>
<td>Genzyme Corp.</td>
<td>3</td>
<td>4,800</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>6</td>
<td>453,768</td>
</tr>
<tr>
<td>GPC Biotech</td>
<td>1</td>
<td>35,020</td>
</tr>
<tr>
<td>Guidant</td>
<td>3</td>
<td>82,680</td>
</tr>
<tr>
<td>Helena Laboratories</td>
<td>1</td>
<td>13,732</td>
</tr>
<tr>
<td>Hoffman-Laroche, Inc.</td>
<td>1</td>
<td>165,690</td>
</tr>
<tr>
<td>Icon Clinical Research, Inc.</td>
<td>3</td>
<td>97,059</td>
</tr>
<tr>
<td>Idec Pharmaceuticals Corp.</td>
<td>1</td>
<td>192,000</td>
</tr>
<tr>
<td>Ingenix</td>
<td>2</td>
<td>16,536</td>
</tr>
<tr>
<td>Intel Corp.</td>
<td>1</td>
<td>30,000</td>
</tr>
<tr>
<td>Intermune, Inc.</td>
<td>2</td>
<td>404,696</td>
</tr>
</tbody>
</table>

#### Isiis Pharmaceuticals, Inc. 3

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Grants</th>
<th>Contract</th>
</tr>
</thead>
<tbody>
<tr>
<td>AstraZeneca</td>
<td>11</td>
<td>851,167</td>
</tr>
<tr>
<td>Aventis Pasteur, Inc.</td>
<td>1</td>
<td>2,400</td>
</tr>
<tr>
<td>Aventis Pharmaceutical, Inc.</td>
<td>5</td>
<td>314,576</td>
</tr>
<tr>
<td>Axonv Corp.</td>
<td>1</td>
<td>135,000</td>
</tr>
<tr>
<td>Berhinger Laboratories</td>
<td>2</td>
<td>257,922</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>2</td>
<td>54,200</td>
</tr>
<tr>
<td>Boeing Coastal Corp.</td>
<td>2</td>
<td>78,600</td>
</tr>
<tr>
<td>Bristol Myers Squibb</td>
<td>5</td>
<td>429,258</td>
</tr>
<tr>
<td>Cardiovascular Clinical Studies</td>
<td>1</td>
<td>39,178</td>
</tr>
<tr>
<td>Carolinas Healthcare</td>
<td>1</td>
<td>38,144</td>
</tr>
<tr>
<td>Celgene Corp.</td>
<td>1</td>
<td>18,470</td>
</tr>
<tr>
<td>Centocor, Inc.</td>
<td>2</td>
<td>103,000</td>
</tr>
<tr>
<td>Cephalon, Inc.</td>
<td>3</td>
<td>110,835</td>
</tr>
<tr>
<td>Cephos Corp.</td>
<td>1</td>
<td>152,451</td>
</tr>
<tr>
<td>Clinical Innovations</td>
<td>1</td>
<td>33,700</td>
</tr>
<tr>
<td>Codia, Inc.</td>
<td>1</td>
<td>17,123</td>
</tr>
<tr>
<td>Cook, Inc.</td>
<td>1</td>
<td>55,350</td>
</tr>
<tr>
<td>Cortex Pharmaceuticals</td>
<td>1</td>
<td>146,320</td>
</tr>
<tr>
<td>Covance, Inc.</td>
<td>2</td>
<td>43,250</td>
</tr>
<tr>
<td>Cyberonics, Inc.</td>
<td>1</td>
<td>42,378</td>
</tr>
<tr>
<td>Cycle Solutions</td>
<td>4</td>
<td>313,760</td>
</tr>
<tr>
<td>DCL Medical Laboratories</td>
<td>1</td>
<td>988</td>
</tr>
<tr>
<td>Dialysis, Inc.</td>
<td>3</td>
<td>541,565</td>
</tr>
<tr>
<td>Digene Corp.</td>
<td>4</td>
<td>179,008</td>
</tr>
<tr>
<td>Digestive Care, Inc.</td>
<td>1</td>
<td>75,420</td>
</tr>
<tr>
<td>Elan Pharmaceuticals</td>
<td>1</td>
<td>42,982</td>
</tr>
<tr>
<td>Eli Lilly</td>
<td>8</td>
<td>573,002</td>
</tr>
<tr>
<td>Emphasys Medical, Inc.</td>
<td>1</td>
<td>332,000</td>
</tr>
<tr>
<td>Encysive, LP</td>
<td>1</td>
<td>101,192</td>
</tr>
<tr>
<td>Etez Corp.</td>
<td>1</td>
<td>30,361</td>
</tr>
<tr>
<td>Ethicon</td>
<td>1</td>
<td>12,256</td>
</tr>
<tr>
<td>Ezem, Inc.</td>
<td>1</td>
<td>1,540</td>
</tr>
<tr>
<td>Forest Labs, Inc.</td>
<td>3</td>
<td>61,938</td>
</tr>
<tr>
<td>Forest Research Inst.</td>
<td>3</td>
<td>151,249</td>
</tr>
<tr>
<td>Fujiwasa Healthcare, Inc.</td>
<td>4</td>
<td>180,700</td>
</tr>
<tr>
<td>Galen Holdings PLC</td>
<td>1</td>
<td>9,000</td>
</tr>
<tr>
<td>Gambro Renal Products, Inc.</td>
<td>1</td>
<td>16,008</td>
</tr>
<tr>
<td>Genentech, Inc.</td>
<td>1</td>
<td>45,455</td>
</tr>
<tr>
<td>Genphar, Inc.</td>
<td>3</td>
<td>329,778</td>
</tr>
<tr>
<td>Genzyme Corp.</td>
<td>3</td>
<td>4,800</td>
</tr>
<tr>
<td>GlaxoSmithKline</td>
<td>6</td>
<td>453,768</td>
</tr>
<tr>
<td>GPC Biotech</td>
<td>1</td>
<td>35,020</td>
</tr>
<tr>
<td>Guidant</td>
<td>3</td>
<td>82,680</td>
</tr>
<tr>
<td>Helena Laboratories</td>
<td>1</td>
<td>13,732</td>
</tr>
<tr>
<td>Hoffman-Laroche, Inc.</td>
<td>1</td>
<td>165,690</td>
</tr>
<tr>
<td>Icon Clinical Research, Inc.</td>
<td>3</td>
<td>97,059</td>
</tr>
<tr>
<td>Idec Pharmaceuticals Corp.</td>
<td>1</td>
<td>192,000</td>
</tr>
<tr>
<td>Ingenix</td>
<td>2</td>
<td>16,536</td>
</tr>
<tr>
<td>Intel Corp.</td>
<td>1</td>
<td>30,000</td>
</tr>
<tr>
<td>Intermune, Inc.</td>
<td>2</td>
<td>404,696</td>
</tr>
<tr>
<td>Corporation</td>
<td>FY 2004</td>
<td>FY 2005</td>
</tr>
<tr>
<td>-------------------------------------------------</td>
<td>----------</td>
<td>----------</td>
</tr>
<tr>
<td>Takeda Pharmaceuticals</td>
<td>50,803</td>
<td>63,504</td>
</tr>
<tr>
<td>Tap Pharmaceuticals, Inc.</td>
<td>37,600</td>
<td>47,000</td>
</tr>
<tr>
<td>Targacept, Inc.</td>
<td>83,460</td>
<td>104,326</td>
</tr>
<tr>
<td>Technical Products, Inc.</td>
<td>3,695</td>
<td>4,619</td>
</tr>
<tr>
<td>The Medicines Co.</td>
<td>82,400</td>
<td>103,000</td>
</tr>
<tr>
<td>Titan Pharmaceuticals, Inc.</td>
<td>28,680</td>
<td>35,850</td>
</tr>
<tr>
<td>TKL Research</td>
<td>32,000</td>
<td>40,000</td>
</tr>
<tr>
<td>Univ. Internal Medical Associates</td>
<td>8,000</td>
<td>10,000</td>
</tr>
<tr>
<td>V.I. Technologies, Inc.</td>
<td>980</td>
<td>1,225</td>
</tr>
<tr>
<td>Vasogen, Inc.</td>
<td>169,872</td>
<td>212,340</td>
</tr>
<tr>
<td>Ventana Medical Systems</td>
<td>105,096</td>
<td>138,198</td>
</tr>
<tr>
<td>Virtually Better, Inc.</td>
<td>24,687</td>
<td>30,859</td>
</tr>
<tr>
<td><strong>Corporate Totals</strong></td>
<td>291</td>
<td>23,001,642</td>
</tr>
<tr>
<td><strong>Total (147 Agencies)</strong></td>
<td><strong>386</strong></td>
<td><strong>132,218,707</strong></td>
</tr>
</tbody>
</table>

### Federal

<table>
<thead>
<tr>
<th>Agency</th>
<th>FY 2004</th>
<th>FY 2005</th>
</tr>
</thead>
<tbody>
<tr>
<td>AHCPR/AHRQ</td>
<td>2,210,946</td>
<td>2,967,038</td>
</tr>
<tr>
<td>CDC</td>
<td>2,387,613</td>
<td>2,992,739</td>
</tr>
<tr>
<td>Dept. of Education</td>
<td>580,424</td>
<td>679,495</td>
</tr>
<tr>
<td>Dept. of Justice</td>
<td>279,686</td>
<td>347,725</td>
</tr>
<tr>
<td>DHEC</td>
<td>1,128,000</td>
<td>1,128,494</td>
</tr>
<tr>
<td>DHHS</td>
<td>525,250</td>
<td>689,400</td>
</tr>
<tr>
<td>DHHS/Children's Bureau</td>
<td>157,981</td>
<td>206,713</td>
</tr>
<tr>
<td>DOD</td>
<td>131,232</td>
<td>170,276</td>
</tr>
<tr>
<td>DOD/ONR</td>
<td>61,644</td>
<td>90,000</td>
</tr>
<tr>
<td>DOD/US Army</td>
<td>309,054</td>
<td>394,344</td>
</tr>
<tr>
<td>DOE</td>
<td>3,496,893</td>
<td>4,521,380</td>
</tr>
<tr>
<td>EPA</td>
<td>35,055</td>
<td>35,055</td>
</tr>
<tr>
<td>FDA</td>
<td>227,606</td>
<td>325,865</td>
</tr>
<tr>
<td>Geo-Centers/DOD</td>
<td>1,339,062</td>
<td>1,800,407</td>
</tr>
<tr>
<td>HRSA</td>
<td>3,556,368</td>
<td>3,565,479</td>
</tr>
<tr>
<td>HRSA/BHP/Assoc. Health Professions</td>
<td>594,990</td>
<td>611,269</td>
</tr>
<tr>
<td>HRSA/BHP/Medicine</td>
<td>2,113,844</td>
<td>2,867,153</td>
</tr>
<tr>
<td>HRSA/BHP/Nursing</td>
<td>382,559</td>
<td>406,798</td>
</tr>
<tr>
<td>NASA</td>
<td>190,532</td>
<td>222,954</td>
</tr>
<tr>
<td>Natl. Inst. of Standards and Technology</td>
<td>12,059,000</td>
<td>12,059,000</td>
</tr>
<tr>
<td>Natl. Network of Libraries of Med.</td>
<td>31,336</td>
<td>39,483</td>
</tr>
<tr>
<td>Natl. Park Service</td>
<td>21,739</td>
<td>25,000</td>
</tr>
<tr>
<td>NIH/NCCAM</td>
<td>150,000</td>
<td>204,841</td>
</tr>
<tr>
<td>NIH/NICNI</td>
<td>5,670,934</td>
<td>7,862,160</td>
</tr>
<tr>
<td>NIH/NICHD</td>
<td>506,129</td>
<td>738,948</td>
</tr>
<tr>
<td>NIH/NCGCR</td>
<td>10,789,027</td>
<td>12,929,241</td>
</tr>
<tr>
<td>NIH/NEI</td>
<td>1,902,234</td>
<td>2,835,099</td>
</tr>
<tr>
<td><strong>Federal Totals</strong></td>
<td><strong>386</strong></td>
<td><strong>132,218,707</strong></td>
</tr>
<tr>
<td><strong>Total (50 Agencies)</strong></td>
<td><strong>386</strong></td>
<td><strong>132,218,707</strong></td>
</tr>
</tbody>
</table>

### Foundation

<table>
<thead>
<tr>
<th>Foundation</th>
<th>FY 2004</th>
<th>FY 2005</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAMC</td>
<td>239,657</td>
<td>307,066</td>
</tr>
<tr>
<td>ACOG</td>
<td>15,000</td>
<td>15,000</td>
</tr>
<tr>
<td>Airline Pilots Assoc.</td>
<td>8,904</td>
<td>13,000</td>
</tr>
<tr>
<td>Alcohol Bev. Medical Research Fnd.</td>
<td>34,609</td>
<td>38,900</td>
</tr>
<tr>
<td>Allegheny-Singer Research Inst.</td>
<td>18,962</td>
<td>21,156</td>
</tr>
<tr>
<td>Alpha-1 Fdn.</td>
<td>207,519</td>
<td>207,519</td>
</tr>
<tr>
<td>Ambulatory Pediatric Assoc.</td>
<td>71,976</td>
<td>81,647</td>
</tr>
<tr>
<td>Amer. Acad. of Child Psychiatry</td>
<td>137,500</td>
<td>137,500</td>
</tr>
<tr>
<td>Amer. Assoc. for Dental Research</td>
<td>2,400</td>
<td>2,400</td>
</tr>
<tr>
<td>Amer. Cancer Soc.</td>
<td>240,000</td>
<td>240,000</td>
</tr>
<tr>
<td>Amer. Coll. of Radiology</td>
<td>41,368</td>
<td>46,475</td>
</tr>
<tr>
<td>Amer. Fdn. for Pharmaceutical Educ.</td>
<td>16,000</td>
<td>16,000</td>
</tr>
<tr>
<td>Amer. Federation for Aging</td>
<td>0</td>
<td>5,000</td>
</tr>
<tr>
<td>Amer. Health Assistance Fdn.</td>
<td>135,000</td>
<td>135,000</td>
</tr>
<tr>
<td>Amer. Health Fdn.</td>
<td>35,390</td>
<td>50,608</td>
</tr>
<tr>
<td>Amer. Heart Assoc.</td>
<td>412,091</td>
<td>451,000</td>
</tr>
<tr>
<td>Amer. Heart Assoc./Mid-Atlantic</td>
<td>78,200</td>
<td>84,200</td>
</tr>
<tr>
<td>Amer. Inst. for Cancer Research</td>
<td>72,925</td>
<td>80,105</td>
</tr>
<tr>
<td>Amer. Medical Student Assoc.</td>
<td>36,697</td>
<td>39,632</td>
</tr>
<tr>
<td>Amer. Soc. for GI Endoscopy</td>
<td>10,000</td>
<td>10,000</td>
</tr>
<tr>
<td>Amer. Soc. of Hypertension</td>
<td>93,450</td>
<td>93,450</td>
</tr>
<tr>
<td>Annie E. Casey Fdn.</td>
<td>400,000</td>
<td>400,000</td>
</tr>
<tr>
<td>AO Fdn.</td>
<td>35,927</td>
<td>35,927</td>
</tr>
<tr>
<td>Apgo Medical Education Fdn.</td>
<td>15,000</td>
<td>15,000</td>
</tr>
<tr>
<td>Arthritis Fdn.</td>
<td>371,323</td>
<td>394,651</td>
</tr>
<tr>
<td>Assoc. of Teachers of Preventive Med.</td>
<td>315,564</td>
<td>382,912</td>
</tr>
<tr>
<td>Burroughs Wellcome Fdn.</td>
<td>80,000</td>
<td>80,000</td>
</tr>
<tr>
<td>Cancer &amp; Leukemia Group B</td>
<td>19,740</td>
<td>21,714</td>
</tr>
<tr>
<td>Charleston Research Inst.</td>
<td>22,941</td>
<td>22,941</td>
</tr>
<tr>
<td>Charlotte Geyer Fdn.</td>
<td>86,234</td>
<td>94,857</td>
</tr>
<tr>
<td>Cystic Fibrosis Fdn.</td>
<td>220,751</td>
<td>220,751</td>
</tr>
<tr>
<td>Donald W. Reynolds Fdn.</td>
<td>185,935</td>
<td>205,306</td>
</tr>
<tr>
<td>Duke Endowment</td>
<td>970,417</td>
<td>970,417</td>
</tr>
<tr>
<td>Health Sciences Fdn.</td>
<td>57,612</td>
<td>57,612</td>
</tr>
<tr>
<td>Heart Failure Soc. Of Amer.</td>
<td>65,000</td>
<td>65,000</td>
</tr>
<tr>
<td>Joubert Syndrome</td>
<td>10,000</td>
<td>10,000</td>
</tr>
<tr>
<td>Juvenile Diabetes Fdn.</td>
<td>232,261</td>
<td>250,000</td>
</tr>
<tr>
<td>Koppaka Family Fdn.</td>
<td>4,000</td>
<td>4,000</td>
</tr>
<tr>
<td>Lupus Fdn.</td>
<td>3,000</td>
<td>3,000</td>
</tr>
<tr>
<td>March of Dimes</td>
<td>85,455</td>
<td>90,000</td>
</tr>
<tr>
<td>Margot Anderson Brain Restoration Fund</td>
<td>20,000</td>
<td>20,000</td>
</tr>
<tr>
<td>Mayo Clinic</td>
<td>78,061</td>
<td>78,061</td>
</tr>
<tr>
<td>Mayo Fdn. For Medical Research</td>
<td>30,124</td>
<td>43,980</td>
</tr>
<tr>
<td>Mizutani Fdn.</td>
<td>34,745</td>
<td>38,219</td>
</tr>
<tr>
<td>Organization</td>
<td>FY 2004</td>
<td>FY 2005</td>
</tr>
<tr>
<td>-----------------------------------------</td>
<td>-----------</td>
<td>-----------</td>
</tr>
<tr>
<td>Myelin Project Fdn.</td>
<td>90,000</td>
<td>90,000</td>
</tr>
<tr>
<td>NARSAD</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>90,000</td>
<td>90,000</td>
<td></td>
</tr>
<tr>
<td>Nati. Childhood Cancer Fndtn</td>
<td>56,926</td>
<td>68,312</td>
</tr>
<tr>
<td>Natl. Environmental Educ. and Training Fd</td>
<td>8,333</td>
<td>10,000</td>
</tr>
<tr>
<td>Oklahoma Univ. Health Sc. Center</td>
<td>4,397</td>
<td>4,837</td>
</tr>
<tr>
<td>Research Fdn. For Mental Hygiene</td>
<td>136,510</td>
<td>195,209</td>
</tr>
<tr>
<td>Research to Prevent Blindness</td>
<td>110,000</td>
<td>110,000</td>
</tr>
<tr>
<td>Robert Wood Johnson Fdn.</td>
<td>35,385</td>
<td>38,216</td>
</tr>
<tr>
<td>Scleroderma Fdn.</td>
<td>138,888</td>
<td>150,000</td>
</tr>
<tr>
<td>SCUREF</td>
<td>1,621,687</td>
<td>1,698,210</td>
</tr>
<tr>
<td>Foundation Totals</td>
<td>106</td>
<td>7,988,329</td>
</tr>
<tr>
<td>(61 Agencies)</td>
<td></td>
<td>8,504,844</td>
</tr>
</tbody>
</table>

### Other Support

<table>
<thead>
<tr>
<th>Organization</th>
<th>FY 2004</th>
<th>FY 2005</th>
</tr>
</thead>
<tbody>
<tr>
<td>Boston Univ.</td>
<td>20,262</td>
<td>21,883</td>
</tr>
<tr>
<td>Children's Hospital of Oakland</td>
<td>18,000</td>
<td>18,000</td>
</tr>
<tr>
<td>Church of the Holy Cross</td>
<td>17,850</td>
<td>19,278</td>
</tr>
<tr>
<td>Clemson Univ.</td>
<td>14,450</td>
<td>15,895</td>
</tr>
<tr>
<td>CGI</td>
<td>39,652</td>
<td>45,600</td>
</tr>
<tr>
<td>Coll. of Charleston</td>
<td>128,196</td>
<td>175,000</td>
</tr>
<tr>
<td>Cornell Univ. Medical Center</td>
<td>2,467</td>
<td>3,602</td>
</tr>
<tr>
<td>Dartmouth Coll.</td>
<td>6,180</td>
<td>7,725</td>
</tr>
<tr>
<td>Duke Clinical Research Institute</td>
<td>239,400</td>
<td>299,250</td>
</tr>
<tr>
<td>Duke Univ.</td>
<td>269,865</td>
<td>394,001</td>
</tr>
<tr>
<td>Emory Univ.</td>
<td>110,432</td>
<td>161,032</td>
</tr>
<tr>
<td>Family Resource Center</td>
<td>112,637</td>
<td>121,468</td>
</tr>
<tr>
<td>Fred Hutchison Cancer Center</td>
<td>60,224</td>
<td>87,925</td>
</tr>
<tr>
<td>George Washington Univ.</td>
<td>44,459</td>
<td>48,905</td>
</tr>
<tr>
<td>Georgetown Univ.</td>
<td>67,248</td>
<td>84,060</td>
</tr>
<tr>
<td>Greenwood Genetic Center</td>
<td>86,925</td>
<td>116,999</td>
</tr>
<tr>
<td>Hope Heart Inst.</td>
<td>91,371</td>
<td>75,000</td>
</tr>
<tr>
<td>Howard University</td>
<td>43,948</td>
<td>59,375</td>
</tr>
<tr>
<td>Inst. For Cancer Prevention</td>
<td>12,787</td>
<td>18,669</td>
</tr>
<tr>
<td>Johns Hopkins Univ.</td>
<td>86,843</td>
<td>126,791</td>
</tr>
<tr>
<td>Life Point</td>
<td>107,374</td>
<td>157,561</td>
</tr>
<tr>
<td>Long Island Jewish Health System</td>
<td>15,137</td>
<td>22,100</td>
</tr>
<tr>
<td>Lowcountry Children's Center</td>
<td>30,000</td>
<td>30,000</td>
</tr>
<tr>
<td>Loyola University</td>
<td>26,400</td>
<td>33,000</td>
</tr>
<tr>
<td>Mayo Clinic</td>
<td>139,780</td>
<td>204,079</td>
</tr>
<tr>
<td>MCP Hahmemann Univ.</td>
<td>57,223</td>
<td>71,566</td>
</tr>
<tr>
<td>Medical Coll. of Georgia</td>
<td>57,548</td>
<td>79,299</td>
</tr>
<tr>
<td>Mt. Sinai Medical Center</td>
<td>36,438</td>
<td>45,547</td>
</tr>
<tr>
<td>New Jersey Medical School</td>
<td>84,533</td>
<td>123,418</td>
</tr>
<tr>
<td>Research Triangle Inst.</td>
<td>23,874</td>
<td>34,140</td>
</tr>
<tr>
<td>SC State Univ.</td>
<td>82,951</td>
<td>97,525</td>
</tr>
<tr>
<td>Scrips Research Inst.</td>
<td>40,411</td>
<td>50,000</td>
</tr>
<tr>
<td>St. Jude's Children's Hospital</td>
<td>30,282</td>
<td>44,358</td>
</tr>
<tr>
<td>Tennessee State Univ.</td>
<td>47,619</td>
<td>60,000</td>
</tr>
<tr>
<td>Other Support Totals</td>
<td>114</td>
<td>5,149,563</td>
</tr>
<tr>
<td>(64 Agencies)</td>
<td></td>
<td>6,903,219</td>
</tr>
</tbody>
</table>

### State of South Carolina

<table>
<thead>
<tr>
<th>Organization</th>
<th>FY 2004</th>
<th>FY 2005</th>
</tr>
</thead>
<tbody>
<tr>
<td>SC AHEC</td>
<td>12,700</td>
<td>12,700</td>
</tr>
<tr>
<td>SC Biomedical Research Network</td>
<td>35,500</td>
<td>35,500</td>
</tr>
<tr>
<td>SC Dept. of Education</td>
<td>39,060</td>
<td>39,060</td>
</tr>
<tr>
<td>SC Dept. of Natural Resources</td>
<td>142,034</td>
<td>178,962</td>
</tr>
<tr>
<td>SC Dept. of Public Safety</td>
<td>126,495</td>
<td>126,495</td>
</tr>
<tr>
<td>SC DHEC</td>
<td>607,754</td>
<td>637,736</td>
</tr>
<tr>
<td>SC DHHS</td>
<td>153,846</td>
<td>200,000</td>
</tr>
<tr>
<td>SC Emergency Preparedness Div.</td>
<td>1,079,640</td>
<td>1,079,640</td>
</tr>
<tr>
<td>State of South Totals</td>
<td>46</td>
<td>4,135,568</td>
</tr>
<tr>
<td>(12 Agencies)</td>
<td></td>
<td>4,400,304</td>
</tr>
</tbody>
</table>

Grand Totals: 943 $141,156,921 $175,028,716
College and Department Funding

In comparison of colleges, two colleges and administration posted gains while three schools posted decreases from last year. In Administration, the number of awards increased from 8 to 20 and the amount increased 582% from $854 thousand to $5.83 million. The two largest additions are a $2.8 million NCRR construction grant and a NHLBI supported Proteomics Administrative contract from NIH.

Extramural research in the College of Medicine increased $20.2 million for a 14.5% increase. The number of proposals submitted increased from 1,016 to 1,086 and the awards increased by one to 823 awards for $158.9 million. Departments ranking in the NIH top 20 include Anatomy and Cell Biology (15th), Biostatistics, Bioinformatics and Epidemiology (6th), Ophthalmology (10th), Otolaryngology (12th), and Psychiatry (20th).

The College of Nursing has 30 proposals and 16 awards and experienced 7.8% growth to $2.9 million. Proposals and awards increased by 1 respectively over FY03. Federal grants remained stable but budgets were trimmed for a net decrease in federal support. Increases in Foundation and Corporate support made up for the federal budget cuts.

The number of proposals submitted in Dental Medicine declined from 21 to 11 during FY04 while the amount requested increased slightly from $6.34 million to $6.41 million. The number of awards remained the same at 9 with the funding decreasing from $2.81 million to $2.61 million, a 7.2% decrease. The major cause of the decrease is reduced budgets on continuing Federal grants.
While the number of proposals increased in Health Professions from 69 to 84 and the number of awards increased from 41 to 50, funding decreased 28.1% from $4.18 million to $3.00 million. Federal budget cuts are on the increase and five NIH funded grants were transferred.

In the College of Pharmacy, the number of proposals decreased from 38 to 30 but the amount requested remained stable at $3.6 million. The number of award increased from 23 to 25 but experienced a decrease in funding from $1.87 million to $1.74 million. The department has two fewer federal grants and federal budget reductions also account for the decrease.
### Proposal and Award Comparison

<table>
<thead>
<tr>
<th>Colleges Departments</th>
<th># Submitted</th>
<th>$ Submitted</th>
<th># Funded</th>
<th>$ Funded</th>
</tr>
</thead>
<tbody>
<tr>
<td>Administration</td>
<td>21</td>
<td>$6,532,235</td>
<td>20</td>
<td>$5,830,884</td>
</tr>
<tr>
<td>Dental Medicine</td>
<td>11</td>
<td>$6,415,500</td>
<td>9</td>
<td>2,610,166</td>
</tr>
<tr>
<td>Biochemistry</td>
<td>2</td>
<td>610,601</td>
<td>1</td>
<td>257,400</td>
</tr>
<tr>
<td>Microbiology &amp; Immunology</td>
<td>7</td>
<td>5,759,899</td>
<td>4</td>
<td>2,044,090</td>
</tr>
<tr>
<td>Pediatric Dentistry</td>
<td>2</td>
<td>45,000</td>
<td>4</td>
<td>308,676</td>
</tr>
<tr>
<td>Graduate Studies</td>
<td>1</td>
<td>274,260</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Health Professions</td>
<td>84</td>
<td>9,384,149</td>
<td>50</td>
<td>3,006,889</td>
</tr>
<tr>
<td>Clinical Services</td>
<td>18</td>
<td>551,740</td>
<td>21</td>
<td>546,632</td>
</tr>
<tr>
<td>Health Admin. And Policy</td>
<td>30</td>
<td>3,311,365</td>
<td>8</td>
<td>666,022</td>
</tr>
<tr>
<td>Health Professions</td>
<td>23</td>
<td>3,807,369</td>
<td>12</td>
<td>1,300,976</td>
</tr>
<tr>
<td>Rehabilitation Sciences</td>
<td>13</td>
<td>1,713,675</td>
<td>9</td>
<td>493,259</td>
</tr>
<tr>
<td>Medicine</td>
<td>1,086</td>
<td>250,936,959</td>
<td>823</td>
<td>158,951,435</td>
</tr>
<tr>
<td>Biochemistry</td>
<td>50</td>
<td>12,440,907</td>
<td>39</td>
<td>10,521,215</td>
</tr>
<tr>
<td>Biostatistics, Bioinformatics &amp;</td>
<td>64</td>
<td>14,040,220</td>
<td>30</td>
<td>6,866,685</td>
</tr>
<tr>
<td>Epidemiology</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cell &amp; Molecular Pharmacology</td>
<td>26</td>
<td>7,578,124</td>
<td>16</td>
<td>4,662,421</td>
</tr>
<tr>
<td>Cell Biology &amp; Anatomy</td>
<td>66</td>
<td>20,735,936</td>
<td>34</td>
<td>10,138,402</td>
</tr>
<tr>
<td>Comparative Medicine</td>
<td>17</td>
<td>1,242,359</td>
<td>10</td>
<td>1,183,546</td>
</tr>
<tr>
<td>Dean's Office</td>
<td>6</td>
<td>2,251,618</td>
<td>8</td>
<td>14,475,255</td>
</tr>
<tr>
<td>Family Medicine</td>
<td>13</td>
<td>3,733,898</td>
<td>13</td>
<td>3,337,871</td>
</tr>
<tr>
<td>Medicine</td>
<td>279</td>
<td>67,061,639</td>
<td>234</td>
<td>34,998,794</td>
</tr>
<tr>
<td>Microbiology &amp; Immunology</td>
<td>38</td>
<td>10,190,664</td>
<td>31</td>
<td>4,453,101</td>
</tr>
<tr>
<td>Neurological Surgery</td>
<td>4</td>
<td>1,039,767</td>
<td>6</td>
<td>1,075,864</td>
</tr>
<tr>
<td>Neurology</td>
<td>35</td>
<td>6,224,846</td>
<td>17</td>
<td>3,499,832</td>
</tr>
<tr>
<td>Obstetrics &amp; Gynecology</td>
<td>15</td>
<td>1,521,464</td>
<td>11</td>
<td>295,662</td>
</tr>
<tr>
<td>Ophthalmology</td>
<td>19</td>
<td>2,452,092</td>
<td>23</td>
<td>3,013,146</td>
</tr>
<tr>
<td>Orthopaedic Surgery</td>
<td>7</td>
<td>483,820</td>
<td>7</td>
<td>374,914</td>
</tr>
<tr>
<td>Otolaryngology</td>
<td>11</td>
<td>3,195,575</td>
<td>7</td>
<td>2,563,982</td>
</tr>
<tr>
<td>Pathology</td>
<td>30</td>
<td>10,144,701</td>
<td>20</td>
<td>3,191,867</td>
</tr>
<tr>
<td>Pediatrics</td>
<td>108</td>
<td>15,934,263</td>
<td>95</td>
<td>8,839,537</td>
</tr>
<tr>
<td>Physiology &amp; Neuroscience</td>
<td>74</td>
<td>15,129,914</td>
<td>42</td>
<td>9,352,786</td>
</tr>
<tr>
<td>Psychiatry &amp; Behavioral Sciences</td>
<td>161</td>
<td>40,328,533</td>
<td>133</td>
<td>24,414,588</td>
</tr>
<tr>
<td>Radiation Oncology</td>
<td>3</td>
<td>271,018</td>
<td>1</td>
<td>18,669</td>
</tr>
<tr>
<td>Radiology</td>
<td>17</td>
<td>2,509,787</td>
<td>18</td>
<td>1,586,188</td>
</tr>
<tr>
<td>Surgery</td>
<td>40</td>
<td>12,318,843</td>
<td>23</td>
<td>9,659,876</td>
</tr>
<tr>
<td>Urology</td>
<td>3</td>
<td>106,971</td>
<td>5</td>
<td>427,234</td>
</tr>
<tr>
<td>Nursing</td>
<td>29</td>
<td>4,508,058</td>
<td>16</td>
<td>2,905,023</td>
</tr>
<tr>
<td>Pharmacy</td>
<td>30</td>
<td>3,585,990</td>
<td>25</td>
<td>1,724,319</td>
</tr>
<tr>
<td>Pharmaceutical Sciences</td>
<td>25</td>
<td>3,086,284</td>
<td>20</td>
<td>1,565,134</td>
</tr>
<tr>
<td>Pharmacy Practice</td>
<td>5</td>
<td>499,706</td>
<td>5</td>
<td>159,185</td>
</tr>
<tr>
<td></td>
<td>1,262</td>
<td>$281,637,151</td>
<td>943</td>
<td>$175,028,716</td>
</tr>
</tbody>
</table>
### Summary of Awards by College and Department

<table>
<thead>
<tr>
<th>College</th>
<th>Department</th>
<th># PI's</th>
<th># Awards</th>
<th>Direct Costs</th>
<th>Total Awards</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Administration</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Academic Affairs / Provost</td>
<td>1</td>
<td>2</td>
<td>3,004,346</td>
<td>3,004,346</td>
</tr>
<tr>
<td></td>
<td>Engineering &amp; Facilities</td>
<td>2</td>
<td>4</td>
<td>1,105,515</td>
<td>1,105,515</td>
</tr>
<tr>
<td></td>
<td>Library</td>
<td>5</td>
<td>11</td>
<td>701,039</td>
<td>948,994</td>
</tr>
<tr>
<td></td>
<td>President's Office</td>
<td>2</td>
<td>2</td>
<td>535,965</td>
<td>768,784</td>
</tr>
<tr>
<td></td>
<td>Public Safety</td>
<td>1</td>
<td>1</td>
<td>3,245</td>
<td>3,245</td>
</tr>
<tr>
<td></td>
<td><strong>Totals for Administration</strong></td>
<td>11</td>
<td>20</td>
<td><strong>$5,350,110</strong></td>
<td><strong>$5,830,884</strong></td>
</tr>
<tr>
<td><strong>College of Dental Medicine</strong></td>
<td>Biochemistry &amp; Molecular Biology</td>
<td>1</td>
<td>1</td>
<td>180,000</td>
<td>257,400</td>
</tr>
<tr>
<td></td>
<td>Microbiology &amp; Immunology</td>
<td>2</td>
<td>4</td>
<td>1,412,523</td>
<td>2,044,090</td>
</tr>
<tr>
<td></td>
<td>Pediatric Dentistry/Orthodontics</td>
<td>1</td>
<td>4</td>
<td>303,933</td>
<td>308,676</td>
</tr>
<tr>
<td></td>
<td><strong>Totals for College of Dental Medicine</strong></td>
<td>4</td>
<td>9</td>
<td><strong>$1,896,456</strong></td>
<td><strong>$2,610,166</strong></td>
</tr>
<tr>
<td><strong>College of Health Professions</strong></td>
<td>Clinical Services</td>
<td>3</td>
<td>21</td>
<td>444,878</td>
<td>546,632</td>
</tr>
<tr>
<td></td>
<td>Health Administration and Policy</td>
<td>5</td>
<td>8</td>
<td>505,905</td>
<td>666,022</td>
</tr>
<tr>
<td></td>
<td>Health Professions</td>
<td>6</td>
<td>12</td>
<td>1,083,853</td>
<td>1,300,976</td>
</tr>
<tr>
<td></td>
<td>Rehabilitation Sciences</td>
<td>7</td>
<td>9</td>
<td>476,611</td>
<td>493,259</td>
</tr>
<tr>
<td></td>
<td><strong>Totals for College of Health Professions</strong></td>
<td>21</td>
<td>50</td>
<td><strong>$2,511,247</strong></td>
<td><strong>$3,006,889</strong></td>
</tr>
<tr>
<td><strong>College of Medicine</strong></td>
<td>Biochemistry &amp; Molecular Biology</td>
<td>16</td>
<td>39</td>
<td>7,711,655</td>
<td>10,521,215</td>
</tr>
<tr>
<td></td>
<td>Biostatistics, Bioinformatics &amp; Epidemiology</td>
<td>13</td>
<td>30</td>
<td>5,331,793</td>
<td>6,866,685</td>
</tr>
<tr>
<td></td>
<td>Cell &amp; Molecular Pharmacology</td>
<td>8</td>
<td>16</td>
<td>3,500,943</td>
<td>4,662,421</td>
</tr>
<tr>
<td></td>
<td>Cell Biology &amp; Anatomy</td>
<td>18</td>
<td>34</td>
<td>7,581,495</td>
<td>10,138,402</td>
</tr>
<tr>
<td></td>
<td>Comparative Medicine</td>
<td>3</td>
<td>10</td>
<td>1,009,622</td>
<td>1,183,546</td>
</tr>
<tr>
<td></td>
<td>Dean's Office</td>
<td>4</td>
<td>8</td>
<td>14,239,624</td>
<td>14,475,255</td>
</tr>
<tr>
<td></td>
<td>Family Medicine</td>
<td>6</td>
<td>13</td>
<td>3,010,383</td>
<td>3,337,871</td>
</tr>
<tr>
<td></td>
<td>Medicine</td>
<td>87</td>
<td>234</td>
<td>27,817,514</td>
<td>34,998,794</td>
</tr>
<tr>
<td></td>
<td>Microbiology &amp; Immunology</td>
<td>10</td>
<td>31</td>
<td>3,658,445</td>
<td>4,453,101</td>
</tr>
<tr>
<td></td>
<td>Neurological Surgery</td>
<td>2</td>
<td>6</td>
<td>884,438</td>
<td>1,075,864</td>
</tr>
<tr>
<td></td>
<td>Neurology</td>
<td>8</td>
<td>17</td>
<td>2,618,158</td>
<td>3,499,832</td>
</tr>
<tr>
<td></td>
<td>Obstetrics &amp; Gynecology</td>
<td>5</td>
<td>11</td>
<td>248,166</td>
<td>295,662</td>
</tr>
<tr>
<td></td>
<td>Ophthalmology</td>
<td>12</td>
<td>23</td>
<td>2,340,169</td>
<td>3,013,146</td>
</tr>
<tr>
<td></td>
<td>Orthopedic Surgery</td>
<td>4</td>
<td>7</td>
<td>289,818</td>
<td>374,914</td>
</tr>
<tr>
<td></td>
<td>Otolaryngology</td>
<td>6</td>
<td>7</td>
<td>1,883,932</td>
<td>2,563,982</td>
</tr>
<tr>
<td></td>
<td>Pathology &amp; Laboratory Medicine</td>
<td>11</td>
<td>20</td>
<td>2,420,468</td>
<td>3,191,867</td>
</tr>
<tr>
<td></td>
<td>Pediatrics</td>
<td>39</td>
<td>95</td>
<td>7,165,349</td>
<td>8,839,537</td>
</tr>
<tr>
<td></td>
<td>Physiology &amp; Neuroscience</td>
<td>20</td>
<td>42</td>
<td>7,050,578</td>
<td>9,352,786</td>
</tr>
<tr>
<td></td>
<td>Psychiatry &amp; Neuroscience</td>
<td>48</td>
<td>133</td>
<td>18,956,806</td>
<td>24,414,588</td>
</tr>
<tr>
<td></td>
<td>Radiation Oncology</td>
<td>1</td>
<td>1</td>
<td>12,787</td>
<td>18,669</td>
</tr>
<tr>
<td></td>
<td>Radiology</td>
<td>10</td>
<td>18</td>
<td>1,284,637</td>
<td>1,586,188</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
<td>12</td>
<td>23</td>
<td>8,139,561</td>
<td>9,659,876</td>
</tr>
<tr>
<td></td>
<td>Urology</td>
<td>2</td>
<td>5</td>
<td>342,708</td>
<td>427,234</td>
</tr>
<tr>
<td></td>
<td><strong>Totals for College of Medicine</strong></td>
<td>345</td>
<td>823</td>
<td><strong>$127,499,049</strong></td>
<td><strong>$158,951,435</strong></td>
</tr>
<tr>
<td>College Department</td>
<td># PI's</td>
<td># Awards</td>
<td>Direct Costs</td>
<td>Total Awards</td>
<td></td>
</tr>
<tr>
<td>-------------------------</td>
<td>--------</td>
<td>----------</td>
<td>--------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td><strong>College of Nursing</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nursing</td>
<td>12</td>
<td>16</td>
<td>2,524,882</td>
<td>2,905,023</td>
<td></td>
</tr>
<tr>
<td><strong>Totals for College of Nursing</strong></td>
<td>12</td>
<td>16</td>
<td>$2,524,882</td>
<td>$2,905,023</td>
<td></td>
</tr>
<tr>
<td><strong>College of Pharmacy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pharmaceutical Sciences</td>
<td>11</td>
<td>20</td>
<td>1,250,686</td>
<td>1,565,134</td>
<td></td>
</tr>
<tr>
<td>Pharmacy Practice</td>
<td>3</td>
<td>5</td>
<td>124,491</td>
<td>159,185</td>
<td></td>
</tr>
<tr>
<td><strong>Totals for College of Pharmacy</strong></td>
<td>14</td>
<td>25</td>
<td>$1,375,177</td>
<td>$1,724,319</td>
<td></td>
</tr>
<tr>
<td><strong>Grand Totals:</strong></td>
<td>407</td>
<td>943</td>
<td>$141,156,921</td>
<td>$175,028,716</td>
<td></td>
</tr>
</tbody>
</table>
Faculty Activity

Investigators and Projects Listing
Research Faculty Activity FY 2003-2004

Carlson, Barbara
Principal Investigator

Library
REACG 2010 Charleston and Georgetown Coalition Diabetes e-Information Partnership Planning Project
Award: N01-LM-1-3515 (03061803)
Direct: $15,873
F&A: 4,126

Coleman, Walker
Principal Investigator

President's Office
Administrative Core
Sponsor: SC Spinal Cord Injury Fund
Budget Dates: 7/1/2003 - 6/30/2004
Direct: $29,836
Award: (02090301)
Project Dates: 7/1/2002 - 6/30/2004
F&A: 0

Malmrose, John
Principal Investigator

Engineering & Facilities
South Carolina Energy Office Rewards for Higher Education Energy Efficiency Projects
Sponsor: SC DHEC
Direct: $20,000
Award: 024002-01-1170 (04022607)
F&A: 0

Rivers, David
Principal Investigator

Library
Support-National Environmental Policy Institute
Sponsor: SC State Univ.
Award: 03-130461-UTC-MUSC (03112102)
Budget Dates: 10/1/2003 - 9/30/2004
Project Dates: 10/1/2003 - 9/30/2004
Direct: $50,000
F&A: 0

Our Health Television Program
Sponsor: Howard University
Direct: $43,948
Award: 633553-H202407/MC (03112011)
F&A: 11,427

Community Leaders Workshops
Sponsor: SCUREF
Direct: $50,337
Award: 03-094(03061804)
F&A: 19,663

Co-PI or Project Leader

Schachte, Margaret
Principal Investigator

Library
National Heart, Lung and Blood Institute Proteomics Administrative Center
Sponsor: NIH/NHLBI
Direct: $462,537
Award: N01 HV 28181 (03042202)
F&A: 191,280
**President's Office**

**EXPORT Center on Metabolic Syndrome and Minority Health**

- **Sponsor:** NIH/NCMHD
- **Award:** 5 P60 MD000267-02 (03080109)
- **Budget Dates:** 9/1/2003 - 8/31/2004
- **Direct:** $506,129
- **Project Dates:** 9/30/2002 - 8/31/2007
- **F&A:** 232,819

**Academic Affairs / Provost**

**National Heart, Lung and Blood Institute Proteomics Administrative Center**

- **Pl:** SCHACHTE, MARGARET P.
- **Sponsor:** NIH/NHLBI
- **Award:** N01 HV 28181 (03042202)
- **Budget Dates:** 9/30/2002 - 8/31/2007
- **Direct:** $462,537
- **F&A:** 191,280

**Library**

**SC-BRIN:Training and Mentoring Core**

- **Sponsor:** Univ. of South Carolina
- **Award:** P20 RR16461 (03112601)
- **Budget Dates:** 9/1/2003 - 6/30/2004
- **Direct:** $10,995
- **F&A:** 5,057

**FY2004 SC EPScOR Travel**

- **Sponsor:** SC EPScOR
- **Award:** H5178 (03103010)
- **Budget Dates:** 10/1/2003 - 6/30/2004
- **Direct:** $4,267
- **F&A:** 0

**Engineering & Facilities**

**South Carolina Energy Office Rewards for Higher Education Energy Efficiency Projects**

- **Pl:** MALMROSE, JOHN
- **Sponsor:** SC DHEC
- **Award:** 024002-01-1170 (04022607)
- **Budget Dates:** 4/15/2004-4/15/2005
- **Direct:** $20,000
- **F&A:** 0

**FY2004 Collegiate Recycling Grant**

- **Pl:** MALMROSE, JOHN
- **Sponsor:** SC DHEC
- **Award:** 10.1CR04 (03091604)
- **Budget Dates:** 11/1/2003-6/30/2004
- **Direct:** $5,875
- **F&A:** 0

**Public Safety**

**Bureau of Justice Assistance Bulletproof Vest Partnership Grant**

- **Sponsor:** SC Dept. of Public Safety
- **Award:** (03040201)
- **Budget Dates:** 1/1/2004 - 12/31/2004
- **Direct:** $3,245
- **F&A:** 0

**Engineering & Facilities**

**Medical University of South Carolina Shutter/Flood Barrier Retrofit - Various**

- **Pl:** PARRISH, SIM
- **Sponsor:** SC Emergency Preparedness Div.
- **Award:** 1229-0037 (01062914-03)
- **Budget Dates:** 1/25/2002-1/25/2005
- **Direct:** $781,000
- **F&A:** 0

**Medical University of South Carolina Shutter/Flood Barrier Retrofit - Institute of Psychiatry Wind Damage Prevention**

- **Pl:** PARRISH, SIM
- **Sponsor:** SC Emergency Preparedness Div.
- **Award:** 1229-0037 (01062914-02)
- **Budget Dates:** 7/15/2001-7/14/2004
- **Direct:** $298,640
- **F&A:** 0
## College of Dental Medicine

### Balish, Edward

**Microbiology & Immunology**

**Lethal Oroesophageal Candidiasis: Immunotherapy**

- **Sponsor:** NIH/NIDCR  
- **Budget Dates:** 8/1/2003 - 7/31/2004  
- **Award:** 5 R01 DE013968-05 (03061202)  
- **Direct:** $170,000  
- **F&A:** $73,100

**SC COBRE in Lipidomics and Pathobiology - Core C: Animal Pathobiology Core**

- **PI:** OBEID, LINA  
- **Sponsor:** NIH/NCRR  
- **Budget Dates:** 9/1/2003 - 6/30/2007  
- **Direct:** $177,348  
- **F&A:** $81,580

### London, Steven

**Microbiology & Immunology**

**College of Dental Medicine Summer Research Program**

- **Sponsor:** NIH/NIDCR  
- **Budget Dates:** 3/1/2004 - 2/28/2005  
- **Direct:** $34,458  
- **F&A:** $2,757

**South Carolina COBRE for Oral Health**

- **Sponsor:** NIH/NCRR  
- **Budget Dates:** 9/1/2003 - 6/30/2004  
- **Direct:** $100,000  
- **F&A:** $46,000

### Pilcher, Elizabeth

**Prosthodontics**

**Geriatric Oral Health Education Project**

- **PI:** FORTI, ESTHER  
- **Sponsor:** HRSA  
- **Direct:** $100,000

### Ravenel, Michele

**Stomatology**

**Geriatric Oral Health Education Project**

- **PI:** FORTI, ESTHER  
- **Sponsor:** HRSA  
- **Direct:** $100,000

### Ries, William

**Stomatology**

**Phase II Study of Alendronate Sodium (Fosamax) in Juvenile Osteoporosis**

- **PI:** KEY, L. LYNDON  
- **Sponsor:** FDA  
- **Direct:** $227,606

### Salinas, Carlos

**Pediatric Dentistry/Orthodontics**

**Craniofacial Anomalies and Cleft Lip and Palate Team**

- **Sponsor:** SC DHEC  
- **Budget Dates:** 4/15/2003 - 4/15/2004  
- **Direct:** $18,518

**More Smiling Faces in Beautiful Places**

- **Sponsor:** SC DHEC  
- **Budget Dates:** 4/15/2003 - 11/30/2005  
- **Direct:** $23,220

**Dental Program for the Diagnosis and Treatment of Children with Special Health Care Needs**

- **Sponsor:** Duke Endowment  
- **Budget Dates:** 8/1/2003 - 7/1/2004  
- **Direct:** $243,676

**Craniofacial Anomalies and Cleft Lip and Palate Team**

- **Sponsor:** CR3-798 (00051201)  
- **Budget Dates:** 4/15/2003 - 4/15/2004  
- **Direct:** $18,518
Salinas, Carlos
Co-PI or Project Leader

**Pediatric Dentistry/Orthodontics**

**South Carolina COBRE for Oral Health - Core C: Clinical Research Core**

- **PI:** LONDON, STEVEN D.
- **Sponsor:** NIH/NCRR
- **Project Dates:** 9/30/2002-6/30/2007
- **Award:** 5 P20 RR017696-02 (03080503-03)
- **Direct:** $295,878
- **F&A:** 136,104

**South Carolina COBRE for Oral Health**

- **PI:** LONDON, STEVEN D.
- **Sponsor:** NIH/NCRR
- **Project Dates:** 9/30/2002-6/30/2007
- **Award:** 5 P20 RR017696-02 (03080503-01)
- **Direct:** $182,951
- **F&A:** 84,158

Schwabe, Christian
Principal Investigator

**Biochemistry & Molecular Biology**

**Relaxin-Like Factor in Male Gonadal Development**

- **Sponsor:** NIH/NICHD
- **Budget Dates:** 4/1/2004 - 3/31/2005
- **Direct:** $180,000
- **Award:** 5 R01 HD040406-04 (04012116)
- **Project Dates:** 4/1/2001 - 3/31/2006
- **F&A:** 77,400
Bradford, W.
Principal Investigator
Health Administration and Policy
CHEPS and MRNC/CMR Services
Sponsor: Medical Review of North Carolina, Inc.
Direct: $26,443
F&A: 7,933
Evalutation of SC Medicaid Program
Sponsor: SC DHHS
Budget Dates: 7/1/2003 - 6/30/2004
Direct: $153,846
F&A: 46,154
Impact of Direct to Consumer Pharmaceutical Marketing
Sponsor: AHCPR/AHRQ
Budget Dates: 7/7/2003 - 6/30/2004
Direct: $211,013
F&A: 83,850

Brotherton, Sandra
Principal Investigator
Rehabilitation Sciences
Frequency, Severity and Risk Factors for Falls and Fall-Related Injuries Sustained by Individuals with Incomplete Spinal Cord Injury
Sponsor: SC Spinal Cord Injury Fund
Direct: $74,996
F&A: 0

Brown, Ronald
Principal Investigator
Health Professions
A Phase IIIb, Open-Label, Multi-Center Study to Assess Safety, Tolerability and Effectiveness Associated with the Use of ADDERALL XR in Adults with Attention Deficit Hyperactivity Disorder and Evaluate an ADHD-Specific Novel Quality of Life Measure
Sponsor: Shire Pharmaceutical Development
Direct: $40,500
F&A: 10,125

Coker, Jennifer
Co-Investigator
A 6-Year Longitudinal Study of Community Integration, Subjective Well-Being, and Health after Spinal Cord Injury: Relationship with Gender, Race/Ethnicity, and Environmental Factors
Pt: KRAUSE, JAMES S.
Sponsor: Dept. of Education
Budget Dates: 10/1/2003-9/30/2005
Direct: $117,690
F&A: 32,251

Daum, Heather
Co-Investigator
Quantitative Polymerase Chain Reaction and Sequencing for MD Anderson
Pt: HOLLADAY, E. BLAIR
Sponsor: Ventana Medical Systems
Direct: $2,808
F&A: 702
## Faculty Activity by College

### College of Health Professions

#### Health Professions

**HPV DNA Sequencing for Cervical Tissue Specimens**
- **PI:** HOLLADAY, E. BLAIR
- **Sponsor:** Ventana Medical Systems
- **Direct:** $7,289
- **Award:** 16 (03091504)
- **F&A:** $1,822
- **Project Dates:** 8/6/2003-6/30/2004

**Comparison of HPV with Digene HCII and Polymerase Chain Reaction for LabCorp**
- **PI:** HOLLADAY, E. BLAIR
- **Sponsor:** Ventana Medical Systems
- **Direct:** $10,514
- **Award:** 15 (03091503)
- **F&A:** $2,629
- **Project Dates:** 8/4/2003-6/30/2004

**Tissue Procurement for Ventana Medical Systems, Inc.**
- **PI:** HOLLADAY, E. BLAIR
- **Sponsor:** Ventana Medical Systems
- **Direct:** $3,953
- **Award:** (03072804)
- **F&A:** $1,700
- **Project Dates:** 6/16/2003-6/30/2004

**Comparison of HPV with Digene HCII and Polymerase Chain Reaction for McGee**
- **PI:** HOLLADAY, E. BLAIR
- **Sponsor:** Ventana Medical Systems
- **Direct:** $8,577
- **Award:** 12 (03072803)
- **F&A:** $3,688
- **Project Dates:** 7/8/2003-6/30/2004

#### Forti, Esther

**South Carolina Geriatric Education Center Grant**
- **Sponsor:** HRSA/BHP/Medicine
- **Budget Dates:** 7/1/2003 - 6/30/2004
- **Direct:** $274,643
- **Award:** 5 D31 HP70148-03 (03072505)
- **F&A:** 21,971
- **Project Dates:** 7/1/2001 - 6/30/2006

**Geriatric Oral Health Education Project**
- **Sponsor:** HRSA
- **Budget Dates:** 9/1/2003 - 6/30/2004
- **Direct:** $100,000
- **Award:** 3 D31 HP70148-03-01 (03071102)
- **F&A:** 8,000
- **Project Dates:** 7/1/2001 - 6/30/2006

#### Gells, Karen

**SC Cooperative for Healthy Aging in Minority Populations**
- **PI:** TILLEY, BARBARA
- **Sponsor:** NIH/NIA
- **Budget Dates:** 9/30/2002-8/31/2007
- **Direct:** $410,013
- **Award:** 5 P30 AG021677-02 (03071007)
- **F&A:** 161,960
- **Project Dates:** 9/30/2002-8/31/2007

#### Holladay, E.

**Comparison of Sensitivity and Specificity of P16 Protein and Novel Markers for Progressive Cervical Disease with Hybrid Capture II**
- **Sponsor:** Digene Corp.
- **Budget Dates:** 6/1/2004 - 12/31/2004
- **Direct:** $34,378
- **Award:** PROTOCOL #29 (04052716)
- **F&A:** 7,813
- **Project Dates:** 6/1/2004 - 12/31/2004

**ThinPrep Specimen Assessment for Cytyc Corporation, Protocol #27**
- **Sponsor:** Digene Corp.
- **Budget Dates:** 6/1/2004 - 12/31/2004
- **Direct:** $11,631
- **Award:** PROTOCOL #27 (04051403)
- **F&A:** 2,908
- **Project Dates:** 6/1/2004 - 12/31/2004

**Comparison of Inform HPV with Digene HCII and Polymerase Chain Reaction for Lexington Medical Center, Protocol #25**
- **Sponsor:** Ventana Medical Systems
- **Budget Dates:** 2/1/2004 - 12/31/2004
- **Direct:** $11,866
- **Award:** PROTOCOL #25 (04041402)
- **F&A:** 2,966
- **Project Dates:** 2/1/2004 - 12/31/2004

**SurePath Specimen Procurement for MIME/DCL Medical Laboratories Protocol #26**
- **Sponsor:** DCL Medical Laboratories
- **Budget Dates:** 2/1/2004 - 12/31/2004
- **Direct:** $968
- **Award:** PROTOCOL #26 (04032613)
- **F&A:** 242
- **Project Dates:** 2/1/2004 - 12/31/2004

**HPV DNA Sequencing for Paraffin-Embedded Cervical Tissue Specimens, (Amendment to Protocol #6)**
- **Sponsor:** Ventana Medical Systems
- **Budget Dates:** 2/1/2004 - 12/31/2004
- **Direct:** $2,920
- **Award:** (04030814)
- **F&A:** 730
- **Project Dates:** 2/1/2004 - 12/31/2004

**Tissue Acquisition for Inform HPV DNA Analysis, Protocol #21**
- **Sponsor:** Ventana Medical Systems
- **Budget Dates:** 2/1/2004 - 12/31/2004
- **Direct:** $1,472
- **Award:** PROTOCOL 21 (04030813)
- **F&A:** 368
- **Project Dates:** 2/1/2004 - 12/31/2004

**Clinical Evaluation of Novel Markers as an Adjunct to High-Risk HPV DNA Testing by HC2 and HC2-Plus**
- **Sponsor:** Digene Corp.
- **Budget Dates:** 2/1/2004 - 12/31/2004
- **Direct:** $127,626
- **Award:** PROTOCOL #22 (04012709)
- **F&A:** 44,670
- **Project Dates:** 2/1/2004 - 12/31/2004
Holladay, E.
Principal Investigator

**Clinical Services**

**HPV DNA Sequencing and Inform Analysis for Glandular Cervical Tissue Specimens**

- **Sponsor:** Ventana Medical Systems
- **Budget Dates:** 12/16/2003 - 1/16/2004
- **Direct:** $7,640
- **F&A:** $1,910

**HPV DNA Sequencing and Inform Analysis for Glandular Lesions Diagnosed by Liquid Pap Tests**

- **Sponsor:** Ventana Medical Systems
- **Budget Dates:** 12/16/2003 - 12/31/2004
- **Direct:** $4,560
- **F&A:** $1,140

**Comparison of Inform HPV with Digene HCII and Polymerase Chain Reaction for CPL, Inc.**

- **Sponsor:** Ventana Medical Systems
- **Budget Dates:** 12/16/2003 - 6/30/2004
- **Direct:** $21,519
- **F&A:** $5,380

**SurePath Specimen Procurement for Digene Corporation**

- **Sponsor:** Ventana Medical Systems
- **Budget Dates:** 12/16/2003 - 12/31/2004
- **Direct:** $4,560
- **F&A:** $1,140

**Quantitative Polymerase Chain Reaction and Sequencing for MD Anderson**

- **Sponsor:** Ventana Medical Systems
- **Budget Dates:** 12/16/2003 - 6/30/2004
- **Direct:** $2,808
- **F&A:** $702

**Comparison of HPV with Digene HCII and Polymerase Chain Reaction for LabCorp**

- **Sponsor:** Ventana Medical Systems
- **Budget Dates:** 8/4/2003 - 6/30/2004
- **Direct:** $10,514
- **F&A:** $2,629

**Tissue Procurement for Ventana Medical Systems, Inc.**

- **Sponsor:** Ventana Medical Systems
- **Budget Dates:** 6/16/2003 - 6/30/2004
- **Direct:** $3,953
- **F&A:** $1,700

**Comparison of HPV with Digene HCII and Polymerase Chain Reaction for McGee**

- **Sponsor:** Ventana Medical Systems
- **Budget Dates:** 7/8/2003 - 6/30/2004
- **Direct:** $8,577
- **F&A:** $3,688

**Comparison of Inform HPV with Digene HCH and Polymerase Chain Reaction for IMPATH, Inc.**

- **Sponsor:** Ventana Medical Systems
- **Budget Dates:** 4/15/2003 - 6/30/2004
- **Direct:** $1,422
- **F&A:** $611

**ThinPrep and SurePath Specimen Procurement for Ventana Medical Systems, Inc.**

- **Sponsor:** Ventana Medical Systems
- **Budget Dates:** 10/1/2002 - 8/30/2003
- **Direct:** $20,556
- **F&A:** $9,456

Jacques, Paul
Principal Investigator

**Health Administration and Policy**

**Evaluation of SC Medicaid Program**

- **Pt.: BRADFORD, W. DAVID**
- **Sponsor:** SC DHHS
- **Budget Dates:** 7/1/2003 - 6/30/2004
- **Direct:** $153,846
- **F&A:** $46,154

Jones, Walter
Co-Investigator

**Health Administration and Policy**

**Evaluation of SC Medicaid Program**

- **Pt.: BRADFORD, W. DAVID**
- **Sponsor:** SC DHHS
- **Budget Dates:** 7/1/2003 - 6/30/2004
- **Direct:** $153,846
- **F&A:** $46,154

Kilpatrick, Anne
Co-Investigator

**Health Professions**

**Aging after Spinal Cord Injury: Three Decades of Longitudinal Research**

- **Sponsor:** Dept. of Education
- **Budget Dates:** 9/1/2003 - 8/31/2005
- **Direct:** $130,433
- **F&A:** $19,565

Krause, James
Principal Investigator

**Health Administration and Policy**

**Evaluation of SC Medicaid Program**

- **Pt.: BRADFORD, W. DAVID**
- **Sponsor:** SC DHHS
- **Budget Dates:** 7/1/2003 - 6/30/2004
- **Direct:** $153,846
- **F&A:** $46,154
Krause, James  
**Health Professions**  
A 6-Year Longitudinal Study of Community Integration, Subjective Well-Being, and Health after Spinal Cord Injury: Relationship with Gender, Race/Ethnicity, and Environmental Factors  
Sponsor: Dept. of Education  
Award: H133G020218-03 (03100214)  
Budget Dates: 10/1/2003 - 9/30/2004  
Direct: $117,690  
F&A: 32,251

**Risk for Early Mortality after Spinal Cord Injury**  
Sponsor: Dept. of Education  
Award: H133G030117 (0211403)  
Budget Dates: 10/1/2003 - 9/30/2006  
Direct: $102,729  
F&A: 47,255

Lee, Frances  
**Health Administration and Policy**  
Evaluation of SC Medicaid Program  
Pt: BRADFORD, W. DAVID  
Sponsor: SC DHHS  
Award: (03072101)  
Budget Dates: 7/1/2003 - 6/30/2004  
Direct: $153,846  
F&A: 46,154

Lindrooth, Richard  
**Health Administration and Policy**  
Hospital Finances and the Quality of Hospital Care  
Sponsor: Virginia Commonwealth Univ.  
Award: 5 R01 HS13094-03 (03121004)  
Budget Dates: 10/1/2003 - 9/30/2005  
Direct: $122,898  
F&A: 46,000

Martin, Margaret  
**Health Administration and Policy**  
ALLIANCEnet: Anytime/Anywhere Learning Linkages in Allied Health and Nursing Continuing Education  
Pt: RICCIARDO, ELIZABETH  
Sponsor: Duke Endowment  
Award: 5 R01 HS01312-03 (03080001)  
Budget Dates: 7/1/2003 - 6/30/2005  
Direct: $150,000  
F&A: 69,000

McIlwain, Thomas  
**Health Administration and Policy**  
Impact of Direct to Consumer Pharmaceutical Marketing  
Pt: BRADFORD, W. DAVID  
Sponsor: AHCPR/AHRQ  
Award: 1 R01 HS011326-01A2 (02062806)  
Budget Dates: 7/1/2003 - 6/30/2005  
Direct: $211,013  
F&A: 83,850

Mitcham, Maralynne  
**Rehabilitation Sciences**  
Community Connections: Partners for Service and Learning  
Sponsor: HRSA/BHP/Assoc. Health Professions  
Award: 5 D37 HP00876-02 0 (03072506)  
Budget Dates: 7/1/2003 - 6/30/2004  
Direct: $117,504  
F&A: 9,400

Morrisette, David  
**Rehabilitation Sciences**  
The Prevalence of Upper Quarter Pain Among Persons with Long-Term Spinal Cord Injury  
Sponsor: SC Spinal Cord Injury Fund  
Award: SCIRF 0603 (03051601)  
Budget Dates: 9/1/2003 - 9/30/2005  
Direct: $75,000  
F&A: 0

Norman, Michele  
**Rehabilitation Sciences**  
Research Supplement for Underrepresented Minorities - SC Cooperative for Healthy Aging in Minority Populations  
Pt: TILLEY, BARBARA  
Sponsor: NIH/NIA  
Award: 3 P30 AG021677-02S3 (04022401-01)  
Direct: $24,452  
F&A: 11,248

Poth, Elizabeth  
**Dean's Office**  
Experimental and Clinical Studies of Presbyacusis  
Pt: MILLS, JOHN H.  
Sponsor: NIH/NIDCD  
Award: 5 P50 DC000422-17 (03042903)  
Budget Dates: 7/1/1987-6/30/2007  
Direct: $1,060,058  
F&A: 487,627

Reed, Sarah  
**Health Professions**  
Comparison of Sensitivity and Specificity of P16 Protein and Novel Markers for Progressive Cervical Disease with Hybrid Capture II  
Pt: HOLLADAY, E. BLAIR  
Sponsor: Digene Corp.  
Budget Dates: 7/1/2003 - 9/30/2005  
Direct: $34,378  
F&A: 0
**Reed, Sarah**  
Co-Investigator  

**Health Professions**

**ThinPrep Specimen Assessment for Cytyc Corporation, Protocol #27**
- PI: HOLLADAY, E. BLAIR
- Sponsor: Digene Corp.
- Award: PROTOCOL #27 (04051403)
- F&A: 7,813

**Comparison of Inform HPV with Digene HCII and Polymerase Chain Reaction for Lexington Medical Center, Protocol #25**
- PI: HOLLADAY, E. BLAIR
- Sponsor: Ventana Medical Systems
- Project Dates: 8/1/2003-12/31/2004
- Award: PROTOCOL #25 (04041402)
- F&A: 2,908

**HPV DNA Sequencing for Paraffin-Embedded Cervical Tissue Specimens, (Amendment to Protocol #6)**
- PI: HOLLADAY, E. BLAIR
- Sponsor: Ventana Medical Systems
- Project Dates: 12/16/2003-12/31/2004
- Award: PROTOCOL #19 (04012707)
- F&A: 1,140

**Clinical Evaluation of Novel Markers as an Adjunct to High-Risk HPV DNA Testing by HC2 and HC2-Plus**
- PI: HOLLADAY, E. BLAIR
- Sponsor: Digene Corp.
- Project Dates: 12/16/2003-6/30/2004
- Award: PROTOCOL #20 (03121702)
- F&A: 5,380

**Tissue Acquisition for Inform HPV DNA Analysis, Protocol #21**
- PI: HOLLADAY, E. BLAIR
- Sponsor: Ventana Medical Systems
- Project Dates: 2/1/2004-12/31/2004
- Award: PROTOCOL 21 (04030813)
- F&A: 368

**SurePath Specimen Procurement for Digene Corporation**
- PI: HOLLADAY, E. BLAIR
- Sponsor: Digene Corp.
- Project Dates: 9/2/2003-6/30/2004
- Award: 5044-SP (03080601)
- F&A: 1,343

---

**Ricciardone, Elizabeth**  
Principal Investigator  

**Rehabilitation Sciences**

**ALLIANCEnet: Anytime/Anywhere Learning Linkages in Allied Health and Nursing Continuing Education**
- Sponsor: Duke Endowment
- Project Dates: 7/1/2003 - 6/30/2004
- Award: 5044-SP (03080601)
- Direct: $122,898

**Health Professions**

**A Randomized, Double-Blind, Placebo-Controlled Trial of Valproate to Attenuate the Progression of Alzheimer's Disease**
- Sponsor: Univ. of California
- Award: PO 10226030-001 & 1 (03101603)
- Direct: $59,338

---

**Ripich, Danielle**  
Principal Investigator  

**Health Professions**

**EXPORT Center for Metabolic Syndrome and Minority Health**
- Sponsor: SC State Univ.
- Award: 04-446422-1890-MUS (04032607)
- Direct: $12,636

---

**Robinson, William**  
Principal Investigator  

**Health Administration and Policy**

**Southeastern Node of the Clinical Trials Network**
- PI: BRADY, KATHLEEN T.
- Sponsor: NIH/NIDA
- Project Dates: 9/30/2000-8/31/2005
- Award: 5 U10 DA13727-04 (03062618)
- Direct: $1,307,975

---

**Saladin, Michael**  
Principal Investigator  

**Rehabilitation Sciences**

**Virtual Reality Cue Exposure for Crack Cocaine Dependence**
- Sponsor: Virtually Better, Inc.
- Project Dates: 7/1/2003 - 6/30/2004
- Award: R41-DA016462-01 (03121601)
- Direct: $24,687

---

**Southeastern Node of the Clinical Trials Network**

**PI: BRADY, KATHLEEN T.**  
**Sponsor: NIH/NIDA**  
**Project Dates: 9/30/2000-8/31/2005**  
**Award: 5 U10 DA13727-04 (03062618)**  
**Direct: $1,307,975**  
**F&A: 392,075**
<table>
<thead>
<tr>
<th>Faculty Activity by College</th>
<th>Medical University of South Carolina</th>
</tr>
</thead>
</table>

### Rehabilitation Sciences

#### ORWH: SCOR on Sex and Gender Factors Affecting Women's Health
- **PI:** BRADY, KATHLEEN T.
- **Sponsor:** NIH/NIDA
- **Project Dates:** 9/30/2002-6/30/2007
- **Award:** 5 P50 DA016511-02 (03050502)
- **F&A:** 266,552
- **Direct:** 579,460

#### A Program to Increase Living Donations in African Americans
- **PI:** BALIGA, PRABHAKAR
- **Sponsor:** NIH/NIDDK
- **Project Dates:** 9/15/2002-6/30/2007
- **Award:** 5 R01 DK062596-02 (03050204)
- **F&A:** 69,000
- **Direct:** 150,000

### Health Professions

#### ALLIANCEnet: Anytime/Anywhere Learning Linkages in Allied Health and Nursing Continuing Education
- **PI:** RICCIARDONE, ELIZABETH
- **Sponsor:** Duke Endowment
- **Project Dates:** 7/1/2002-6/30/2005
- **Award:** 5044-SP (03080601)
- **F&A:** 0
- **Direct:** 122,898

### Health Administration and Policy

#### Economic Analysis of FAS Preventive Intervention
- **Sponsor:** Cornell Univ. Medical Center
- **Budget Dates:** 8/1/2003 - 7/31/2004
- **Direct:** 2,467
- **Award:** 36435-7298/R01 AA1 (03111202)

#### Assessing the Impact of Substance Abuse on Employment Status
- **Sponsor:** Robert Wood Johnson Fdn.
- **Budget Dates:** 1/1/2004 - 6/30/2004
- **Direct:** 35,385
- **Award:** 049981 (03100802)

### Clinical Services

#### Nurse Anesthetist Traineeship
- **Sponsor:** HRSA/BHP/Nursing
- **Budget Dates:** 7/1/2003 - 6/30/2004
- **Direct:** 13,853
- **Award:** 2 A22 HP00023-04 (02102307)

### Health Administration and Policy

#### Evaluation of SC Medicaid Program
- **PI:** BRADFORD, W. DAVID
- **Sponsor:** SC DHHS
- **Project Dates:** 7/1/2003-6/30/2004
- **Award:** (03072101)
- **F&A:** 46,154
- **Direct:** 153,846

#### Health Administration Traineeships and Special Projects
- **Sponsor:** HRSA/BHP/Assoc. Health Professions
- **Budget Dates:** 7/1/2003 - 6/30/2004
- **Direct:** 37,157
- **Award:** 2 A19 HP10187-04 (03011703)

#### A Comparison of Urban and Rural Patterns of Physical Therapy Practice: A Secondary Analysis Project
- **Sponsor:** Univ. of Montana
- **Budget Dates:** 7/1/2003 - 11/30/2003
- **Direct:** 7,174
- **Award:** M25845 (03120301)

### Rehabilitation Sciences

#### South Carolina COBRE for Oral Health - Project 3: Oral Health in African American Adolescents with Diabetes
- **PI:** LONDON, STEVEN D.
- **Sponsor:** NIH/NCRR
- **Project Dates:** 9/30/2002-6/30/2007
- **Award:** 5 P20 RR017696-02 (03080503-05)
- **F&A:** 50,908
- **Direct:** 110,670

#### Institutional Research Grant: Driving Ability in Head and Neck Cancer Survivors
- **PI:** REED, CAROLYN E.
- **Sponsor:** Amer. Cancer Soc.
- **Project Dates:** 11/1/2003-10/31/2004
- **Award:** IRG-97-219-05 (02100801-04)
- **F&A:** 0
- **Direct:** 19,500
### Psychiatry & Behavioral Sciences

**Sexual Assault and Domestic Violence Intervention: A Training Program for Students in Health Care Professions**
- **Sponsor:** SC Dept. of Public Safety
- **Budget Dates:** 10/1/2003 - 9/30/2004
- **Direct:** $50,552
- **Award:** 1K03040 (03052303)

**Prevention of Posttraumatic Psychopathology and Drug Abuse/Web Based Intervention Following September 11th Attacks**
- **Sponsor:** SC Dept. of Public Safety
- **Budget Dates:** 10/1/2003 - 9/30/2004
- **Direct:** $50,552
- **Award:** 1K03040 (03052303)

### Radiology

**A Phase IIb, Open-Label, Non-Randomized, Multi-Center Trial to Assess the Ability of DMP 115 Contrast Enhanced Ultrasound Imaging to Correctly Detect and Characterize Liver or Kidney Pathology**
- **Sponsor:** Bristol Myers Squibb
- **Budget Dates:** 1/31/2004 - 1/31/2005
- **Direct:** $10,200
- **Award:** PROTOCOL DMP115-3 (04012102)

**A Phase III, Open-Label, Multi-Center Trial to Compare the Diagnostic Accuracy for Definity (R)-Enhanced Ultrasound Imaging Versus Contrast-Enhanced Computed Tomography (CT) for Characterization of Liver Lesions**
- **Sponsor:** Bristol Myers Squibb
- **Budget Dates:** 2/6/2004 - 1/31/2005
- **Direct:** $37,860
- **Award:** DMP 115-306 (04012101)

**Evaluation of the Ziver Vascular Stent in the Iliac Arteries**
- **Sponsor:** Cook, Inc.
- **Budget Dates:** 7/1/2003 - 6/30/2004
- **Direct:** $55,350
- **Award:** PROTOCOL # 02-513 (04021903)

### Surgery

**Ethicon-Minimally Invasive Resident Education Center**
- **Sponsor:** Ethicon
- **Budget Dates:** 11/15/1999 - 11/15/2003
- **Direct:** $12,256
- **Award:** (99051302)

### Medicine

**Oncology Center: Human Tissue Procurement Service and Tumor Bank**
- **Sponsor:** DOE
- **Budget Dates:** 11/15/1999 - 11/15/2003
- **Direct:** $80,954
- **Award:** DE-FG02-01ER63121 (03051401-03)

**Matrix Metalloproteinase Dysregulation in Diastolic Heart Failure**
- **Sponsor:** Heart Failure Soc. Of Amer.
- **Budget Dates:** 7/1/2003 - 6/30/2004
- **Direct:** $65,000
<table>
<thead>
<tr>
<th>Award</th>
<th>Project Dates</th>
<th>F&amp;A</th>
</tr>
</thead>
<tbody>
<tr>
<td>(03013116)</td>
<td>7/1/2003 - 6/30/2004</td>
<td>0</td>
</tr>
</tbody>
</table>

**Biostatistics, Bioinformatics & Epidemiology**

**Development of cDNA Microarrays for Analysis of Environmental Stressors and Disease in Local Populations of White Shrimp, Litopenaeus - Third Year Renewal for SC Sea Grant Project # R/MT-6**

*Almeida, Jonas*

Co-PI or Project Leader

**Orthopedic Surgery**

**Tolerability and Performance of Cross-Linked Hyaluronic Acid Pellets Implanted into Osteochondral Defects in the Patellar Groove: A Feasibility Study in the New Zealand White Rabbit**

*An, Y.*

Principal Investigator

**Evaluation of Composite Cement Consisting of Calcium Phosphate and Iliac Crest Autograft Bone in a Rabbit Radius Defect Model**

**Novel Processing of Biomaterials for Improved Biocompatibility**

**The Use of Platelet-Rich Plasma for Repairing Cartilage Defects**

*Anderson, Deborah*

Co-Investigator

**A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Six Weeks, Flexible, Oral Dose Clinical Study of Mecamylamine HCl in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)**

**Cystic Fibrosis Center - MUSC**

*Almeida, Jonas*

Co-PI or Project Leader

**Award:** (03013116)

**Project Dates:** 7/1/2003 - 6/30/2004

**F&A:** 0

**Cardiovascular Proteomics Center - Administrative Core C: Bioinformatics Core Unit**

**National Heart, Lung and Blood Institute Proteomics Administrative Center**

**Cardiovascular Proteomics Center**

**Functional Genomic Approach to Signal Transduction and Innate Immunity in Shrimp**

**Cardiovascular Proteomics Center**

**Novel Processing of Biomaterials for Improved Biocompatibility**

**A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Six Weeks, Flexible, Oral Dose Clinical Study of Mecamylamine HCl in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)**

**Cystic Fibrosis Center - MUSC**

*An, Y.*

Principal Investigator

**Orthopedic Surgery**

**Tolerability and Performance of Cross-Linked Hyaluronic Acid Pellets Implanted into Osteochondral Defects in the Patellar Groove: A Feasibility Study in the New Zealand White Rabbit**

**Evaluation of Composite Cement Consisting of Calcium Phosphate and Iliac Crest Autograft Bone in a Rabbit Radius Defect Model**

**Novel Processing of Biomaterials for Improved Biocompatibility**

**The Use of Platelet-Rich Plasma for Repairing Cartilage Defects**

**A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Six Weeks, Flexible, Oral Dose Clinical Study of Mecamylamine HCl in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)**

**Cystic Fibrosis Center - MUSC**

*Anderson, Deborah*

Co-Investigator

**Pediatrics**

**A Phase IIIb, Open-Label, Multi-Center Study to Assess Safety, Tolerability and Effectiveness Associated with the Use of ADDERALL XR in Adults with Attention Deficit Hyperactivity Disorder and Evaluate an ADHD-Specific Novel Quality of Life Measure**

**A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Six Weeks, Flexible, Oral Dose Clinical Study of Mecamylamine HCl in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)**

**Cystic Fibrosis Center - MUSC**
## Medical University of South Carolina Faculty Activity by College

### ANNIBALE College of Medicine

#### Annibale, David
**Principal Investigator**

**Pediatrics**

**SC Neonatal Medicine Consortium**

- **Sponsor:** March of Dimes
- **Budget Dates:** 4/1/2004 - 3/30/2005
- **Direct:** $35,000

#### Psychiatry & Behavioral Sciences

**A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Arpiprazole in the Maintenance of Abstinence from Alcohol in Subjects with Alcoholism (Study No. CN138-089-001)**

- **Sponsor:** Bristol Myers Squibb
- **Budget Dates:** 4/1/2004 - 3/31/2006
- **Direct:** $238,254

**A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Alcohol Dependence**

- **Sponsor:** Ortho-McNeil Pharmaceuticals
- **Budget Dates:** 3/15/2004 - 9/30/2005
- **Direct:** $187,755

**Randomized, Placebo-Controlled Parallel Group Study Comparing Effect of Three Doses of CP-866,087 and Naltrexone on Acute Alcohol Consumption and Craving after Seven Days of Treatment in Alcohol Dependent (DSM IV) Subjects Who Are Not Currently Seeking T**

- **Sponsor:** Pfizer, Inc.
- **Budget Dates:** 3/15/2004 - 1/31/2006
- **Direct:** $191,040

**Gabapentin as an Adjunct to Naltrexone for Alcoholism**

- **Sponsor:** NIH/NIAAA
- **Budget Dates:** 9/15/2003 - 8/31/2004
- **Direct:** $269,696

#### Linkage Disequilibrium Studies of Alcohol Dependence

- **Sponsor:** Yale Univ.
- **Budget Dates:** 5/1/2003 - 4/30/2004
- **Direct:** $94,673

#### Alcohol Research Center-Treatment and Implications: Pilot Core:Homer Proteins in Ethanol-Induced Plasticity

- **PI:** RANDALL, CARRIE L.
- **Sponsor:** NIH/NIAAA
- **Project Dates:** 12/10/1995-11/30/2005
- **Direct:** $167,059

#### Alcohol Research Center-Treatment and Implications: Research Component 1:Combining Medications:Alcohol Reactivity and Consumption

- **PI:** RANDALL, CARRIE L.
- **Sponsor:** NIH/NIAAA
- **Project Dates:** 12/10/1995-11/30/2005
- **Direct:** $277,918

#### Training in Alcohol Research

- **PI:** WOODWARD, JOHN J
- **Sponsor:** NIH/NIAAA
- **Project Dates:** 9/30/1987-3/31/2008
- **Direct:** $78,189

### Anton, Raymond
**Principal Investigator**

**Psychiatry & Behavioral Sciences**

**A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Arpiprazole in the Maintenance of Abstinence from Alcohol in Subjects with Alcoholism (Study No. CN138-089-001)**

- **Sponsor:** March of Dimes
- **Budget Dates:** 4/1/2004 - 3/30/2005
- **Direct:** $35,000

**A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Alcohol Dependence**

- **Sponsor:** Ortho-McNeil Pharmaceuticals
- **Budget Dates:** 3/15/2004 - 9/30/2005
- **Direct:** $187,755

**Randomized, Placebo-Controlled Parallel Group Study Comparing Effect of Three Doses of CP-866,087 and Naltrexone on Acute Alcohol Consumption and Craving after Seven Days of Treatment in Alcohol Dependent (DSM IV) Subjects Who Are Not Currently Seeking T**

- **Sponsor:** Pfizer, Inc.
- **Budget Dates:** 3/15/2004 - 1/31/2006
- **Direct:** $191,040

**Gabapentin as an Adjunct to Naltrexone for Alcoholism**

- **Sponsor:** NIH/NIAAA
- **Budget Dates:** 9/1/2002-8/31/2007
- **Direct:** $277,918

**Linkage Disequilibrium Studies of Alcohol Dependence**

- **Sponsor:** Yale Univ.
- **Budget Dates:** 5/1/2003 - 4/30/2004
- **Direct:** $94,673

**Alcohol Research Center-Treatment and Implications: Pilot Core:Homer Proteins in Ethanol-Induced Plasticity**

- **PI:** RANDALL, CARRIE L.
- **Sponsor:** NIH/NIAAA
- **Project Dates:** 12/10/1995-11/30/2005
- **Direct:** $167,059

**Alcohol Research Center-Treatment and Implications: Research Component 1:Combining Medications:Alcohol Reactivity and Consumption**

- **PI:** RANDALL, CARRIE L.
- **Sponsor:** NIH/NIAAA
- **Project Dates:** 12/10/1995-11/30/2005
- **Direct:** $277,918

### Appiagyei-Dankah, Yaw
**Principal Investigator**

**Pediatrics**

**SEARCH Pediatric Diabetes**

- **Sponsor:** Univ. of South Carolina
- **Budget Dates:** 9/30/2001 - 9/29/2005
- **Direct:** $35,967

### Argraves, Kelley
**Principal Investigator**

**Cell Biology & Anatomy**

**The Role of Sphingosine-1-Phosphate in Vasculoogenesis and Angiogenesis**

- **Sponsor:** Amer. Heart Assoc.
- **Budget Dates:** 1/1/2004 - 12/31/2004
- **Direct:** $59,091

**SC COBRE in Lipidomics and Pathobiology - Project 1: Role of Sphingosine - 1 Phosphate in Early Blood Vessel Formation**

- **PI:** OBEID, LINA
- **Sponsor:** NIH/NCCR
- **Project Dates:** 9/26/2002-6/30/2007
- **Direct:** $149,413

---

**ANNIBALE**

**College of Medicine**

---

**Co-PI or Project Leader**

**SEARCH Pediatric Diabetes**

- **PI:** RANDALL, CARRIE L.
- **Sponsor:** NIH/NIAAA
- **Project Dates:** 12/10/1995-11/30/2005
- **Direct:** $167,059

**Alcohol Research Center-Treatment and Implications: Pilot Core:Homer Proteins in Ethanol-Induced Plasticity**

- **PI:** RANDALL, CARRIE L.
- **Sponsor:** NIH/NIAAA
- **Project Dates:** 12/10/1995-11/30/2005
- **Direct:** $277,918

**Training in Alcohol Research**

- **PI:** WOODWARD, JOHN J
- **Sponsor:** NIH/NIAAA
- **Project Dates:** 9/30/1987-3/31/2008
- **Direct:** $265,582

**Naltrexone Treatment of Adolescent Alcoholics**

- **PI:** DEAS, DEBORAH
- **Sponsor:** NIH/NIAAA
- **Project Dates:** 9/1/2002-8/31/2007
- **Direct:** $265,582

---

**Co-Investigator**

**SEARCH Pediatric Diabetes**

- **PI:** RANDALL, CARRIE L.
- **Sponsor:** NIH/NIAAA
- **Project Dates:** 12/10/1995-11/30/2005
- **Direct:** $65,181

---

**Appiagyei-Dankah, Yaw**

**Principal Investigator**

**Pediatrics**

**SEARCH Pediatric Diabetes**

- **Sponsor:** Univ. of South Carolina
- **Budget Dates:** 9/30/2001 - 9/29/2005
- **Direct:** $78,189

---

**Argraves, Kelley**

**Principal Investigator**

**Cell Biology & Anatomy**

**The Role of Sphingosine-1-Phosphate in Vasculoogenesis and Angiogenesis**

- **Sponsor:** Amer. Heart Assoc.
- **Budget Dates:** 1/1/2004 - 12/31/2004
- **Direct:** $59,091

**SC COBRE in Lipidomics and Pathobiology - Project 1: Role of Sphingosine - 1 Phosphate in Early Blood Vessel Formation**

- **PI:** OBEID, LINA
- **Sponsor:** NIH/NCCR
- **Project Dates:** 9/26/2002-6/30/2007
- **Direct:** $149,413

---

**Annual Report for Research FY04**

29
Faculty Activity by College

Medical University of South Carolina

College of Medicine

**Argraves, Kelley**
Co-Investigator

**Cell Biology & Anatomy**

**Cytokine Regulation of Early Events in Blood Vessel Form**

- PI: DRAKE, CHRISTOPHER
- Sponsor: NIH/NHLBI
- Direct: $150,000
- F&A: $69,000

**Project Dates:** 1/1/1997-3/31/2007

**Award:** 5 R01 HL057375-07 (04020410)

**Sphingolipids in Cancer Therapy and Angiogenesis**

- PI: HANNUN, YUSUF
- Sponsor: NCI
- Direct: $715,167
- F&A: 318,811

**Project Dates:** 8/1/2003-7/31/2008

**Award:** 1 P01 CA97132-01A1 (01100808)

**Argraves, W.**
Principal Investigator

Co-PI or Project Leader

**Cell Biology & Anatomy**

**Cancer Center Microarray Bioinformatics Facility**

- Sponsor: NIH/NCI
- Direct: $171,058
- F&A: 73,555

**Budget Dates:** 4/1/2004 - 3/31/2005

**Award:** 5 R24 CA095841-03 (04013001)

**Project Dates:** 4/1/2002 - 3/31/2007

**The Role of Megalin in Craniofacial Development**

- PI: MARKWALD, ROGER R.
- Sponsor: NIH/NIDCR
- Direct: $200,000
- F&A: 92,000

**Budget Dates:** 2/1/2004 - 1/31/2005

**Award:** 5 R01 DE014347-02 (03120303)

**Project Dates:** 5/1/2003 - 1/31/2007

**Medicine**

**Proteomics Core Facility**

- Sponsor: Dialysis Clinics, Inc.
- Direct: $322,665
- F&A: 0

**Budget Dates:** 12/5/2003 - 12/5/2004

**Award:** (01082804)

**Project Dates:** 12/5/2001 - 12/5/2004

**Co-Investigator**

**Arnaud, Philippe**
Co-Investigator

**Microbiology & Immunology**

**Specialized Centers of Research on Sex and Gender Affecting Women's Health**

- PI: DEVANE, C. LINDSAY
- Sponsor: Emory Univ.
- Direct: $110,432
- F&A: 50,797

**Budget Dates:** 9/21/2002-7/31/2007

**Award:** 1 P50 MH68036-01 (02031408)

**Arthur, John**
Principal Investigator

Co-PI or Project Leader

**Cardiovascular Proteomics Center - Administrative Core A - Gel Electrophoresis Core Unit**

- PI: KNAPP, DANIEL R.
- Sponsor: NIH/NHLBI
- Direct: $80,076
- F&A: 36,835

**Budget Dates:** 9/30/2002-9/29/2009

**Award:** N01-HV-281-81-000 (02030610-19)

**Project Dates:** 9/30/2002-9/29/2009

**Cardiovascular Proteomics Center - Project 4: Improved Methods for Separation and Identification of Proteins on Two-Dimensional Gels**

- PI: KNAPP, DANIEL R.
- Sponsor: NIH/NHLBI
- Direct: $150,360
- F&A: 69,166

**Budget Dates:** 9/30/2002-9/29/2009

**Award:** N01-HV-281-81-000 (02030610-15)

**Project Dates:** 9/30/2002-9/29/2009

**Atz, Andrew**
Principal Investigator

**Pediatrics**

**A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study of Oral Sildenafil in the Treatment of Children, Aged 1-16 Years with Pulmonary Arterial Hypertension**

- Sponsor: Pfizer, Inc.
- Direct: $64,621
- F&A: 16,155

**Budget Dates:** 3/30/2004 - 5/31/2005

**Award:** A1481131-1040 (04061601)

**Project Dates:** 3/30/2004 - 5/31/2005

**Study of Newborns/Infants with Intraarterial Catheters**

- Sponsor: Suntech Medical Instruments
- Direct: $28,200
- F&A: 7,050

**Budget Dates:** 3/1/2004 - 6/30/2005

**Award:** (04032304)

**Project Dates:** 3/1/2004 - 6/30/2005

**Functional Health Changes in Survivors of Surgery for Hypoplastic Left Heart Syndrome: Improving Outcomes for Hypoplastic Left Heart Syndrome: Yearly Survey**

- Sponsor: Dartmouth Coll.
- Direct: $6,180
- F&A: 1,545

**Budget Dates:** 7/1/2003 - 6/30/2004

**Award:** 20000354/5-38179-5 (02012808)

**Project Dates:** 12/1/2001 - 6/30/2004
### Pediatrics

**Atz, Andrew**  
Co-Investigator  
**Randomized Clinical Trials for Pediatric Heart Disease**  
<table>
<thead>
<tr>
<th>Pt: SAUL, J. PHILIP</th>
<th>Sponsor: NIH/NHLBI</th>
<th>Direct: $394,514</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Dates: 9/1/2001-8/31/2006</td>
<td>Award: 5 U01 HL068281-03 (03071403)</td>
<td>F&amp;A: 55,806</td>
</tr>
</tbody>
</table>

### Psychiatry & Behavioral Sciences

**Austin, Linda**  
Co-Investigator  
**Southeastern Node of the Clinical Trials Network**  
<table>
<thead>
<tr>
<th>Pt: BRADY, KATHLEEN T.</th>
<th>Sponsor: NIH/NIDA</th>
<th>Direct: $1,307,975</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Dates: 9/30/2000-8/31/2005</td>
<td>Award: 5 U10 DA013727-04 (03062618)</td>
<td>F&amp;A: 392,075</td>
</tr>
</tbody>
</table>

### Medicine

**Awgulewitsch, Alexander**  
Principal Investigator  
**Roles of Hox Genes in Skin and Hair Follicle Development**  
<table>
<thead>
<tr>
<th>Sponsor: NIH/NIAMS</th>
<th>Budget Dates: 8/1/2003 - 7/31/2005</th>
<th>Direct: $188,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Award: 5 R01 AR047204-04 (03060202)</td>
<td>Project Dates: 8/1/2000 - 7/31/2005</td>
<td>F&amp;A: 80,840</td>
</tr>
</tbody>
</table>

### Pediatrics

**Baatz, John**  
Principal Investigator  
**Role of Surfactant Protein B in Innate Airway Defense**  
<table>
<thead>
<tr>
<th>Sponsor: NIH/NHLBI</th>
<th>Budget Dates: 7/1/2003 - 6/30/2004</th>
<th>Direct: $200,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Award: 5 R01 HL066066-03 (03042905)</td>
<td>Project Dates: 7/1/2001 - 6/30/2005</td>
<td>F&amp;A: 85,088</td>
</tr>
</tbody>
</table>

### Spectroscopy of Biomembrane Monolayers

| --- | --- | --- |  

### Psychiatry & Behavioral Sciences

**Back, Sudie**  
Principal Investigator  
**Cocaine Dependence and PTSD: The Role of Stress Reactivity**  
| --- | --- | --- |  

### Medicine

**Baliga, Prabhakar**  
Principal Investigator  
**Load-Induced Cardiac Hypertrophy in the Adult Mammal**  
<table>
<thead>
<tr>
<th>Sponsor: NIH/NHLBI</th>
<th>Budget Dates: 8/1/1993-7/31/2008</th>
<th>Direct: $1,400,000</th>
</tr>
</thead>
</table>

### Surgery

**Bai, Catalin**  
Co-Investigator  
**A Program to Increase Living Donations in African Americans**  
<table>
<thead>
<tr>
<th>Sponsor: NIH/NIDDK</th>
<th>Budget Dates: 7/1/2003 - 6/30/2004</th>
<th>Direct: $150,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Award: 5 R01 DK062596-02 (03050204)</td>
<td>Project Dates: 9/15/2002-6/30/2007</td>
<td>F&amp;A: 69,000</td>
</tr>
</tbody>
</table>

---

**Medical University of South Carolina**  
**Faculty Activity by College**  
**Annual Report for Research FY04**  
31
**College of Medicine**

**Baliga, Prabhakar**  
Principal Investigator  

**Surgery**  
A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitors Treatment To Sirolimus Treatment Versus Continued Calcineurin Inhibitor Treatment in Liver Allograft Recipients Undergoing Maintenance Therapy  
*Principal Investigator:* Baliga, Prabhakar  
*Sponsor:* Wyeth-Ayerst  
*Award:* 0468H1-313-US (03012102)  
*Direct:* $8,500  
*F&A:* 2,125

**Banik, Naren**  
Principal Investigator  

**Neurology**  
**Role of Proteinase in Spinal Cord Injury**  
*Principal Investigator:* Banik, Naren  
*Sponsor:* NIH/NINDS  
*Award:* 5 R01 NS031622-11 (03103003)  
*Budget Dates:* 12/1/2003 - 11/30/2004  
*Direct:* $222,500  
*F&A:* 95,675

**Calpain Activation of T Cells in Demyelinating Disease**  
*Principal Investigator:* Banik, Naren  
*Sponsor:* NIH/NINDS  
*Award:* 5 R01 NS041088-04 (03102701)  
*Budget Dates:* 12/1/2003 - 11/30/2004  
*Direct:* $225,000  
*F&A:* 96,750

**Calpain in the Pathophysiology of Demyelinating Disease**  
*Principal Investigator:* Banik, Naren  
*Sponsor:* NIH/NINDS  
*Award:* 5 R01 NS038146-05 (03052706)  
*Budget Dates:* 12/1/2003 - 11/30/2004  
*Direct:* $146,334  
*F&A:* 96,750

**Estrogen Efficacy in Spinal Cord Injury**  
*Principal Investigator:* Banik, Naren  
*Sponsor:* NIH/NINDS  
*Award:* 5 R01 NS045967-01A (03031207)  
*Budget Dates:* 9/30/2003 - 6/30/2004  
*Direct:* $185,000  
*F&A:* 73,600

**Proteolytic Control of Glioblastoma**  
*Principal Investigator:* Banik, Naren  
*Sponsor:* NIH/NCI  
*Award:* 1 R01 CA091460-01A1 (03041602)  
*Budget Dates:* 8/1/2003-7/31/2008  
*Direct:* $150,000  
*F&A:* 69,000

**Barbosa, Ernest**  
Principal Investigator  

**Neurology**  
**Anti-Inflammatory Approaches for Spinal Cord Injury**  
*Principal Investigator:* Barbosa, Ernest  
*Sponsor:* SC Spinal Cord Injury Fund  
*Award:* SCIRF 1103 (03112006)  
*Budget Dates:* 11/1/2003 - 5/30/2005  
*Direct:* $75,000  
*F&A:* 0

**Psychiatry & Behavioral Sciences**  
**Effects on Virtual Reality Driving Performance in ADHD Adults Treated with Strattera**  
*Principal Investigator:* Barkley, Russell  
*Sponsor:* Eli Lilly  
*Award:* B42-US-X023 (04040101)  
*Direct:* $77,500  
*F&A:* 19,375

**A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Six Weeks, Flexible, Oral Dose Clinical Study of Mecamylamine HCI in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)**  
*Principal Investigator:* Barkley, Russell  
*Sponsor:* Targacept, Inc.  
*Award:* TC5231 (03091605)  
*Direct:* $83,460  
*F&A:* 20,865

**A Compensatory Functional Neuroanatomy of ADHD**  
*Principal Investigator:* Barkley, Russell  
*Sponsor:* Univ. of Maryland  
*Award:* 1 R01 MH066310-01A (03061306)  
*Budget Dates:* 4/1/2004 - 1/31/2005  
*Direct:* $15,503  
*F&A:* 7,131

**Reporting Department: Health Professions**  
**Multimethod Assessment of Driving Skills in ADHD Teens**  
*Principal Investigator:* Barkley, Russell  
*Sponsor:* NIH/NICHD  
*Award:* 7 R01 HD028171-05 (03011409)  
*Budget Dates:* 7/1/2003 - 6/30/2004  
*Direct:* $77,357  
*F&A:* 35,584

**Barredo, Julio**  
Principal Investigator  

**Pediatrics**  
**Pediatric Hydroxyurea Phase III Clinical Trial–Clinical Center**  
*Principal Investigator:* Barredo, Julio  
*Sponsor:* NIH/NHLBI  
*Award:* N01-HB-07154 (99100606)  
*Direct:* $112,286  
*F&A:* 48,283

**Growth Factor in Clinical Setting**  
*Principal Investigator:* Barredo, Julio  
*Sponsor:* Amgen  
*Award:* (04022620)  
*Budget Dates:* 10/1/2003 - 10/31/2003  
*Direct:* $1,600  
*F&A:* 400

**Children's Oncology Chair Grant**  
*Principal Investigator:* Barredo, Julio  
*Sponsor:* Natl Childhood Cancer Fndtn  
*Award:* U10 CA98543-01 (0301505)  
*Direct:* $10,669  
*F&A:* 2,134
<table>
<thead>
<tr>
<th>Name</th>
<th>College</th>
<th>Title</th>
<th>Sponsor(s)</th>
<th>Budget Dates</th>
<th>Direct:</th>
<th>F&amp;A:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barredo, Julio</td>
<td>College of Medicine</td>
<td>Molecular Determinants of Methotrexate Metabolism in ALL</td>
<td>NIH/NCI</td>
<td>5/1/2004 - 4/30/2005</td>
<td>$205,000</td>
<td></td>
</tr>
<tr>
<td>Barredo, Julio</td>
<td>College of Medicine</td>
<td>Molecular Correlates of Methotrexate in Childhood ALL</td>
<td>Wayne State Univ.</td>
<td>1/1/2004 - 12/31/2004</td>
<td>$18,412</td>
<td></td>
</tr>
<tr>
<td>Basco, William</td>
<td>Pediatrics</td>
<td>Faculty Development in Primary Care</td>
<td>HRSA/BHP/Medicine</td>
<td>7/1/2002-6/30/2005</td>
<td>$286,001</td>
<td></td>
</tr>
<tr>
<td>Bastia, Depak</td>
<td>Biochemistry &amp; Molecular Biology</td>
<td>Mechanism of Termination of DNA Replication</td>
<td>NIH/NIGMS</td>
<td>2/1/2004 - 1/31/2005</td>
<td>$240,000</td>
<td>103,200</td>
</tr>
<tr>
<td>Becker, Howard</td>
<td>Psychiatry &amp; Behavioral Sciences</td>
<td>Treatment and Gene/Protein Analysis of Ethanol Relapse</td>
<td>NIH/NIAAA</td>
<td>3/1/2004 - 2/28/2005</td>
<td>$250,000</td>
<td>115,000</td>
</tr>
<tr>
<td>Becker, Howard</td>
<td>Co-Investigator</td>
<td>Alcohol Research Center-Treatment and Implications: Research Component 4:Pharmacotherapy for Multiple Ethanol Withdrawals</td>
<td>RANDALL, CARRIE L.</td>
<td>12/10/1995-11/30/2005</td>
<td>$172,959</td>
<td></td>
</tr>
<tr>
<td>Becker, Howard</td>
<td>Co-Investigator</td>
<td>ORWH: SCOR on Sex and Gender Factors Affecting Women's Health</td>
<td>NIH/NIDA</td>
<td>9/30/2002-6/30/2007</td>
<td>$579,460</td>
<td></td>
</tr>
</tbody>
</table>
### Bell, Norman

**Principal Investigator**

**Medicine**

**Cloning and Characterization of Human CYP25**
- **Sponsor:** NIH/NIDDK
- **Award:** 5 R01 DK056603-04 (03111803)
- **Budget Dates:** 2/1/2004 - 1/31/2005
- **F&A:** 43,680
- **Direct:** $168,000

**Study of Osteoporosis Treatment**
- **Sponsor:** Merck
- **Award:** 227-00 (03080701)
- **Budget Dates:** 7/3/2003 - 12/31/2004
- **F&A:** 9,206
- **Direct:** $36,824

**Regulation of Vitamin D Metabolism**
- **Sponsor:** DOD/US Army
- **Award:** DAMD17-01-1-0816 (00121502)
- **Budget Dates:** 9/13/2001 - 9/12/2005
- **F&A:** 35,780
- **Direct:** $137,613

**Evaluation of Vitamin D Requirements During Pregnancy**
- **PI:** HOLLIS, BRUCE W.
- **Sponsor:** NIH/NICHD
- **Award:** 1 R01 HD043921-01 (02053004)
- **Budget Dates:** 9/1/2003 - 7/31/2008
- **F&A:** 155,995
- **Direct:** $382,526

**Neurology**

**A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multi-Center, Fixed Dose-Response Study to Evaluate the Efficacy and Safety of 10, 20 and 40mg/d Oral Doses of KW-6002 (Istradefylline) as Treatment for Parkinson's Disease in Patie**
- **Sponsor:** Lineberry Research Associates
- **Budget Dates:** 6/28/2004 - 12/31/2005
- **F&A:** 17,600
- **Direct:** $70,400
- **Award:** 6002-US-018 (04070213)

**Psychiatry & Behavioral Sciences**

**Continuation ECT vs Pharmacotherapy: Efficacy and Safety**
- **Sponsor:** Mayo Fdn. For Medical Research
- **Budget Dates:** 6/1/2004 - 5/31/2005
- **F&A:** 6,928
- **Direct:** $15,062

**Comparing Three Electrode Placements to Optimize ECT**
- **Sponsor:** New Jersey Medical School
- **Budget Dates:** 10/4793/R01 MH6720 (02121904)
- **F&A:** 38,885
- **Direct:** $84,533

**Continuation ECT vs Pharmacotherapy: Efficacy and Safety**
- **Sponsor:** Long Island Jewish Health System
- **Budget Dates:** 2 R01 MH55486 (02082207)
- **F&A:** 6,963
- **Direct:** $12,014

**Continuation ECT Versus Pharmacotherapy: Efficacy and Safety**
- **Sponsor:** Mayo Fdn. For Medical Research
- **Budget Dates:** 5/1/2002 - 4/30/2004
- **F&A:** 5,526
- **Direct:** $15,062

**Psychiatry & Behavioral Sciences**

**Bioterrorism Training Cooperative Agreement Program**
- **Sponsor:** DHEC
- **Budget Dates:** 4/1/2004 - 8/30/2004
- **F&A:** 494
- **Direct:** $6,172

**Child and Adult Trauma Victims: A Training Program**
- **PI:** KILPATRICK, DEAN G.
- **Sponsor:** NIH/NIMH
- **Budget Dates:** 1/1/1988-6/30/2008
- **F&A:** 15,190
- **Direct:** $209,370

**Neurology**

**MAP Kinases in Oligodendrocyte Cell Signaling**
- **Sponsor:** NIH/NINDS
- **Budget Dates:** 6/1/2004 - 5/31/2005
- **F&A:** 76,475
- **Direct:** $166,250

**MAP Kinase Regulation of Microglial Activation**
- **Sponsor:** NIH/NINDS
- **Budget Dates:** 4/1/2004 - 3/31/2005
- **F&A:** 64,500
- **Direct:** $150,000

**Therapeutic Use of Minocycline for Spinal Cord Injury**
- **Sponsor:** SC Spinal Cord Injury Fund
- **Budget Dates:** 9/1/2003 - 12/1/2004
- **F&A:** 0
- **Direct:** $24,988
### Department of Neurology

**Principal Investigator**

**Bhat, Narayan**

**MAP Kinases in Oligodendrocyte Cell Signaling**
- **Sponsor:** NIH/NINDS
- **Budget Dates:** 7/1/2003 - 5/31/2004
- **Award:** 5 R01 NS041396-02 (03070701)
- **Project Dates:** 7/1/2002 - 5/31/2005
- **Direct:** $166,250
- **F&A:** $76,475

### Department of Biochemistry & Molecular Biology

**Principal Investigator**

**Bielawska, Alicja**

**Role of Ceramide Phosphate in Prostaglandin Synthesis**
- **Sponsor:** Virginia Commonwealth Univ.
- **Budget Dates:** 1/1/2004 - 12/31/2004
- **Direct:** $10,000
- **Award:** 1 R01 HL072925-01A (04030805)
- **Project Dates:** 7/1/2003 - 5/31/2004
- **F&A:** 4,600

**Molecular Pathogenesis of Apoptosis in Liver Cells**
- **Sponsor:** Univ. of North Carolina
- **Budget Dates:** 6/1/2001 - 5/31/2004
- **Direct:** $71,057
- **Award:** 5 P01 DK59340-03 (03110305)
- **Project Dates:** 6/1/2001 - 5/31/2004
- **F&A:** 30,554

### Department of Physiology and Neuroscience

**Principal Investigator**

**Bimonte, Heather**

**Progesterone, Aging, and Memory Loss**
- **Sponsor:** NIH/NIA
- **Budget Dates:** 5/15/2004 - 4/30/2005
- **Award:** 1 R03 AG023925-01 (04022704)
- **Project Dates:** 5/15/2004 - 4/30/2006
- **Direct:** $45,000
- **F&A:** 18,630

### Department of Pediatrics

**Principal Investigator**

**Blaufax, Andrew**

**Evaluation of Pediatric ECG Rhythms for Automated ECG Analysis**
- **Sponsor:** Zoll Medical Corp.
- **Budget Dates:** 4/15/2003 - 8/31/2004
- **Direct:** $1,400
- **Award:** (03042906)
- **Project Dates:** 4/15/2003 - 8/31/2004
- **F&A:** 350

**Randomized Clinical Trials for Pediatric Heart Disease**
- **Sponsor:** NIH/NHLBI
- **Budget Dates:** 9/1/2001-8/31/2006
- **Direct:** $394,514
- **Award:** 5 U01 HL068281-03 (03071403)
- **Project Dates:** 9/1/2001-8/31/2006
- **F&A:** 55,806

### Department of Surgery

**Principal Investigator**

**Block, Mark**

**DOD Phase VI: Project 16 -Translational Research and Cancer Prevention and Control and Risk Factor Identification**
- **Sponsor:** Geo-Centers/DOD
- **Budget Dates:** 9/2/2003-8/28/2005
- **Direct:** $4,557
- **Award:** GC-3532-03-42153CM (03080703-20)
- **Project Dates:** 9/2/2003-8/28/2005
- **F&A:** 0

**South Carolina COBRE for Oral Health - Project 5: Field Cancerization and the Impact of Tobacco Carcinogens on Oral Mucosal Proteins**
- **Sponsor:** NIH/NCCR
- **Budget Dates:** 9/30/2002-6/30/2007
- **Direct:** $146,468
- **Award:** 5 P20 RR017696-02 (03080503-06)
- **Project Dates:** 9/30/2002-6/30/2007
- **F&A:** 67,375
<table>
<thead>
<tr>
<th>Faculty Activity by College</th>
<th>Medical University of South Carolina</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>College of Medicine</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Blue, Amy</strong></td>
<td></td>
</tr>
<tr>
<td>Co-Investigator</td>
<td></td>
</tr>
<tr>
<td><em>Family Medicine</em></td>
<td></td>
</tr>
<tr>
<td>SC Cooperative for Healthy Aging in Minority Populations</td>
<td>Sponsor: NIH/NIA</td>
</tr>
<tr>
<td>Pt: TILLEY, BARBARA</td>
<td>Project Dates: 9/30/2002-8/31/2007</td>
</tr>
<tr>
<td>Clinical Research Curriculum Award</td>
<td>Sponsor: NIH/NHLBI</td>
</tr>
<tr>
<td>Pt: KEY, L. LYNDON</td>
<td>Project Dates: 9/30/2000-8/31/2005</td>
</tr>
<tr>
<td><strong>Bohning, Daryl</strong></td>
<td></td>
</tr>
<tr>
<td>Principal Investigator</td>
<td></td>
</tr>
<tr>
<td><em>Radiology</em></td>
<td></td>
</tr>
<tr>
<td>Award: (99102806)</td>
<td>Project Dates: 10/1/1999 - 9/30/2005</td>
</tr>
<tr>
<td><strong>Bolster, Marcy</strong></td>
<td></td>
</tr>
<tr>
<td>Principal Investigator</td>
<td></td>
</tr>
<tr>
<td>Co-Investigator</td>
<td></td>
</tr>
<tr>
<td><em>Medicine</em></td>
<td></td>
</tr>
<tr>
<td>Cardiovascular Disease Risk in Young Patients with RA</td>
<td>Sponsor: Amgen</td>
</tr>
<tr>
<td>Award: (03080603)</td>
<td>Project Dates: 7/1/2003 - 12/13/2004</td>
</tr>
<tr>
<td>NIAMS Clinical Research Center for Rheumatoid Disease</td>
<td>Sponsor: NIH/NIAMS</td>
</tr>
<tr>
<td>Pt: SILVER, RICHARD M.</td>
<td>Project Dates: 4/15/2003-3/31/2008</td>
</tr>
<tr>
<td>CHORD Fellowship</td>
<td>Sponsor: Arthritis Fdn.</td>
</tr>
<tr>
<td>Pt: KAMEN, DIANE</td>
<td>Project Dates: 7/1/2003-6/30/2005</td>
</tr>
<tr>
<td>Leah Triplet Rheumatology Fellowship</td>
<td>Sponsor: Thomas Mem. Hosp.</td>
</tr>
<tr>
<td>Pt: TRIPPLET, LEAH</td>
<td>Project Dates: 7/1/2003-6/30/2005</td>
</tr>
<tr>
<td>Scleroderma Lung Study</td>
<td>Sponsor: NIH/NHLBI</td>
</tr>
<tr>
<td>Pt: SILVER, RICHARD M.</td>
<td>Project Dates: 8/10/1999-6/30/2005</td>
</tr>
<tr>
<td><strong>Boockfor, Fredric</strong></td>
<td></td>
</tr>
<tr>
<td>Principal Investigator</td>
<td></td>
</tr>
<tr>
<td><em>Cell Biology &amp; Anatomy</em></td>
<td></td>
</tr>
<tr>
<td>A Molecular Dynamics Approach to GnRh Pulsatility</td>
<td>Sponsor: NIH/NICHD</td>
</tr>
<tr>
<td>Relaxin-Like Factor in Male Gonadal Development</td>
<td>Sponsor: NIH/NICHD</td>
</tr>
<tr>
<td>Pt: SCHWABE, CHRISTIAN</td>
<td>Project Dates: 4/1/2001-3/31/2006</td>
</tr>
<tr>
<td><strong>Book, Sarah</strong></td>
<td></td>
</tr>
<tr>
<td>Principal Investigator</td>
<td></td>
</tr>
<tr>
<td><em>Psychiatry &amp; Behavioral Sciences</em></td>
<td>Sponsor: NIH/NIAAA</td>
</tr>
<tr>
<td>Paroxetine for Social Anxiety Disorder and Alcoholism</td>
<td>Sponsor: NIH/NIAAA</td>
</tr>
<tr>
<td>Pt: RANDALL, CARRIE L.</td>
<td>Project Dates: 3/1/2002-2/28/2006</td>
</tr>
<tr>
<td><strong>Bowman, Michael</strong></td>
<td></td>
</tr>
<tr>
<td>Principal Investigator</td>
<td></td>
</tr>
<tr>
<td><em>Pediatrics</em></td>
<td></td>
</tr>
<tr>
<td>A Blinded, Multi-Center, Randomized, Placebo-Controlled Trial with Aztreonam for Inhalation (AI) in Cystic Fibrosis Patients with Lung Disease Due to P. Aeruginosa Infection</td>
<td>Sponsor: Salus Pharma, Inc.</td>
</tr>
</tbody>
</table>
**Bowman, Michael**
Principal Investigator

**Pediatrics**
Cystic Fibrosis Center - MUSC

- **Award:** CP-AI003 (03121703)
- **Project Dates:** 12/17/2003 - 9/30/2004
- **F&A:** $7,701

**Sponsor:** Cystic Fibrosis Fdn.

- **Award:** C104-03 (02082201)
- **Project Dates:** 7/1/2003 - 6/30/2004
- **Direct:** $48,337

**Boylan, Alice**
Principal Investigator

**Role of a Novel Oncogene in Mesothelioma**

- **Sponsor:** NIH/NIEHS
- **Budget Dates:** 7/1/2003 - 6/30/2004
- **Direct:** $166,250

- **Award:** C104-03 (02082201)
- **Project Dates:** 7/1/2003 - 6/30/2004
- **Direct:** $166,250

**Bradley, Anna**
Principal Investigator

**The Role of Thrombin and Its Receptor on Myofibroblast Differentiation in Scleroderma Lung Fibrosis**

- **Sponsor:** NIH/NIAAMS
- **Budget Dates:** 7/1/2003 - 6/30/2004
- **Direct:** $111,293

- **Award:** 5 K01 AR002220-04 (03090801)
- **Project Dates:** 9/1/2003 - 6/30/2008
- **F&A:** $76,475

**Bradshaw, Amy**
Principal Investigator

**SPARC Modulates Extracellular Matrix Dynamics in Skin**

- **Sponsor:** NIH/NIAAMS
- **Budget Dates:** 7/1/2003 - 6/30/2004
- **Direct:** $111,293

- **Award:** 5 K01 AR002220-04 (03090801)
- **Project Dates:** 9/1/2003 - 6/30/2008
- **F&A:** $76,475

**Brady, Kathleen**
Principal Investigator

**Genetics of Cocaine Dependence**

- **Sponsor:** Yale Univ.
- **Budget Dates:** 9/1/2003 - 9/30/2004
- **Direct:** $49,762

- **Award:** 1 R01 DA12849-02 (99012103)
- **Project Dates:** 9/1/2003 - 9/30/2004
- **F&A:** $21,398

**Placebo-Controlled Trial of Risperidone Augmentation for SSRI-Resistant Civilian PTSD**

- **Sponsor:** Janssen Medical Affairs, LLC
- **Budget Dates:** 5/1/2004 - 4/30/2006
- **Direct:** $172,292

- **Award:** RIS-EMR-4005 (04060103)
- **Project Dates:** 5/1/2004 - 4/30/2006
- **F&A:** $43,073

**Southeastern Node of the Clinical Trials Network: CTN-0018 and CTN-0019**

- **Sponsor:** NIH/NIDA
- **Budget Dates:** 9/1/2003 - 9/30/2004
- **Direct:** $413,046

- **Award:** 3 U10 DA013727-04S (04032306)
- **Project Dates:** 9/1/2003 - 9/30/2004
- **F&A:** $56,943

**Southeastern Node of the Clinical Trials Network**

- **Sponsor:** NIH/NIDA
- **Budget Dates:** 9/1/2003 - 9/30/2004
- **Direct:** $1,307,975

- **Award:** 3 U10 DA013727-04 (03062618)
- **Project Dates:** 9/1/2003 - 9/30/2004
- **F&A:** $392,075

**Clinical Investigation of Drug Abuse Disorders**

- **Sponsor:** NIH/NIDA
- **Budget Dates:** 8/1/2003 - 7/31/2004
- **Direct:** $79,968

- **Award:** 5 K24 DA000435-05 (03052907)
- **Project Dates:** 8/1/2003 - 7/31/2004
- **F&A:** $6,397

**ORWH: SCOR on Sex and Gender Factors Affecting Women's Health**

- **Sponsor:** NIH/NIDA
- **Budget Dates:** 12/1/2003 - 6/30/2004
- **Direct:** $27,029

- **Award:** 5 P50 DA016511-02 (03050502)
- **Project Dates:** 9/30/2000 - 6/30/2005
- **F&A:** $266,552

**Open-Label Treatment with Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients with Major Depression**

- **Sponsor:** Eli Lilly
- **Budget Dates:** 12/1/2003 - 5/31/2005
- **Direct:** $23,520

- **Award:** F1J-US-HMBZ (02123003)
- **Project Dates:** 12/1/2003 - 5/31/2005
- **F&A:** $5,880

**Alcohol Research Center-Treatment and Implications: Research Component 5: Post-Traumatic Stress Disorder and Alcoholism: The Role of the Hypothalamic-Pituitary-Adrenal Axis**

- **PI:** RANDALL, CARRIE L.
- **Sponsor:** NIH/NIAAA
- **Budget Dates:** 12/10/1995-11/30/2005
- **Direct:** $27,029

- **Award:** 5 P50 AA010761-09 (03121002-07)
- **Project Dates:** 12/10/1995-11/30/2005
- **F&A:** $11,622
**Psychiatry & Behavioral Sciences**

- **A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of GABITRIL at Dosages up to 16mg/day in the Treatment of Chronic Post-Traumatic Stress Disorder in Adults**
  - **PI:** SONNE, SUSAN
  - **Sponsor:** Cephalon, Inc.
  - **Direct:** $62,560
  - **Award:** C6671A/205/PT/US (03070702-01)
  - **F&A:** 15,640

- **Paroxetine Treatment in Outpatients with Comorbid PTSD and Substance Dependence**
  - **PI:** SONNE, SUSAN
  - **Sponsor:** GlaxoSmithKline
  - **Direct:** $8,960
  - **Project Dates:** 10/1/2002-7/31/2005
  - **Award:** CPMS 857 (02091702-02)
  - **F&A:** 2,240

- **Virtual Reality Cue Exposure for Crack Cocaine Dependence**
  - **PI:** SALADIN, MICHAEL E.
  - **Sponsor:** Virtually Better, Inc.
  - **Direct:** $24,687
  - **Project Dates:** 7/1/2003-6/30/2004
  - **Award:** R41-DA016462-01 (03121601)
  - **F&A:** 6,172

- **A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of GABITRIL, at Dosages up to 16 mg/day, in Adults with Chronic, Post-Traumatic Stress Disorder**
  - **PI:** SONNE, SUSAN
  - **Sponsor:** Cephalon, Inc.
  - **Direct:** $48,275
  - **Project Dates:** 7/21/2003-7/21/2004
  - **Award:** C6671A/302/PT/US (03082702)
  - **F&A:** 12,069

- **Evaluating the Safety and Efficacy of Aripiprazole in Patients with Schizophrenia and Comorbid Substance Use Disorder**
  - **PI:** MCRAE, AIMEE
  - **Sponsor:** Bristol Myers Squibb
  - **Direct:** $123,700
  - **Project Dates:** 5/1/2003-11/30/2004
  - **Award:** (03082504)
  - **F&A:** 30,925

- **Combined Pharmaco/Behavior Therapy in Adolescent Smokers**
  - **PI:** UPADHYAYA, HIMANSHU
  - **Sponsor:** NIH/NIDA
  - **Direct:** $225,000
  - **Project Dates:** 9/30/2003-6/30/2008
  - **Award:** 1 R01 DA017460-01 (03041101)
  - **F&A:** 103,500

- **CBT and Modafinil For Cocaine Addiction**
  - **PI:** MALCOLM, JR., ROBERT J.
  - **Sponsor:** NIH/NIDA
  - **Direct:** $271,637
  - **Project Dates:** 9/30/2003-6/30/2007
  - **Award:** 1 R01 DA016368-01A1 (03022404)
  - **F&A:** 107,862

**Medicine**

- **A 2x2 Factorial, Randomized, Phase III Study of Intermittent Oral Capecitabine in Combination with Intravenous Oxaliplatin (Q3W) (Xelox) with/without Intravenous Bevacizumab (Q3W) vs Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin (Q3W)**
  - **Sponsor:** Hoffman-LaRoche, Inc.
  - **Direct:** $165,690
  - **Award:** NO16966C (04070113)
  - **F&A:** 41,423

- **Phase II, Randomized, Open-Label Study Evaluating the Antitumor Activity of MEDI-522, A Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin, +/- Dacarbazine in Patients with Metastatic Melanoma**
  - **Sponsor:** Medimmune, Inc.
  - **Direct:** $46,223
  - **Budget Dates:** 3/17/2004 - 1/1/2005
  - **Award:** MI-CP095 (04021807)
  - **F&A:** 11,556

- **Understanding & Eliminating Health Disparities in Blacks**
  - **PI:** TILLEY, BARBARA
  - **Sponsor:** AHCPR/AHRQ
  - **Direct:** $1,583,666
  - **Project Dates:** 9/21/2000-8/31/2005
  - **Award:** 5 P01 HS010871-04 (03071008)
  - **F&A:** 574,732

**Radiology**

- **Vasodilator Induced Stress in CONcordance with Adenosine (VISION-301)**
  - **PI:** GORDON, LEONIE
  - **Sponsor:** King Pharmaceuticals
  - **Direct:** $181,456
  - **Project Dates:** 1/1/2004-1/1/2005
  - **Award:** MRE0470P-301 (03111408)
  - **F&A:** 45,364

**Surgery**

- **Obliteration of the Aneurysmal Sac in Abdominal Aortic Aneurysm in an Animal Model**
  - **PI:** UFLACKER, RENAN P.
  - **Sponsor:** Marine Polymer Technologies
  - **Direct:** $11,881
  - **Project Dates:** 5/2/2002-6/30/2004
  - **Award:** (02021202-03)
  - **F&A:** 5,109

**Dean's Office**

- **Functional Genomic Approach to Signal Transduction and Innate Immunity in Shrimp**
  - **PI:** WARR, GREGORY W.
  - **Sponsor:** NSF
  - **Direct:** $107,143
  - **Project Dates:** 8/15/2003-8/31/2006
  - **Award:** MCB-0315393 (03021801)
  - **F&A:** 27,857
Brown, Clark  
Principal Investigator

**Pediatrics**

*Optimizing Primary Stroke Prevention in SC Anemia Children-STOPPi*

- **Sponsor:** Medical Coll. of Georgia  
- **Budget Dates:** 7/1/2003 - 6/30/2004  
- **Direct:** $52,048  
- **Award:** 5 U01 HL52193-09 (03101404)  
- **Project Dates:** 7/1/2003 - 6/30/2004

**Genetic Risk Factors for Children with HB SS**

- **Sponsor:** Medical Coll. of Georgia  
- **Budget Dates:** 7/1/2003 - 6/30/2004  
- **Direct:** $5,500  
- **Award:** (03092512)

**Chlamydia Infection as a Risk Factor for Cerebrovascular Disease in Sickle Cell Anemia**

- **Sponsor:** Children's Hospital of Oakland  
- **Budget Dates:** 7/1/2003 - 6/30/2004  
- **Direct:** $18,000  
- **Award:** HL 069114-03 (03092508)

**A Phase III Study to Evaluate PEN 110-Treated Red Blood Cells in Chronically Transfused Patients**

- **Sponsor:** V.I. Technologies, Inc.  
- **Budget Dates:** 1/1/2003 - 12/31/2005  
- **Direct:** $980  
- **Award:** PEN110-0101 (02122001)

Brunson, Chris  
Co-Investigator

**Medicine**

*A Prospectively Randomized, Phase III, Multi-Center, Controlled Trial to Evaluate the Safety and Efficacy of Zevalin TM Therapeutic Regimen Plus Rituxan Compared with Rituxan Alone in Patients with Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma*

- **PI:** SPICER, KENNETH M.  
- **Budget Dates:** 7/30/2003-7/31/2007  
- **Direct:** $192,000  
- **Award:** Idec Pharmaceuticals Corp.  
- **Project Dates:** 7/30/2003-7/31/2007

**Inflammatory Control of Erythropoiesis in Sickle Disease**

- **PI:** MEANS, ROBERT  
- **Budget Dates:** 9/30/2001-7/31/2005  
- **Direct:** $125,000  
- **Award:** NIH/NHLBI  
- **Project Dates:** 9/30/2001-7/31/2005

Bryant, Deborah  
Co-Investigator

**Otolaryngology**

*Auditory Analysis and Speech Recognition*

- **PI:** DUBNO, JUDY R.  
- **Budget Dates:** 12/1/1981-1/31/2006  
- **Direct:** $227,500  
- **Award:** NIH/NIDCD  
- **Project Dates:** 12/1/1981-1/31/2006

**Experimental and Clinical Studies of Presbyacusis**

- **PI:** MILLS, JOHN H.  
- **Budget Dates:** 7/1/1987-6/30/2007  
- **Direct:** $1,060,058  
- **Award:** NIH/NIDCD  
- **Project Dates:** 7/1/1987-6/30/2007

Bullesbach, Erika  
Co-Investigator

**Biochemistry & Molecular Biology**

*Relaxin-Like Factor in Male Gonadal Development*

- **PI:** SCHWABE, CHRISTIAN  
- **Budget Dates:** 4/1/2001-3/31/2006  
- **Direct:** $180,000  
- **Award:** NIH/NICHD  
- **Project Dates:** 4/1/2001-3/31/2006

Buse, Maria  
Principal Investigator

**Medicine**

*Factors That Modify Insulin Action*

- **PI:** MAINOUS, ARCH  
- **Budget Dates:** 5/1/2004-7/30/2005  
- **Direct:** $174,376  
- **Award:** NIH/NIDDK  
- **Project Dates:** 5/1/2004-7/30/2005

Campbell, Jeffrey  
Principal Investigator

**Neurological Surgery**

*Community Demonstration Program to Increase Booster Seat Use Among Older Children*

- **PI:** Think First Fdn.  
- **Budget Dates:** 10/1/2003 - 9/30/2004  
- **Direct:** $19,036  
- **Award:** DTHH22-03-H-05154 (04060701)  
- **Project Dates:** 10/1/2003 - 9/30/2004

Cantey, J.  
Principal Investigator

**Medicine**

*Ryan White CARE Act Title II (Trident)*

- **PI:** MAINOUS, ARCH  
- **Budget Dates:** 4/1/2004-3/31/2005  
- **Direct:** $1,121,828  
- **Award:** DHEC  
- **Project Dates:** 4/1/2004-3/31/2005

Carek, Peter  
Co-Investigator

**Family Medicine**

*Faculty Development in Primary Care*

- **PI:** MAINOUS, ARCH  
- **Budget Dates:** 7/1/2002-6/30/2005  
- **Direct:** $265,638  
- **Award:** HRSA/BHP/Medicine  
- **Project Dates:** 7/1/2002-6/30/2005
Carpenter, Hyland, Ezekiel
Principal Investigator

**Physiology and Neuroscience**

**Ethanol and Synaptic Plasticity**

**Sponsor:** NIH/NIAAA  
**Award:** 5 F31 AA013355-03 (03052906)  
**Budget Dates:** 8/16/2003 - 8/15/2004  
**Direct:** $25,218  
**F&A:** 0

**Principal Investigator**

Carter, Cindy
Co-Investigator

**Radiation Oncology**

**Understanding & Eliminating Health Disparities in Blacks**

**PI:** TILLEY, BARBARA  
**Sponsor:** AHCPR/AHRQ  
**Award:** 5 P01 HS010871-04 (03071008)  
**Project Dates:** 8/16/2001 - 8/15/2004  
**Direct:** $1,583,666  
**F&A:** 574,732

**Co-Investigator**

Carter, James
Co-Investigator

**Obstetrics/Gynecology**

**The Validation of the Menstrual Pictogram Against the Alkaline Hematin Method in Measuring Menstrual Blood Loss in Women with Uterine Leiomyomata**

**PI:** SOPER, DAVID  
**Sponsor:** Tap Pharmaceuticals, Inc.  
**Award:** C03-061/TAP-03-00423 (04041501)  
**Project Dates:** 5/1/2004-4/30/2005  
**Direct:** $37,600  
**F&A:** 0

**Co-Investigator**

Carter, Rickey
Principal Investigator

**Biostatistics, Bioinformatics & Epidemiology**

**ALS Creative Study**

**Reporting Department:** Health Professions  
**Sponsor:** Carolinas Healthcare  
**Award:** 30282 (03031102)  
**Budget Dates:** 12/1/2002 - 2/25/2006  
**Direct:** $15,000  
**F&A:** 0

**Principal Investigator**

Carter, Timothy
Principal Investigator

**Neurology**

**PRoFESS-Prevention Regimen for Effectively Avoiding Second Strokes: A Double-Blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel + Aspirin, With and Without Micardis**

**Sponsor:** Boehringer Ingelheim Pharmaceuticals  
**Award:** PROTOCOL 9.159 (03111002)  
**Project Dates:** 2/5/2004 - 9/30/2007  
**Direct:** $27,600  
**F&A:** 6,900

**Principal Investigator**

Castell, Donald
Principal Investigator

**Medicine**

**Use of Combined Multi-Channel Intraluminal Impedance to Evaluate the Effects of Prokinetic Agents on Esophageal Function and Gastroesophageal Reflux**

**Sponsor:** Pfizer, Inc.  
**Award:** (04063006)  
**Budget Dates:** 6/1/2004 - 6/30/2004  
**Direct:** $130,554  
**F&A:** 32,638

**Comparison of Clinical Innovations CI Catheter with Solid State Catheters for Validation**

**Sponsor:** Clinical Innovations  
**Award:** (04030313)  
**Budget Dates:** 3/1/2004 - 3/31/2004  
**Direct:** $33,700  
**F&A:** 8,425

**A Multi-Center, Open-Label Trial to Evaluate the Safety of OSB-IR 40 mg in Patients with Benign Gastric or Duodenal Ulcers, Symptomatic Gastroesophageal Reflux Disease (GERD) or Erosive Esophagitis (EE)**

**Sponsor:** TKL Research  
**Award:** (03120108)  
**Budget Dates:** 11/1/2003 - 3/31/2004  
**Direct:** $32,000  
**F&A:** 8,000

**Extension of SWAL-QOL for Use in Esophageal Dysphagia**

**Sponsor:** VAMC  
**Award:** (03071006)  
**Budget Dates:** 7/1/2003 - 6/30/2004  
**Direct:** $27,543  
**F&A:** 0

**MII to Characterize Reflux in Barrett's Esophagus**

**Sponsor:** NIH/NIDDK  
**Award:** 1 R21 DK065154-01A (03062606)  
**Budget Dates:** 6/1/2004 - 4/30/2005  
**Direct:** $36,243  
**F&A:** 41,400
CASTELL

**College of Medicine**

**Castell, Donald**
Principal Investigator

**Medicine**
Effect of Inflammation on Esophageal Motility

- **Sponsor:** MCP Hahnemann Univ.
- **Budget Dates:** 4/1/2003 - 3/31/2005
- **Award:** 220192/5 R01 DK571 (03012801)
- **Direct:** $57,223
- **F&A:** $14,343

**Chandler, L.**
Principal Investigator

**Physiology and Neuroscience**
Ethanol and ERK/PKB Signaling in Brain

- **Sponsor:** NIH/NIAAA
- **Budget Dates:** 5/1/2004 - 4/30/2005
- **Award:** 5 R01 AA010983-08 (04050304)
- **Direct:** $225,000
- **F&A:** 103,500

Ethanol and Glutamate Receptor Regulation of Dendritic Spine Dynamics

- **Sponsor:** Alcoholic Bev. Medical Research Fnd.
- **Budget Dates:** 1/1/2004 - 12/31/2004
- **Direct:** $34,609
- **F&A:** 5,191

**Chang, Eugene**
Co-PI or Project Leader

**Obstetrics/Gynecology**
Platelet Function and PreEclampsia

- **PI:** LAZARCHICK, JOHN
- **Sponsor:** Helena Laboratories
- **Director:** $13,732
- **F&A:** 3,433

**Chao, Julie**
Principal Investigator

**Biochemistry & Molecular Biology**
Kallistatin in Hypertension

- **Sponsor:** NIH/NHLBI
- **Budget Dates:** 7/1/2003 - 6/30/2004
- **Award:** 0256305U (02011608)
- **Direct:** $172,890
- **F&A:** 76,072

Regulation and Function of Tissue Kallikrein

- **Sponsor:** NIH/NHLBI
- **Budget Dates:** 7/1/2003 - 6/30/2004
- **Award:** 2 R01 HL029397-21 (02102502)
- **Direct:** $225,000
- **F&A:** 103,500

Adrenomedullin Signaling in Cardiomyocyte Apoptosis

- **Sponsor:** Amer. Heart Assoc./Mid-Atlantic
- **Budget Dates:** 7/1/2003 - 6/30/2004
- **Award:** 1 P01 CA97132-01A1 (01100808)
- **Direct:** $60,000
- **F&A:** 318,811

**Co-PI or Project Leader**

SC COBRE in Lipidomics and Pathobiology - Core D: Protein Science Core

- **PI:** OBEID, LINA
- **Sponsor:** NIH/NCRR
- **Budget Dates:** 9/26/2002-6/30/2007
- **Award:** 5 P20 RR017677-02 (03071704-11)
- **Direct:** $177,348
- **F&A:** 81,580

**Co-Investigator**

Sphingolips in Cancer Therapy and Angiogenesis

- **PI:** HANNUN, YUSUF
- **Sponsor:** NIH/NCI
- **Budget Dates:** 8/1/2003-7/31/2008
- **Award:** 1 P01 CA97132-01A1 (01100808)
- **Direct:** $715,167
- **F&A:** 318,811

**Chao, Lee**
Co-Investigator

**Biochemistry & Molecular Biology**
Regulation and Function of Tissue Kallikrein

- **PI:** CHAO, JULIE
- **Sponsor:** NIH/NHLBI
- **Budget Dates:** 7/1/1986-6/30/2007
- **Award:** 2 R01 HL029397-21 (02102502)
- **Direct:** $225,000
- **F&A:** 103,500

**Chapman, Robert**
Principal Investigator

**Dean’s Office**
SC InterAgency Contract Agreement for Matthew Jenny

- **Sponsor:** SC Dept. of Natural Resources
- **Budget Dates:** 1/2/2004 - 8/31/2004
- **Award:** 04 030825 (03111307)
- **Direct:** $2,000
- **F&A:** 520

SC InterAgency Contract Agreement for Joan Colglazier

- **Sponsor:** SC Dept. of Natural Resources
- **Budget Dates:** 11/15/2003 - 8/31/2004
- **Award:** 04 030881 (03111305)
- **Direct:** $41,145
- **F&A:** 10,697

**EPA Fellowship Award**

- **Sponsor:** EPA
- **Budget Dates:** 8/1/2003 - 7/31/2004
- **Award:** U-91618501-0 (03061602)
- **Direct:** $22,995
- **F&A:** 0

**Chaptiaux, Nicolas**
Principal Investigator

**Physiology and Neuroscience**
The Role of Nicotinic Receptors Activation in Behavioral Sensitization to Cocaine

- **Sponsor:** Philip Morris, Inc.
- **Budget Dates:** 1/1/2004 - 12/31/2004
- **Award:** (03010709)
- **Direct:** $40,000
- **F&A:** 3,200

---

Annual Report for Research FY04 41
Pediatrics

Population Based Surveillance of Autism Spectrum Disorders and Other Developmental Disabilities
Sponsor: CDC
Direct: $302,709
Award: U3/CCU418882-04 (03051405)
F&A: 139,246

Charles, Jane
Principal Investigator

A Program to Increase Living Donations in African Americans
Sponsor: NIH/NIDDK
Direct: $150,000
Award: 5 R01 DK062596-02 (03050204)
F&A: 69,000

Chavin, Kenneth
Co-Investigator

Drug Interactions and Bioavailability of Cranberry
Sponsor: NIH/NCCAM
Budget Dates: 1/6/2004-12/31/2005
Direct: $150,000
Award: 1 R21 AT002073-01 (03051607)
Project Dates: 1/6/2004-12/31/2005
F&A: 41,423

Chaudhary, Uzair
Principal Investigator

A Phase I Study of Concurrent Docetaxel with Radiation Therapy and Hormonal Therapy for Clinically Localized High Risk Prostate Cancer
Sponsor: Aventis Pharmaceutical, Inc.
Direct: $84,260
Award: IIT16159 (04060702)
F&A: 21,065

Cheek, Deanna
Principal Investigator

A Phase II/III, Multi-Center, Randomized, Double-Blind Study of Docetaxel Plus DN-101 or Placebo in Androgen Independent Prostate Cancer (AIPC)
Sponsor: Novacea
Budget Dates: 10/10/2003 - 10/10/2004
Direct: $46,810
Award: DN101-002 (03103007)
Project Dates: 10/10/2003 - 10/10/2005
F&A: 11,703

Chiaramida, Salvatore
Principal Investigator

Clinical Investigation of Spinal Cord Stimulation for the Treatment of Refractory Angina
Sponsor: Medtronic, Inc.
Budget Dates: 7/1/2003 - 12/31/2005
Direct: $54,600
Award: 1569 (03061207)
Project Dates: 7/1/2003 - 12/31/2005
F&A: 13,650

A 2x2 Factorial, Randomized, Phase III Study of Intermittent Oral Capecitabine in Combination with Intravenous Oxaliplatin (Q3W) (Xelox) with/without Intravenous Bevacizumab (Q3W) vs Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin with/without Intravenous Bevacizumab (Q3W) vs Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin (Q3W) vs Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin (Q3W) vs Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin (Q3W) vs Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin
Pt: BRESCIA, FRANK J.
Sponsor: Hoffman-Laroche, Inc.
Direct: $165,690
Award: NO16966C (04070113)
F&A: 41,423

Co-PI or Project Leader

A 2x2 Factorial, Randomized, Phase III Study of Intermittent Oral Capecitabine in Combination with Intravenous Oxaliplatin (Q3W) (Xelox) with/without Intravenous Bevacizumab (Q3W) vs Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin (Q3W) vs Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin (Q3W) vs Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin (Q3W) vs Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin (Q3W) vs Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin (Q3W) vs Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin
Pt: BRESCIA, FRANK J.
Sponsor: Hoffman-Laroche, Inc.
Direct: $165,690
Award: NO16966C (04070113)
F&A: 41,423

Co-Investigator
<table>
<thead>
<tr>
<th>Name</th>
<th>College/Department</th>
<th>Project Title</th>
<th>PI Name</th>
<th>Sponsor</th>
<th>Direct Costs</th>
<th>F&amp;A Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chiaramida, Salvatore</td>
<td>Medicine</td>
<td>A Multi-Center, Pilot Study to Evaluate the Efficacy of Adenoscan R (Adenosine) as a Pharmacologic Stress Agent to Assess Coronary Artery Disease by Myocardial Perfusion Using Contrast Enhanced MRI in Comparison to Conventional X-Ray Angiography</td>
<td>Spicer, Kenneth M.</td>
<td>Fujisawa Healthcare, Inc.</td>
<td>$70,000</td>
<td>$17,500</td>
</tr>
<tr>
<td>Church, L. W.</td>
<td>Medicine</td>
<td>Expanding Existing Surveillance Systems to Include Pfiesteria, Other Harmful Algal Blooms and Marine Toxins</td>
<td>Spicer, Kenneth M.</td>
<td>CDC-CHURCH-V2C5 (04010903)</td>
<td>$10,000</td>
<td>$4,600</td>
</tr>
<tr>
<td>Clancy, Dawn</td>
<td>Medicine</td>
<td>Understanding &amp; Eliminating Health Disparities in Blacks - Pilot Study 1: Implementing Successful Managed Care Models of Healthcare Delivery in a Medically Underserved African American Patient Population with Type 2 Diabetes</td>
<td>Spicer, Kenneth M.</td>
<td>AHCPR/AHRQ</td>
<td>$58,728</td>
<td>$25,253</td>
</tr>
<tr>
<td>Cochran, Joel</td>
<td>Pediatrics</td>
<td>A Randomized, Blinded Study of Infasurf (Calfactant in Acute Pediatric Respiratory Failure)</td>
<td>Churchill, L. W.</td>
<td>Ony, Inc.</td>
<td>$2,927</td>
<td>$673</td>
</tr>
<tr>
<td>Cole, David</td>
<td>Surgery</td>
<td>In Vivo Effector Cell Response to Peptide Vaccination</td>
<td>Reed, Carolyn E.</td>
<td>NIH/NCI</td>
<td>$157,500</td>
<td>$7,250</td>
</tr>
<tr>
<td>Collins, Beth</td>
<td>Obstetrics/Gynecology</td>
<td>Evaluation of Vitamin D Requirements During Pregnancy</td>
<td>Hollis, Bruce W.</td>
<td>NIH/NICHD</td>
<td>$382,526</td>
<td>$155,995</td>
</tr>
<tr>
<td>Colwell, John</td>
<td>Medicine</td>
<td>Genetics of Kidney in Diabetes (GoKinD)</td>
<td>Gillanders, William E.</td>
<td>George Washington Univ.</td>
<td>$44,459</td>
<td>$4,446</td>
</tr>
<tr>
<td>Contreras, Miquel</td>
<td>Pediatrics</td>
<td>Fatty Acid Oxidation in X-Linked Adrenoleukodystrophy</td>
<td>Singh, Inderjit</td>
<td>NIH/NINDS</td>
<td>$365,092</td>
<td>$151,920</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fatty Acid Oxidation in X-Linked Adrenoleukodystrophy</td>
<td>Singh, Inderjit</td>
<td>NIH/NINDS</td>
<td>$34,636</td>
<td>$15,933</td>
</tr>
<tr>
<td>Cook, James</td>
<td>Physiology and Neuroscience</td>
<td>Role of Eicosanoids in Shock</td>
<td>Singh, Inderjit</td>
<td>NIH/NGMS</td>
<td>$247,596</td>
<td>$105,279</td>
</tr>
</tbody>
</table>

Annual Report for Research FY04 43
<table>
<thead>
<tr>
<th>Faculty Activity by College</th>
<th>Medical University of South Carolina</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cooper, George</strong></td>
<td>Principal Investigator</td>
</tr>
<tr>
<td><strong>Medicine</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Basic Mechanisms of Cardiac Hypertrophy and Failure</strong></td>
<td>Sponsor: VAMC Merit Award</td>
</tr>
<tr>
<td>Award: REAP-111-98F (03063017)</td>
<td>Project Dates: 10/1/1999 - 9/30/2004</td>
</tr>
<tr>
<td>Direct: $212,500</td>
<td>F&amp;A: 0</td>
</tr>
<tr>
<td><strong>Growth Regulation of Adult Cardiac Muscle Cells</strong></td>
<td>Sponsor: VAMC Merit Award</td>
</tr>
<tr>
<td>Award: CARD-007-00S (03063006)</td>
<td>Project Dates: 10/1/2000 - 9/30/2005</td>
</tr>
<tr>
<td>Direct: $140,000</td>
<td>F&amp;A: 0</td>
</tr>
<tr>
<td><strong>Load-Induced Cardiac Hypertrophy in the Adult Mammal</strong></td>
<td>Sponsor: NIH/NHLBI</td>
</tr>
<tr>
<td>Award: 2 P01 HL048788-11 (03012709)</td>
<td>Project Dates: 8/1/1993 - 7/31/2008</td>
</tr>
<tr>
<td><strong>Co-Investigator</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Cotton, Peter</strong></td>
<td>Principal Investigator</td>
</tr>
<tr>
<td><strong>Medicine</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Multi-Center, Prospective, Randomized, Controlled Trial of the Nitinol Zilver Expandable Endoprosthesis in the Palliation of Extrahepatic Malignant Biliary Obstruction (MOZARTI)</strong></td>
<td>Sponsor: Wilson Cook</td>
</tr>
<tr>
<td>Award: 03-M02-03 (03082502)</td>
<td>Project Dates: 10/1/2000 - 9/30/2004 Direct: $6,000</td>
</tr>
<tr>
<td><strong>Boston Scientific Fellowship IV</strong></td>
<td>Sponsor: Boston Scientific Corp.</td>
</tr>
<tr>
<td>Award: (03072507)</td>
<td>Project Dates: 8/1/2003 - 12/31/2004 Direct: $46,296</td>
</tr>
<tr>
<td><strong>Co-Investigator</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Cowart, Lauren</strong></td>
<td>Principal Investigator</td>
</tr>
<tr>
<td><strong>Medicine</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Spingolipid-Dependent Transcriptional Responses to Heat</strong></td>
<td>Sponsor: NIH/NIGMS</td>
</tr>
<tr>
<td><strong>Obstetrics/Gynecology</strong></td>
<td></td>
</tr>
<tr>
<td><strong>A Multi-Center, Randomized, Phase III, Comparative Study to Compare the Efficacy and Safety of Taxotere/Carboplatin Combination Therapy Versus Sequential Therapy with Taxotere then Carboplatin as Second-Line Treatment of Patients with Relapsed, Platinum-Resistant Ovarian Cancer</strong></td>
<td>Sponsor: PPD Development</td>
</tr>
<tr>
<td>Award: DUMC 03 (03122203-01)</td>
<td>Project Dates: 12/22/2003-12/1/2006 Direct: $39,600</td>
</tr>
<tr>
<td><strong>Creasman, William</strong></td>
<td>Co-PI or Project Leader</td>
</tr>
<tr>
<td><strong>Ophthalmology</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Core Resources for Vision Research at MUSC</strong></td>
<td>Sponsor: NIH/NEI</td>
</tr>
<tr>
<td><strong>Adenosine Agonists: Potential Antiglaucoma Agents</strong></td>
<td>Sponsor: NIH/NEI</td>
</tr>
<tr>
<td><strong>Crouch, Rosalie</strong></td>
<td>Principal Investigator</td>
</tr>
<tr>
<td><strong>Ophthalmology</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Synthetic Retinal Pigments and Binding Proteins</strong></td>
<td>Sponsor: NIH/NEI</td>
</tr>
<tr>
<td>Award: 5 R01 EY004939-21 (04020302)</td>
<td>Project Dates: 4/1/2002 - 3/31/2006 Direct: $250,000</td>
</tr>
<tr>
<td><strong>Synthetic Retinal Pigments and Binding Proteins - Supplement</strong></td>
<td>Sponsor: NIH/NEI</td>
</tr>
<tr>
<td><strong>Co-Investigator</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Transgenic Rod Development and Function</strong></td>
<td>Sponsor: NIH/NEI</td>
</tr>
<tr>
<td>Award: 1 R03 EY013728-01A (02030509)</td>
<td>Project Dates: 7/1/2003-6/30/2006 Direct: $100,000</td>
</tr>
<tr>
<td>Name</td>
<td>College</td>
</tr>
<tr>
<td>---------------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>Cunningham, Phillipe</td>
<td>College of Medicine</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Darby, Charles</td>
<td></td>
</tr>
<tr>
<td>Darden, Paul</td>
<td></td>
</tr>
<tr>
<td>Davies, Christopher</td>
<td></td>
</tr>
<tr>
<td>De Arellano, Michael</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## College of Medicine

### Psychiatry & Behavioral Sciences

#### Child and Adult Trauma Victims: A Training Program
- **PI:** KILPATRICK, DEAN G.  
- **Sponsor:** NIH/NIMH  
- **Direct:** $209,370  
- **Project Dates:** 1/1/1988-6/30/2008  
- **Award:** 2 T32 MH018869-16 (02050903)  
- **F&A:** $15,190

#### Naltrexone Treatment of Adolescent Alcoholics
- **Sponsor:** NIH/NIAAA  
- **Budget Dates:** 9/1/2003 - 8/31/2004  
- **Direct:** $277,918  
- **Award:** 5 R01 AA13933-02 (03071405)  
- **Direct:** $8,000  
- **Award:** A0501061 (02050903)

#### A Multi-Center, 10-Week, Randomized, Double-Blind Study of Sertraline and Placebo in Children and Adolescents with Post Traumatic Stress Disorder (PTSD)
- **Sponsor:** Pfizer, Inc.  
- **Budget Dates:** 11/1/2002 - 10/31/2004  
- **Direct:** $8,000  
- **Award:** A0501061 (02050903)

#### Combined Pharmacotherapy in Adolescent Smokers
- **PI:** UPADHYAYA, HIMANSHU  
- **Sponsor:** NIH/NIDA  
- **Direct:** $225,000  
- **Project Dates:** 9/30/2003-6/30/2008  
- **Award:** 1 R01 DA017460-01 (03041101)

#### Linkage Disequilibrium Studies of Alcohol Dependence
- **PI:** ANTON, JR., RAYMOND F.  
- **Sponsor:** Yale Univ.  
- **Direct:** $94,673  
- **Project Dates:** 5/1/2002-4/30/2007  
- **Award:** 5 R01 AA11330-05 (03010302)

### Biochemistry & Molecular Biology

#### Spingolipid-Mediated Fungal Pathogenesis
- **Sponsor:** NIH/NIAID  
- **Budget Dates:** 2/1/2004 - 1/31/2005  
- **Direct:** $200,000  
- **Award:** 1 R01 AI056168-01A1 (03062602)

#### Role of Ipc 1 in Fungal Pathogenesis
- **Sponsor:** NIH/NIAID  
- **Budget Dates:** 9/15/2003 - 8/31/2004  
- **Direct:** $86,480  
- **Award:** 1 R01 AI051924-01A1 (02022714)

#### Roles for Inositol Phosphoryl Ceramide Synthase 1 (IPC1) in Fungal-Host Interaction
- **Sponsor:** Burroughs Wellcome Fdn.  
- **Budget Dates:** 7/1/2003 - 6/30/2004  
- **Direct:** $80,000  
- **Award:** 1003642 (01103103)

### Medicine

#### Endoscopic Implantation of Enteryx for the Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD)
- **Sponsor:** Boston Scientific Corp.  
- **Budget Dates:** 8/1/2003 - 12/31/2007  
- **Direct:** $8,076  
- **Award:** 302-1001 (03091801)

#### A Study to Further Assess the Efficacy of Bowel Preparation with the Use of a Pre-Packed Diet/Bowel Prep Kit Versus Usual and Customary Bowel Preparation for Colonoscopy
- **Sponsor:** Ezem, Inc.  
- **Budget Dates:** 3/1/2001 - 6/30/2003  
- **Direct:** $1,540  
- **Award:** EZEM-01-001 (01042603)

### Pediatrics

#### Myocyte Proliferation in the Embryonic Chick Heart
- **PI:** THOMPSON, ROBERT P.  
- **Sponsor:** NIH/NHLBI  
- **Direct:** $200,000  
- **Project Dates:** 7/1/1993-2/28/2008  
- **Award:** 2 R01 HL050582-10A1 (03030704)

### Psychiatry & Behavioral Sciences

#### Specialized Centers of Research on Sex and Gender Affecting Women's Health
- **Sponsor:** Emory Univ.  
- **Budget Dates:** 8/1/2003 - 7/31/2007  
- **Direct:** $110,432  
- **Award:** 1 P50 MH68036-01 (02031408)

#### Atypical Antipsychotic Drug Interactions with P-Glycoprotein (Pgp)
- **Sponsor:** Astrazeneca  
- **Budget Dates:** 7/1/2000 - 6/30/2001  
- **Direct:** $1,626  
- **Award:** (00072112)
MARKOWITZ

Devane, C.
Co-PI or Project Leader

Psychiatry & Behavioral Sciences
Pharmacokinetics of Olanzapine after Oral Administration of Standard Tablet Versus Normal and Sublingual Administration of Orally Disintegrating Tablets (Zyprexa-Zydis) in Healthy Adults
Pt: MARKOWITZ, JOHN S. Sponsor: Eli Lilly Direct: $75,850

Co-Investigator

Is Catechin Absorption Passive or Carrier Mediated?
Pt: DONOVAN, JENNIFER Sponsor: Nestec, Inc. Direct: $34,048
Project Dates: 11/26/2003-7/1/2004 Award: (03092403) F&A: 15,662

Dobson, Joseph
Co-Investigator

Pediatrics
A Randomized, Double-Blind, Clinical Study of Continuous Nebulization of Levalbuterol, in Comparison to Racemic-Albuterol, in a Cohort of Pediatric Patients with Status Asthmaticus
Pt: SCHAFFER, FREDERICK Sponsor: Sepracor, Inc. Direct: $80,880

Donald, Carlton
Principal Investigator

Pathology & Laboratory Medicine
Role of Mitochondrial DNA Damage in Cancer Disparities among African-Americans

Functional Analysis of Beta-Defensin Loss of Expression

Dong, Jianyun
Principal Investigator

Microbiology & Immunology
Salary Subcontract
Award: (04012110) Project Dates: 7/1/2003 - 6/30/2004 F&A: 15,105

Persistent Adeno-EBV Vectors for Gene Therapy
Award: 5 R01 DK057997-03 (03040106) Project Dates: 7/1/2003 - 6/30/2005 F&A: 58,050

Development of an HIV Drug Resistance Test; 2) Further Development of a Method forTreating Tumors Using FAS-L and TRAIL Induced Apoptosis; 3) Collection of Data from Small Animals Regarding GenPhar's Pending Patent on Genetic Vaccines; and 4) Assist wit

GenPhar Trainee Scholarship Program
Award: 890 (01080803) Project Dates: 7/1/2001 - 6/30/2003 F&A: 6,296

Co-Investigator

Viral Vector Core Facility
Pt: NORRIS, JAMES S. Sponsor: NIH/NCI Direct: $101,278

Donovan, Jennifer
Principal Investigator

Psychiatry & Behavioral Sciences
Is Catechin Absorption Passive or Carrier Mediated?
Award: (03092403) Project Dates: 11/26/2003 - 7/1/2004 F&A: 15,662
Donovan, Jennifer

Principal Investigator

Psychiatry & Behavioral Sciences

Drug Interactions and Bioavailability of Cranberry

Sponsor: NIH/NCCAM
Award: 1 R21 AT002073-01 (03051607)

Direct: $150,000

Project Dates: 1/6/2004 - 12/31/2005
F&A: 54,841

Specialized Centers of Research on Sex and Gender Affecting Women's Health

Pt: DEVANE, C. LINDSAY
Sponsor: Emory Univ.

Direct: $110,432

Donovan, Jennifer

Cell Biology & Anatomy

Cardiac Valvuloseptal Morphogenesis-Project 3: Vascular Signals and Receptors in Endocardial Morphogenesis

Pt: DEVANE, C. LINDSAY
Sponsor: Emory Univ.

Direct: $110,432

Donovan, Jennifer

Medicine

Antegren under Protocol ELN 100226-CD307

Pt: HOFFMAN, BRENDA J.
Sponsor: Elan Pharmaceuticals

Direct: $57,000

Project Dates: 1/6/2004 - 12/31/2005
F&A: 14,250

Dowdle, Merriman

Co-Investigator

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, 52-Week, Dose Comparison Study of the Efficacy and Safety of 25mg QD and 50mg QD of OPC 6535 Oral Tablets and 800mg BID of Asacol in the Maintenance of Remission in Ulce

Pt: HOHN, ROGER R.
Sponsor: Icon Clinical Research, Inc.

Direct: $45,922

F&A: 11,481

Drake, Christopher

Principal Investigator

Cell Biology & Anatomy

Cytokine Regulation of Early Events in Blood Vessel Form

Sponsor: NIH/NHLBI
Award: 5 R01 HL057375-07 (04020410)

Direct: $150,000

F&A: 69,000

Cardiac Valvuloseptal Morphogenesis-Project 3: Vascular Signals and Receptors in Endocardial Morphogenesis

Pt: MARKWALD, ROGER R.
Sponsor: NIH/NHLBI

Direct: $204,437

F&A: 72,808

TROJANOWSKA, MARIA E.

Mechanisms of Endothelial Cell Damage in Scleroderma

Pt: TROJANOWSKA, MARIA E.
Sponsor: NIH/NIAMS

Selection: 9/30/2003-5/31/2005
Direct: $100,000

Project Dates: 9/30/2003-5/31/2005
F&A: 46,000

Mechanisms of Endothelial Cell Damage in Scleroderma

Pt: TROJANOWSKA, MARIA E.
Sponsor: NIH/NIAMS

Selection: 9/30/2003-5/31/2005
Direct: $100,000

Project Dates: 9/30/2003-5/31/2005
F&A: 46,000

OGAWA, MAKIO

Mechanisms of Endothelial Cell Damage in Scleroderma

Pt: OGAWA, MAKIO
Sponsor: NIH/NHLBI

Direct: $250,000

F&A: 65,000

Sphingolipids in Cancer Therapy and Angiogenesis

Pt: HANNUN, YUSUF
Sponsor: NIH/NCI

Selection: 8/1/2003-7/31/2008
Direct: $715,167

Project Dates: 8/1/2003-7/31/2008
F&A: 318,811

HANNUN, YUSUF
Dubno, Judy
Principal Investigator

Otolaryngology
Auditory Analysis and Speech Recognition
Sponsor: NIH/NIDCD
Award: 5 R01 DC000184-23 (03112007)
Budget Dates: 2/1/2004 - 1/31/2005
F&A: $97,825
Direct: $227,500

Symposia for Association for Research in Otolaryngology
Sponsor: NIH/NIDCD
Award: 5 R13 DC000275-20 (03061007)
F&A: 0
Direct: $39,278
Project Dates: 9/1/1999 - 8/31/2004

Egan, Brent
Principal Investigator

Medicine
TROPHY: Trial of Preventing Hypertension
Sponsor: Astrazeneca
Award: 197 (99061101)
Budget Dates: 4/1/1999 - 6/30/2005
F&A: $8,564
Direct: $37,233
Project Dates: 4/1/1999 - 6/30/2005

ACCOMPLISH-Avoiding Cardiovascular Events Through Combination Therapy in Patients with Systolic Hypertension
Sponsor: Novartis Corp.
Award: COIB002123 (04042801)
Budget Dates: 4/1/2004 - 6/1/2005
F&A: $63,140
Direct: $252,560
Project Dates: 4/1/2004 - 6/1/2005

Durkalski, Valerie
Principal Investigator

Biostatistics, Bioinformatics & Epidemiology
Smoking Cessation Study
Sponsor: Duke Univ.
Award: (04063010)
F&A: $13,548
Direct: $29,452

Fatty Acids, Angiotensin and Oxidative Stress
Sponsor: NIH/NHLBI
Award: 5 R01 HL058794-06 (04021706)
Budget Dates: 4/1/2004 - 6/1/2005
F&A: 0
Direct: $333,870
Project Dates: 4/1/2004 - 6/1/2005

Hypertension Initiative of South Carolina
Sponsor: SC DHEC
Award: CY-04-046 (03121001)
F&A: 0
Direct: $40,000

Leveraging the Impact of the Clinical Hypertension Specialist in the Local Community
Sponsor: Duke Endowment
Award: 4815-SP (02082602)
Budget Dates: 7/1/2002 - 6/30/2005
F&A: 0
Direct: $1,778
Project Dates: 7/1/2002 - 6/30/2005

Understanding & Eliminating Health Disparities in Blacks - Project 1: Reducing the Racial Disparity in CV Disease through Better BP Control
Sponsor: AHCPR/AHRQ
Award: 5 P01 HS010871-04 (03071008-04)
Budget Dates: 9/21/2000 - 8/31/2005
F&A: $153,351
Direct: $356,633
Project Dates: 9/21/2000 - 8/31/2005

Arterial Compression of the Ventro-Lateral Medulla
Sponsor: NIH/NHLBI
Award: 5 K23 HL067993-03 (04020301)
F&A: $9,411
Direct: $127,056
<table>
<thead>
<tr>
<th>College</th>
<th>Department</th>
<th>Co-Investigator</th>
<th>Principal Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Direct</th>
<th>Award</th>
<th>F&amp;A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical</td>
<td>Medicine</td>
<td>Egan, Brent</td>
<td>Co-Investigator</td>
<td>Prospective Study on the Effect of Beta Blocker Treatment with Toprol-XL to Reduce C-Reactive Protein Levels in High-Risk Patients with Hypertension, Diabetes and/or Heart Failure</td>
<td>AstraZeneca</td>
<td>$115,987</td>
<td>03111407</td>
<td>28,997</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EXPORT Center on Metabolic Syndrome and Minority Health</td>
<td>NIH/NCMHD</td>
<td>$506,129</td>
<td>03080109</td>
<td>232,819</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dietary Fiber and Cardiovascular Inflammatory Markers</td>
<td>NIH/NHLBI</td>
<td>$302,806</td>
<td>03052904</td>
<td>113,623</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Egede, Leonard</td>
<td>VAMC Merit Award</td>
<td>$178,704</td>
<td>04063020</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Collaborative Management of Diabetes in Blacks</td>
<td>NIH/NIDDK</td>
<td>$52,190</td>
<td>03011704</td>
<td>24,007</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Emovon, Osemwegie</td>
<td>Amer. Heart Assoc.</td>
<td>$60,000</td>
<td>0355766U (03011704)</td>
<td>6,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Epps, Amy</td>
<td>Amersham Health</td>
<td>$23,600</td>
<td>04042901</td>
<td>5,900</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Faison, Warachal</td>
<td>Research Fdn. For Mental Hygiene</td>
<td>$136,510</td>
<td>1003756/1/23532 (03052004)</td>
<td>58,699</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Depression in Alzheimer's Disease Study 2 (DIADS-2)</td>
<td>NIH/NIMH</td>
<td>$49,979</td>
<td>1 U01 MH066176-01A1 (03032808)</td>
<td>22,990</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Falsetti, Sherry</td>
<td>NIH/NCI</td>
<td>$209,370</td>
<td>0401300 (04013010)</td>
<td>15,190</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Falsetti, Sherry</td>
<td>NIH/NIMH</td>
<td>$209,370</td>
<td>0401300 (04013010)</td>
<td>15,190</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fan, Weimin</td>
<td>NIH/NCI</td>
<td>$178,000</td>
<td>04011402</td>
<td>76,540</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Emovon, Osemwegie</td>
<td>NIH/NIDDK</td>
<td>$52,190</td>
<td>03022508</td>
<td>24,007</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Emovon, Osemwegie</td>
<td>NIH/NIDDK</td>
<td>$52,190</td>
<td>03022508</td>
<td>24,007</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Falsetti, Sherry</td>
<td>NIH/NIMH</td>
<td>$209,370</td>
<td>02050903</td>
<td>15,190</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Fan, Weimin</td>
<td>NIH/NCI</td>
<td>$178,000</td>
<td>04011402</td>
<td>76,540</td>
</tr>
<tr>
<td>Name</td>
<td>College</td>
<td>Department</td>
<td>Project Title</td>
<td>Sponsor</td>
<td>Budget Dates</td>
<td>Direct Costs</td>
<td>F&amp;A Costs</td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>-----------------------------</td>
<td>-------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-----------------------</td>
<td>----------------------</td>
<td>--------------</td>
<td>------------</td>
<td></td>
</tr>
<tr>
<td>Ferguson, Pamela</td>
<td>South Carolina College of Medicine</td>
<td>Biostatistics, Bioinformatics &amp; Epidemiology</td>
<td>South Carolina Epidemiological Studies of Epilepsy and Seizure Disorder</td>
<td>AAMC</td>
<td>10/1/2002-9/30/2005</td>
<td>$239,657</td>
<td>67,409</td>
<td></td>
</tr>
<tr>
<td>Fernandes, Jyotika</td>
<td>South Carolina College of Medicine</td>
<td>Medicine</td>
<td>Effect of Weight Loss Liquid Meal Replacements and Nutritional Bars in a Structured Weight Loss Program on Body Weight and Metabolic Parameters in Individuals with Type 2 Diabetes</td>
<td>Abbott Labs</td>
<td>6/25/2004 - 6/24/2009</td>
<td>$111,800</td>
<td>27,950</td>
<td></td>
</tr>
<tr>
<td>Fernandes, Valerian</td>
<td>South Carolina College of Medicine</td>
<td>Medicine</td>
<td>Lupus Educational and Awareness Outreach Program</td>
<td>DHHS</td>
<td>9/30/2003 - 9/29/2004</td>
<td>$7,692</td>
<td>2,308</td>
<td></td>
</tr>
<tr>
<td>Ferraro, Frank</td>
<td>South Carolina College of Medicine</td>
<td>Medicine</td>
<td>A Six-Month, Double-Blind, Randomized, International, Multi-Center Trial to Evaluate the Glucoregulatory Effects of Risperidone and Olanzapine in Subjects with Schizophrenia or Schizoaffective Disorder</td>
<td>Janssen Pharmaceutica</td>
<td>5/20/2002 - 6/30/2005</td>
<td>$6,552</td>
<td>1,638</td>
<td></td>
</tr>
</tbody>
</table>
### College of Medicine

**Feussner, John**

**Principal Investigator**

**Feussner, John**

Medicine Grand Rounds-Dr. Goyal

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Award: (04061401)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Fitzgibbon, Wayne**

**Co-Investigator**

Renal Constitutive and Inducible Na+/Urea Transporters

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Dates: 2/1/2004-7/31/2005</td>
<td>Award: C-2229 (03121013)</td>
<td>F&amp;A: 0</td>
</tr>
<tr>
<td>Sponsor: Pfizer, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award: (04061401)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Flume, Patrick**

**Principal Investigator**

Venticute (rSP-C Surfactant) in Patients with Pneumonia or Aspiration of Gastric Contents Leading to Intubation, Mechanical Ventilation, and Severe Oxygenation Impairment (VALID Study)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor: Pfizer, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award: (04061401)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Ford, Dee**

**Co-PI or Project Leader**

Institutional Research Grant: Assessing Barriers to Enrollment in Hospice: A Survey of Family Members of Hospice Beneficiaries and Physicians

<table>
<thead>
<tr>
<th>PI: REED, CAROLYN E.</th>
<th>Sponsor: Amer. Cancer Soc.</th>
<th>Direct: $19,500</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Dates: 11/1/2003-10/31/2004</td>
<td>Award: IRG-97-219-05 (02100801-03)</td>
<td>F&amp;A: 0</td>
</tr>
<tr>
<td>Sponsor: Pfizer, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award: (04061401)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Fowler, Sandra**

**Principal Investigator**

Clinical Trials for Antiviral Therapies

<table>
<thead>
<tr>
<th>Sponsor: Univ. of Alabama</th>
<th>Budget Dates: 8/1/2003 - 7/31/2010</th>
<th>Direct: $58,400</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Dates: 8/1/2003 - 7/31/2010</td>
<td>Award: 5 R01 HL066066-03 (03042905)</td>
<td>F&amp;A: 0</td>
</tr>
<tr>
<td>Sponsor: Pfizer, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award: (04061401)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A Survey of Influenza Immunization in High-Risk, Chronically Ill Children in Subspeciality Clinic Settings

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor: Pfizer, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award: (04061401)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A Phase III, Double-Blind, Randomized Study to Compare: 1) The Immunogenicity and Safety of 3 Commercial Scale Consistency Lots of GlaxoSmithKline Biologicals' Herpes Simplex Candidate Vaccine (9gD2-AS04) in Healthy HSV-1 and -2 Seronegative (HSV 1-/2-)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Dates: 1/20/2004 - 8/31/2004</td>
<td>Award: PROTOCOL 208141/0 (03102403)</td>
<td>F&amp;A: 9,871</td>
</tr>
<tr>
<td>Sponsor: Pfizer, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award: (04061401)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A Phase IV, Randomized, Multi-Center Trial Comparing the Safety of GlaxoSmithKline's Combination Hepatitis A and Hepatitis B Vaccine (Twinrix) with the Monovalent Vaccines, Havrix and Engerix-B in Healthy Adults Aged 18 Years of Age and Older

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Dates: 7/20/2001 - 7/30/2002</td>
<td>Award: 208127/091 (01073105)</td>
<td>F&amp;A: 4,865</td>
</tr>
<tr>
<td>Sponsor: Pfizer, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award: (04061401)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Fraig, Mostafa**

**Co-Investigator**

The Role of Thromboxane A2 in Bladder Cancer

<table>
<thead>
<tr>
<th>PI: WATSON, DENNIS K.</th>
<th>Sponsor: NIH/NCI</th>
<th>Direct: $90,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor: Pfizer, Inc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award: (04061401)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Department</td>
<td>Principal Investigator</td>
<td>Project Title</td>
</tr>
<tr>
<td>------------</td>
<td>------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Co-PI or Project Leader</td>
</tr>
<tr>
<td>Psychiatry &amp; Behavioral Sciences</td>
<td>Frueh, B.</td>
<td>CBT for PTSD among Public Sector Consumers (Minority Supplement)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trauma Within the Psychiatric Setting</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Telepsychiatry Service Delivery to Trauma Victims</td>
</tr>
<tr>
<td>Medicine</td>
<td>Garnovskaya, Maria</td>
<td>Early Regulation of the Retinoblastoma Gene Product in Vascular Smooth Muscle Cells</td>
</tr>
<tr>
<td></td>
<td></td>
<td>South Carolina State Loan Repayment Program</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Community Incentive for Diversity Program</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Common Health Conditions in Rural African Americans</td>
</tr>
</tbody>
</table>
Gattoni-Celli, Sebastiano  
Principal Investigator

Radiation Oncology
South Carolina Prostate Cancer Telehealth Program - Phase III  
Sponsor: Inst. For Cancer Prevention  
Direct: $12,787  
Award: (04012704)  
F&A: 5,882

Co-PI or Project Leader

MUSC's Activities in Support of the Charleston Health and Risk Assessment (HERA) of Bottlenose Dolphin Populations Project: Task 1 - Development of Cell Lines  
Pt: PEDEN-ADAMS, MARGIE  
Sponsor: NOAA  
Direct: $54,311  
Award: WC133C04CN0012 (04021801-07)  
F&A: 14,120

Gelasco, Andrew  
Principal Investigator

Medicine
Identification of 5-HT 1A Receptor Phosphorylation Sites  
Sponsor: NIH/NIMH  
Budget Dates: 5/1/2004 - 4/30/2005  
Direct: $50,000  
Award: 5 R03 MH064795-02 (04030317)  
F&A: 13,000

Cellular Effects of Indoxyl Sulfate-A Uremic Toxin  
Sponsor: NIH/NIDDK  
Budget Dates: 7/1/2003 - 6/30/2004  
Direct: $126,123  
Award: 5 K25 DK059950-03 (03051402)  
F&A: 10,090

George, Mark  
Principal Investigator

Psychiatry & Behavioral Sciences
A Pilot, Proof of Concept Study Assessing the Effects of DAR-0100 on Regional Brain Activity (Blood Flow and Task-Specific Activation) in Patients with Schizophrenia  
Sponsor: The Stanley Foundation  
Budget Dates: 4/1/2004 - 9/30/2005  
Direct: $258,195  
Award: (04061704)  
F&A: 21,805

Extension Study of the Efficacy and Safety of a Single Dose of the Ampakine Compound, CX516, on Measures of Sleepiness and Performance in Sleep-Deprived Healthy Young Volunteers  
Sponsor: Cortex Pharmaceuticals  
Budget Dates: 10/10/2003 - 10/31/2004  
Direct: $146,320  
Award: CORX-CX516-015 (03101301)  
F&A: 27,780

Vagal Nerve Stimulation Synchronized fMRI-VNS  
Pt: BOHNING, DARYL E.  
Sponsor: Cyberonics, Inc.  
Budget Dates: 10/1/1999-9/30/2005  
Direct: $42,378  
Award: (99102806-04)  
F&A: 9,747

Interleaved Prefrontal TMS/fMRI in Schizophrenia  
Pt: NAHAS, ZIAD  
Sponsor: NIH/NIMH  
Budget Dates: 12/1/2002-11/30/2005  
Direct: $125,000  
Award: 5 R21 MH065630-02 (03111208)  
F&A: 57,500

Efficacy and Safety of Olanzapine in Patients with Borderline Personality Disorder: A Randomized Double-Blind Comparison with Placebo  
Pt: NAHAS, ZIAD  
Sponsor: Eli Lilly  
Budget Dates: 1/1/2004-12/31/2005  
Direct: $119,200  
Award: (03101501)  
F&A: 29,800

An fMRI Study of Depressed Mothers Hearing Infant Cries  
Pt: KOSE, SAMET  
Sponsor: NARSAD  
Budget Dates: 11/1/2003-12/31/2005  
Direct: $60,000  
Award: (02072903)  
F&A: 0

An fMRI Study of Healthy Mothers Hearing Infant Cries  
Pt: LORBERBAUM, JEFFREY  
Sponsor: NIH/NINDS  
Budget Dates: 9/1/2000-8/31/2005  
Direct: $30,000  
Award: 5 R01 NS40259-03 (02072501)  
F&A: 13,800

Ghatak, Shibnath  
Co-Investigator

Cell Biology & Anatomy
Tumor Cell-Stromal Interactions in Cancer  
Pt: TOOLE, BRYAN P.  
Sponsor: NIH/NCI  
Budget Dates: 7/1/2003-5/31/2005  
Direct: $247,775  
Award: 5 R01 CA079866-06 (04033104)  
F&A: 72,710

Tumor Cell-Stromal Interactions in Cancer  
Pt: TOOLE, BRYAN P.  
Sponsor: NIH/NCI  
Direct: $220,001  
Award: 7 R01 CA079866-05 (03061001)  
F&A: 75,918
<table>
<thead>
<tr>
<th>Name</th>
<th>Department/Program</th>
<th>Sponsor</th>
<th>Direct</th>
<th>Project Dates</th>
<th>Award Information</th>
<th>F&amp;A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ghatak, Shibnath</td>
<td>Co-Investigator</td>
<td>NCI</td>
<td>$171,839</td>
<td>9/25/2003-12/31/2004</td>
<td>7 R01 CA082867-06 (03060905)</td>
<td>79,046</td>
</tr>
<tr>
<td>Gilkeson, Gary</td>
<td>Principal Investigator</td>
<td>NIAID</td>
<td>$200,000</td>
<td>4/1/2004 - 12/31/2004</td>
<td>5 R01 AI047469-05 (04011503)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Role of Complement Factor B in the Pathogenesis of SLE</td>
<td>NIAID</td>
<td>$235,000</td>
<td>3/1/2000 - 12/31/2005</td>
<td>5 R01 AR045476-05 (04010901)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nitric Oxide in Systemic Lupus Erythematosus</td>
<td>NIAID</td>
<td>$190,000</td>
<td>12/1/2003 - 11/30/2004</td>
<td>5 R01 AR047451-04 (03092510)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gilkeson Miscellaneous SLE Support</td>
<td>Lupus Fdn.</td>
<td>$3,000</td>
<td>10/15/2003 - 10/14/2004</td>
<td>(03101502)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LCTC Participating Center</td>
<td>Lupus Clinical Trials Consortium</td>
<td>$100,000</td>
<td>10/15/2003 - 10/30/2005</td>
<td>(03093006)</td>
<td></td>
</tr>
<tr>
<td>Kirkland Scholar Award</td>
<td>Mary Kirkland Ctr. For Lupus Research</td>
<td>DOE</td>
<td>$60,000</td>
<td>10/1/2003 - 9/30/2006</td>
<td>(03012204)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Role of PPARGamma and PPARGamma Agonists in Lupus Nephritis</td>
<td>NIAID</td>
<td>$190,000</td>
<td>12/1/2003 - 11/30/2004</td>
<td>5 R01 AR047451-04 (03092510)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Molecular and Structural Characteristics of Glomerulotrophic Antibodies</td>
<td>VAMC Merit Award</td>
<td>$125,000</td>
<td>10/1/2003 - 9/30/2004</td>
<td>(03063008)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Histone Deacetylases are the Therapeutic Targets in SLE</td>
<td>SUNY Research Fdn.</td>
<td>$1,031</td>
<td>9/1/1999 - 9/29/2003</td>
<td>412-3324A (00010503)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Comparison of IV Cyclophosphamide to Mycophenolate Mofetil in SLE</td>
<td>DOE</td>
<td>$62,273</td>
<td>6/1/2003-5/31/2008</td>
<td>DE-FC09-02CH11109 (04030301)</td>
<td>28,646</td>
</tr>
<tr>
<td></td>
<td>NIAIMS Clinical Research Center for Rheumatoid Disease-Project C</td>
<td>NIAIMS</td>
<td>$147,871</td>
<td>4/15/2003-3/31/2008</td>
<td>5 P60 AR049459-02 (04020403)</td>
<td>47,018</td>
</tr>
<tr>
<td></td>
<td>NIAIMS Clinical Research Center for Rheumatoid Disease</td>
<td>NIAIMS</td>
<td>$855,775</td>
<td>4/15/2003-3/31/2008</td>
<td>5 P60 AR049459-02 (04020403)</td>
<td>321,995</td>
</tr>
<tr>
<td></td>
<td>NIAIMS Clinical Research Center for Rheumatoid Disease-Minority Supplement</td>
<td>NIAIMS</td>
<td>$57,450</td>
<td>1/1/2004-6/30/2005</td>
<td>3 P60 AR049459-01S (03111301)</td>
<td>26,427</td>
</tr>
<tr>
<td></td>
<td>Training Grant in Glomerular Function and Disease</td>
<td>NIDDK</td>
<td>$105,389</td>
<td>8/17/1998-7/31/2008</td>
<td>2 T32 DK007752-06 (03010901)</td>
<td>7,600</td>
</tr>
</tbody>
</table>

Annual Report for Research FY04 55
**College of Medicine**

**Gilkeson, Gary**  
Co-Investigator

**Medicine**

**CLEAR Registry**  
Principal Investigator: SMITH, EDWIN A.  
Sponsor: Univ. of Alabama, Birmingham  
Award: N01-AR-0-2247 (00060609)  
Direct: $77,555  
F&A: 33,349

**Gillanders, William**  
Principal Investigator

**Surgery**

Molecular Detection of Breast Cancer in Peripheral Blood  
Sponsor: NIH/NCI  
Budget Dates: 7/1/2003 - 6/30/2004  
Direct: $124,950  
Award: 1 K23 CA93419-02 (01103106)  
Direct: $9,996

**Gillespie, M.**  
Principal Investigator

**Otolaryngology**

Tracheostomy-Related Quality of Life with the Speak-EZ Tracheostomy Tube  
Sponsor: Technical Products, Inc.  
Direct: $3,695  
Award: (04031502)  
F&A: 924

**Giri, Shalindra**  
Co-Investigator

**Pediatrics**

Simvastatin and Interferon B Therapy for Multiple Sclerosis  
Principal Investigator: SINGH, INDERJIT  
Sponsor: Myelin Project Fdn.  
Direct: $90,000  
Award: (03100905)  
F&A: 0

**Gold, Michael**  
Principal Investigator

**Medicine**

Contak Renewal 3 AVT Protocol  
Sponsor: Guidant  
Direct: $49,800  
Award: (04020201)  
F&A: 12,450

Cardiomyopathy and Syncope ICD Study (CASIS) Investigational Protocol  
Sponsor: Loyola University  
Direct: $26,400  
Award: CASIS (03111001)  
F&A: 6,600

Multiple Atrial Therapies in Congestive Heart Failure Treatment: MATCH  
Sponsor: Medtronic, Inc.  
Direct: $93,200  
Award: (03100304)  
F&A: 23,300

The CRT Optimization Algorithm Validation Study  
Sponsor: Guidant  
Direct: $4,800  
Award: CSB031 (03061002)  
F&A: 1,200

Educational Grant in Support of an EP Fellowship  
Sponsor: Medtronic, Inc.  
Budget Dates: 10/1/2002 - 6/30/2005  
Direct: $92,593  
Award: (02102214)  
Project Dates: 10/1/2002 - 6/30/2005  
F&A: 7,407

**Psychiatry & Behavioral Sciences**

Community Integration of Persons with Severe Mental Illness (SMI)  
Sponsor: NIH/NIMH  
Budget Dates: 8/1/2003 - 7/31/2004  
Direct: $127,348  
Award: 5 K23 MH001903-04 (03070207)  
Project Dates: 8/1/2000 - 7/31/2005  
F&A: 10,188

**Family Medicine**

SC Cooperative for Healthy Aging in Minority Populations  
Principal Investigator: TILLEY, BARBARA  
Sponsor: NIH/NIA  
Direct: $20,000  
Award: 3 P30 AG021677-02S2 (03090905)  
F&A: 9,200

**Comparative Medicine**

The Yucatan Micropig Cardiovascular Model of Menopause  
Sponsor: NIH/NCCR  
Direct: $250,000  
Award: 5 R24 RR016535-03 (04032302)  
F&A: 115,000
<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Department</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>Award</th>
<th>Project Dates</th>
<th>F&amp;A</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>A Prospectively Randomized, Phase III, Multi-Center, Controlled Trial to Evaluate the Safety and Efficacy of Zevalin TM Therapeutic Regimen Plus Rituxan Compared with Rituxan Alone in Patients with Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma</td>
<td>Idec Pharmaceuticals Corp.</td>
<td>7/30/2003-7/31/2007</td>
<td>$192,000</td>
<td>5 P01 HD039946-04 (04050605)</td>
<td>7/30/2003 - 7/31/2007</td>
<td>32,240</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cardiac Pacemaking and Conduction System Symposium</td>
<td>NIH/NHLBI</td>
<td>4/1/2004 - 3/31/2005</td>
<td>$10,000</td>
<td>5 R01 HL056728-07 (03052002)</td>
<td>5 R01 HL056728-07 (03052002)</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Patterning of Gap Junction Coupling in Developing Heart</td>
<td>NIH/NHLBI</td>
<td>7/1/2003 - 6/30/2004</td>
<td>$175,000</td>
<td>5 R01 HL056728-07 (03052002)</td>
<td>5 R01 HL056728-07 (03052002)</td>
<td>0</td>
</tr>
</tbody>
</table>
Granholt, Ann-Charlotte
Co-PI or Project Leader

**Physiology and Neuroscience**

**Effects of Lipopolysaccharide Injections on BDNF and GDNF Partial Knockout Animals**
- PI: ROHRER, BAERBEL M.
- Sponsor: Health Sciences Fdn.
- Project Dates: 7/1/2003-12/31/2004
- Award: (03071011-01)
- Direct: $57,612
- F&A: 0

**Green, Mark**
Principal Investigator

**Medicine**

**CALGB Sponsored Studies**
- Sponsor: Cancer & Leukemia Group B
- Award: (96092506)
- Direct: $19,740
- F&A: 1,974

**A Phase III, Randomized Study of TLK 286 Versus Gefitinib (Iressa) as Third-Line Therapy in Locally Advanced Metastatic Non-Small Cell Lung Cancer**
- Sponsor: PPD Development
- Award: TLK286.3020 (04060101)
- Direct: $33,440
- F&A: 8,360

**A Phase I Study of Topotecan in Combination with Vinorelbine in Recurrent Lung Cancer**
- Sponsor: GlaxoSmithKline
- Award: 104864-725 (04012111)
- Direct: $67,600
- F&A: 16,900

**Randomized Trial of Pivanex Plus Docetaxel or Docetaxel Monotherapy in Patients with Chemotherapy Resistant Advanced Non-Small Cell Carcinoma of the Lung (NSCLC)**
- Sponsor: Titian Pharmaceuticals, Inc.
- Award: TTN 200301 (03080801)
- Direct: $28,680
- F&A: 7,170

**Gregory, Mary**
Principal Investigator

**Physiology and Neuroscience**

**Prefrontal Glutamate and Working Memory**
- Sponsor: NIH/NIMH
- Award: 1 F30 MH071944-01 (03040711)
- Direct: $24,517
- F&A: 0

**Gross, Paul**
Principal Investigator

**Biochemistry & Molecular Biology**

**Development of cDNA Microarrays for Analysis of Environmental Stressors and Disease in Local Populations of White Shrimp, Litopenaeus - Third Year Renewal for SC Sea Grant Project # R/MT-6**
- Sponsor: SC Sea Grant Consortium
- Award: V388 (03081102)
- Direct: $59,600
- F&A: 0

**Research Experiences for Undergraduates (REU) Supplement to Shrimp Immunity: Genetic and Functional Studies of Diversity in an Antimicrobial Peptide**
- Sponsor: NSF
- Award: MCB-0110576 (03041801)
- Direct: $121,194
- F&A: 52,113

**Identification and Functional Characterization of Toll-Like Family of Pathogen Receptors from the Pacific White Shrimp Litopenaeus Vannamei**
- Sponsor: USDA
- Award: 2004-35205-14219 (03011307)
- Budget Dates: 1/1/2004 - 1/14/2005
- Direct: $41,479
- F&A: 0

**Analysis of a New and Potentially Multi-Functional Antimicrobial Peptide Family Identified in the Pacific White Shrimp, Litopenaeus Vannamei**
- Sponsor: USDA
- Award: 2004-35204-14201 (02112502)
- Budget Dates: 1/1/2004 - 12/31/2005
- Direct: $86,501
- F&A: 18,499

**Grubaugh, Anouk**
Co-Investigator

**Psychiatry & Behavioral Sciences**

**CBT for PTSD among Public Sector Consumers (Minority Supplement)**
- PI: FRUEH, B. CHRISTOPHER
- Sponsor: NIH/NIMH
- Project Dates: 1/1/2003-12/31/2005
- Award: 3 R21 MH065248-02S1 (0302209)
- Direct: $38,833
- F&A: 17,863

**Habib, David**
Principal Investigator

**Pediatrics**

**Sublingual Capnometry and Indices of Tissue Perfusion in Neonates with Heart Defects**
- Sponsor: Nellcor-Tyco Healthcare
- Award: (04022402)
- Direct: $5,600
- F&A: 1,400

**Multidisciplinary Crisis Prevention Program**
- Sponsor: Lowcountry Children's Center
- Award: 1995-JS-FX-0001 (03112009)
- Budget Dates: 10/1/2003 - 9/30/2004
- Direct: $30,000
- F&A: 0
<table>
<thead>
<tr>
<th>College of Medicine</th>
<th>HUESTON College of Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hainer, Barry</strong></td>
<td>Co-Investigator</td>
</tr>
<tr>
<td><strong>Family Medicine</strong></td>
<td></td>
</tr>
<tr>
<td>Academic Administrative Units in Primary Care</td>
<td>Sponsor: HRSA/BHP/Medicine</td>
</tr>
<tr>
<td>Pt: HUESTON, WILLIAM</td>
<td>Award: 8 D54 HP00023-04 (02122002)</td>
</tr>
<tr>
<td>Project Dates: 9/1/2000-8/31/2006</td>
<td>Direct: $152,000</td>
</tr>
<tr>
<td><strong>Psychiatry &amp; Behavioral Sciences</strong></td>
<td></td>
</tr>
<tr>
<td>Substance Outcomes for Youth in Psychiatric Crisis - Minority Supplement</td>
<td>Sponsor: NIH/NIDA</td>
</tr>
<tr>
<td>Sponsor: NIH/NIDA</td>
<td>Award: 3 R21 DA016899-01S (03111401)</td>
</tr>
<tr>
<td>Substance Outcomes for Youth in Psychiatric Crisis</td>
<td>Sponsor: NIH/NIDA</td>
</tr>
<tr>
<td>Sponsor: NIH/NIDA</td>
<td>Award: 1 R21 DA016899-01 (02121701)</td>
</tr>
<tr>
<td>Project Dates: 8/15/2003 - 6/30/2005</td>
<td>Direct: $50,000</td>
</tr>
<tr>
<td><strong>Halushka, Perry</strong></td>
<td>Principal Investigator</td>
</tr>
<tr>
<td><strong>Cell &amp; Molecular Pharmacology</strong></td>
<td></td>
</tr>
<tr>
<td>Graduate Education at the Interface of Human Biology and New Technologies</td>
<td>Sponsor: NIH/NIAMS</td>
</tr>
<tr>
<td>Sponsor: NIH/NIAMS</td>
<td>Award: 5 R01 AR047451-04 (03092510)</td>
</tr>
<tr>
<td>Project Dates: 7/1/2001-11/30/2005</td>
<td>Direct: $190,000</td>
</tr>
<tr>
<td>Training Program for Medical Scientists</td>
<td>Sponsor: NIH/NIGMS</td>
</tr>
<tr>
<td>Sponsor: NIH/NIGMS</td>
<td>Award: 5 T32 GM008716-05 (02120601)</td>
</tr>
<tr>
<td>Project Dates: 7/1/1999 - 6/30/2004</td>
<td>Direct: $8,987</td>
</tr>
<tr>
<td>Role of PPARgamma and PPARgamma Agonists in Lupus Nephritis</td>
<td>Sponsor: NIH/NIAMS</td>
</tr>
<tr>
<td>Pt: GILKESON, GARY</td>
<td>Award: 5 R01 AR047451-04 (03092510)</td>
</tr>
<tr>
<td>The Role of Thromboxane A2 in Bladder Cancer</td>
<td>Sponsor: NIH/NCI</td>
</tr>
<tr>
<td>Pt: WATSON, DENNIS K.</td>
<td>Award: 1 R21 CA106570-01 (03060304)</td>
</tr>
<tr>
<td>Role of Eicosanoids in Shock</td>
<td>Sponsor: NIH/NIAMS</td>
</tr>
<tr>
<td>Pt: COOK, JAMES A.</td>
<td>Award: 5 R01 GM027673-22 (03042902)</td>
</tr>
<tr>
<td><strong>Hama, Hiroko</strong></td>
<td>Principal Investigator</td>
</tr>
<tr>
<td><strong>Biochemistry &amp; Molecular Biology</strong></td>
<td></td>
</tr>
<tr>
<td>Role of Hydroxyceramide-Based Glycolipids in Lipidraft Formation</td>
<td>Sponsor: Mizutani Fdn.</td>
</tr>
<tr>
<td>Sponsor: Mizutani Fdn.</td>
<td>Award: 040602 (03082510)</td>
</tr>
<tr>
<td>SC COBRE in Lipidomics and Pathobiology - Project 3: Function and Regulation of Mammalian Fatty Acid Alpha-Hydroxylase Gene</td>
<td>Sponsor: NIH/NCRR</td>
</tr>
<tr>
<td>Pt: OBEID, LINA</td>
<td>Award: 5 P20 RR017677-02 (03071704-04)</td>
</tr>
<tr>
<td>Institutionnal Research Grant: Role of FA2H in Aberrant Glycolipid Microdomain Formation</td>
<td>Sponsor: Amer. Cancer Soc.</td>
</tr>
<tr>
<td>Pt: REED, CAROLYN E.</td>
<td>Award: IRG-97-219-05 (02100801-02)</td>
</tr>
<tr>
<td>Project Dates: 11/1/2003-10/31/2004</td>
<td>Direct: $19,500</td>
</tr>
<tr>
<td><strong>Hammad, Samar</strong></td>
<td>Principal Investigator</td>
</tr>
<tr>
<td><strong>Medicine</strong></td>
<td></td>
</tr>
<tr>
<td>Markers and Mechanisms for Pre-Eclampsia in Women with Type 1 Diabetes</td>
<td>Sponsor: Oklahoma Univ. Health Sc. Center</td>
</tr>
<tr>
<td>Sponsor: Oklahoma Univ. Health Sc. Center</td>
<td>Award: 1-2001-844 (04022711)</td>
</tr>
<tr>
<td>Mitochondrial Ceramide in Chemotherapy-Induced Apoptosis</td>
<td>Sponsor: NIH/NIA</td>
</tr>
<tr>
<td>Pt: OBEID, LINA</td>
<td>Award: 5 R01 AG016583-06 (03062703)</td>
</tr>
<tr>
<td>Project Dates: 7/1/1998-8/31/2005</td>
<td>Direct: $175,000</td>
</tr>
<tr>
<td><strong>Hammond, Lyn</strong></td>
<td>Co-Investigator</td>
</tr>
<tr>
<td><strong>Pediatrics</strong></td>
<td></td>
</tr>
<tr>
<td>Cystic Fibrosis Center - MUSC</td>
<td>Sponsor: Cystic Fibrosis Fdn.</td>
</tr>
<tr>
<td>Pt: BOWMAN, MICHAEL</td>
<td>Award: C104-03 (02082201)</td>
</tr>
<tr>
<td>Hamner, Mark</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------</td>
</tr>
</tbody>
</table>
| **Psychiatry & Behavioral Sciences**
A Double-Blind, Eight-Week, Placebo and Risperidone Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of SR142801 in the Treatment of Patients with Schizophrenia or Schizoaffective Disorder

**Sponsor:** Sanofi Synthelabo, Inc.  
**Budget Dates:** 2/24/2004 - 2/28/2005  
**Direct:** $198,416

**Award:** DFIS413 (04021203)  
**Project Dates:** 2/24/2004 - 2/28/2005  
**F&A:** 22,104

<table>
<thead>
<tr>
<th>Co-Investigator</th>
</tr>
</thead>
</table>
| **A Multi-Center, Open Label, Flexible-Dose, Parallel-Group Evaluation of the Cataractogenic Potential of Quetiapine Fumarate (SEROQUEL tm) and Risperidone (RISPERDAL tm) in the Long-Term Treatment of Patients with Schizophrenia and Schizoaffective Disorder**

**Sponsor:** AstraZeneca  
**Budget Dates:** 2/2/2004 - 1/29/2006  
**Direct:** $234,640

**Award:** PROTOCOL # 5077IL/0 (04021203)  
**Project Dates:** 2/2/2004 - 1/29/2006  
**F&A:** 58,660

<table>
<thead>
<tr>
<th>Hannun, Yusuf</th>
<th>Principal Investigator</th>
</tr>
</thead>
</table>
| **Biochemistry & Molecular Biology**
Modeling and Analysis of Yeast Sphingolipid Metabolism

**Sponsor:** NIH/NIGMS  
**Budget Dates:** 4/1/2004 - 3/31/2005  
**Direct:** $100,000

**Award:** 5 R01 GM063265-04 (04012903)  
**Project Dates:** 4/1/2004 - 3/31/2005  
**F&A:** 43,000

<table>
<thead>
<tr>
<th>Co-Investigator</th>
</tr>
</thead>
</table>
| **Sphingomyelin Turnover and Cellular Regulation**

**Sponsor:** NIH/NIGMS  
**Budget Dates:** 7/1/2003 - 6/30/2004  
**Direct:** $225,000

**Award:** 5 R01 GM043825-15 (03110303)  
**Project Dates:** 7/1/2003 - 6/30/2004  
**F&A:** 108,100

<table>
<thead>
<tr>
<th>Co-Investigator</th>
</tr>
</thead>
</table>
| **Development of Chemical and Structural Biology**

**Sponsor:** SC Research Authority  
**Budget Dates:** 9/1/2003 - 8/31/2004  
**Direct:** $1,403

**Award:** 0005 (03091003)  
**Project Dates:** 9/1/2003 - 8/31/2004  
**F&A:** 0

<table>
<thead>
<tr>
<th>Co-Investigator</th>
</tr>
</thead>
</table>
| **Ceramide Activated Protein Phosphatases**

**Sponsor:** NIH/NCI  
**Budget Dates:** 7/1/2003 - 6/30/2005  
**Direct:** $225,000

**Award:** 5 R01 CA087584-04 (03041603)  
**Project Dates:** 7/1/2003 - 6/30/2005  
**F&A:** 96,750

<table>
<thead>
<tr>
<th>Co-Investigator</th>
</tr>
</thead>
</table>
| **Role and Regulation of Protein Kinase C Isoenzymes**

**Sponsor:** NIH/NHLBI  
**Budget Dates:** 7/1/2003 - 6/30/2004  
**Direct:** $225,000

**Award:** 5 R01 HL043707-14 (03041603)  
**Project Dates:** 7/1/2003 - 6/30/2004  
**F&A:** 96,750

<table>
<thead>
<tr>
<th>Co-Investigator</th>
</tr>
</thead>
</table>
| **Mitochondrial Sphingolipids in Apoptosis**

**Sponsor:** Univ. of North Carolina  
**Budget Dates:** 6/1/2003 - 5/31/2004  
**Direct:** $111,971

**Award:** 5 P01 DK59340-02 (02092305)  
**Project Dates:** 6/1/2003 - 5/31/2004  
**F&A:** 48,148

<table>
<thead>
<tr>
<th>Co-Investigator</th>
</tr>
</thead>
</table>
| **Sphingolipids in Cancer Therapy and Angiogenesis**

**Sponsor:** NIH/NCI  
**Budget Dates:** 8/1/2003 - 7/31/2004  
**Direct:** $715,167

**Award:** 1 P01 CA97132-01A1 (01100808)  
**Project Dates:** 8/1/2003 - 7/31/2004  
**F&A:** 318,811

<table>
<thead>
<tr>
<th>Co-Investigator</th>
</tr>
</thead>
</table>
| **Development of Structural and Chemical Biology**

**Sponsor:** SC EPSCOR  
**Budget Dates:** 6/1/2002 - 6/30/2004  
**Direct:** $1,470,753

**Award:** EP5-0132573 (01073104)  
**Project Dates:** 6/1/2002 - 6/30/2004  
**F&A:** 147,072

<table>
<thead>
<tr>
<th>Co-Investigator</th>
</tr>
</thead>
</table>
| **Sphingolipid-Dependent Transcriptional Responses to Heat**

**Sponsor:** NIH/NIGMS  
**Budget Dates:** 12/1/2002-11/30/2003  
**Direct:** $25,860

**Award:** 1 F32 GM063270-01A1 (02081603-01)  
**Project Dates:** 12/1/2002-11/30/2003  
**F&A:** 0

<table>
<thead>
<tr>
<th>Co-Investigator</th>
</tr>
</thead>
</table>
| **SC COBRE in Lipidomics and Pathobiology**

**Sponsor:** NIH/NCRR  
**Budget Dates:** 9/26/2002-6/30/2007  
**Direct:** $1,573,324

**Award:** 5 P20 RR017677-02 (03030701)  
**Project Dates:** 9/26/2002-6/30/2007  
**F&A:** 667,145

<table>
<thead>
<tr>
<th>Co-Investigator</th>
</tr>
</thead>
</table>
| **Supplement to P20 RR17677: Development of NMR Spectroscopy**

**Sponsor:** NIH/NCRR  
**Budget Dates:** 9/26/2003-6/30/2004  
**Direct:** $500,000

**Award:** 3 P20 RR017677-02S1 (03030701)  
**Project Dates:** 9/26/2003-6/30/2004  
**F&A:** 0
<table>
<thead>
<tr>
<th>Faculty Name</th>
<th>College</th>
<th>Project Title</th>
<th>PI</th>
<th>Sponsor</th>
<th>Direct</th>
<th>F&amp;A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gillanders, Yusuf</td>
<td>College of Medicine</td>
<td>Molecular Detection of Breast Cancer in Peripheral Blood</td>
<td>Gillanders, William E.</td>
<td>NIH/NCI</td>
<td>$124,950</td>
<td>9,996</td>
</tr>
<tr>
<td>Hanson, Rochelle</td>
<td>Psychiatry &amp; Behavioral Sciences</td>
<td>Service Systems Models IDE Program</td>
<td>Saunders, Benjamin E.</td>
<td>SAMHSA/CMHS</td>
<td>$469,197</td>
<td>130,659</td>
</tr>
<tr>
<td>Harley, Russell</td>
<td>Pathology &amp; Laboratory Medicine</td>
<td>Effects of the Injection of DEAC-Glucosamine in High Flow Vessels</td>
<td>Uflacker, Renan P.</td>
<td>Marine Polymer Technologies</td>
<td>$36,457</td>
<td>16,770</td>
</tr>
<tr>
<td>Hartsock, Langdon</td>
<td>Orthopedic Surgery</td>
<td>Synthes General Research and Education</td>
<td>Synthes (USA)</td>
<td>Direct</td>
<td>$40,000</td>
<td>0</td>
</tr>
<tr>
<td>Hawes, Robert</td>
<td>Medicine</td>
<td>North American Pancreatitis Study 2 (NAPS2)</td>
<td>Univ. of Pittsburgh</td>
<td>Direct</td>
<td>$5,993</td>
<td>2,757</td>
</tr>
<tr>
<td>Haynes, Louise</td>
<td>Psychiatry &amp; Behavioral Sciences</td>
<td>Study of the NDO Surgical Plication System for the Treatment of Symptomatic Gastroesophageal Reflux Disease</td>
<td>NDO Surgical, Inc.</td>
<td>Direct</td>
<td>$32,175</td>
<td>9,652</td>
</tr>
<tr>
<td>Hazen-Martin, Debra</td>
<td>Pathology &amp; Laboratory Medicine</td>
<td>A Study to Further Assess the Efficacy of Bowel Preparation with the Use of a Pre-Packed Diet/Bowel Prep Kit</td>
<td>Delegee, Mark</td>
<td>Direct</td>
<td>$1,540</td>
<td>354</td>
</tr>
</tbody>
</table>
### Pathology & Laboratory Medicine

**Hormonal Modulation of Taxol Action in Solid Tumors**  
*PI: FAN, WEIMIN*  
*Sponsor: NIH/NCI*  
*Award: 5 R01 CA092280-03 (04011402) Direct: $178,000 F&A: 76,540*

**Estrogen Efficacy in Spinal Cord Injury**  
*PI: BANIK, NAREN L.*  
*Sponsor: NIH/NINDS*  
*Award: 1 R01 NS045967-01A1 (03031207) Direct: $185,000 F&A: 73,600*

### Otolaryngology

**Auditory Analysis and Speech Recognition**  
*PI: DUBNO, JUDY R.*  
*Sponsor: NIH/NIDCD*  
*Award: 698400 Direct: $227,500 F&A: 97,825*

**Experimental and Clinical Studies of Presbyacusis**  
*PI: MILLS, JOHN H.*  
*Sponsor: NIH/NIDCD*  
*Award: 5 P50 DC000422-17 (03142007) Direct: $1,060,058 F&A: 487,627*

### Medicine

**Improving Physician Skill at Providing End-of-Life Care**  
*PI: SILVESTRI, GERARD A.*  
*Sponsor: Univ. of Washington*  
*Award: 698400 Direct: $207,415 F&A: 89,189*

**Vasodilator Induced Stress in CONcordance with Adenosine (VISION-301)**  
*PI: GORDON, LEONIE*  
*Sponsor: King Pharmaceuticals*  
*Award: MRE0470P-301 Direct: $181,456 F&A: 45,364*

### Psychiatry & Behavioral Sciences

**BlueSky Project**  
*Sponsor: Annie E. Casey Fdn.*  
*Budget Dates: 3/1/2004 - 2/28/2005 Direct: $400,000 F&A: 0*

**Effectiveness Trial: MST Juvenile Offenders**  
*Sponsor: NIH/NIMH*  

**MST with Alcohol Abusing Delinquents: Outcomes and Cost**  
*Sponsor: NIH/NIAAA*  
*Award: 5 R01 AA012202-05 (03061902) Project Dates: 9/2/1999 - 8/31/2004 Direct: $214,111 F&A: 92,068*

**Randomized Clinical Trial of Juvenile Drug Court and MST-Supplement**  
*Sponsor: NIH/NIDA*  

**Randomized Clinical Trial of Juvenile Drug Court and MST**  
*Sponsor: NIH/NIDA*  

**Implementing Evidenced-Based Treatment for Youths - Supplement**  
*Sponsor: NIH/NIDA*  
*Award: 3 R01 DA015844-02S (03050702) Project Dates: 7/1/2003 - 6/30/2004 Direct: $65,750 F&A: 16,905*

**Implementing Evidenced-Based Treatment for Youths**  
*Sponsor: NIH/NIDA*  
*Award: 5 R01 DA015844-02 (03042502) Project Dates: 7/1/2003 - 6/30/2004 Direct: $425,293 F&A: 111,412*

**Adoption and Implementation of Adolescent EBT State-Wide**  
*Sponsor: NIH/NIDA*  

**Evidenced-Based Treatment in Juvenile Drug Court**  
*Sponsor: SAMSHA/CSAT*  
**Psychiatry & Behavioral Sciences**

**Understanding & Eliminating Health Disparities in Blacks - Pilot Study 3: Improving the Evaluation of Therapist Adherence to Multisystemic Therapy with Ethnically Diverse, Adolescent Drug Offenders**

Pl: TILLEY, BARBARA  
Sponsor: AHCPR/HRQ  
Direct:  
Award:  
Project Dates: 9/21/2000-8/31/2005  
F&A: 12,747

**Pediatrics**

**A Multi-Center, Multi-National, Open-Label Study of the Efficacy, Safety and Pharmacokinetics of Candesartan Cilexetil in Hypertensive Pediatric Subjects 6-<17 Years of Age**

Sponsor: Astrazeneca  
Direct:  
F&A: 5,320

**A Dose-Ranging and Safety Study of Candesartan Cilexetil in Hypertensive Pediatric Subjects 6-<17 Years of Age: A 4-Week, Multi-National, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study**

Sponsor: Astrazeneca  
Budget Dates: 5/19/2004 - 6/30/2005  
Direct:  
F&A: 3,870

**2004 ACCF/Pfizer Visiting Professorship in Cardiovascular Medicine**

Pl: SAUL, J. PHILIP  
Sponsor: Pfizer, Inc.  
Direct:  
F&A: 0

**FPH02 (STRIDE-11): A Phase III, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Sitaxsentan Sodium Treatment with an Open-Label Bosentan Arm in Patients with Pulmonary Arterial Hypertension**

Pl: STRANGE, CHARLIE  
Sponsor: Cycle Solutions  
Direct:  
F&A: 17,276

**FPH 02X: An Open-Label Study to Evaluate the Long-Term Safety of Sitaxsentan Sodium Treatment with a Bosentan Arm in Patients with Pulmonary Arterial Hypertension**

Pl: STRANGE, CHARLIE  
Sponsor: Cycle Solutions  
Direct:  
F&A: 23,776

**FPH 03: A Long-Term, Open Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients with Pulmonary Arterial Hypertension Who Have Failed Bosentan Therapy**

Pl: STRANGE, CHARLIE  
Sponsor: Cycle Solutions  
Direct:  
F&A: 26,112

**Phase II: Comparative, Pharmacokinetic and Pharmacodynamic Study of Epoetin Alfa (Procrit) in Anemic Critically Ill Patients Randomized to One of Six Dose Regimens for 15 Days**

Pl: STRANGE, CHARLIE  
Sponsor: Ortho Biotech  
Direct:  
F&A: 5,824

**Effect of Inflammation on Esophageal Motility**

Pl: CASTELL, DONALD O.  
Sponsor: MCP Hahnemann Univ.  
Direct:  
F&A: 14,343
<table>
<thead>
<tr>
<th>College of Medicine</th>
<th>Medical University of South Carolina</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cell &amp; Molecular Pharmacology</strong></td>
<td><strong>HILDEBRANDT</strong></td>
</tr>
<tr>
<td><strong>Hormone Regulated GTP Binding Proteins</strong></td>
<td><strong>Cell &amp; Molecular Pharmacology</strong></td>
</tr>
<tr>
<td><strong>Sponsor:</strong> NIH/NIDDK</td>
<td><strong>Sponsor:</strong> NIH/NIDDK</td>
</tr>
<tr>
<td><strong>Budget Dates:</strong> 7/1/2003 - 6/30/2005</td>
<td><strong>Budget Dates:</strong> 7/1/2003 - 6/30/2005</td>
</tr>
<tr>
<td><strong>Direct:</strong> $218,545</td>
<td><strong>Direct:</strong> $218,545</td>
</tr>
<tr>
<td><strong>Award:</strong> 5 R01 DK037219-17 (03050201)</td>
<td><strong>F&amp;A:</strong> 93,974</td>
</tr>
<tr>
<td><strong>Project Dates:</strong> 7/1/1991 - 6/30/2005</td>
<td><strong>Project Dates:</strong> 7/1/1991 - 6/30/2005</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Radiology</strong></th>
<th><strong>Hildebrandt, John</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACRIN 6660: Whole-body MRI in the Evaluation of Pediatric Malignancies</strong></td>
<td><strong>Cell &amp; Molecular Pharmacology</strong></td>
</tr>
<tr>
<td><strong>Sponsor:</strong> Amer. Coll. of Radiology</td>
<td><strong>Sponsor:</strong> NIH/NIDDK</td>
</tr>
<tr>
<td><strong>Budget Dates:</strong> 1/1/2004 - 12/31/2004</td>
<td><strong>Budget Dates:</strong> 7/1/2003 - 6/30/2005</td>
</tr>
<tr>
<td><strong>Direct:</strong> $29,208</td>
<td><strong>Direct:</strong> $218,545</td>
</tr>
<tr>
<td><strong>Award:</strong> C80090/4244 (04030817)</td>
<td><strong>Award:</strong> 5 R01 DK037219-17 (03050201)</td>
</tr>
<tr>
<td><strong>Project Dates:</strong> 1/1/2004 - 12/31/2007</td>
<td><strong>Project Dates:</strong> 7/1/1991 - 6/30/2005</td>
</tr>
<tr>
<td><strong>F&amp;A:</strong> 2,067</td>
<td><strong>F&amp;A:</strong> 93,974</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Pathology &amp; Laboratory Medicine</strong></th>
<th><strong>Hildebrandt, John</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ThinPrep Specimen Assessment for Cytyc Corporation, Protocol #27</strong></td>
<td><strong>Pathology &amp; Laboratory Medicine</strong></td>
</tr>
<tr>
<td><strong>Sponsor:</strong> Digene Corp.</td>
<td><strong>Sponsor:</strong> NIH/NIDDK</td>
</tr>
<tr>
<td><strong>Budget Dates:</strong> 5/19/2003 - 5/31/2005</td>
<td><strong>Budget Dates:</strong> 7/1/2003 - 6/30/2005</td>
</tr>
<tr>
<td><strong>Direct:</strong> $190,532</td>
<td><strong>Direct:</strong> $218,545</td>
</tr>
<tr>
<td><strong>Award:</strong> PROTOCOL #27 (04051403)</td>
<td><strong>Award:</strong> 5 R01 DK037219-17 (03050201)</td>
</tr>
<tr>
<td><strong>Project Dates:</strong> 5/19/2003 - 5/31/2006</td>
<td><strong>Project Dates:</strong> 7/1/1991 - 6/30/2005</td>
</tr>
<tr>
<td><strong>F&amp;A:</strong> 32,422</td>
<td><strong>F&amp;A:</strong> 93,974</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Biostatistics, Bioinformatics &amp; Epidemiology</strong></th>
<th><strong>Hildebrandt, John</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Savannah River Site Former Production Workers Medical Surveillance Program-Phase II Year 5</strong></td>
<td><strong>Biostatistics, Bioinformatics &amp; Epidemiology</strong></td>
</tr>
<tr>
<td><strong>Sponsor:</strong> DOE</td>
<td><strong>Sponsor:</strong> NIH/NIDDK</td>
</tr>
<tr>
<td><strong>Budget Dates:</strong> 9/1/2003 - 2/28/2005</td>
<td><strong>Budget Dates:</strong> 7/1/2003 - 6/30/2005</td>
</tr>
<tr>
<td><strong>Direct:</strong> $381,452</td>
<td><strong>Direct:</strong> $218,545</td>
</tr>
<tr>
<td><strong>Award:</strong> DE-FC03-97SF21513 (03111404)</td>
<td><strong>Award:</strong> 5 R01 DK037219-17 (03050201)</td>
</tr>
<tr>
<td><strong>Project Dates:</strong> 9/25/1997 - 2/28/2005</td>
<td><strong>Project Dates:</strong> 7/1/1991 - 6/30/2005</td>
</tr>
<tr>
<td><strong>F&amp;A:</strong> 79,945</td>
<td><strong>F&amp;A:</strong> 93,974</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Clinical and Translational Science</strong></th>
<th><strong>Hildebrandt, John</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>The Analysis of the Potential Health Risk from High LET Radiation</strong></td>
<td><strong>Biostatistics, Bioinformatics &amp; Epidemiology</strong></td>
</tr>
<tr>
<td><strong>Sponsor:</strong> NASA</td>
<td><strong>Sponsor:</strong> NIH/NIDDK</td>
</tr>
<tr>
<td><strong>Budget Dates:</strong> 5/19/2003 - 5/31/2005</td>
<td><strong>Budget Dates:</strong> 7/1/2003 - 6/30/2005</td>
</tr>
<tr>
<td><strong>Direct:</strong> $190,532</td>
<td><strong>Direct:</strong> $218,545</td>
</tr>
<tr>
<td><strong>Award:</strong> NAG 9-1518 (02112606)</td>
<td><strong>Award:</strong> 5 R01 DK037219-17 (03050201)</td>
</tr>
<tr>
<td><strong>Project Dates:</strong> 5/19/2003 - 5/31/2006</td>
<td><strong>Project Dates:</strong> 7/1/1991 - 6/30/2005</td>
</tr>
<tr>
<td><strong>F&amp;A:</strong> 32,422</td>
<td><strong>F&amp;A:</strong> 93,974</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Clinical and Translational Science</strong></th>
<th><strong>Hildebrandt, John</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Environmental Biosciences Program: Risk Assess-Low Dose Radiation</strong></td>
<td><strong>Biostatistics, Bioinformatics &amp; Epidemiology</strong></td>
</tr>
<tr>
<td><strong>Sponsor:</strong> DOE</td>
<td><strong>Sponsor:</strong> NIH/NIDDK</td>
</tr>
<tr>
<td><strong>Budget Dates:</strong> 4/6/2004 - 5/31/2005</td>
<td><strong>Budget Dates:</strong> 7/1/2003 - 6/30/2005</td>
</tr>
<tr>
<td><strong>Direct:</strong> $42,982</td>
<td><strong>Direct:</strong> $218,545</td>
</tr>
<tr>
<td><strong>Award:</strong> ELN 100226-CD307 (04041505)</td>
<td><strong>Award:</strong> 5 R01 DK037219-17 (03050201)</td>
</tr>
<tr>
<td><strong>Project Dates:</strong> 4/6/2004 - 5/31/2005</td>
<td><strong>Project Dates:</strong> 7/1/1991 - 6/30/2005</td>
</tr>
<tr>
<td><strong>F&amp;A:</strong> 10,746</td>
<td><strong>F&amp;A:</strong> 93,974</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Co-PI or Project Leader</strong></th>
<th><strong>Hildebrandt, John</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antegren under Protocol ELN 100226-CD307</strong></td>
<td><strong>Co-PI or Project Leader</strong></td>
</tr>
<tr>
<td><strong>Sponsor:</strong> Elan Pharmaceuticals</td>
<td><strong>Sponsor:</strong> NIH/NIDDK</td>
</tr>
<tr>
<td><strong>Budget Dates:</strong> 4/6/2004 - 5/31/2005</td>
<td><strong>Budget Dates:</strong> 7/1/2003 - 6/30/2005</td>
</tr>
<tr>
<td><strong>Direct:</strong> $42,982</td>
<td><strong>Direct:</strong> $218,545</td>
</tr>
<tr>
<td><strong>Award:</strong> ELN 100226-CD307 (04041505)</td>
<td><strong>Award:</strong> 5 R01 DK037219-17 (03050201)</td>
</tr>
<tr>
<td><strong>Project Dates:</strong> 4/6/2004 - 5/31/2005</td>
<td><strong>Project Dates:</strong> 7/1/1991 - 6/30/2005</td>
</tr>
<tr>
<td><strong>F&amp;A:</strong> 10,746</td>
<td><strong>F&amp;A:</strong> 93,974</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Co-PI or Project Leader</strong></th>
<th><strong>Hildebrandt, John</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, 52-Week, Dose Comparison Study of the Efficacy and Safety of 25mg QD and 50mg QD of OPC 6535 Oral Tablets and 800mg BID of Asacol in the Maintenance of Remission in Ulce</strong></td>
<td><strong>Co-PI or Project Leader</strong></td>
</tr>
<tr>
<td><strong>Sponsor:</strong> Otsuka Medical Research Inst.</td>
<td><strong>Sponsor:</strong> NIH/NIDDK</td>
</tr>
<tr>
<td><strong>Budget Dates:</strong> 3/28/2003 - 4/30/2005</td>
<td><strong>Budget Dates:</strong> 7/1/2003 - 6/30/2005</td>
</tr>
<tr>
<td><strong>Direct:</strong> $37,904</td>
<td><strong>Direct:</strong> $218,545</td>
</tr>
<tr>
<td><strong>Award:</strong> 197-02-218 (03061206)</td>
<td><strong>Award:</strong> 5 R01 DK037219-17 (03050201)</td>
</tr>
<tr>
<td><strong>Project Dates:</strong> 3/28/2003 - 4/30/2005</td>
<td><strong>Project Dates:</strong> 7/1/1991 - 6/30/2005</td>
</tr>
<tr>
<td><strong>F&amp;A:</strong> 9,476</td>
<td><strong>F&amp;A:</strong> 93,974</td>
</tr>
</tbody>
</table>
Hoffman, Brenda

Co-PI or Project Leader

**Medicine**

A Phase III, Multi-National, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, 26 Week Study to Assess the Safety and Efficacy of the Humanise Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed at weeks 0,2,4 then 4-weekly to Week 24), In th

PI: WILSON, FREDERICK A.  
Sponsor: Icon Clinical Research, Inc.  
Award: CDP870-031 (04012204-01)  
F&A: 11,481  
Direct: $45,922

A Phase III, Multi-National, Multi-Center, Open-Label, 52 Week, Safety Study to Assess the Safety of Chronic Therapy with the Humanise Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed 4-weekly to 48 week), in the Treatment of Patients with Active Crohn’ s

PI: WILSON, FREDERICK A.  
Sponsor: Icon Clinical Research, Inc.  
Award: CDP870-033 (04012203-01)  
F&A: 6,357  
Direct: $25,426

A Phase III, Multi-National, Multi-Center, Open Label, 52 Week, Safety Study to Assess the Safety of Re-Exposure after a Variable Interval and Subsequent Chronic Therapy with the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc (dosed at weeks 0,2 and 4

PI: WILSON, FREDERICK A.  
Sponsor: Icon Clinical Research, Inc.  
Award: CDP870-034 (04012202-01)  
F&A: 6,428  
Direct: $25,711

Endoscopic Implantation of Enteryx for the Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD)

PI: DELEGGE, MARK  
Sponsor: Boston Scientific Corp.  
Award: EZEM-01-001 (01042603)  
F&A: 354  
Direct: $32,304

Surrogate Biomarkers of Micrometastatic Gastric Cancer

PI: SMOLKA, ADAM J.  
Sponsor: NIH/NCI  
Award: 1 R01 CA101123-01 (02072201)  
F&A: 23,000  
Direct: $50,000

A Study to Further Assess the Efficacy of Bowel Preparation with the Use of a Pre-Packed Diet/Bowel Prep Kit Versus Usual and Customary Bowel Preparation for Colonoscopy

PI: DELEGGE, MARK  
Sponsor: Ezem, Inc.  
Award: EZEM-01-001 (01042603)  
F&A: 354  
Direct: $1,540

Hoffman, Stanley

Principal Investigator

**Medicine**

PKC-Related Proteins in Lung Fibrosis

Sponsor: NIH/NHLBI  
Award: 1 R01 HL073718-01 (02091904)  
F&A: 115,000  
Direct: $250,000

Environmental Biosciences Program: EnvTox-Hoffman-Molecular Mechanisms

PI: MOHR, JR., LAWRENCE C.  
Sponsor: DOE  
Award: DE-FC09-02CH11109 (04030301-09)  
F&A: 36,019  
Direct: $78,302

Cspq2 Gene and Cardiac Outlet Morphogenesis

PI: MJAATVEDT, COREY  
Sponsor: NIH/NHLBI  
Award: 5 R01 HL066231-03 (03042809)  
F&A: 86,000  
Direct: $200,000

Hogan, Edward

Co-Investigator

**Neurology**

Role of Proteinase in Spinal Cord Injury

PI: BANIK, NAREN L.  
Sponsor: NIH/NINDS  
Award: 5 R01 NS031622-11 (03103003)  
F&A: 95,675  
Direct: $222,500

Hollis, Bruce

Principal Investigator

**Pediatrics**

Glucocorticoid-Induced Osteopenia in Children

Sponsor: Univ. of Pennsylvania  
Award: 20573-03-02/DK6003 (03062702)  
F&A: 3,697  
Direct: $8,597

Evaluation of Vitamin D Requirements During Pregnancy

Sponsor: NIH/NICHD  
Budget Dates: 9/1/2003 - 7/31/2004  
Award: 1 R01 HD043921-01 (02053004)  
F&A: 155,995  
Direct: $382,526

Cloning and Characterization of Human CYP25

PI: BELL, NORMAN H.  
Sponsor: NIH/NIDDK  
Award: 5 R01 DK056603-04 (03111803)  
F&A: 43,680  
Direct: $168,000

Phase II Study of Alendronate Sodium (Fosamax) in Juvenile Osteoporosis

PI: KEY, L. LYNDON  
Sponsor: FDA  
Award: FD-R-001847-03 (03040706)  
F&A: 98,259  
Direct: $227,606
### Pediatrics

**Regulation of Vitamin D Metabolism**
- **Pt:** BELL, NORMAN H.
- **Sponsor:** DOD/US Army
- **Project Dates:** 9/13/2001-9/12/2005
- **Direct:** $137,613
- **F&A:** $35,780

### Medicine

**A Multi-Center, Randomized, Double-Blind Study to Compare the Effects of 24 Week Treatment with LAF237 (50mg, qd, 50mg bid, or 100 mg. qd) to Placebo in Drug Naive Patients with Type 2 Diabetes**
- **Pt:** HERMAYER, KATHIE
- **Sponsor:** Novartis Corp.
- **Project Dates:** 3/30/2004-8/1/2006
- **Direct:** $157,326
- **F&A:** $39,331

**Substituting Lantus (Insulin Glargine [RDNA Origin] Injection) for a Thiazolidinedione vs a Third Oral Agent as Add-On Therapy in Patients Failing a Thiazolidinedione and Sulfonylurea or Glucophage (Metformin) Combination**
- **Pt:** HERMAYER, KATHIE
- **Sponsor:** Aventis Pharmaceutical, Inc.
- **Project Dates:** 10/2/2003-11/12/2005
- **Direct:** $57,400
- **F&A:** $14,350

### Psychiatry & Behavioral Sciences

**The South Carolina Traumatic Brain Injury Registry**
- **Pt:** SELASSIE, ANBESAW
- **Sponsor:** CDC
- **Project Dates:** 8/1/2002-7/31/2005
- **Direct:** $586,674
- **F&A:** $125,628

### Otolaryngology

**Auditory Analysis and Speech Recognition**
- **Pt:** DUBNO, JUDY R.
- **Sponsor:** NIH/NIDCD
- **Project Dates:** 12/1/1981-1/31/2006
- **Direct:** $227,500
- **F&A:** $97,825

**Experimental and Clinical Studies of Presbyacusis**
- **Pt:** MILLS, JOHN H.
- **Sponsor:** NIH/NIDCD
- **Project Dates:** 7/1/1987-6/30/2007
- **Direct:** $1,060,058
- **F&A:** $487,627

### Radiology

**Multi-Center, Open-Label Study of the Safety (Open-Label) and Efficacy (Open-Label and Blinded Reader) of a Single Administration of Approximately 0.1 mmol/kg of Magnevist Injection-Enhanced Magnetic Resonance Arteriography (MRA and 2-dimensional, etc)**
- **Pt:** NOONE, TARA
- **Sponsor:** Berlex Laboratories
- **Project Dates:** 3/3/2004-3/31/2005
- **Direct:** $58,800
- **F&A:** $14,700

### Cell Biology & Anatomy

**Role of an Epithelial Ets Factor in Breast Cancer**
- **Pt:** WATSON, DENNIS K.
- **Sponsor:** NIH/NCI
- **Project Dates:** 7/1/2003-6/30/2008
- **Direct:** $222,500
- **F&A:** $102,350

### Pathology & Laboratory Medicine

**Control of Epithelial Morphogenesis in Drosophila Ovary**
- **Sponsor:** NIH/NIGMS
- **Budget Dates:** 7/1/2003 - 6/30/2004
- **Direct:** $190,000
- **F&A:** $87,400

**Regulation of Nitric Oxide and Catecholamine Signaling in Drosophila Tracheal Development: New Angiogenic Models**
- **Sponsor:** Univ. of Alabama
- **Budget Dates:** 2/1/2004 - 1/31/2005
- **Direct:** $30,000
- **F&A:** $13,800

### Biochemistry & Molecular Biology

**Mechanism of Apoptosis Inhibition by Bcl-XL**
- **Sponsor:** NIH/NINDS
- **Budget Dates:** 5/1/2004 - 4/30/2005
- **Direct:** $150,000
- **F&A:** $64,500

**SC COBRE for Cardiovascular Disease: Project 3 - BCL-2 and Bax Regulation of Apoptosis in Cardiovascular**
- **Pt:** MARKWALD, ROGER R.
- **Sponsor:** NIH/NCRR
- **Project Dates:** 9/30/2001-6/30/2006
- **Direct:** $158,223
- **F&A:** $68,036
Biochemistry & Molecular Biology

**DOD Phase VI: Project 15 - Translational Research and Cancer Prevention and Control and Risk Factor Identification**

*PI:* REED, CAROLYN E.  
*Sponsor:* Geo-Centers/DOD  
*Direct:* $51,370  
*Award:* GC-3532-03-42153CM (03080703-19)  
*F&A:* 0

---

**Huang, Peng**

Co-Investigator

**Biostatistics, Bioinformatics & Epidemiology**

**Parkinson's Disease Clinical Trial: Statistical Center**

*PI:* TILLEY, BARBARA  
*Sponsor:* NIH/NINDS  
*Direct:* $265,225  
*Award:* 5 U01 NS043127-03 (03060207)  
*F&A:* 114,047

---

**Huang, Yan**

Principal Investigator

**The Effects of Insulin-Sensitizing Thiazolidinediones on the Stability of Atherosclerotic Plaque**

*Sponsor:* VAMC Merit Award  
*Direct:* $153,900  
*Award:* (03063009)  
*F&A:* 0

---

**Hueston, William**

Principal Investigator

**Academic Administrative Units in Primary Care**

*Sponsor:* HRSA/BHP/Medicine  
*Direct:* $152,000  
*Award:* 8 D54 HP00023-04 (02122002)  
*F&A:* 12,160

---

**Huggins, J.**

Co-Investigator

**Effect of Roflumilast on Exacerbation Rate in Patients with Chronic Obstructive Pulmonary Disease: A 52 Week, Multi-Center, Double-Blind Study with 500 mcg Roflumilast Once Daily Versus Placebo**

*PI:* SAHN, STEVEN A.  
*Sponsor:* Altana Pharma  
*Direct:* $90,291  
*Award:* BY217/M2-111 (04051805)  
*F&A:* 22,573

---

**A Multi-Center, Multi-National, Randomized, Double-Blind, Parallel Group Study of the Effects of Ciclesonide HFA-MDI 640 PG/Day and Beclomethasone HFA-MDI 640 PG/Day on Lens Opacification in Adults Subjects with Moderate to Severe Persistent Asthma**

*PI:* SAHN, STEVEN A.  
*Sponsor:* Aventis Pharmaceutical, Inc.  
*Direct:* $51,340  
*Award:* ONO-612POU011 (04030312)  
*F&A:* 8,537

---

**A Randomized, Double-Blind, Placebo-Controlled, Multi-National, Phase III Study of the Safety and Efficacy of 200 ug Subcutaneous Interferon Gamma-1B (IFN-y-1b) in Patients with Idiopathic Pulmonary Fibrosis GIPF-007**

*PI:* SAHN, STEVEN A.  
*Sponsor:* Intermune, Inc.  
*Direct:* $230,240  
*Award:* PROTOCOL GIPF-007 (04012806)  
*F&A:* 57,500

---

**Hulsey, Thomas**

Principal Investigator

**Evaluation of Echinacea in a Human Rhinovirus Challenge Model**

*Sponsor:* Univ. of Virginia  
*Direct:* $13,211  
*Award:* GC10694-119532 (03082902)  
*F&A:* 5,860
Hulsey, Thomas  
Co-Investigator

**Pediatrics**

**Molecular Determinants of Methotrexate Metabolism in ALL**

<table>
<thead>
<tr>
<th>PI: BARREDO, JULIO</th>
<th>Sponsor: NIH/NCI</th>
<th>Direct: $205,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Dates: 5/1/2004-4/30/2009</td>
<td>Award: 1 R01 CA098152-01A2 (03063003)</td>
<td>F&amp;A: 94,300</td>
</tr>
</tbody>
</table>

**Clinical Research Curriculum Award**

<table>
<thead>
<tr>
<th>PI: KEY, L. LYDON</th>
<th>Sponsor: NIH/NHLBI</th>
<th>Direct: $185,185</th>
</tr>
</thead>
</table>

**Evaluation of Vitamin D Requirements During Pregnancy**

<table>
<thead>
<tr>
<th>PI: HOLLIS, BRUCE W.</th>
<th>Sponsor: NIH/NICHD</th>
<th>Direct: $382,526</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Dates: 9/1/2003-7/31/2008</td>
<td>Award: 1 R01 HD043921-01 (02053004)</td>
<td>F&amp;A: 155,995</td>
</tr>
</tbody>
</table>

**Faculty Development in Primary Care**

<table>
<thead>
<tr>
<th>PI: DARDEN, PAUL M.</th>
<th>Sponsor: HRSA/BHP/Medicine</th>
<th>Direct: $286,001</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Dates: 7/1/2002-6/30/2005</td>
<td>Award: 1 D14 HP00175-02 (02041704)</td>
<td>F&amp;A: 19,272</td>
</tr>
</tbody>
</table>

**Ophthalmology**

**PGF 2a, Natriuretic Peptides and IOP**

|---|---|---|

**Effects of Some Alcon's Compound on MMP Secretion from Ciliary Muscle Cells**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Award: (03111206)</td>
<td>Project Dates: 10/20/2003 - 12/31/2004</td>
<td>F&amp;A: 6,000</td>
</tr>
</tbody>
</table>

**Surgery**

**Extracellular Mechanisms for Thoracic Aortic Aneurysms**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Award: 1 R01 HL075488-01 (03012704)</td>
<td>Project Dates: 12/1/2003 - 11/30/2007</td>
<td>F&amp;A: 103,500</td>
</tr>
</tbody>
</table>

**Co-PI or Project Leader**

**SC COBRE for Cardiovascular Disease: Project 1 - Transgenic Approach to Metalloproteinase Induced Cardiovascular Remodeling**

<table>
<thead>
<tr>
<th>PI: MARKWALD, ROGER R.</th>
<th>Sponsor: NIH/NCRR</th>
<th>Direct: $158,190</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Dates: 9/30/2001-6/30/2006</td>
<td>Award: 5 P20 RR016434-03 (03092304-13)</td>
<td>F&amp;A: 68,022</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sponsor: NIH/NCRR</th>
<th>Budget Dates: 9/30/2001-6/30/2006</th>
<th>Direct: $0</th>
</tr>
</thead>
<tbody>
<tr>
<td>Award: 1 R01 HL075488-01 (03012704)</td>
<td>Project Dates: 12/1/2003 - 11/30/2007</td>
<td>F&amp;A: 0</td>
</tr>
</tbody>
</table>

**SC COBRE for Cardiovascular Disease: Selective Endothelin-A Receptor Inhibition Following Cardiac Surgery: A Safety Study**

<table>
<thead>
<tr>
<th>PI: SPINALE, FRANCIS G.</th>
<th>Sponsor: Encysive, LP</th>
<th>Direct: $101,192</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Dates: 5/1/2004-10/31/2004</td>
<td>Award: (04041504)</td>
<td>F&amp;A: 25,298</td>
</tr>
</tbody>
</table>

**Jaffa, Ayad**

**Principal Investigator**

**Medicine**

**Short-Term Training in Health Professional Schools**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Award: 2 T35 DK007431-20 (04022709)</td>
<td>Project Dates: 5/1/1981 - 4/30/2005</td>
<td>F&amp;A: 8,630</td>
</tr>
</tbody>
</table>

**Kinins Role in Mesangial Cell Fibrosis**

<table>
<thead>
<tr>
<th>Sponsor: NIH/NIDDK</th>
<th>Budget Dates: 5/1/2004 - 4/30/2005</th>
<th>Direct: $175,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Award: 5 R01 DK046543-09 (04022811)</td>
<td>Project Dates: 7/1/1995 - 4/30/2006</td>
<td>F&amp;A: 75,250</td>
</tr>
</tbody>
</table>

**Co-PI or Project Leader**

**Markers and Mechanisms of Vascular Disease in Diabetes: Project 3 - Kallkreins, Kinins and Diabetic Vascular Complications**

<table>
<thead>
<tr>
<th>PI: LOPES-VIRELLA, MARIA</th>
<th>Sponsor: NIH/NHLBI</th>
<th>Direct: $193,348</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Dates: 9/30/1996-8/31/2001</td>
<td>Award: 5 P01 HL055782-08 (03071705-03)</td>
<td>F&amp;A: 83,139</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Award: 5 P01 HL055782-08 (03071705)</td>
<td>Project Dates: 7/1/1995 - 4/30/2006</td>
<td>F&amp;A: 404,925</td>
</tr>
</tbody>
</table>
**JAMES College of Medicine**

### James, Eric
- **Principal Investigator**
- **Ophthalmology**
  - **Molecular Mechanism of Heavy Metal Accumulation by Acanthocephalans**
  - **Sponsor**: Univ. of South Carolina
  - **Budget Dates**: 5/16/2003 - 6/30/2004
  - **Award**: P20 RR16461 (03012405)
  - **Direct**: $43,000

### Jenrette, Joseph
- **Co-Investigator**
- **Radiation Oncology**
  - **Phase V GliaSite Radiation Therapy System (RTS) Registry Protocol for the Treatment of Resectable Malignant Brain Tumors**
  - **PI**: PATEL, SUNIL
  - **Sponsor**: Proxima Therapeutics
  - **Budget Dates**: 6/1/2003-6/1/2013
  - **Direct**: $42,700

### Johnson, Donna
- **Co-Investigator**
- **Obstetrics/Gynecology**
  - **Evaluation of Vitamin D Requirements During Pregnancy**
  - **PI**: HOLLIS, BRUCE W.
  - **Sponsor**: NIH/NICHD
  - **Budget Dates**: 9/1/2003-7/31/2008
  - **Direct**: $382,526

### Johnson, George
- **Principal Investigator**
- **Pediatrics**
  - **SC Children's AIDS Care System**
  - **Sponsor**: SC DHEC
  - **Budget Dates**: 8/1/2003 - 7/31/2004
  - **Direct**: $123,889
- **Perinatal HIV Prevention Services**
  - **Sponsor**: SC DHEC
  - **Budget Dates**: 8/1/2000 - 12/31/2003
  - **Direct**: $123,889

### Jollow, David
- **Co-Investigator**
- **Cell & Molecular Pharmacology**
  - **Environmental Biosciences Program: EnvTox-Environmental Toxicology**
  - **PI**: MOHR, JR., LAWRENCE C.
  - **Sponsor**: DOE
  - **Budget Dates**: 6/1/2003-5/31/2008
  - **Direct**: $432,856
- **Primaquine-Induced Hemolytic Anemia**
  - **PI**: MCMILLAN, DAVID C.
  - **Sponsor**: NIH/NIAID
  - **Budget Dates**: 1/1/2001-12/31/2004
  - **Direct**: $200,000

### Judson, Marc
- **Principal Investigator**
- **Medicine**
  - **The Development and Validation of a Lupus Pernio Score (LuPAS) in Sarcoidosis**
  - **Sponsor**: Univ. Internal Medical Associates
  - **Budget Dates**: 11/1/2003 - 10/31/2004
  - **Direct**: $8,000
- **A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy Infliximab in Subjects with Chronic Sarcoidosis with Pulmonary Involvement**
  - **Sponsor**: Centocor, Inc.
  - **Budget Dates**: 8/1/2003 - 3/15/2005
  - **Direct**: $45,800
- **Mycophenolate for Pulmonary Sarcoidosis**
  - **Sponsor**: Roche Laboratories
  - **Budget Dates**: 8/1/2003 - 3/15/2005
  - **Direct**: $105,790
- **A Phase II, Multi-Center, Randomized, Parallel-Group, Dose-Finding Study Evaluating the Safety and Efficacy of Inflimad Administration in Symptomatic Subjects with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)**
  - **PI**: SAHN, STEVEN A.
  - **Sponsor**: Centocor, Inc.
  - **Budget Dates**: 8/1/2003 - 3/15/2005
  - **Direct**: $57,200

### Kalivas, Peter
- **Principal Investigator**
- **Physiology and Neuroscience**
  - **The Neurobiology of Addiction Research Center**
  - **Sponsor**: NIH/NIDA
  - **Budget Dates**: 5/1/2004 - 6/30/2004
  - **Direct**: $838,437
- **Cocaine Opioids and Drug Abuse**
  - **Sponsor**: NIH/NIDA
  - **Budget Dates**: 6/1/2004 - 5/31/2005
  - **Direct**: $175,000
<table>
<thead>
<tr>
<th>Name</th>
<th>Department</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F&amp;A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kalivas, Peter</td>
<td>Physiology and Neuroscience</td>
<td>Glutamate and Craving for Cocaine</td>
<td>NIH/NIDA</td>
<td>2/1/2004 - 1/31/2005</td>
<td>$144,798</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Neurobiology of Addiction Research Center (NARC)</td>
<td>NIH/NIDA</td>
<td>8/1/2003 - 4/30/2004</td>
<td>$895,481</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Treatment and Gene/Protein Analysis of Ethanol Relapse</td>
<td>NIH/NIAAA</td>
<td>3/1/2003-2/29/2008</td>
<td>$250,000</td>
<td></td>
</tr>
<tr>
<td>Kamen, Diane</td>
<td>Medicine</td>
<td>CHORD Fellowship</td>
<td>Arthritis Fdn.</td>
<td>7/1/2003 - 6/30/2005</td>
<td>$35,500</td>
<td></td>
</tr>
<tr>
<td>Kang, Qian</td>
<td>Orthopedic Surgery</td>
<td>The Use of Platelet-Rich Plasma for Repairing Cartilage Defects</td>
<td>AO Fdn.</td>
<td>03-K35 (03040105)</td>
<td>$35,927</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Markers and Mechanisms of Vascular Disease in Diabetes</td>
<td>NIH/NHLBI</td>
<td>9/30/1996-8/31/2006</td>
<td>$1,402,342</td>
<td></td>
</tr>
<tr>
<td>Keane, Thomas</td>
<td>Urology</td>
<td>MVAC in Organ Confined Bladder Cancer Based on PS3 Status</td>
<td>Univ. of Southern California</td>
<td>7/1/2003 - 7/1/2003</td>
<td>$5,560</td>
<td></td>
</tr>
</tbody>
</table>

**Faculty Activity by College**

**Medical University of South Carolina**

**College of Medicine**

<table>
<thead>
<tr>
<th>Principal Investigator</th>
<th>Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F&amp;A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kalivas, Peter</td>
<td>Physiology and Neuroscience</td>
<td>NIH/NIDA</td>
<td>2/1/2004 - 1/31/2005</td>
<td>$144,798</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Neurobiology of Addiction Research Center (NARC)</td>
<td>NIH/NIDA</td>
<td>8/1/2003 - 4/30/2004</td>
<td>$895,481</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Treatment and Gene/Protein Analysis of Ethanol Relapse</td>
<td>NIH/NIAAA</td>
<td>3/1/2003-2/29/2008</td>
<td>$250,000</td>
<td></td>
</tr>
<tr>
<td>Kamen, Diane</td>
<td>Medicine</td>
<td>Arthritis Fdn.</td>
<td>7/1/2003 - 6/30/2005</td>
<td>$35,500</td>
<td></td>
</tr>
<tr>
<td>Kang, Qian</td>
<td>Orthopedic Surgery</td>
<td>AO Fdn.</td>
<td>03-K35 (03040105)</td>
<td>$35,927</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Markers and Mechanisms of Vascular Disease in Diabetes</td>
<td>NIH/NHLBI</td>
<td>9/30/1996-8/31/2006</td>
<td>$1,402,342</td>
<td></td>
</tr>
<tr>
<td>Keane, Thomas</td>
<td>Urology</td>
<td>Univ. of Southern California</td>
<td>7/1/2003 - 7/1/2003</td>
<td>$5,560</td>
<td></td>
</tr>
</tbody>
</table>
Keane, Thomas  
**Principal Investigator**

**Urology**
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5mg Administered Orally Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer  
Sponsor: GlaxoSmithKline  
Award: AR140006 (03052901)

Kern, Michael  
**Co-PI or Project Leader**

**Cell Biology & Anatomy**
SC COBRE for Cardiovascular Disease: Core B - Transgenic Mouse Core  
Pt: MARKWALD, ROGER R.  
Sponsor: NIH/NCRR  
Project Dates: 9/1/2003-6/30/2005  
Award: 5 P20 RR016434-03 (03012111-01)

Kerrigan, Susan  
**Co-Investigator**

**Obstetrics/Gynecology**
Efficacy and Safety of Duloxetine Compared with Placebo in Subjects with Symptoms of Bladder Overactivity Due to Pure Detrusor Instability or Sensory Urgency  
Pt: SWIFT, STEVEN E.  
Sponsor: Quintiles Pacific, Inc.  
Project Dates: 7/1/2003-6/30/2005  
Award: F1J-MC-SBBL (01060702)

Key, Janice  
**Principal Investigator**

**Pediatrics**
Comprehensive Care of Adolescent Families  
Sponsor: APHA0002040-03-00 (03032105)  
Award: 1R01 HL107405-01 (03062617)

Key, L.  
**Principal Investigator**

**Pediatrics**
Educational Grant for Residency Program  
Sponsor: Novartis Corp.  
Award: (03092303)

Preventing Diabetes Using Simvastatin in the NOD Mouse Model  
Sponsor: Merck  
Award: (03071501)

Clinical Research Curriculum Award  
Sponsor: NIH/NHLBI  
Award: 5 K30 HL004536-04 (03062617)

Phase II Study of Alendronate Sodium (Fosamax) in Juvenile Osteoporosis  
Sponsor: FDA  
Award: FD-R-001847-03 (03040706)

Clinical Trial of Alendronate +/- Nutropin AQ in Patients with OI  
Sponsor: Genentech, Inc.  
Award: 302-F05R (02031914)

Evaluation of Vitamin D Requirements During Pregnancy  
Pt: HOLLIS, BRUCE W.  
Sponsor: NIH/NICHD  
Project Dates: 9/1/2003-7/31/2008  
Award: 1 R01 HD043921-01 (02053004)
### Pediatrics

**Reactive Nitrogen and Cerebral Ischemic Injury**
- **Principal Investigator**: Khan, Mush
- **Sponsor**: NIH/NINDS
- **Award**: 5 R01 NS040144-05 (03013003)
- **Budget Dates**: 4/15/2000 - 3/31/2005
- **Direct**: $135,090
- **F&A**: $58,089

**Cell & Molecular Pharmacology**

**Individual Predoctoral Dental Scientist Fellowship**
- **Principal Investigator**: Kibbey, Megan
- **Sponsor**: NIH/NIDCR
- **Budget Dates**: 10/1/2003 - 9/30/2004
- **Direct**: $23,718

### Psychiatry & Behavioral Sciences

**Placebo-Controlled Trial of Risperidone Augumentation for SSRI-Resistant Civilian PTSD**
- **PI**: BRADY, KATHLEEN T.
- **Sponsor**: Janssen Medical Affairs, LLC
- **Direct**: $172,292
- **F&A**: $43,073

**A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of GABITRIL, at Dosages up to 16 mg/day, in Adults with Chronic, Post-Traumatic Stress Disorder**
- **PI**: SONNE, SUSAN
- **Sponsor**: Cephalon, Inc.
- **Budget Dates**: 7/21/2003-7/21/2004
- **Direct**: $48,275
- **F&A**: $12,069

**A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of GABITRIL at Dosages up to 16mg/day in the Treatment of Chronic Post-Traumatic Stress Disorder in Adults**
- **PI**: SONNE, SUSAN
- **Sponsor**: Cephalon, Inc.
- **Budget Dates**: 4/1/2003-4/1/2005
- **Direct**: $62,560
- **F&A**: $15,640

**Southeastern Node of the Clinical Trials Network**
- **PI**: BRADY, KATHLEEN T.
- **Sponsor**: NIH/NIDA
- **Budget Dates**: 9/30/2000-8/31/2005
- **Direct**: $1,307,975
- **F&A**: $392,075

**Paroxetine Treatment in Outpatients with Comorbid PTSD and Substance Dependence**
- **PI**: SONNE, SUSAN
- **Sponsor**: GlaxoSmithKline
- **Budget Dates**: 10/1/2002-7/31/2005
- **Direct**: $8,960
- **F&A**: $2,240

**Graduate Psychology Education Programs: Internship Training in Health and Community Psychology**
- **Sponsor**: HRSA/BHP/Medicine
- **Budget Dates**: 5/1/2004 - 4/30/2005
- **Direct**: $127,824
- **F&A**: $10,226

**Disaster Research Education and Mentoring Center**
- **Sponsor**: NIH/NIMH
- **Budget Dates**: 4/14/2004 - 12/31/2004
- **Direct**: $250,000
- **F&A**: $12,062

**Child Violence, Adult Victimization, Injury and Health**
- **Sponsor**: CDC
- **Budget Dates**: 9/30/2003 - 9/29/2005
- **Direct**: $208,426
- **F&A**: $89,623

**Graduate Psychology Education Programs: Internship Training in Behavioral Medicine and Trauma**
- **Sponsor**: HRSA/BHP/Medicine
- **Budget Dates**: 9/30/2002 - 4/30/2004
- **Direct**: $79,637
- **F&A**: $6,371

**Child and Adult Trauma Victims: A Training Program**
- **Sponsor**: NIH/NIMH
- **Budget Dates**: 7/1/2003 - 6/30/2004
- **Direct**: $209,370
- **F&A**: $15,190

**Prevention of Postrape Psychopathology and Drug Abuse/Web Based Intervention Following September 11th Attacks**
- **Sponsor**: NIH/NIDA
- **Budget Dates**: 7/1/1999-6/30/2005
- **Direct**: $340,209
- **F&A**: $340,209

**Primary Prevention of Child Sexual Abuse**
- **Sponsor**: CDC
- **Budget Dates**: 9/1/2003-8/31/2005
- **Direct**: $91,922
- **F&A**: $7,354
**KINDY College of Medicine**

**Kindy, Mark**
Principal Investigator

**Physiology and Neuroscience**

**Neuroscience Institute's Development Grant**

- **Sponsor:** Janssen Pharmaceutica  
  - **Budget Dates:** 1/1/2004 - 12/31/2004
  - **Award:** 4336390-4336393 (04052402)
  - **Project Dates:** 1/1/2004 - 12/31/2004
  - **Direct:** $45,000
  - **F&A:** 0

**Nephrilysin and Abeta-Degradation in Alzheimer's Disease**

- **Sponsor:** NIH/NIA  
  - **Budget Dates:** 12/1/2003 - 11/30/2004
  - **Award:** 5 R01 AG019323-03 (03100101)
  - **Project Dates:** 2/1/2002 - 11/30/2005
  - **Direct:** $186,000
  - **F&A:** 39,560

**Oxidized Lipoproteins in Neurodegeneration**

- **Sponsor:** NIH/NINDS  
  - **Budget Dates:** 9/1/2003 - 8/31/2004
  - **Award:** 5 R01 NS039588-04 (03070102)
  - **Project Dates:** 11/1/2002 - 8/31/2005
  - **Direct:** $200,000
  - **F&A:** 92,000

**Neprilysin and Amyloid-Beta Degradation in Alzheimer's Disease**

- **Sponsor:** VAMC Merit Award  
  - **Budget Dates:** 4/1/2004 - 3/31/2005
  - **Award:** NEUD-021-01F (03063010)
  - **Project Dates:** 4/1/2002 - 3/31/2006
  - **Direct:** $85,000
  - **F&A:** 0

**King, Dana**
Principal Investigator

**Family Medicine**

**Prospective Study on the Effect of Beta Blocker Treatment with Toprol-XL to Reduce C-Reactive Protein Levels in High-Risk Patients with Hypertension, Diabetes and/or Heart Failure**

- **Sponsor:** Astrazeneca  
  - **Budget Dates:** 1/1/2004 - 12/31/2004
  - **Award:** (03111407)
  - **Project Dates:** 1/1/2004 - 12/31/2004
  - **Direct:** $115,987
  - **F&A:** 28,997

**Dietary Fiber and Cardiovascular Inflammatory Markers**

- **Sponsor:** NIH/NHLBI  
  - **Budget Dates:** 5/15/2004 - 3/31/2004
  - **Award:** 1 R01 HL076271-01 (03052904)
  - **Project Dates:** 5/15/2004 - 3/31/2007
  - **Direct:** $302,806
  - **F&A:** 113,623

**Co-Investigator**

**Common Health Conditions in Rural African Americans**

- **PI:** MAINOUS, ARCH  
  - **Sponsor:** Univ. of South Carolina  
  - **Direct:** $53,563
  - **Project Dates:** 9/1/2001-8/31/2005
  - **Award:** 5 U1C RH00045-03 (03021102)
  - **F&A:** 24,639

**Klein, Richard**
Principal Investigator

**Medicine**

**Interactions of Lipoproteins and Cells in Diabetes Mellitus**

- **Sponsor:** VAMC Merit Award  
  - **Budget Dates:** 10/1/2003 - 9/30/2004
  - **Award:** (03063021)
  - **Project Dates:** 10/1/2002 - 9/30/2005
  - **Direct:** $174,184
  - **F&A:** 0

**Markers and Mechanisms of Vascular Disease in Diabetes**

- **PI:** LOPEZ-IRELIA, MARIO  
  - **Sponsor:** NIH/NHLBI  
  - **Project Dates:** 9/30/1996-8/31/2006
  - **Award:** 5 P01 HL055782-08 (03071705)
  - **Direct:** $1,402,342
  - **F&A:** 404,925

**Co-Investigator**

**Klett, Eric**
Principal Investigator

**Medicine**

**Affects of Ezetimibe and Simvastatin on Plant Sterol Levels in Patients with Type II Diabetes Mellitus**

- **Sponsor:** Merck  
  - **Budget Dates:** 7/1/2003 - 7/1/2005
  - **Award:** PROTOCOL 03-055 (03060301)
  - **Project Dates:** 7/1/2003 - 7/1/2005
  - **Direct:** $17,600
  - **F&A:** 4,400

**Klett, Nicole**
Co-PI or Project Leader

**Medicine**

**Cardiovascular Disease Risk in Young Patients with RA**

- **PI:** BOLSTER, MARCY B.  
  - **Sponsor:** Amgen  
  - **Project Dates:** 7/1/2003-12/31/2004
  - **Award:** (03080603-01)
  - **Direct:** $25,000
  - **F&A:** 0

**Knapp, Daniel**
Principal Investigator

**Cell & Molecular Pharmacology**

**Microfluidic System for Cancer Proteome Analysis**

- **Sponsor:** NIH/NCI  
  - **Budget Dates:** 2/5/2004 - 1/31/2005
  - **Award:** 4 R33 CA086285-02 (03120304)
  - **Project Dates:** 6/1/2002 - 1/31/2007
  - **Direct:** $195,308
  - **F&A:** 77,422

**South Carolina Biomedical Research Infrastructure Network**

- **Sponsor:** Univ. of South Carolina  
  - **Budget Dates:** 9/1/2003 - 6/30/2004
  - **Award:** P20 RR16461 (03102802)
  - **Project Dates:** 9/30/2001 - 8/31/2004
  - **Direct:** $140,995
  - **F&A:** 41,858

**Cardiovascular Proteomics Center**

- **Sponsor:** NIH/NHLBI  
  - **Budget Dates:** 9/30/2003 - 9/29/2004
  - **Award:** N01-HV-281-81-000 (02030610)
  - **Project Dates:** 9/30/2002 - 9/29/2009
  - **Direct:** $1,491,326
  - **F&A:** 573,283

---

**Annual Report for Research FY04 73**
Cell & Molecular Pharmacology

Synthetic Retinal Pigments and Binding Proteins
Pt: CROUCH, ROSALIE K. Sponsor: NIH/NEI Direct: $250,000
Project Dates: 8/1/1983-3/31/2006 Award: 5 R01 EY004939-21 (04020302) F&A: 115,000

Synthetic Retinal Pigments and Binding Proteins - Supplement
Pt: CROUCH, ROSALIE K. Sponsor: NIH/NEI Direct: $82,700
Project Dates: 4/1/2002-3/31/2006 Award: 3 R01 EY004939-20S1 (03011705) F&A: 38,042

Biostatistics, Bioinformatics & Epidemiology

CBT for PTSD among Public Sector Consumers
Pt: FRUEH, B. CHRISTOPHER Sponsor: NIH/NIMH Direct: $104,812
Project Dates: 1/1/2003-12/31/2005 Award: 5 R21 MH065248-02 (03102207) F&A: 20,861

Trauma Within the Psychiatric Setting
Pt: FRUEH, B. CHRISTOPHER Sponsor: NIH/NIMH Direct: $150,000
Project Dates: 7/22/2002-6/30/2005 Award: 5 R01 MH065517-02 (03042503) F&A: 39,100

Telepsychiatry Service Delivery to Trauma Victims
Pt: FRUEH, B. CHRISTOPHER Sponsor: AHCPR/AHRQ Direct: $174,295
Project Dates: 7/5/2002-6/30/2005 Award: 5 R01 HS011642-02 (03022802) F&A: 80,176

Continuation ECT vs Pharmacotherapy: Efficacy and Safety
Pt: BERNSTEIN, HILARY Sponsor: Univ. of Texas Direct: $12,014

Continuation ECT Versus Pharmacotherapy: Efficacy and Safety
Pt: BERNSTEIN, HILARY Sponsor: Long Island Jewish Health System Direct: $15,137
Project Dates: 8/26/2002-4/30/2005 Award: 2 R01 MH55486 (02082206) F&A: 6,963

Continuation ECT Versus Pharmacotherapy: Efficacy and Safety
Pt: BERNSTEIN, HILARY Sponsor: Mayo Fdn. For Medical Research Direct: $15,062
Project Dates: 5/1/2002-4/30/2004 Award: R01 MH55484-06 (02082204) F&A: 6,928

Medicine

An Randomized, Open-Label Study Comparing Treatment with Either Pegylated Liposomal Doxorubicin or Capectabine as First Line Chemotherapy for Metastatic Breast Cancer in Women 65 Years or Older

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral CCI-779 Administered in Combination with Letrozole vs Letrozole Alone as First Line Hormonal Therapy in Postmenopausal Women with Locally Advanced or Metastatic Breast Cancer

A Randomized, Open-Label, Phase III Study of RPR109881 IV Every 3 Weeks Versus Capectabine (Xeloda) Tablets Twice Daily for 2 Weeks in 3-Week Cycles in Patients with Metastatic Breast Cancer Progressing after Taxanes and Anthracycline Therapy

Obstetrics/Gynecology

A Multi-Center, Randomized, Phase III, Comparative Study to Compare the Efficacy and Safety of Taxotere/Carboplatin Combination Therapy Versus Sequential Therapy with Taxotere then Carboplatin as Second-Line Treatment of Patients with Relapsed, Platinum-
Award: DUMC 03 (03122203) Project Dates: 12/22/2003 - 12/1/2006 Direct: 9,900

Ophthalmology

Structure and Function of Rod and Cone Pigments
Award: 5 R01 EY013748-03 (03112604) Project Dates: 3/1/2002 - 2/28/2005 Direct: 75,250
<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Description</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct/Indirect</th>
<th>Co-Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kono, Masahiro</td>
<td><strong>Ophthalmology</strong></td>
<td>Characterization of Rod and Cone-Specific Elements in the Salamander Green Rod/Blue Cone Promoter</td>
<td>Univ. of South Carolina</td>
<td>9/1/2003-6/30/2004</td>
<td>$29,691</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Award: 1 P20 RR16461-04 (03100901)</td>
<td></td>
<td>Project Dates: 5/16/2002 - 6/30/2004</td>
<td>$0</td>
<td></td>
</tr>
<tr>
<td>Koopman, Richell</td>
<td><strong>Family Medicine</strong></td>
<td>Academic Administrative Units in Primary Care</td>
<td>HRSA/BHP/Medicine</td>
<td>9/1/2000-8/31/2006</td>
<td>$152,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Award: 8 D54 HP00023-04 (02122002)</td>
<td></td>
<td>Project Dates: 11/1/2003 - 12/31/2005</td>
<td>$12,160</td>
<td></td>
</tr>
<tr>
<td>Kose, Samet</td>
<td><strong>Psychiatry &amp; Behavioral Sciences</strong></td>
<td>An fMRI Study of Depressed Mothers Hearing Infant Cries</td>
<td>NARSAD</td>
<td>11/1/2003-12/31/2005</td>
<td>$60,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Award: (02072903)</td>
<td></td>
<td>Project Dates: 11/1/2003 - 12/31/2005</td>
<td>$0</td>
<td></td>
</tr>
<tr>
<td>Kozel, Frank</td>
<td><strong>Psychiatry &amp; Behavioral Sciences</strong></td>
<td>A Systemic Plan of Studies Geared to Reducing to Practice the Ability to Use FMRI to Detect Deception within Cooperative Healthy Adults</td>
<td>Cephos Corp.</td>
<td>1/1/2004-5/6/2005</td>
<td>$152,451</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Award: (03111701)</td>
<td></td>
<td>Project Dates: 12/1/2003-12/31/2005</td>
<td>$0</td>
<td></td>
</tr>
<tr>
<td>Kraft, Andrew</td>
<td><strong>Medicine</strong></td>
<td>Hollings Cancer Center Planning Grant</td>
<td>NIH/NCI</td>
<td>8/24/2001-7/31/2005</td>
<td>$59,499</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Award: 5 P20 CA093282-03 (03060206)</td>
<td></td>
<td>Project Dates: 8/24/2001-7/31/2005</td>
<td>$25,584</td>
<td></td>
</tr>
<tr>
<td>Kraveka, Jacqueline</td>
<td><strong>Pediatrics</strong></td>
<td>Children's Oncology Chair Grant</td>
<td>Natl Childhood Cancer Fndtn</td>
<td>3/1/2003-2/29/2004</td>
<td>$15,000</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Role of Ceramide in Human Neuroblastoma Differentiation</td>
<td>NIH/NCI</td>
<td>9/1/2003-8/31/2004</td>
<td>$124,950</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Award: 1 K01 CA100767-01 (02053003)</td>
<td></td>
<td>Project Dates: 9/1/2003-8/31/2008</td>
<td>$9,996</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>SC COBRE in Lipidomics and Pathobiology - Project 4: Role of Ceramide in Human Neuroblastoma Differentiation and Treatment</td>
<td>NIH/NCRR</td>
<td>9/26/2002-6/30/2007</td>
<td>$138,535</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Project Dates: 9/26/2002-6/30/2007</td>
<td></td>
<td>Award: 5 P20 RR017677-02 (03071704-05)</td>
<td>$63,726</td>
<td></td>
</tr>
<tr>
<td>Kruesi, Markus</td>
<td><strong>Psychiatry &amp; Behavioral Sciences</strong></td>
<td>Childhood Social Phobia: Long Term Follow-up</td>
<td>Univ. of Maryland</td>
<td>1/1/2001-12/31/2004</td>
<td>$8,520</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Award: (99101304)</td>
<td></td>
<td>Project Dates: 1/1/2000-12/31/2004</td>
<td>$3,664</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Effects on Virtual Reality Driving Performance in ADHD Adults Treated with Strattera</td>
<td>Eli Lilly</td>
<td>3/1/2004-8/30/2005</td>
<td>$77,500</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Department</td>
<td>Role</td>
<td>Project Title</td>
<td>PI/Co-Investigator</td>
<td>Sponsor</td>
<td>Budget Dates</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------------------------</td>
<td>-------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-----------------------------</td>
<td>--------------------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 9/30/2002-9/29/2009 Award</td>
<td>N01-HV-281-81-000 (02030610)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Biology</td>
<td></td>
<td>Project Dates: 8/1/1998 - 5/31/2006 Award</td>
<td>5 R01 DK054388-08 (04031903)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 8/1/1998 - 5/31/2006 Award</td>
<td>5 R01 DK054388-07 (03052306)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kubalak, Steven</td>
<td>Cell Biology &amp; Anatomy</td>
<td>Principal Investigator</td>
<td>Cardiovascular Remodeling Mediated by RxRα Receptors</td>
<td>Gourdie, Robert</td>
<td>NIH/NICHD</td>
<td>10/1/2003 - 6/30/2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 10/1/2003 - 6/30/2004 Award</td>
<td>P20 RR16461 (03093016)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 10/1/2003 - 6/30/2004 Award</td>
<td>5 P01 HD039946-05 (04050605-07)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 10/1/2003 - 6/30/2004 Award</td>
<td>5 P01 HL052813-10 (04022612-08)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kuppuswamy, Dhandapani</td>
<td>Medicine</td>
<td>Principal Investigator</td>
<td>S6K Activation in Hypertrophying Myocardium</td>
<td>Gourdie, Robert</td>
<td>VAMC Merit Award</td>
<td>10/1/2003 - 9/30/2004</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 10/1/2003 - 9/30/2004 Award</td>
<td>CARD-006-02(S (03063011)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Co-Investigator</td>
<td>Load-Induced Cardiac Hypertrophy in the Adult Mammal - Project 5: Integrin Signaling in Cardiac Hypertrophy</td>
<td>Cooper, IV, George</td>
<td>NIH/NHLBI</td>
<td>8/1/1993-7/31/2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 10/1/2002 - 9/30/2006 Award</td>
<td>2 P01 HL048788-11 (03012709-10)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Co-Investigator</td>
<td>Signaling Pathways Mediating NCX1 Expression</td>
<td>Menick, Donald R.</td>
<td>NIH/NHLBI</td>
<td>9/30/2001-7/31/2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 10/1/2002 - 9/30/2006 Award</td>
<td>5 P01 HL066223-03 (03060204)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 10/1/2003 - 9/30/2004 Award</td>
<td>(03060909)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Co-Investigator</td>
<td>SC Cooperative for Healthy Aging in Minority Populations</td>
<td>Tille, Barbara</td>
<td>NIH/NIA</td>
<td>9/30/2002-8/31/2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 10/1/2003 - 9/30/2004 Award</td>
<td>5 P30 AG021677-02 (03071007)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 10/1/2003 - 9/30/2004 Award</td>
<td>DE-FC09-02CH11109 (04030301-05)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Co-Investigator</td>
<td>Inhibition of IGF Mediated Tumorigenesis</td>
<td>Rozen, Steven</td>
<td>NIH/NCI</td>
<td>4/1/2000-3/31/2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Project Dates: 10/1/2003 - 9/30/2004 Award</td>
<td>5 R01 CA078887-05 (04020303)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Kurtz, David  
Co-Investigator

**Role of Retinal Pigment Epithelium in Choroidal Neovascularization**  
PI: ROSENZWEIG, STEVEN A.  
Sponsor: Amer, Health Assistance Fdn.  
Award: (03102102)  
Direct: $50,000  
F&A: 0

**Role of Eicosanoids in Shock**  
PI: COOK, JAMES A.  
Sponsor: NIH/NIGMS  
Award: 5 R01 GM027673-22 (03042902)  
Direct: $247,596  
F&A: 105,279

**Effects of Neurotropin on Gene Expression in Leukocytes of Allergic Rhinitis Patients**  
PI: KUSUMAM, JOSEPH  
Sponsor: Nippon Zoki Pharmaceuticals  
Award: (04060404)  
Direct: $70,000  
F&A: 0

**Effect of Weight Loss Liquid Meal Replacements and Nutritional Bars in a Structured Weight Loss Program on Body Weight and Metabolic Parameters in Individuals with Type 2 Diabetes**  
PI: FERNANDES, JYOTIKA K.  
Sponsor: Abbott Labs  
Award: SRDB30 (04062309)  
Direct: $111,800  
F&A: 27,950

Lackland, Daniel  
Principal Investigator

**Arterial Compliance in Periodontal Patients (Grad. Student-Amal Rastogi)**  
PI: FERNANDES, JYOTIKA K.  
Sponsor: Amer. Assoc. for Dental Research  
Award: (04011504)  
Direct: $2,400  
F&A: 0

**Markers and Mechanisms of Vascular Disease in Diabetes: Core B - Biostatistics and Epidemiology Core**  
PI: LOPES-VIRELLA, MARIA  
Sponsor: NIH/NHLBI  
Award: 5 P01 HL055782-08 (03071705)  
Direct: $1,402,342  
F&A: 404,925

Kusumam, Joseph  
Principal Investigator

**Effects of Neurotropin on Gene Expression in Leukocytes of Allergic Rhinitis Patients**  
PI: KUSUMAM, JOSEPH  
Sponsor: Nippon Zoki Pharmaceuticals  
Direct: $70,000  
F&A: 0

Kwon, Soonho  
Co-Investigator

**Effect of Weight Loss Liquid Meal Replacements and Nutritional Bars in a Structured Weight Loss Program on Body Weight and Metabolic Parameters in Individuals with Type 2 Diabetes**  
PI: FERNANDES, JYOTIKA K.  
Sponsor: Abbott Labs  
Project Dates: 5/20/2002-6/30/2005  
Award: SRDB30 (04062309)  
Direct: $111,800  
F&A: 27,950

**Markers and Mechanisms of Vascular Disease in Diabetes**  
PI: LOPES-VIRELLA, MARIA  
Sponsor: NIH/NHLBI  
Award: 5 P01 HL055782-08 (03071705)  
Direct: $1,402,342  
F&A: 404,925

**Understanding & Eliminating Health Disparities in Blacks**  
PI: TILLEY, BARBARA  
Sponsor: AHCPR/AHRQ  
Project Dates: 9/21/2000-8/31/2005  
Award: 5 P01 HS010871-04 (03071008)  
Direct: $1,583,666  
F&A: 574,732

**Markers and Mechanisms of Vascular Disease in Diabetes**  
PI: LOPES-VIRELLA, MARIA  
Sponsor: NIH/NHLBI  
Award: 5 P01 HL055782-08 (03071705)  
Direct: $1,402,342  
F&A: 404,925

**Savannah River Site Former Production Workers Medical Surveillance Program-Phase II Year 5**  
PI: HOEL, DAVID G.  
Sponsor: DOE  
Award: DE-FC03-97SF21513 (03111404)  
Direct: $381,452  
F&A: 79,945
Faculty Activity by College

Medical University of South Carolina

College of Medicine

Lackland, Daniel  
Co-Investigator

Biostatistics, Bioinformatics & Epidemiology  
Immune Mechanisms of Micro/Macrovacular Disease in Type 1 Diabetes  
Pt: LOPES-VIRELLA, MARIA  
Sponsor: Juvenile Diabetes Fdn.  
Project Dates: 8/1/2002-7/31/2005  
Award: 1 2002-812 (02021503)  
Direct: $232,261  
F&A: 17,739

Black Pooling Project  
Pt: LACKLAND, DANIEL T.  
Sponsor: NIH/NHLBI  
Award: 1 R01 HL72377-01 (02020110)  
Direct: $150,000  
F&A: 69,000

Lacy, Eric  
Principal Investigator

Cell Biology & Anatomy  
Hollings Visiting Scholar Award  
Sponsor: Jardon and Howard Tech.  
Budget Dates: 5/1/2004 - 4/30/2005  
Direct: $99,950  
Award: 1 R01 HL72377-01 (02020110)  
Direct: $22,995  
F&A: 0

Lage, Janice  
Co-Investigator

Pathology & Laboratory Medicine  
Experimental and Clinical Studies of Presbyacusis  
Pt: MILLS, JOHN H.  
Sponsor: NIH/NIDCD  
Project Dates: 7/1/1987-6/30/2007  
Award: 5 P50 DC000422-17 (03042903)  
Direct: $1,060,058  
F&A: 487,627

Lambert, Paul  
Co-PI or Project Leader

Otolaryngology  
Experimental and Clinical Studies of Presbyacusis - Core B  
Pt: MILLS, JOHN H.  
Sponsor: NIH/NIDCD  
Project Dates: 7/1/1987-6/30/2007  
Award: 5 P50 DC000422-17 (03042903-05)  
Direct: $187,198  
F&A: 86,111

Latham, Patricia  
Principal Investigator

Psychiatry & Behavioral Sciences  
Cost-Effectiveness of Alcohol Treatment  
Sponsor: Research Triangle Inst.  
Budget Dates: 8/2/2003 - 7/31/2004  
Direct: $23,874  
Award: 3-42U-7901 (0110701)  
Direct: $23,874  
F&A: 10,266

Lathers, Deanne  
Principal Investigator

Otolaryngology  
CD34+ Cells in Head and Neck Cancer  
Sponsor: VAMC Merit Award  
Budget Dates: 8/1/2003 - 7/31/2004  
Direct: $195,471  
Project Dates: 8/1/2003 - 7/31/2004  
Award: (04063021)  
Direct: $195,471  
F&A: 0

Lavin, Antonieta  
Principal Investigator

Physiology and Neuroscience  
Dopaminergic Modulation of Thalamocortical Circuits  
Sponsor: NIH/NIDA  
Budget Dates: 2/1/2004 - 1/31/2005  
Direct: $150,000  
Award: 5 R01 DA014698-03 (04011301)  
Direct: $150,000  
F&A: 69,000

Lazarchick, John  
Principal Investigator

Physiology and Neuroscience  
Dopamine & Ach Regulation of Inhibition in PFC  
Pt: SEAMANS, JEREMY  
Sponsor: NIH/NIMH  
Award: 5 R01 MH064569-02 (03112605)  
Direct: $150,000  
F&A: 69,000

Fast and Slow Dopamine Signaling in Prefrontal Cortex  
Pt: SEAMANS, JEREMY  
Sponsor: NIH/NIMH  
Project Dates: 8/1/2002-7/31/2007  
Award: 5 R01 MH065924-02 (03052305)  
Direct: $175,000  
F&A: 80,500

Leclerc, Guy  
Co-Investigator

Pathology & Laboratory Medicine  
Platelet Function and PreEclampsia  
Sponsor: Helena Laboratories  
Direct: $13,732  
Award: (03101402)  
Direct: $13,732  
F&A: 3,433

Pediatrics  
Molecular Determinants of Metotrexate Metabolism in ALL  
Pt: BARREDO, JULIO  
Sponsor: NIH/NCI  
Award: 1 R01 CA098152-01A2 (03063003)  
Direct: $205,000  
F&A: 94,300
Lee, David  
Principal Investigator

**Ophthalmology**
A Multi-Center, Multi-National, Randomized, Double-Blind, Parallel Group Study of the Effects of Ciclosonide HFA-MDI 640 ug/Day and Beclomethadone HFA-MDI 640 ug/Day on Lens Opacification in Adult Subjects with Moderate to Severe Persistent Asthma

- **Sponsor:** PPD Development
- **Budget Dates:** 4/19/2004 - 12/31/2006
- **Direct:** $13,715

**Award:** XRP1526B (04061810)

**Lee, Fu-Shing**  
Co-Investigator

**Otolaryngology**
Experimental and Clinical Studies of Presbyacusis

- **PI:** MILLS, JOHN H.
- **Sponsor:** NIH/NIDCD
- **Budget Dates:** 7/1/2003 - 6/30/2005
- **Direct:** $1,060,058

**Award:** 5 P50 DC000422-17 (03042903)

**Leman, Robert**  
Principal Investigator

**Medicine**
Inhibition of Unnecessary RV Pacing with AV Search Hysteresis in ICDs Study (INTRINSIC RV)

- **Sponsor:** Guidant
- **Budget Dates:** 7/1/2003 - 6/30/2005
- **Direct:** $28,080

**Award:** (03070705)

**Dual Chamber and VVI Implantable Defibrillator (DAVID) II Trial**

- **Sponsor:** Univ. of Washington
- **Budget Dates:** 7/1/2003 - 8/31/2006
- **Direct:** $67,078

**Award:** DAVID II (03062609)

**Lichtenstein, Leonard**  
Co-Investigator

**Medicine**
18 Week, Open Label, Cross-Over Study Design Comparing Atorvastatin to Simvastatin in Study Subjects with Type Ila and Iib Hypercholesterolemia and Small LDL Cholesterol Particles

- **PI:** THOMAS, JAMES C.
- **Sponsor:** Pfizer, Inc.
- **Budget Dates:** 6/1/2000-9/30/2002
- **Direct:** $10,976

**Award:** (00061904)

**Lin, Angello**  
Principal Investigator

**Surgery**
Optimizing Prograf Therapy in Maintenance Allografts

- **Sponsor:** Fujisawa Healthcare, Inc.
- **Budget Dates:** 10/3/2003 - 6/30/2005
- **Direct:** $56,940

**Award:** 20-02-002 (03101403)

**Lindsey, Merry**  
Co-Investigator

**Surgery**
Extracellular Mechanisms for Thoracic Aortic Aneurysms

- **PI:** IKONOMIDIS, JOHN
- **Sponsor:** NIH/NHLBI
- **Budget Dates:** 12/1/2003-11/30/2007
- **Direct:** $250,000

**Award:** 1 R01 HL075488-01 (03012704)

**Lipsitz, Stuart**  
Principal Investigator

**Biostatistics, Bioinformatics & Epidemiology**
Methods for Analyzing Repeated Categorical Data

- **Sponsor:** NIH/NHLBI
- **Budget Dates:** 8/1/2003 - 7/31/2005
- **Direct:** $200,000

**Award:** 5 R01 HL069800-12 (03052308)

**Inference in Regression Models with Missing Covariates**

- **Sponsor:** Univ. of North Carolina
- **Budget Dates:** 7/1/2003 - 3/31/2005
- **Direct:** $23,077

**Award:** 5-31637/5 R01 CA74 (03010705)

**Co-PI or Project Leader**
Understanding & Eliminating Health Disparities in Blacks - Biostatistics Core B

- **PI:** TILLEY, BARBARA
- **Sponsor:** AHCPR/AHRQ
- **Budget Dates:** 9/21/2000-8/31/2005
- **Direct:** $299,106

**Award:** 5 P01 HS010871-04 (03071008)

**NIAMS Clinical Research Center for Rheumatoid Disease**

- **PI:** SILVER, RICHARD M.
- **Sponsor:** NIH/NIAMS
- **Budget Dates:** 4/15/2003-3/31/2008
- **Direct:** $855,775

**Award:** 5 P60 AR049459-02 (04020403)

**Lokensgard, Rita**  
Co-Investigator

**Physiology and Neuroscience**
Basolateral Amygdala - A Substrate for Relapse

- **PI:** SEE, RONALD E.
- **Sponsor:** NIH/NIDA
- **Budget Dates:** 4/10/1997-5/31/2007
- **Direct:** $150,000

**Award:** 5 R01 DA010462-08 (04032608)

**London, Lucille**  
Principal Investigator

**Microbiology & Immunology**
Pathogenesis of Viral Specific Fibrosis

- **Sponsor:** SC Biomedical Research Network
- **Budget Dates:** 1/1/2004 - 6/30/2004
- **Direct:** $10,500

**Award:** 1 P20 RR16461 (03092504)
London, Lucille  
Principal Investigator  

Microbiology & Immunology  

Effect of Protein Based Therapeutics on Reovirus 1/L Induced ARDS  
Sponsor: Eli Lilly  
Budget Dates: 1/1/2004 - 12/31/2004  
Direct: $194,892  
Award: (02011109)  
Project Dates: 1/1/2002 - 12/31/2004  
F&A: 89,650  

Environmental Biosciences Program: EnvTox-London-PCB Mixtures  
Pr: MOHR, JR., LAWRENCE C.  
Sponsor: DOE  
Direct: $22,941  
Award: (02011109)  
Project Dates: 9/1/2003 - 8/30/2004  
F&A: 0  

Medicine  

Markers and Mechanisms of Vascular Disease in Diabetes  
Sponsor: Univ. of Oklahoma  
Direct: $95,000  
Award: (04050601)  
Project Dates: 9/1/2000 - 8/31/2005  
F&A: 14,250  

Challenge Study  
Sponsor: Charleston Research Inst.  
Direct: $1,402,342  
Award: 5 P01 HL055782-08  
F&A: 404,925  

Ma, Jian-Xing  
Co-Investigator  

Ophthalmology  

Synthetic Retinal Pigments and Binding Proteins - Supplement  
Pr: CROUCH, ROSALIE K.  
Sponsor: NIH/NEI  
Direct: $82,700  
Award: 3 R01 EY004939-20S1 (03011705)  
F&A: 38,042  

### Pediatrics

**Promoting Happy and Healthy Youth**
- **PI:** SPRATT, EVE
- **Sponsor:** HRSA
- **Direct:** $13,889
- **Award:** 1 T21 MC00123-01 O (03062613)
- **F&A:** 1,111

#### Co-Investigator
- Macias, Michelle
  - **Department:** Pediatrics
  - **Project Dates:** 7/1/2003-6/30/2006

**Phase II Study of Alendronate Sodium (Fosamax) in Juvenile Osteoporosis**
- **PI:** KEY, L. LYNDON
- **Sponsor:** FDA
- **Direct:** $227,606
- **Award:** FD-R-001847-03 (03040706)
- **F&A:** 98,259

#### Co-Investigator
- Madyastha, Prema
  - **Department:** Pediatrics
  - **Project Dates:** 9/30/2000-9/29/2006

### Psychiatry & Behavioral Sciences

**Southeastern Node of the Clinical Trials Network**
- **PI:** BRADY, KATHLEEN T.
- **Sponsor:** NIH/NIDA
- **Direct:** $1,307,975
- **Award:** 5 U10 DA013727-04 (03062618)
- **F&A:** 392,075

#### Co-Investigator
- Magruder, Kathryn
  - **Department:** Psychiatry & Behavioral Sciences
  - **Project Dates:** 9/30/2000-8/31/2005

### Family Medicine

**Faculty Development in Primary Care**
- **Sponsor:** HRSA/BHP/Medicine
- **Budget Dates:** 7/1/2003 - 6/30/2004
- **Direct:** $265,638
- **Award:** 5 D14 HP00161-02 (03042810)
- **F&A:** 18,820

#### Co-PI or Project Leader
- Mainous, Arch
  - **Department:** Family Medicine
  - **Project Dates:** 7/1/2000-8/31/2005

**Common Health Conditions in Rural African Americans**
- **Sponsor:** Univ. of South Carolina
- **Budget Dates:** 9/1/2003 - 8/31/2005
- **Direct:** $53,563
- **Award:** 5 U1C RH00045-03 (03021102)
- **F&A:** 24,639

#### Co-Investigator
- Malcolm, Robert
  - **Department:** Psychiatry & Behavioral Sciences
  - **Project Dates:** 9/1/2000-8/31/2005

### Psychiatry & Behavioral Sciences

**CBT and Modafinil For Cocaine Addiction**
- **Sponsor:** NIH/NIDA
- **Budget Dates:** 9/30/2003 - 6/30/2004
- **Direct:** $271,637
- **Award:** 1 R01 DA016368-01 (03022404)
- **F&A:** 107,862

#### Co-PI or Project Leader
- Malcolm, Robert
  - **Department:** Psychiatry & Behavioral Sciences
  - **Project Dates:** 9/30/2003 - 6/30/2007

**Genetics of Cocaine Dependence**
- **PI:** BRADY, KATHLEEN T.
- **Sponsor:** Yale Univ.
- **Direct:** $49,762
- **Award:** 1 R01 DA12849-02 (99012103)
- **F&A:** 21,398

#### Co-Investigator
- Malcolm, Robert
  - **Department:** Psychiatry & Behavioral Sciences
  - **Project Dates:** 9/30/1999-8/31/2004

### Pharmacokinetics of Olanzapine after Oral Administration of Standard Tablet Versus Normal and Sublingual Administration of Orally Disintegrating Tablets (Zyprexa-Zydis) in Healthy Adults
- **PI:** MARKOWITZ, JOHN S.
- **Sponsor:** Eli Lilly
- **Direct:** $75,850
- **Award:** F1D-MC-X259 (04012109)
- **F&A:** 18,962

### Southeastern Node of the Clinical Trials Network
- **PI:** BRADY, KATHLEEN T.
- **Sponsor:** NIH/NIDA
- **Direct:** $1,307,975
- **Award:** 5 U10 DA13727-04 (03062618)
- **F&A:** 392,075

### Gabapentin as an Adjunct to Naltrexone for Alcoholism
- **PI:** ANTON, JR., RAYMOND F.
- **Sponsor:** NIH/NIAAA
- **Direct:** $317,382
- **Award:** 5 R01 AA009568-12 (03022404)
- **F&A:** 145,996

### Methylphenidate-Ethanol Interaction in ADHD and Coabuse
- **PI:** PATRICK, KENNERLY S.
- **Sponsor:** NIH/NIDA
- **Direct:** $175,000
- **Award:** 5 R01 DA15797-02 (03061802)
- **F&A:** 80,500

---

*Annual Report for Research FY04*
<table>
<thead>
<tr>
<th>College of Medicine</th>
<th>Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mao, Cungui</td>
<td>Co-PI or Project Leader</td>
</tr>
<tr>
<td>REED</td>
<td>DOD Phase VI: Project 4 - Translational Research and Cancer Prevention and Control and Risk Factor Identification</td>
</tr>
<tr>
<td>Pt: REED, CAROLYN E.</td>
<td>Sponsor: Geo-Centers/DOD</td>
</tr>
<tr>
<td>Direct: $51,370</td>
<td>Award: GC-3532-03-42153CM (03080703-06)</td>
</tr>
<tr>
<td>SC COBRE in Lipidomics and Pathobiology - Project 5: Human Alkaline Phytoceramidase Regulation of Angiogenesis</td>
<td></td>
</tr>
<tr>
<td>Pt: OBEID, LINA</td>
<td>Sponsor: NIH/NCCR</td>
</tr>
<tr>
<td>Direct: $154,438</td>
<td>Award: 5 P20 RR017677-02 (03071704-06)</td>
</tr>
<tr>
<td>Sphingosine Phosphate Phosphatases - Regulation and Role</td>
<td></td>
</tr>
<tr>
<td>Pt: OBEID, LINA</td>
<td>Sponsor: NIH/NIGMS</td>
</tr>
<tr>
<td>Direct: $150,000</td>
<td>Award: 5 R01 GM062887-04 (04022608)</td>
</tr>
<tr>
<td>F&amp;A: 64,500</td>
<td>Project Dates: 5/1/2001-4/30/2005</td>
</tr>
<tr>
<td>Co-Investigator</td>
<td>PI: MARKWALD, ROGER</td>
</tr>
<tr>
<td></td>
<td>Principal Investigator</td>
</tr>
<tr>
<td></td>
<td>Cardiac Valvuloseptal Morphogenesis</td>
</tr>
<tr>
<td>Direct: $1,245,970</td>
<td>Award: 5 P01 HL052813-10 (04022612)</td>
</tr>
<tr>
<td>SC COBRE for Cardiovascular Disease:</td>
<td></td>
</tr>
<tr>
<td>Direct: $1,722,041</td>
<td>Award: 5 P20 RR016434-03 (03092304)</td>
</tr>
<tr>
<td>Mucopolysaccharide Metabolism in Cardiac Anomalies</td>
<td></td>
</tr>
<tr>
<td>Direct: $250,000</td>
<td>Award: 5 R01 HL033756-21 (03050603)</td>
</tr>
<tr>
<td>Supplement to P20 RR16434: COBRE Core C Enhancement</td>
<td></td>
</tr>
<tr>
<td>Direct: $262,937</td>
<td>Award: 3 P20 RR016434-03S (03021401)</td>
</tr>
<tr>
<td>Cardiovascular Tissue Engineering</td>
<td></td>
</tr>
<tr>
<td>Direct: $86,645</td>
<td>Award: H51 65 (01102206)</td>
</tr>
<tr>
<td>NASA/EPSCoR: Cardiovascular Tissue Engineering</td>
<td></td>
</tr>
<tr>
<td>Sponsor: Coll. of Charleston</td>
<td>Budget Dates: 8/1/2003 - 7/31/2005</td>
</tr>
<tr>
<td>Direct: $128,196</td>
<td>Award: NCC5-575 (00120601)</td>
</tr>
<tr>
<td>F&amp;A: 46,804</td>
<td>Project Dates: 8/1/2003 - 7/31/2005</td>
</tr>
<tr>
<td>Co-PI or Project Leader</td>
<td>PI: KAPP, DANIEL R.</td>
</tr>
<tr>
<td></td>
<td>Sponsor: NIH/NHLBI</td>
</tr>
<tr>
<td>Direct: $117,784</td>
<td>Award: 5 N01-HV-281-81-000 (02030610-14)</td>
</tr>
<tr>
<td>Maroulakou, Ioanna</td>
<td>Co-Investigator</td>
</tr>
<tr>
<td></td>
<td>Medicine</td>
</tr>
<tr>
<td></td>
<td>Role of an Epithelial Ets Factor in Breast Cancer</td>
</tr>
<tr>
<td>Pt: WATSON, DENNIS K.</td>
<td>Sponsor: NIH/NCI</td>
</tr>
<tr>
<td>Direct: $222,500</td>
<td>Award: 1 R01 CA102297-01 (02100204)</td>
</tr>
<tr>
<td></td>
<td>Pediatrics</td>
</tr>
<tr>
<td>Marsh, Linda</td>
<td>Co-Investigator</td>
</tr>
<tr>
<td></td>
<td>Comprehensive Care of Adolescent Families</td>
</tr>
<tr>
<td>Pt: KEY, JANICE</td>
<td>Sponsor: DHHS</td>
</tr>
<tr>
<td>Direct: $179,625</td>
<td>Award: APHPA002040-03-00 (03032105)</td>
</tr>
</tbody>
</table>
Marsh, Linda  
Co-Investigator  
**Pediatrics**  
Best Chance  
Pt: KEY, JANICE  
Sponsor: DHHS  
Project Dates: 7/1/2002-6/30/2007  
Award: 5 APHPA002071-02-00 (03032104)  
Direct: $183,171  
F&A: 46,429

Martin-Harris, Bonnie  
Principal Investigator  
**Otolaryngology**  
Standardized Assessment of Swallowing Impairment  
Sponsor: NIH/NIDCD  
Budget Dates: 5/1/2004 - 4/30/2005  
Direct: $182,930  
Award: 5 K23 DC005764-02 (04022606)  
Project Dates: 7/1/2003 - 4/30/2008  
F&A: 13,174

Matthews, Lois  
Co-Investigator  
**Otolaryngology**  
Experimental and Clinical Studies of Presbyacusis  
Pt: MILLS, JOHN H.  
Sponsor: NIH/NIDCD  
Project Dates: 7/1/1987-6/30/2007  
Award: 5 P50 DC00422-17 (03042903)  
Direct: $1,060,058  
F&A: 487,627

May, Harold  
Principal Investigator  
**Microbiology & Immunology**  
Microbial Degradation of Petroleum Hydrocarbons and PCB's  
Sponsor: NIH/NIEHS  
Budget Dates: 9/30/2003 - 7/31/2004  
Direct: $150,000  
Award: 1 R21 ES012815-01 (03050206)  
Project Dates: 9/30/2003 - 7/31/2005  
F&A: 61,180

Mayfield, Ronald  
Principal Investigator  
**Medicine**  
A Double-Blind, Randomized, Comparator-Controlled Study in Subjects with Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCI vs Glimepiride on the Rate of Progression of Coronary Atherosclerotic Disease as Measured by Intravascular  
Sponsor: Omni Care  
Direct: $72,317  
Award: 01-01-TL-OP1-516 (04061403)  
F&A: 18,079

McBurney, Patricia  
Principal Investigator  
**Pediatrics**  
Racial Disparities: Is it the Content of the Care?  
Sponsor: Ambulatory Pediatric Assoc.  
Budget Dates: 7/1/2003 - 6/30/2004  
Direct: $7,500  
Award: (03072204)  
Project Dates: 7/1/2003 - 6/30/2004  
F&A: 0

McCarthy, Robert  
Co-Investigator  
**Cell Biology & Anatomy**  
The Role of Megalin in Craniofacial Development  
Pt: ARGRAVES, W. SCOTT  
Sponsor: NIH/NIDCR  
Award: 5 R01 DE014347-02 (03120303)  
Direct: $200,000  
F&A: 92,000
### College of Medicine

#### McDermott, Paul

**Principal Investigator**

**Medicine**

*Contractile Regulation of Cardiocyte Protein in Synthesis*

- **Sponsor:** VAMC Merit Award
- **Budget Dates:** 4/1/2004 - 3/31/2005
- **Direct:** $167,987
- **Award:** GMED-007-00F (03063022)
- **Project Dates:** 4/1/2001 - 3/31/2005
- **F&A:** 0

Co-PI or Project Leader

*Load-Induced Cardiac Hypertrophy in the Adult Mammal - Project 1: Translational Regulation of Cardiocyte Protein Synthesis*

- **PI:** COOPER, IV, GEORGE
- **Sponsor:** NIH/NHLBI
- **Direct:** $156,948
- **Project Dates:** 8/1/1993-7/31/2008
- **Award:** 2 P01 HL048788-11 (03012709-03)
- **F&A:** 72,196

#### McEvoy, Matthew

**Co-PI or Project Leader**

**Anesthesiology**

*A Prospective, Consecutive Series, Clinical Evaluation of Primary Hip Replacement Utilizing Exeter Femoral Stems (with Orthinox Femoral Heads) for Cemented Indications in Combinations with Cementless Trident Hemispherical Acetabular Shell and CrossFire*

- **PI:** SCHRUTTE, DEL
- **Sponsor:** Stryker Howmedica Osteonics
- **Direct:** $54,696
- **Project Dates:** 7/1/2003-1/1/2009
- **Award:** (03031901-01)
- **F&A:** 13,674

#### McFarland, Krista

**Principal Investigator**

**Physiology and Neuroscience**

*Stress-Induced Reinstatement of Cocaine-Seeking Behavior*

- **Sponsor:** NIH/NIDA
- **Budget Dates:** 4/10/2004 - 3/31/2005
- **Direct:** $175,000
- **Award:** 1 R01 DA015851-01A (03062402)
- **Project Dates:** 4/10/2004 - 3/31/2009
- **F&A:** 57,500

Co-PI or Project Leader

*The Neurobiology of Addiction Research Center: Mapping Brain Circuitry of Drug-Seeking Behavior Project 1*

- **PI:** KALIVAS, PETER
- **Sponsor:** NIH/NIDA
- **Direct:** $61,644
- **Project Dates:** 8/1/2003-4/30/2008
- **Award:** 5 P50 DA01539-02 (04042701-04)
- **F&A:** 28,356

Co-Investigator

*The Neurobiology of Addiction Research Center*

- **PI:** KALIVAS, PETER
- **Sponsor:** NIH/NIDA
- **Direct:** $202,250
- **Project Dates:** 8/1/2003-4/30/2008
- **Award:** 5 P50 DA01539-02 (04042701-05)
- **F&A:** 93,035

#### McGinty, Jacqueline

**Principal Investigator**

**Physiology and Neuroscience**

*Telencephalic Opioid Neurons: Psychostimulant Effects*

- **Sponsor:** NIH/NIDA
- **Budget Dates:** 5/1/2004 - 5/31/2004
- **Direct:** $200,000
- **Award:** 5 R01 DA008392-21 (04032603)
- **Project Dates:** 5/1/2004 - 5/31/2006
- **F&A:** 86,000

**Drug Abuse Training Program**

- **Sponsor:** NIH/NIDA
- **Budget Dates:** 7/1/2003 - 6/30/2004
- **Direct:** $242,129
- **Award:** 5 T32 DA007288-12 (03030306)
- **Project Dates:** 9/30/1991 - 6/30/2007
- **F&A:** 17,722

Co-PI or Project Leader

*The Neurobiology of Addiction Research Center: Changes in Gene and Protein Expression Project 2*

- **PI:** KALIVAS, PETER
- **Sponsor:** NIH/NIDA
- **Direct:** $202,250
- **Project Dates:** 8/1/2003-4/30/2008
- **Award:** 5 P50 DA01539-02 (04042701-05)
- **F&A:** 93,035

*The Neurobiology of Addiction Research Center Pilot Core C*

- **PI:** KALIVAS, PETER
- **Sponsor:** NIH/NIDA
- **Direct:** $91,602
- **Project Dates:** 8/1/2003-4/30/2008
- **Award:** 5 P50 DA01539-02 (04042701-03)
- **F&A:** 42,137

Co-Investigator

*Treatment and Gene/Protein Analysis of Ethanol Relapse*

- **PI:** BECKER, HOWARD C.
- **Sponsor:** NIH/NIAAA
- **Direct:** $250,000
- **Project Dates:** 3/1/2003-2/29/2008
- **Award:** 5 R01 AA013885-02 (03122903)
- **F&A:** 115,000

#### McMillan, David

**Principal Investigator**

**Cell & Molecular Pharmacology**

*Primaquine-Induced Hemolytic Anemia*

- **Sponsor:** NIH/NIAID
- **Budget Dates:** 1/1/2004 - 12/31/2004
- **Direct:** $200,000
- **Award:** 5 R01 AI013885-02 (03010204)
- **Project Dates:** 1/1/2001 - 12/31/2004
- **F&A:** 86,000
<table>
<thead>
<tr>
<th>Faculty Name</th>
<th>College</th>
<th>Department</th>
<th>Role</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F&amp;A</th>
<th>Award</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>McMillan, David</td>
<td>College of Medicine</td>
<td>Cell &amp; Molecular Pharmacology</td>
<td>Co-PI or Project Leader</td>
<td>Environmental Biosciences Program: EnvTox-DMcMillan-Formation of TCE</td>
<td>DOE</td>
<td>6/1/2003-5/31/2008</td>
<td>$118,024</td>
<td>54,291</td>
<td>DE-FC09-02CH11109 (04030301-06)</td>
<td>Co-PI or Project Leader</td>
</tr>
<tr>
<td>McMillan, Joellyn</td>
<td></td>
<td>Environmental Biosciences Program: EnvTox-TCE Induced</td>
<td></td>
<td></td>
<td>DOE</td>
<td>6/1/2003-5/31/2008</td>
<td>$97,228</td>
<td>44,725</td>
<td>DE-FC09-02CH11109 (04030301-04)</td>
<td>Co-PI or Project Leader</td>
</tr>
<tr>
<td>McQuinn, Tim</td>
<td>Pediatrics</td>
<td>Measurement of Clinical Physiologic Variables Using 3 Dimensional Echocardiography</td>
<td>Principal Investigator</td>
<td></td>
<td>SC EPSCOR</td>
<td>9/1/2003 - 6/30/2004</td>
<td>$6,725</td>
<td>0</td>
<td>P20 RR16461 (04051806)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fluid Diode for Pediatric Pulmonary Insufficiency</td>
<td></td>
<td></td>
<td>SC Biomedical Research Network</td>
<td>9/1/2003 - 6/30/2004</td>
<td>$25,000</td>
<td>0</td>
<td>P20 RR16461 (04010802)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Molecular Analysis of Pediatric Cardiovascular Disease</td>
<td></td>
<td></td>
<td>NIH/NHLBI</td>
<td>12/1/2003 - 11/30/2004</td>
<td>$225,000</td>
<td></td>
<td>5 R01 HL067135-03 (03093012)</td>
<td></td>
</tr>
<tr>
<td>McRae, Aimee</td>
<td>Psychiatry &amp; Behavioral Sciences</td>
<td>Evaluating the Safety and Efficacy of Aripiprazole in Patients with Schizophrenia and Comorbid Substance Use Disorder</td>
<td>Principal Investigator</td>
<td></td>
<td>Bristol Myers Squibb</td>
<td>5/1/2003 - 11/30/2004</td>
<td>$123,700</td>
<td>30,925</td>
<td>(03082504)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Career Training in Marijuana Dependence</td>
<td></td>
<td></td>
<td>NIH/NIDA</td>
<td>9/1/2003 - 8/31/2004</td>
<td>$109,040</td>
<td>8,193</td>
<td>K23 DA015440-02 (03062002)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of GABITRIL at Dosages up to 16mg/day in the Treatment of Chronic Post-Traumatic Stress Disorder in Adults</td>
<td></td>
<td></td>
<td>Cephalon, Inc.</td>
<td>4/1/2003-4/1/2005</td>
<td>$62,560</td>
<td>15,640</td>
<td>C6671A/205/PT/US (03070702)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>ORWH: SCOR on Sex and Gender Factors Affecting Women's Health</td>
<td></td>
<td></td>
<td>NIH/NIDA</td>
<td>9/30/2002-6/30/2007</td>
<td>$579,460</td>
<td>266,552</td>
<td>P50 DA016511-02 (03050502)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paroxetine Treatment in Outpatients with Comorbid PTSD and Substance Dependence</td>
<td></td>
<td></td>
<td>GlaxoSmithKline</td>
<td>10/1/2002-7/31/2005</td>
<td>$8,960</td>
<td>2,240</td>
<td>CPMS 857 (02081702)</td>
<td></td>
</tr>
<tr>
<td>Means, Robert</td>
<td>Medicine</td>
<td>Inflammatory Control of Erythropoiesis in Sickle Disease</td>
<td>Principal Investigator</td>
<td></td>
<td>NIH/NHLBI</td>
<td>8/1/2003 - 7/31/2004</td>
<td>$125,000</td>
<td>32,500</td>
<td>R01 HL069418-03 (03052001)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anemia Training Grant/Fellowship</td>
<td></td>
<td></td>
<td>Amgen</td>
<td>7/1/2003 - 6/30/2004</td>
<td>$80,000</td>
<td>0</td>
<td>(03010706)</td>
<td></td>
</tr>
<tr>
<td>Menard, Mary</td>
<td>Obstetrics/Gynecology</td>
<td>Premature Birth Information Center</td>
<td>Principal Investigator</td>
<td></td>
<td>March of Dimes</td>
<td>4/1/2003 - 6/30/2004</td>
<td>$45,455</td>
<td>4,545</td>
<td>(03051201)</td>
<td></td>
</tr>
</tbody>
</table>
MENICK

**Medicine**

**Summer Research Program for Minority Medical Students**
- **Sponsor:** NIH/NHLBI
- **Award:** 2 T35 HL007923-06 (03070205)
- **Budget Dates:** 5/1/2004 - 4/30/2005
- **Direct:** $54,912
- **F&A:** 4,393

**Signaling Pathways Mediating NCX1 Expression**
- **Sponsor:** NIH/NHLBI
- **Award:** 5 R01 HL066223-03 (03060204)
- **Budget Dates:** 8/1/2003 - 7/31/2004
- **Direct:** $250,000
- **F&A:** 107,500

**Training to Improve Cardiovascular Drug Therapy**
- **Sponsor:** NIH/NHLBI
- **Award:** 2 T32 HL007260-27 (03030303)
- **Budget Dates:** 6/4/1999 - 6/30/2007
- **Direct:** $54,912
- **F&A:** 4,393

**Co-PI or Project Leader**

**Load-Induced Cardiac Hypertrophy in the Adult Mammal - Project 3: Cardiac Na-Ca Exchanger: Hypertrophic Regulation**
- **PI:** COOPER, IV, GEORGE
- **Sponsor:** NIH/NHLBI
- **Award:** 5 R01 HL048788-03
- **Project Dates:** 8/1/1993-7/31/2008
- **Direct:** $160,765
- **F&A:** 70,471

**Co-Investigator**

**Load-Induced Cardiac Hypertrophy in the Adult Mammal**
- **PI:** COOPER, IV, GEORGE
- **Sponsor:** NIH/NHLBI
- **Award:** 5 R01 HL048788-03
- **Project Dates:** 8/1/1993-7/31/2008
- **Direct:** $1,400,000
- **F&A:** 643,827

**Psychiatry & Behavioral Sciences**

**Alcohol Research Center-Treatment and Implications: Research Component 2: Evaluation of Drugs for Alcohol Abuse: A Murine Model**
- **PI:** RANDALL, CARRIE L.
- **Sponsor:** NIH/NIAAA
- **Award:** 5 P50 AA010761-09
- **Project Dates:** 12/10/1995-11/30/2005
- **Direct:** $116,629
- **F&A:** 50,150

**ORWH: SCOR on Sex and Gender Factors Affecting Women’s Health: Project 4 - Gender Influence on Preclinical Alcohol Pharmacotherapy**
- **PI:** BRADY, KATHLEEN T.
- **Sponsor:** NIH/NIDA
- **Award:** 5 P50 DA016511-02
- **Project Dates:** 9/30/2002-6/30/2007
- **Direct:** $95,932
- **F&A:** 44,129

**Proteolytic Control of Glioblastoma**
- **PI:** RAY, SWAPAN
- **Sponsor:** NIH/NCI
- **Award:** 1 R01 CA091460-01A1
- **Project Dates:** 8/1/2003-7/31/2008
- **Direct:** $150,000
- **F&A:** 69,000

**Middaugh, Lawrence**

**Co-PI or Project Leader**

**A Multi-Center, Double-Blind, Placebo Controlled Trial to Determine Whether Natural Huperzine A Improves Cognitive Function (Corporate Flow-Down)**
- **Sponsor:** Georgetown Univ.
- **Award:** RX 4265-715-USC (04050303)
- **Budget Dates:** 4/1/2004 - 8/31/2005
- **Direct:** $39,676
- **F&A:** 9,919

**A Multi-Center, Double-Blind, Placebo Controlled Trial to Determine Whether Natural Huperzine A Improves Cognitive Function (Federal Flow-Down)**
- **Sponsor:** Georgetown Univ.
- **Award:** RX 4265-715-USC (04050302)
- **Budget Dates:** 4/1/2004 - 8/31/2005
- **Direct:** $27,572
- **F&A:** 6,893

**Alzheimer's Disease Prevention Trial with Estrogens: An Observational Continuation of a Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of Estrogens to Prevent Alzheimer's Disease and Loss of Memory in Women**
- **Sponsor:** Mt. Sinai Medical Center
- **Award:** R01 AG15922-06 (04042804)
- **Budget Dates:** 9/30/2003 - 9/29/2004
- **Direct:** $36,438
- **F&A:** 9,109

**Mills, John**

**Principal Investigator**

**Experimental and Clinical Studies of Presbyacusis**
- **Sponsor:** NIH/NIDCD
- **Award:** 5 P50 DC000422-17 (03042903)
- **Project Dates:** 7/1/1987-6/30/2007
- **Direct:** $1,060,058
- **F&A:** 487,627

**Co-PI or Project Leader**

**Experimental and Clinical Studies of Presbyacusis - Core A**
- **Sponsor:** NIH/NIDCD
- **Award:** 5 P50 DC000422-17 (03042903)
- **Project Dates:** 7/1/1987-6/30/2007
- **Direct:** $84,473
- **F&A:** 38,858

**Mintzer, Jacobo**

**Principal Investigator**

**A Multi-Center, Double-Blind, Placebo Controlled Trial to Determine Whether Natural Huperzine A Improves Cognitive Function (Corporate Flow-Down)**
- **Sponsor:** Georgetown Univ.
- **Award:** RX 4265-715-USC (04050303)
- **Budget Dates:** 4/1/2004 - 8/31/2005
- **Direct:** $39,676
- **F&A:** 9,919

**A Multi-Center, Double-Blind, Placebo Controlled Trial to Determine Whether Natural Huperzine A Improves Cognitive Function (Federal Flow-Down)**
- **Sponsor:** Georgetown Univ.
- **Award:** RX 4265-715-USC (04050302)
- **Budget Dates:** 4/1/2004 - 8/31/2005
- **Direct:** $27,572
- **F&A:** 6,893
Mintzer, Jacobo  
Principal Investigator

**Psychiatry & Behavioral Sciences**

**An Open-Label, Multi-Center, One-Year Extension of the Evaluation of the Safety of Donepezil Hydrochloride (E2020, Aricept) in Patients with Dementia Associated with Cerebrovascular Disease**

- **Sponsor:** Covance, Inc.  
  **Budget Dates:** 3/29/2004 - 3/31/2005  
  **Direct:** $38,856

**Depression in Alzheimer's Disease Study-2. (DIADS-2)**

- **Sponsor:** NIH/NIMH  
  **Budget Dates:** 7/1/2003 - 7/31/2005  
  **Direct:** $49,979

**A Double-Blind, Placebo-Controlled, Study of Leuprolide Acetate Depot in the Treatment of Alzheimer's Disease in Men**

- **Sponsor:** Voyager Pharmaceuticals  
  **Budget Dates:** 2/16/2004 - 1/31/2005  
  **Direct:** $90,979

**Institute for Research Minority Training on Mental Health and Aging (IRMMA)**

- **Sponsor:** NIH/NIA  
  **Budget Dates:** 10/23/2003 - 6/30/2006  
  **Direct:** $406,404

**A 51 Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride (E2020) in Subjects with Mild to Moderate Dementia of the Alzheimer's Type**

- **Sponsor:** Parexel Intl. Corp.  
  **Budget Dates:** 12/23/2003 - 12/31/2004  
  **Direct:** $97,536

**An Evaluation of the Long-Term Safety and Efficacy of Neramexane in Patients with Moderate to Severe Dementia of the Alzheimer's Type**

- **Sponsor:** Johnson and Johnson  
  **Budget Dates:** 4/11/2003 - 4/30/2005  
  **Direct:** $4,972

**Long-Term Safety and Efficacy of Open-Label MKC-230, 80 mg B.I.D. in the Treatment of Probable Alzheimer's Disease: A 6-month Follow-up after Completion of Study MKC-231-A01**

- **Sponsor:** Alzheimer's Disease Cooperative Study  
  **Budget Dates:** 7/1/2003 - 6/30/2006  
  **Direct:** $75,737

**An Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Galantamine HBr in the Treatment of Mild Cognitive Impairment**

- **Sponsor:** Research Fdn. For Mental Hygiene  
  **Budget Dates:** 9/30/2003 - 8/31/2008  
  **Direct:** $16,934

**Antipsychotic Discontinuation in Alzheimer's Disease**

- **Sponsor:** Research Fdn. For Mental Hygiene  
  **Budget Dates:** 9/30/2003 - 8/31/2004  
  **Direct:** $136,610

**A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Neramexane in Patients with Moderate to Severe Dementia of the Alzheimer's Type**

- **Sponsor:** Forest Research Inst.  
  **Budget Dates:** 4/1/2003 - 7/31/2005  
  **Direct:** $76,800

**A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients with Mild to Moderate Dementia of the Alzheimer's Type MEM-MD-12**

- **Sponsor:** Forest Labs, Inc.  
  **Budget Dates:** 4/1/2002 - 10/31/2004  
  **Direct:** $38,400
### Psychiatry & Behavioral Sciences

**Psychiatry & Behavioral Sciences**  
A Long-Term Extension Study Evaluating the Safety and Tolerability of Four Memantine Dosing Regimens in Patients with Moderate to Severe Dementia of the Alzheimer’s Type MEM-MD-03  
**Sponsor:** Forest Labs, Inc.  
**Budget Dates:** 11/1/2001 - 12/31/2004  
**Direct:** $23,538  
**F&A:** $7,062

**Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)**  
**Sponsor:** Univ. of North Carolina  
**Budget Dates:** 1/9/2001 - 9/30/2004  
**Direct:** $11,600

**Aripiprazole in the Treatment of Institutionalized Patients with Psychosis Associated with Dementia of the Alzheimer’s Type**  
**Sponsor:** Bristol Myers Squibb  
**Budget Dates:** 4/7/2000 - 12/31/2003  
**Direct:** $19,244

### Cell Biology & Anatomy

**Cell Biology & Anatomy**  
**Hyaluronan and Drug Resistance**  
**Sponsor:** Univ. of South Carolina  
**Budget Dates:** 7/1/2003 - 6/30/2004  
**Direct:** $100,000  
**F&A:** $39,875

### Surgery

**Detection of Occult Mediastinal Lymph Node Metastases**  
**Sponsor:** Mayo Clinic  
**Budget Dates:** 5/11/2004 - 11/30/2004  
**Direct:** $238,254  
**F&A:** $59,563

### Medicine

**NIAMS Clinical Research Center for Rheumatoid Disease**  
**Sponsor:** NIH/NAMS  
**Budget Dates:** 4/1/2003-3/31/2008  
**Direct:** $855,775  
**F&A:** $321,995

### Cell Biology & Anatomy

**Cspq2 Gene and Cardiac Outlet Morphogenesis**  
**Sponsor:** NIH/NHLBI  
**Budget Dates:** 7/1/2003 - 6/30/2004  
**Direct:** $200,000  
**F&A:** $86,000

**Cardiac Valvuloseptal Morphogenesis-Core C: Recombinant Viral Gene Core**  
**Sponsor:** NIH/NHLBI  
**Budget Dates:** 7/1/2001 - 6/30/2006  
**Direct:** $88,212  
**F&A:** $37,931

**Cardiovascular Proteomics Center**  
**Sponsor:** NIH/NHLBI  
**Budget Dates:** 9/30/2002-9/29/2009  
**Direct:** $1,491,326  
**F&A:** $573,283

### Psychiatry & Behavioral Sciences

**A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Aripiprazole in the Maintenance of Abstinence from Alcohol in Subjects with Alcoholism (Study No. CN138-089-001)**  
**Sponsor:** Bristol Myers Squibb  
**Budget Dates:** 4/1/2004-3/31/2006  
**Direct:** $238,254  
**F&A:** $59,563
Moak, Darlene
Co-Investigator

**Psychiatry & Behavioral Sciences**

**A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Study to Assess the Safety and Efficacy of Topiramate in the Treatment of Alcohol Dependence**

- **PI:** ANTON, JR., RAYMOND F.
- **Sponsor:** Ortho-McNeil Pharmaceuticals
- **Direct:** $187,755
- **Award:** CAPSS-278 (04031509)

Randomized, Placebo-Controlled Parallel Group Study Comparing Effect of Three Doses of CP-866,087 and Naltrexone on Acute Alcohol Consumption and Craving after Seven Days of Treatment in Alcohol Dependent (DSM IV) Subjects Who Are Not Currently Seeking T

- **PI:** ANTON, JR., RAYMOND F.
- **Sponsor:** Pfizer, Inc.
- **Direct:** $191,040
- **Award:** 5 R01 AA013379-03 (04010706)

Moffitt, Gregory
Co-Investigator

**Medicine**

**A One-Year, Open, Randomized, Parallel, Three-Arm Study Comparing Exubera vs Avandia as Add-On Therapy vs Exubera Substitution of Sulfonylurea in Patients with Type 2 Diabetes, Poorly Controlled on Combination Sulfonylurea and Metformin Treatment**

- **PI:** MAYFIELD, RONALD K.
- **Sponsor:** Inveresk Research
- **Direct:** $96,430
- **Award:** A2171017 (03042803)

Mohanty, Bidyut
Co-Investigator

**Biochemistry & Molecular Biology**

**Mechanism of Replication of Drug Resistance Factors**

- **PI:** BASTIA, DEEPAK
- **Sponsor:** NIH/NIAID
- **Direct:** $369,145
- **Award:** 2 R01 AI019881-22A1 (02043004)

Mohr, Lawrence
Principal Investigator

**Medicine**

**Environmental Biosciences Program**

- **Sponsor:** DOE
- **Budget Dates:** 6/1/2004 - 5/31/2005
- **Direct:** $1,891,804
- **Award:** DE-FC09-02CH11109 (04030301)

**Tobacco and Cancer Risk: Dose, Metabolism and Genetics**

- **Sponsor:** Amer. Health Fdn.
- **Budget Dates:** 3/1/2003 - 9/30/2003
- **Direct:** $35,390
- **Award:** P01 CA68384-06 (02101003)

Monnier, Jeannine
Co-Investigator

**Psychiatry & Behavioral Sciences**

**Telepsychiatry Service Delivery to Trauma Victims**

- **PI:** FRUEH, B. CHRISTOPHER
- **Sponsor:** AHCPR/AHRQ
- **Direct:** $174,295
- **Award:** 5 R01 HS011642-02 (03022802)

Moran, Colleen
Principal Investigator

**Pediatrics**

**A Placebo-Controlled Comparison of the Efficacy, Safety and Pharmacokinetics of the Current US Version of Pulmicort (Budesonide) Turbuhaler and the New Version of Pulmicort Turbuhaler in Asthmatic Children and Adolescents**

- **Sponsor:** Astrazeneca
- **Budget Dates:** 2/16/2004 - 2/28/2005
- **Direct:** $56,520
- **Award:** SD-004-0726 (04021802)
<table>
<thead>
<tr>
<th>Name</th>
<th>College</th>
<th>Title</th>
<th>Sponsor</th>
<th>Direct Costs</th>
<th>F&amp;A Costs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moran, Colleen</td>
<td>Pediatrics</td>
<td>Pediatrics: A Comparison of the Safety and Efficacy of Cefdinir Oral Suspension Versus Azithromycin in Pediatric Subjects with Acute Otitis Media</td>
<td>Abbott Labs</td>
<td>$16,000</td>
<td>$4,000</td>
</tr>
<tr>
<td>Morris, Pamela</td>
<td>Cell Biology &amp; Anatomy</td>
<td>EPA Fellowship Award (Joy Van Nostrand) Yr 3</td>
<td>EPA</td>
<td>$6,095</td>
<td>0</td>
</tr>
<tr>
<td>Muise-Helmericks, Robin</td>
<td>Psychiatry &amp; Behavioral Sciences</td>
<td>Psychiatry: Training in Functional Imaging and Alcohol Withdrawal</td>
<td>NIH/NIAAA</td>
<td>$142,250</td>
<td>11,380</td>
</tr>
<tr>
<td>Mukherjee, Rupak</td>
<td>Surgery</td>
<td>Surgery: Endothelin Receptors and the Progression to Heart Failure</td>
<td>NIH/NHLBI</td>
<td>$175,000</td>
<td>69,000</td>
</tr>
<tr>
<td>Myrick, Donald</td>
<td>Psychiatry &amp; Behavioral Sciences</td>
<td>Psychiatry: Randomized, Placebo-Controlled Parallel Group Study Comparing Effect of Three Doses of CP-866,087 and Naltrexone on Acute Alcohol Consumption and Craving after Seven Days of Treatment in Alcohol Dependent (DSM IV) Subjects Who Are Not Currently Seeking T</td>
<td>Pfizer, Inc.</td>
<td>$191,040</td>
<td>47,760</td>
</tr>
<tr>
<td>Nahas, Ziad</td>
<td>Psychiatry &amp; Behavioral Sciences</td>
<td>Psychiatry: Gabapentin as an Adjunct to Naltrexone for Alcoholism</td>
<td>NIH/NIAAA</td>
<td>$317,382</td>
<td>145,996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Psychiatry: Neuronetics Multi-Center Trial: Protocol Numbers:44-01101-000, 44-01102, and 44-0110300</td>
<td>Neuronetics</td>
<td>$241,060</td>
<td>60,265</td>
</tr>
<tr>
<td>College of Medicine</td>
<td>Faculty Activity by College</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>-----------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Surgery**

A Comprehensive Approach to Organ Donation by Incorporation of Family Support Counselors as Members of the Hospital Critical Care Team

<table>
<thead>
<tr>
<th>Sponsor:</th>
<th>Life Point</th>
</tr>
</thead>
<tbody>
<tr>
<td>Award:</td>
<td>R390T01361-01-00 (03060212)</td>
</tr>
<tr>
<td>Direct:</td>
<td>$107,234</td>
</tr>
<tr>
<td>F&amp;A:</td>
<td>49,327</td>
</tr>
</tbody>
</table>

**Microbiology & Immunology**

Viral Vector Core Facility

<table>
<thead>
<tr>
<th>Sponsor:</th>
<th>NIH/NCI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Award:</td>
<td>5 R24 CA088163-04 (03121014)</td>
</tr>
<tr>
<td>Direct:</td>
<td>$101,278</td>
</tr>
<tr>
<td>F&amp;A:</td>
<td>43,550</td>
</tr>
</tbody>
</table>

Co-PI or Project Leader

DOD Phase VI: Project 6 - Translational Research and Cancer Prevention and Control and Risk Factor Identification

<table>
<thead>
<tr>
<th>PI:</th>
<th>REED, CAROLYN E.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor:</td>
<td>Geo-Centers/DOD</td>
</tr>
<tr>
<td>Direct:</td>
<td>$51,370</td>
</tr>
<tr>
<td>F&amp;A:</td>
<td>23,630</td>
</tr>
</tbody>
</table>

Sphingolipids in Cancer Therapy and Angiogenesis - Project 2: Genesis of Bystander Activity in FasL Gene Therapy

<table>
<thead>
<tr>
<th>PI:</th>
<th>HANNUN, YUSUF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor:</td>
<td>NIH/NCI</td>
</tr>
<tr>
<td>Award:</td>
<td>1 P01 CA97132-01A1 (01100808-02)</td>
</tr>
<tr>
<td>Project Dates:</td>
<td>8/1/2003-7/31/2008</td>
</tr>
<tr>
<td>Direct:</td>
<td>$152,121</td>
</tr>
<tr>
<td>Project Dates:</td>
<td>8/1/2007-7/31/2008</td>
</tr>
<tr>
<td>F&amp;A:</td>
<td>69,976</td>
</tr>
</tbody>
</table>

Co-Investigator

Sphingolipids in Cancer Therapy and Angiogenesis

<table>
<thead>
<tr>
<th>PI:</th>
<th>HANNUN, YUSUF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor:</td>
<td>NIH/NCI</td>
</tr>
<tr>
<td>Award:</td>
<td>1 P01 CA97132-01A1 (01100808)</td>
</tr>
<tr>
<td>Project Dates:</td>
<td>8/1/2003-7/31/2008</td>
</tr>
<tr>
<td>Direct:</td>
<td>$715,167</td>
</tr>
<tr>
<td>Project Dates:</td>
<td>8/1/2007-7/31/2008</td>
</tr>
<tr>
<td>F&amp;A:</td>
<td>318,811</td>
</tr>
</tbody>
</table>

**Medicine**

Mitochondrial Ceramide in Chemotherapy-Induced Apoptosis

<table>
<thead>
<tr>
<th>PI:</th>
<th>OBEID, LINA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor:</td>
<td>NIH/NIA</td>
</tr>
<tr>
<td>Award:</td>
<td>5 R01 AG016583-06 (03062703)</td>
</tr>
<tr>
<td>Project Dates:</td>
<td>7/1/1998-8/31/2005</td>
</tr>
<tr>
<td>Direct:</td>
<td>$175,000</td>
</tr>
<tr>
<td>F&amp;A:</td>
<td>75,250</td>
</tr>
</tbody>
</table>

**Psychiatry & Behavioral Sciences**

Estrogen Efficacy in Spinal Cord Injury

<table>
<thead>
<tr>
<th>PI:</th>
<th>BANIK, NAREN L.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor:</td>
<td>NIH/NINDS</td>
</tr>
<tr>
<td>Award:</td>
<td>1 R01 NS045967-01A1 (03031207)</td>
</tr>
<tr>
<td>Direct:</td>
<td>$185,000</td>
</tr>
<tr>
<td>F&amp;A:</td>
<td>73,600</td>
</tr>
</tbody>
</table>

**Medicine**

A Phase 2, Dose Escalation Evaluation of the Pharmacokinetic and Hemodynamic Effects of Carperitide in Subjects with Congestive Heart Failure

<table>
<thead>
<tr>
<th>Sponsor:</th>
<th>Fujisawa Healthcare, Inc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Award:</td>
<td>PROTOCOL#03-0-162</td>
</tr>
<tr>
<td>Project Dates:</td>
<td>8/1/1993-7/31/2008</td>
</tr>
<tr>
<td>Direct:</td>
<td>$52,960</td>
</tr>
<tr>
<td>Project Dates:</td>
<td>8/1/2003-7/31/2008</td>
</tr>
<tr>
<td>F&amp;A:</td>
<td>13,240</td>
</tr>
</tbody>
</table>

Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan in Subjects Hospitalized with Worsening Congestive Heart Failure

<table>
<thead>
<tr>
<th>Sponsor:</th>
<th>Otsuka America Pharmaceutical, Inc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Award:</td>
<td>156-03-236 (03082603)</td>
</tr>
<tr>
<td>Direct:</td>
<td>$118,800</td>
</tr>
<tr>
<td>F&amp;A:</td>
<td>29,700</td>
</tr>
</tbody>
</table>

The Cardiac Conduction System as Regulated by NNX2.5

<table>
<thead>
<tr>
<th>Sponsor:</th>
<th>VAMC Merit Award</th>
</tr>
</thead>
<tbody>
<tr>
<td>Award:</td>
<td>(03063016)</td>
</tr>
<tr>
<td>Project Dates:</td>
<td>10/1/2003 - 9/30/2004</td>
</tr>
<tr>
<td>Direct:</td>
<td>$129,700</td>
</tr>
<tr>
<td>Project Dates:</td>
<td>10/1/2002 - 9/30/2005</td>
</tr>
<tr>
<td>F&amp;A:</td>
<td>0</td>
</tr>
</tbody>
</table>

Multi-Center, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Efficacy and Safety Study to Evaluate the Effects of Oral Administration of Tolvaptan (OPC 4106) Compared to Furosemide in Patients with CHF

<table>
<thead>
<tr>
<th>Sponsor:</th>
<th>Cardiovascular Clinical Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>Award:</td>
<td>(01100808-02)</td>
</tr>
<tr>
<td>Project Dates:</td>
<td>10/1/2000 - 6/30/2003</td>
</tr>
<tr>
<td>Direct:</td>
<td>$30,778</td>
</tr>
<tr>
<td>Project Dates:</td>
<td>10/1/2000 - 6/30/2003</td>
</tr>
<tr>
<td>F&amp;A:</td>
<td>13,235</td>
</tr>
</tbody>
</table>

Load-Induced Cardiac Hypertrophy in the Adult Mammal - Core E: Morphology and Molecular Core

<table>
<thead>
<tr>
<th>PI:</th>
<th>COOPER, IV, GEORGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor:</td>
<td>NIH/NHLBI</td>
</tr>
<tr>
<td>Award:</td>
<td>2 P01 HL048788-11 (03012709-05)</td>
</tr>
<tr>
<td>Project Dates:</td>
<td>8/1/1993-7/31/2008</td>
</tr>
<tr>
<td>Direct:</td>
<td>$32,478</td>
</tr>
<tr>
<td>Project Dates:</td>
<td>10/1/2003-7/31/2008</td>
</tr>
<tr>
<td>F&amp;A:</td>
<td>14,940</td>
</tr>
</tbody>
</table>

Co-Investigator

Candesartan Cilexetil in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM) (SH-AHS-0003) (SH-AHS-0007)

<table>
<thead>
<tr>
<th>PI:</th>
<th>ZILE, MICHAEL R.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor:</td>
<td>Astra Pharmaceuticals, L.P.</td>
</tr>
<tr>
<td>Award:</td>
<td>(99060802)</td>
</tr>
<tr>
<td>Project Dates:</td>
<td>1/1/1999-12/31/2004</td>
</tr>
<tr>
<td>Direct:</td>
<td>$4,065</td>
</tr>
<tr>
<td>Project Dates:</td>
<td>4/1/1999-12/31/2004</td>
</tr>
<tr>
<td>F&amp;A:</td>
<td>935</td>
</tr>
</tbody>
</table>

Patterning by Invasive Mesenchyme in the Embryonic Heart: Project 1 - The Genetic Origin of Structural and Functional Defects of Atrioventricular Conduction in Humans

<table>
<thead>
<tr>
<th>PI:</th>
<th>GOURDIE, ROBERT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor:</td>
<td>NIH/NICHD</td>
</tr>
<tr>
<td>Award:</td>
<td>5 P01 HD039946-04 (04050605)</td>
</tr>
<tr>
<td>Direct:</td>
<td>$985,596</td>
</tr>
<tr>
<td>F&amp;A:</td>
<td>216,356</td>
</tr>
<tr>
<td>College of Medicine</td>
<td>Co-Investigator</td>
</tr>
<tr>
<td>--------------------</td>
<td>----------------</td>
</tr>
<tr>
<td><strong>Medical University of South Carolina</strong></td>
<td>O'Brien, Terrence</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pfizer Visiting Professor-Dr. John Harley</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### College of Medicine

#### Oatis, John
**Co-Investigator**

**Cell & Molecular Pharmacology**

**Primaquine-Induced Hemolytic Anemia**
- **PI:** MCMILLAN, DAVID C.
- **Sponsor:** NIH/NIAID
- **Project Dates:** 1/1/2001-12/31/2004
- **Award:** 5 R01 A046424-04 (03102704)
- **F&A:** $86,000

**Medicine**

**Regulation of Human Alkaline Ceramidases Role in Cancer Biology**
- **Sponsor:** VAMC Merit Award
- **Budget Dates:** 9/1/2003 - 6/30/2004
- **Award:** 5 P20 RR017677-02 (03062704)
- **F&A:** $677,145

**Sphingosine Phosphate Phosphatases - Regulation and Role**
- **Sponsor:** NIH/NIGMS
- **Budget Dates:** 9/1/2003 - 3/31/2005
- **Direct:** $123,400
- **Award:** HEMA-007-99F (02063004)
- **Project Dates:** 4/1/2000 - 3/31/2005
- **F&A:** 0

**SC COBRE in Lipidomics and Pathobiology**
- **Sponsor:** NIH/NCRR
- **Budget Dates:** 9/1/2003 - 6/30/2004
- **Direct:** $1,457,324
- **Award:** 5 P20 RR017677-02S (03030701)
- **Project Dates:** 9/26/2003 - 6/30/2004
- **F&A:** 0

**Supplement to P20 RR17677: Development of NMR Spectroscopy**
- **Sponsor:** NIH/NCRR
- **Budget Dates:** 9/1/2003 - 6/30/2004
- **Direct:** $1,457,324
- **Award:** 5 P20 RR017677-02S (03030701)
- **Project Dates:** 9/26/2003 - 6/30/2004
- **F&A:** 0

**Mitochondrial Ceramide in Chemotherapy-Induced Apoptosis**
- **Sponsor:** NIH/NIA
- **Budget Dates:** 7/1/1998 - 8/31/2005
- **Award:** 5 R01 AG016583-06 (03060701)
- **Direct:** $171,953

**Contributing Editor for the Science of Aging Knowledge Environment**
- **Sponsor:** Amer. Federation for Aging
- **Budget Dates:** 8/1/2003 - 7/31/2004
- **Direct:** $0
- **Award:** (02082101)
- **Project Dates:** 8/1/2002 - 7/31/2004
- **F&A:** 0

**Sphingolipids in Cancer Therapy and Angiogenesis - Project 1: Sphingosine Kinase and Sphingosine-1-Phosphate in Tumor Angiogenesis**
- **PI:** HANNUN, YUSUF
- **Sponsor:** NIH/NCI
- **Budget Dates:** 9/1/2003 - 6/30/2004
- **Direct:** $175,000
- **Award:** 5 R01 RR017677-02 (03062704)
- **Project Dates:** 7/1/1998 - 8/31/2005
- **F&A:** 0

**Co-PI or Project Leader**

**Sphingolipids in Cancer Therapy and Angiogenesis - Project 3: Role of Sphingosine Kinase and Sphingosine-1-Phosphate in Tumor Angiogenesis**
- **PI:** HANNUN, YUSUF
- **Sponsor:** NIH/NCI
- **Budget Dates:** 9/1/2003 - 6/30/2004
- **Direct:** $171,953
- **Award:** 5 P01 CA05132-01A1 (01100808-03)
- **Project Dates:** 8/1/2003 - 7/31/2008
- **F&A:** 79,098

**Obeid, Lina**
**Principal Investigator**

**Ogawa, Makio**
**Principal Investigator**

**Medicine**

**Cytokine Regulation of Stem Cell Phenotypes and Kinetics**
- **Sponsor:** VAMC Merit Award
- **Budget Dates:** 9/1/2003 - 3/31/2008
- **Direct:** $855,775
- **Award:** 5 P60 AR049459-02 (04020403)
- **Project Dates:** 8/1/2003 - 3/31/2008
- **F&A:** 321,995

**Ohtsuka, Rieko**
**Principal Investigator**

**Biochemistry & Molecular Biology**

**Regulation of Telomerase By Ceramide in Lung Cancer**
- **Sponsor:** NIH/NCI
- **Budget Dates:** 4/1/2004 - 3/31/2005
- **Direct:** $174,620
- **Award:** 5 R01 CA088932-03 (04011404)
- **Project Dates:** 4/1/2002 - 3/31/2007
- **F&A:** 76,050

**Sphingolipids in Cancer Therapy and Angiogenesis**
- **PI:** HANNUN, YUSUF
- **Sponsor:** NIH/NCI
- **Budget Dates:** 8/1/2003-7/31/2008
- **Direct:** $171,953
- **Award:** 1 P01 CA97132-01A1 (01100808-03)
- **Project Dates:** 8/1/2003-7/31/2008
- **F&A:** 79,098

**Ogretmen, Besim**
**Principal Investigator**

**Biochemistry & Molecular Biology**

**Regulation of Telomerase By Ceramide in Lung Cancer**
- **Sponsor:** NIH/NCI
- **Budget Dates:** 4/1/2004 - 3/31/2005
- **Direct:** $174,620
- **Award:** 5 R01 CA08932-03 (04011404)
- **Project Dates:** 4/1/2002 - 3/31/2007
- **F&A:** 76,050

**Cytokine Regulation of Stem Cell Phenotypes and Kinetics**
- **Sponsor:** VAMC Merit Award
- **Budget Dates:** 4/1/2004 - 3/31/2005
- **Direct:** $123,400
- **Award:** 4/1/2003 - 3/31/2005
- **F&A:** 0

**Ohtsuka, Rieko**
**Principal Investigator**

**Microbiology & Immunology**

**The Complement System and Immune Response to Breast Cancer**
- **Sponsor:** DOD
- **Budget Dates:** 6/1/2004 - 5/31/2005
- **Direct:** $49,674
- **Award:** 5 R01 HL069123-02 (04020302)
- **Project Dates:** 4/1/2003 - 3/31/2007
- **F&A:** 65,000

---

**Faculty Activity by College**

**Medical University of South Carolina**
Medical University of South Carolina

Faculty Activity by College

OHTA

Award: DAMD17-03-1-0442 (02051703)  
F&A: 3,974

Pediatrics

Peroxisomal Function in Renal Ischemia

Sponsor: Dialysis Clinics, Inc.  
Budget Dates: 1/1/2003 - 12/31/2004  
Direct: $156,000

Project Dates: 1/1/1997 - 12/31/2004  
F&A: 0

Orak, John
Principal Investigator


Family Medicine

Accelerating TRIP in a Practice Partner Research Network

Sponsor: Physician Micro Systems, Inc.  
Budget Dates: 1/1/2003 - 12/31/2004  
Direct: $145,048

Ornstein, Steven
Principal Investigator

Impact of Direct to Consumer Pharmaceutical Marketing

Pt: BRADFORD, W. DAVID  
Sponsor: AHCPR/AHRQ  
Direct: $211,013

Project Dates: 7/7/2003-6/30/2005  
Award: 1 R01 HS011326-01A2 (02101008)  
F&A: 83,850

Oswald, Melanie
Co-Investigator

Project Dates: 1/1/2001-11/1/2004

Pathology & Laboratory Medicine

Platelet Function and Pre-Eclampsia

Pt: LAZARCHICK, JOHN  
Sponsor: Helena Laboratories  
Direct: $13,732

Project Dates: 10/1/2003-6/30/2005  
Award: 1 R01 HS011326-01A2 (02062806)  
F&A: 83,850

Pai, G.
Principal Investigator

SC Neural Tube Defects Surveillance, Prevention and Research Initiative

Sponsor: Greenwood Genetic Center  
Budget Dates: 7/1/2003 - 6/30/2004  
Direct: $47,199

Caring Connection

Sponsor: SC DHEC  
Budget Dates: 10/1/2003 - 9/30/2004  
Direct: $45,092

Palesch, Yuko
Principal Investigator

Biostatistics, Bioinformatics & Epidemiology

Human Serum Albumin Therapy for Stroke

Sponsor: Univ. of Miami  
Budget Dates: 7/1/2003 - 6/30/2004  
Direct: $25,703

Parkinson's Disease Clinical Trial: Statistical Center

Sponsor: NIH/NINDS  
Budget Dates: 10/1/2003 - 9/30/2004  
Direct: $265,225

Pandey, Janardan
Principal Investigator

Co-Investigator

Microbiology & Immunology

Immunogenetic Studies in Lupus

Sponsor: Coda, Inc.  
Direct: $17,123

Immunoglobulin Allotypes in Hepatitis C Virus Infection

Sponsor: Johns Hopkins Univ.  
Budget Dates: 9/1/2003 - 8/31/2005  
Direct: $86,843

Immunogenetic Studies in Myositis

Sponsor: NIH/NIAMS  
Budget Dates: 9/1/2003 - 8/31/2005  
Direct: $20,547

Environmental Biosciences Program: EnvTox-Pandey-TCE Exposure

Pt: MOHR, JR., LAWRENCE C.  
Sponsor: DOE  
Direct: $210,735

Award: DE-FC09-02CH11109 (04030301-10)  
F&A: 96,938

Patel, Rig
Co-PI or Project Leader

Medicine

A Study to Further Assess the Efficacy of Bowel Preparation with the Use of a Pre-Packed Diet/Bowel Prep Kit

Versus Usual and Customary Bowel Preparation for Colonoscopy

Pt: DELEGGE, MARK  
Sponsor: Ezem, Inc.  
Direct: $1,540

Project Dates: 3/1/2001-6/30/2003  
Award: EZEM-01-001 (01042603-02)  
F&A: 354

Annual Report for Research FY04 95
College of Medicine

Patel, Shailendra
Principal Investigator

The Role of Cholesterol in Development
Sponsor: NIH/NHLBI
Budget Dates: 8/1/2003 - 7/31/2004
Direct: $250,000
Award: 5 R01 HL068660-02 (03050205)
Project Dates: 8/1/2002 - 7/31/2006
F&A: 104,810

Affects of Ezetimibe and Simvastatin on Plant Sterol Levels in Patients with Type II Diabetes Mellitus
Pl: KLETT, ERIC L.
Sponsor: Merck
Budget Dates: 7/1/2003-7/1/2005
Direct: $17,600
Award: PROTOCOL 03-055 (03060301-01)
Project Dates: 8/1/2002 - 7/31/2006
F&A: 4,400

Cloning and Characterization of Human CYP25
Pl: BELL, NORMAN H.
Sponsor: NIH/NIDDK
Budget Dates: 2/1/2001-1/31/2006
Direct: $168,000
Award: 5 R01 DK056603-04 (03111803)
Project Dates: 8/1/2002 - 7/31/2006
F&A: 43,680

Phase III, Multi-Center Study of Intratumoral/Interstitial Therapy with TransMID Compared to Best Standard of Care in Patients with Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme
Sponsor: Xenova Biomedix, Ltd.
Direct: $676,664
Award: KSB311R/CIII/001 (04052607)
F&A: 169,166

Arterial Compression of the Ventro-Lateral Medulla
Sponsor: NIH/NHLBI
Direct: $127,056
Award: 5 K23 HL067993-03 (04020301)
F&A: 9,411

Prospective, Multi-Institutional, Randomized Study to Evaluate the Effects of Microvascular Decompression on Type 2 Diabetes Mellitus
Sponsor: Allegheny-Singer Research Inst.
Direct: $18,982
Award: (01070905)
F&A: 2,174

Phase V GliaSite Radiation Therapy System (RTS) Registry Protocol for the Treatment of Resectable Malignant Brain Tumors
Sponsor: Proxima Therapeutics
Budget Dates: 6/1/2003 - 6/1/2013
Direct: $42,700
Award: (03060215)
Project Dates: 6/1/2003 - 6/1/2013
F&A: 10,675

Payne, Mark
Co-Investigator

A Study to Further Assess the Efficacy of Bowel Preparation with the Use of a Pre-Packed Diet/Bowel Prep Kit Versus Usual and Customary Bowel Preparation for Colonoscopy
Pl: DELEGGE, MARK
Sponsor: Ezem, Inc.
Budget Dates: 1/1/2004-6/30/2003
Direct: $1,540
Award: EZEM-01-001 (01042603)
Project Dates: 3/1/2001-6/30/2003
F&A: 354

Peck, Octavia
Principal Investigator

Mechanisms of Gram-Positive Bacterial Tolerance
Sponsor: NIH/NIGMS
Direct: $24,821
Award: 5 F31 GM067559-02 (04011302)
Project Dates: 3/1/2003 - 8/31/2005
F&A: 0

Peden-Adams, Margie
Principal Investigator

MUSC's Activities in Support of the Charleston Health and Risk Assessment (HERA) of Bottlenose Dolphin Populations
Sponsor: NOAA
Direct: $282,880
Award: WC133CO04CN0012 (04021801)
Project Dates: 3/1/2003 - 8/31/2005
F&A: 62,820

Pereira, Naveen
Principal Investigator

Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized with Worsening Congestive Heart Failure
Sponsor: Otsuka Medical Research Inst.
Direct: $118,800
Award: 156-03-236 (04020207)
F&A: 29,700
<table>
<thead>
<tr>
<th>PEREIRA</th>
<th>College of Medicine</th>
</tr>
</thead>
</table>
| **Pereira, Naveen**  
Principal Investigator  
**Medicine**  
A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Effects of Immune Modulation Therapy (IMT) on Mortality and Morbidity in Patients with Chronic Heart Failure (ACCLAIM)  
Sponsor: Vasogen, Inc.  
Award: 0202 (03091001)  
F&A: 42,468  
Direct: $169,872  
| **Randomized, Prospective, Multi-Center Comparison of Prograf, Cellcept and Steroids vs Cyclosporine, Cellcept and Steroids vs Prograf, Rapamune and Steroids in De Novo Cardiac Transplant Recipients**  
Sponsor: Fujisawa Healthcare, Inc.  
Award: (02051606)  
Budget Dates: 5/1/2002 - 12/31/2004  
F&A: 200  
Direct: $800  
Project Dates: 5/1/2002 - 12/31/2004  |
| **Pereyo, Roberto**  
Co-Investigator  
**Obstetrics/Gynecology**  
Performance Implications of Prolonged Work Hours in an Obstetrics and Gynecology Training Program  
PI: NEWMAN, ROGER B.  
Sponsor: ACOG  
Award: 0202 (03091001)  
Budget Dates: 7/1/2003 - 6/30/2004  
F&A: 0  
Direct: $15,000  
Project Dates: 7/1/2003 - 6/30/2004  |
| **Perry, David**  
Principal Investigator  
**Biochemistry & Molecular Biology**  
Zinc Regulation of Apoptotic Caspases  
Sponsor: VAMC Merit Award  
Award: (04053023)  
Budget Dates: 10/1/2001 - 9/30/2004  
F&A: 0  
Direct: $94,421  
Project Dates: 10/1/2001 - 9/30/2004  |
| **Peterson, Richard**  
Principal Investigator  
**Cell Biology & Anatomy**  
Characterizing Disease Implications of Translational Regulation of a Homeobox Gene in Cardiac Tissue  
Sponsor: Amer. Heart Assoc.  
Award: 0315350U (03012111)  
Budget Dates: 7/1/2003 - 6/30/2005  
F&A: 0  
Direct: $20,000  
Project Dates: 7/1/2003 - 6/30/2005  |
| **Pickelsimer, E.**  
Principal Investigator  
**Biostatistics, Bioinformatics & Epidemiology**  
Determination of Occurrence and Causes of Death among South Carolina Residents with Traumatic Spinal Cord Injury  
Sponsor: SC Spinal Cord Injury Fund  
Award: SCIRF 0503 (03080605)  
F&A: 0  
Direct: $145,000  
| **Ocular Hydrodynamics: Modulation by Opioids**  
Sponsor: NIH/NEI  
Award: 5 R01 EY011977-08 (04011607)  
Budget Dates: 7/1/2003 - 6/30/2004  
F&A: 30,945  
Direct: $175,000  
Project Dates: 7/1/2003 - 6/30/2004  |
| **Ocular Natriuretic Peptide Activity: Modulation by Drugs**  
Sponsor: NIH/NEI  
Award: 7 R01 EY012807-04 (03012702)  
F&A: 80,500  
Direct: $86,019  
| **Potter, David**  
Principal Investigator  
**Medicine**  
Renal Constitutive and Inducible Na+/Urea Transporters  
Sponsor: Dialysis Clinics, Inc.  
Award: C-2229 (03121013)  
Budget Dates: 2/1/2004 - 1/31/2005  
F&A: 0  
Direct: $6,290  
Project Dates: 2/1/2004 - 1/31/2005  |
| **Nephrology Fellows Education and Training in Anemia**  
Sponsor: Amgen  
Award: (03091702)  
Budget Dates: 7/1/2003 - 6/30/2004  
F&A: 0  
Direct: $5,000  
Project Dates: 7/1/2003 - 6/30/2004  |
| **Evaluation of Dose Conversion from Variable Dosing Intervals of Darbepoetin Alfa to Variable Dosing Intervals of Epoetin Alfa (PROCRIT) In Patients with the Anemia of Chronic Kidney Disease**  
Sponsor: Ortho Biotech  
Award: PR02-06-044 (03082002)  
F&A: 0  
Direct: $32,210  
| **Ophthalmology**  
**Ocular Hydrodynamics: Modulation by Opioids**  
Sponsor: NIH/NEI  
Award: 5 R01 EY011977-08 (04011607)  
Budget Dates: 7/1/2003 - 6/30/2004  
F&A: 30,945  
Direct: $175,000  
Project Dates: 7/1/2003 - 6/30/2004  |
| **Ocular Natriuretic Peptide Activity: Modulation by Drugs**  
Sponsor: NIH/NEI  
Award: 7 R01 EY012807-04 (03012702)  
F&A: 80,500  
Direct: $86,019  

**Annual Report for Research FY04  97**
Purohit, Dilip  
Principal Investigator  

**Pediatrics**  
Perinatal Regional Systems Development  
Sponsor: SC DHEC  
Award: MC-4-091 (03070801)  
Project Dates: 7/1/2003 - 6/30/2004  
Budget Dates: 7/1/2003 - 6/30/2004  
Direct: $236,080  
F&A: 0

Radjke, Wolfgang  
Co-Investigator  

**Pediatrics**  
Fluid Diode for Pediatric Pulmonary Insufficiency  
Pt: MCQUINN, TIM  
Sponsor: SC Biomedical Research Network  
Award: P20 RR16461 (04010802)  
Project Dates: 9/1/2003-6/30/2004  
Direct: $25,000  
F&A: 0

Rajagopalan, P.  
Principal Investigator  

**Surgery**  
A Randomized, Open-Label, Comparative Evaluation of Conversion from Calcineurin Inhibitors to Sirolimus versus Continued Use of Calcineurin Inhibitors in Renal Allograft Recipients  
Sponsor: Wyeth-Ayerst  
Direct: $26,540  
Award: 0468H1-316-US (02052102)  
Project Dates: 1/23/2002 - 12/31/2005  
F&A: 6,635

Ramamoorthy, Sammanda  
Principal Investigator  

**Physiology and Neuroscience**  
Serotonin Transporter Phosphorylation  
Sponsor: NIH/NIMH  
Award: 5 R01 MH062612-03 (03093015)  
Project Dates: 12/7/2001 - 11/30/2005  
Direct: $150,000  
F&A: 64,500

Rames, Ross  
Principal Investigator  

**Urology**  
Study of Duloxetine HCI in Women of Different Demographic Characteristics and Co-Morbidities with Stress Urinary Incontinence: Evaluation of Efficacy and Safety  
Sponsor: Eli Lilly  
Award: PROTOCOL F1J-US-SBC (01120602)  
Project Dates: 7/1/2003-4/30/2008  
Direct: $27,440  
F&A: 6,860

Ramsdell, Ann  
Principal Investigator  

**Cell Biology & Anatomy**  
Left-Right Axis Determination and Cardiac Development  
Sponsor: Univ. of South Carolina  
Award: 5 R01 HL73270-02 (03101001)  
Project Dates: 9/1/2002 - 7/31/2004  
Direct: $96,734  
F&A: 43,530

Randall, Carrie  
Principal Investigator  

**Psychiatry & Behavioral Sciences**  
Paroxetine for Social Anxiety Disorder and Alcoholism  
Sponsor: NIH/NIAAA  
Award: 5 R01 AA013379-03 (04010706)  
Direct: $258,475  
F&A: 111,144

**Alcohol Research Center-Treatment and Implications**  
Sponsor: NIH/NIAAA  
Award: 5 P50 AA010761-09 (03121002)  
Direct: $1,266,966  
F&A: 533,034

**Mentoring and Career Development in Alcohol Research**  
Sponsor: NIH/NIAAA  
Award: 5 K24 AA013314-03 (03070201)  
Direct: $124,976  
F&A: 9,998

**ORWH: SCOR on Sex and Gender Factors Affecting Women's Health**  
Pt: BRADY, KATHLEEN T.  
Sponsor: NIH/NIDA  
Award: 5 P50 DA016511-02  
Project Dates: 9/30/2002-6/30/2007  
Direct: $137,485  
F&A: 63,243

**Naltrexone Treatment of Adolescent Alcoholics**  
Pt: DEAS, DEBORAH  
Sponsor: NIH/NIAAA  
Award: 5 R01 AA013393-02 (03071405)  
Direct: $277,918  
F&A: 127,842

**Southeastern Node of the Clinical Trials Network**  
Pt: BRADY, KATHLEEN T.  
Sponsor: NIH/NIDA  
Award: 5 U10 DA013727-04 (03062618)  
Project Dates: 9/30/2000-8/31/2005  
Direct: $1,307,975  
F&A: 392,075
## Psychiatry & Behavioral Sciences

### Training in Comorbidity of Alcoholism and Mental Illness

**PI:** BOOK, SARAH  
**Sponsor:** NIH/NIAAA  
**Award:** 1 K23 AA014430-01 (03062616)  
**Project Dates:** 9/29/2003-8/31/2008  
**Direct:** $148,529  
**F&A:** 11,356

### Naltrexone/Acamprosate Plus CBT/MET Light for Alcoholism (The COMBINE Study)

**PI:** ANTON, JR., RAYMOND F.  
**Sponsor:** NIH/NIAAA  
**Award:** 2 U10 AA011783-07 (02102213)  
**Project Dates:** 9/30/1997-8/31/2005  
**Direct:** $269,696  
**F&A:** 123,819

## Radiology

### Renal Safety of VISAPAQUE tm (Iodixanol) in High-Risk Patients with Suspected Pulmonary Embolism Undergoing Contrast-Enhanced Spiral CT Pulmonary Angiography (CTPA)

**PI:** ANTON, JR., RAYMOND F.  
**Sponsor:** Amersham Health  
**Direct:** $466,870  
**Award:** 04-VIS-002  
**F&A:** 116,718

## Neurology

### Estrogen Therapy for Spinal Cord Injury

**PI:** BANIK, NAREN L.  
**Sponsor:** SC Spinal Cord Injury Fund  
**Award:** FY03.153.001 (02062803)  
**Budget Dates:** 9/1/2003 - 2/28/2005  
**Direct:** $137,592  
**F&A:** 95,675

### Proteolytic Control of Glioblastoma

**PI:** BANIK, NAREN L.  
**Sponsor:** NIH/NCI  
**Award:** 1 R01 CA091460-01A  
**Budget Dates:** 12/15/2001-11/30/2005  
**Direct:** $222,500  
**F&A:** 95,875

### Role of Proteinase in Spinal Cord Injury

**PI:** BANIK, NAREN L.  
**Sponsor:** NIH/NINDS  
**Award:** 5 R01 NS031622-11  
**Budget Dates:** 7/1/1999-6/30/2005  
**Direct:** $146,334  
**F&A:** 64,387

### Calpain in the Pathophysiology of Demyelinating Disease

**PI:** BANIK, NAREN L.  
**Sponsor:** NIH/NINDS  
**Award:** 5 R01 NS038146-05  
**Budget Dates:** 10/1/1999-6/30/2004  
**Direct:** $162,500  
**F&A:** 58,482

### G Protein Regulation of NHE Activity (Includes Minority Supplement)

**PI:** BANIK, NAREN L.  
**Sponsor:** NIH/NIDDK  
**Award:** 5 R01 DK052448-07S  
**Budget Dates:** 7/10/1996 - 3/31/2006  
**Direct:** $224,931  
**F&A:** 10,573

### Regulation of EGF Receptors by G Protein Receptor

**PI:** BANIK, NAREN L.  
**Sponsor:** NIH/NIGMS  
**Award:** 5 R01 GM063909-03  
**Budget Dates:** 7/10/1996 - 3/31/2006  
**Direct:** $173,250  
**F&A:** 45,045

### NADPH Oxidase & Mesangial Cell Proliferation & Fibrosis

**PI:** BANIK, NAREN L.  
**Sponsor:** NIH/NIDDK  
**Award:** 5 R01 DK054720-04  
**Budget Dates:** 7/10/1996 - 3/31/2006  
**Direct:** $175,000  
**F&A:** 75,250

## Medicine

### Novel 5-HT Receptor Interacting Proteins

**PI:** BANIK, NAREN L.  
**Sponsor:** VAMC Merit Award  
**Award:** (04063024)  
**Budget Dates:** 4/1/2004 - 3/31/2005  
**Direct:** $62,000  
**F&A:** 0

### G Protein Regulation of NHE Activity (Includes Minority Supplement)

**PI:** BANIK, NAREN L.  
**Sponsor:** NIH/NIDDK  
**Award:** 5 R01 DK052448-08S  
**Budget Dates:** 7/10/1996 - 3/31/2006  
**Direct:** $224,931  
**F&A:** 58,482

### Inflammatory Mediators of Glomerular Disease

**PI:** BANIK, NAREN L.  
**Sponsor:** VAMC Merit Award  
**Award:** (03063027)  
**Budget Dates:** 10/1/2003 - 9/30/2004  
**Direct:** $162,500  
**F&A:** 0

### G Protein Regulation of NHE Activity

**PI:** BANIK, NAREN L.  
**Sponsor:** NIH/NIDDK  
**Award:** 3 R01 DK052448-07S  
**Budget Dates:** 7/10/1996 - 3/31/2006  
**Direct:** $40,667  
**F&A:** 10,573

### Regulating EGF Receptors by G Protein Receptor

**PI:** BANIK, NAREN L.  
**Sponsor:** NIH/NIDDK  
**Award:** 5 R01 GM063909-03  
**Budget Dates:** 8/1/2001 - 7/31/2005  
**Direct:** $173,250  
**F&A:** 45,045

### NADPH Oxidase & Mesangial Cell Proliferation & Fibrosis

**PI:** BANIK, NAREN L.  
**Sponsor:** NIH/NIDDK  
**Award:** 5 R01 DK054720-04  
**Budget Dates:** 8/1/2003 - 7/31/2005  
**Direct:** $175,000  
**F&A:** 75,250
<table>
<thead>
<tr>
<th>Co-Investigator</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F&amp;A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reamy, Rebecca</td>
<td>A Randomized, Double-Blind, Clinical Study of Continuous Nebulization of Levalbuterol, in Comparison to Racemic-Albuterol, in a Cohort of Pediatric Patients with Status Asthmatics</td>
<td>Sepracor, Inc.</td>
<td>4/1/2004-4/30/2005</td>
<td>$80,880</td>
<td>20,220</td>
</tr>
<tr>
<td></td>
<td>Hollings Cancer Center Planning Grant</td>
<td>NIH/NCI</td>
<td>8/1/2001-4/30/2005</td>
<td>$181,480</td>
<td>56,743</td>
</tr>
<tr>
<td></td>
<td>Health Care Facilities and Other Construction</td>
<td>HRSA</td>
<td>5/1/2000-4/30/2005</td>
<td>$106,056</td>
<td>50,510</td>
</tr>
<tr>
<td></td>
<td>Oncology Center:Utilization of Digital Mammography in HCC Breast Screening, Diagnosis, Treatment and Research</td>
<td>DOE</td>
<td>9/1/2003 - 8/31/2005</td>
<td>$759,803</td>
<td>50,510</td>
</tr>
<tr>
<td></td>
<td>Institutional Research Grant</td>
<td>Amer. Cancer Soc.</td>
<td>7/1/2001 - 6/30/2004</td>
<td>$240,000</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>Oncology Center</td>
<td>DOE</td>
<td>7/1/2003 - 6/30/2004</td>
<td>$340,095</td>
<td>146,243</td>
</tr>
</tbody>
</table>
**Resnick, Heidi**  
Principal Investigator  

**Psychiatry & Behavioral Sciences**  
Prevention of Postrape Psychopathology and Drug Abuse/Web Based Intervention Following September 11th Attacks  
**Sponsor:** NIH/NIDA  
**Award:** 5 RO1 DA011158-07 (03070307)  
**Budget Dates:** 9/1/2003 - 6/30/2005  
**Direct:** $340,209  
**F&A:** 138,169

**Disaster Research Education and Mentoring Center**  
**Project:** KILPATRICK, DEAN G.  
**Sponsor:** NIH/NIMH  
**Budget Dates:** 9/1/2003 - 6/30/2005  
**Direct:** $250,000  
**F&A:** 12,062

**Child Violence, Adult Victimization, Injury and Health**  
**PI:** RHEINGOLD, ALYSSA ANN  
**Sponsor:** CDC  
**Budget Dates:** 9/1/2003 - 8/31/2005  
**Direct:** $250,000  
**F&A:** 12,062

**Reuben, Adrian**  
Principal Investigator  

**Medicine**  
A Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Phase III Study of Intravenous Terlipressin in Patients with Hepatorenal Syndrome Type 1  
**Sponsor:** Orphan Therapeutics  
**Award:** PROTOCOL#OT-0401 (04062110)  
**Budget Dates:** 6/21/2004 - 10/1/2005  
**Direct:** $2,800  
**F&A:** 5,700

**IRHC-001: A Phase 3, Randomized, Open-Label Study of the Safety and Efficacy of Two Dose Levels of Interferon Alfacon-1 (Infergen, Ckfn) plus Ribavirin Administered Daily for 48 Weeks Versus No-Treatment in Hepatitis C Infected Patients Who are Nonresponder**  
**Sponsor:** Intermune, Inc.  
**Award:** IRHC-001 (04050301)  
**Budget Dates:** 6/1/2004 - 12/31/2005  
**Direct:** $1,852,962  
**F&A:** 224,414

**Comparison of PEG-Intron 1.5 mcg/kg/wk Plus REBETROL vs PEG-Intron 1 mcg/kg/wk Plus REBETOL vs PEGASYS 180 mcg/wk Plus COPEGUS in Previously Untreated Subjects with Chronic Hepatitis C Infected with Genotype 1**  
**Sponsor:** Schering-Plough Corp.  
**Award:** (02040317)  
**Budget Dates:** 4/1/2002 - 4/30/2005  
**Direct:** $6,960  
**F&A:** 1,740

**Reves, Joseph**  
Principal Investigator  

**Dean's Office**  
Integration of Physician Training and Biomedical Research in South Carolina  
**Sponsor:** Univ. of South Carolina  
**Award:** 04-0909 (03121701)  
**Budget Dates:** 7/1/2003 - 6/30/2004  
**Direct:** $18,000  
**F&A:** 0

**General Clinical Research Center**  
**Sponsor:** NIH/NCRR  
**Award:** 5 M01 RR001070-28 (03120408)  
**Budget Dates:** 3/1/2004 - 2/28/2005  
**Direct:** $1,852,962  
**F&A:** 224,414

**Rheingold, Alyssa**  
Principal Investigator  

**Psychiatry & Behavioral Sciences**  
Primary Prevention of Child Sexual Abuse  
**Sponsor:** CDC  
**Award:** R49/CCR423142-01 (03040705)  
**Budget Dates:** 9/1/2003 - 8/31/2005  
**Direct:** $91,922  
**F&A:** 7,354

**Primary Prevention of Child Sexual Abuse**  
**PI:** RHEINGOLD, ALYSSA ANN  
**Sponsor:** CDC  
**Award:** R49/CCR423142-01 (03040705)  
**Budget Dates:** 9/1/2003 - 8/31/2005  
**Direct:** $91,922  
**F&A:** 7,354

**Child and Adult Trauma Victims:  A Training Program**  
**PI:** KILPATRICK, DEAN G.  
**Sponsor:** NIH/NIMH  
**Budget Dates:** 1/1/1988 - 6/30/2008  
**Direct:** $209,370  
**F&A:** 15,190

**Risch, Samuel**  
Principal Investigator  

**Psychiatry & Behavioral Sciences**  
A Double-Blind, Six-Month Continuation Protocol for Patients Who Successfully Completed Protocol #R-0548/Protocol R-0570  
**Sponsor:** Scirex Corp.  
**Budget Dates:** 11/10/1998 - 11/30/2001  
**Direct:** $40,201  
**F&A:** 0
<table>
<thead>
<tr>
<th>College Activity</th>
<th>Award</th>
<th>Project Dates</th>
<th>F&amp;A</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pediatrics</strong></td>
<td>R-0570 (99010601)</td>
<td>11/10/1998 - 11/30/2001</td>
<td>9,246</td>
</tr>
<tr>
<td>Roberts, James</td>
<td>Principal Investigator</td>
<td><strong>Incorporating Environmental Management of Asthma into Pediatric Medical and Nursing Education</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Management of Lead Intoxicated Children</td>
<td>Sponsor: SC DHEC</td>
<td>Budget Dates: 7/1/2003 - 6/30/2004</td>
</tr>
<tr>
<td></td>
<td>Award: WS-4-204 (03070301)</td>
<td>Project Dates: 7/1/2003 - 6/30/2004</td>
<td>F&amp;A: 0</td>
</tr>
<tr>
<td><strong>Surgery</strong></td>
<td>R-0570 (99010601)</td>
<td>11/10/1998 - 11/30/2001</td>
<td>9,246</td>
</tr>
<tr>
<td>Robison, Jacob</td>
<td>Co-Investigator</td>
<td><strong>The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients with Intermittent Claudication-A Matrix Design</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor: Kos Pharmaceuticals, Inc.</td>
<td>Direct: $69,350</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Award: MA-03-010401 (04012114)</td>
<td>F&amp;A: 17,337</td>
<td></td>
</tr>
<tr>
<td><strong>Biostatistics, Bioinformatics &amp; Epidemiology</strong></td>
<td>R-0570 (99010601)</td>
<td>11/10/1998 - 11/30/2001</td>
<td>9,246</td>
</tr>
<tr>
<td>Rodgers, Keith</td>
<td>Co-PI or Project Leader</td>
<td><strong>Tobacco and Cancer Risk: Dose, Metabolism and Genetics</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor: Amer. Health Fdn.</td>
<td>Direct: $35,390</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Award: P01 CA68384-06 (02101003-02)</td>
<td>F&amp;A: 15,218</td>
<td></td>
</tr>
<tr>
<td><strong>Ophthalmology</strong></td>
<td>R-0570 (99010601)</td>
<td>11/10/1998 - 11/30/2001</td>
<td>9,246</td>
</tr>
<tr>
<td>Rohrer, Baerbel</td>
<td>Principal Investigator</td>
<td><strong>Effects of Lipopolysaccharide Injections on BDNF and GDNF Partial Knockout Animals</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor: Health Sciences Fdn.</td>
<td>Direct: $57,612</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Award: (03071011)</td>
<td>F&amp;A: 0</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Rod Neurodegenerative and Protective Genes</strong></td>
<td>Sponsor: NIH/NEI</td>
<td>Direct: $100,000</td>
</tr>
<tr>
<td></td>
<td>Award: 5 R01 EY013520-03 (03042501)</td>
<td>F&amp;A: 35,225</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Transgenic Rod Development and Function</strong></td>
<td>Sponsor: NIH/NEI</td>
<td>Direct: $50,000</td>
</tr>
<tr>
<td></td>
<td>Award: 1 R03 EY013728-01A (02030509)</td>
<td>F&amp;A: 0</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Role of Alzheimer's APP in Retinal Degeneration</strong></td>
<td>Sponsor: Amer. Health Assistance Fdn.</td>
<td>Direct: $50,000</td>
</tr>
<tr>
<td></td>
<td>Award: M-2004-05/31/2006</td>
<td>F&amp;A: 0</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Psychiatry &amp; Behavioral Sciences</strong></td>
<td>R-0570 (99010601)</td>
<td>11/10/1998 - 11/30/2001</td>
</tr>
<tr>
<td>Roitzsch, John</td>
<td>Co-Investigator</td>
<td><strong>Graduate Psychology Education Programs: Internship Training in Behavioral Medicine and Trauma</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor: HRSA/BHP/Medicine</td>
<td>Direct: $79,637</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Award: 1 D40 HP00017-01 (02052201)</td>
<td>F&amp;A: 6,371</td>
<td></td>
</tr>
<tr>
<td><strong>Cell &amp; Molecular Pharmacology</strong></td>
<td>R-0570 (99010601)</td>
<td>11/10/1998 - 11/30/2001</td>
<td>9,246</td>
</tr>
<tr>
<td>Rosenzweig, Steven</td>
<td>Principal Investigator</td>
<td><strong>Inhibition of IGF Mediated Tumorigenesis</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsor: NIH/NCI</td>
<td>Direct: $205,059</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Award: 5 R01 CA078887-05 (04062030)</td>
<td>F&amp;A: 86,766</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Role of Retinal Pigment Epithelium in Choroidal Neovascularization</strong></td>
<td>Sponsor: Amer. Health Assistance Fdn.</td>
<td>Direct: $50,000</td>
</tr>
<tr>
<td></td>
<td>Award: (03102102)</td>
<td>F&amp;A: 0</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>DOD Phase VI: Project 8 -Translational Research and Cancer Prevention and Control and Risk Factor Identification</strong></td>
<td>Sponsor: Geo-Centers/DOD</td>
<td>Direct: $51,370</td>
</tr>
<tr>
<td></td>
<td>Award: GC-3532-03-42153CM (03080703-10)</td>
<td>F&amp;A: 23,630</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>TGF-Beta Receptor Signaling in Scleroderma</strong></td>
<td>Sponsor: NIH/NIAMS</td>
<td>Direct: $188,000</td>
</tr>
<tr>
<td></td>
<td>Award: 5 R01 AR044883-07 (04033102)</td>
<td>F&amp;A: 86,480</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Individual Predoctoral Dental Scientist Fellowship</strong></td>
<td>Sponsor: NIH/NIDCR</td>
<td>Direct: $23,718</td>
</tr>
<tr>
<td></td>
<td>Award: 1 F30 DE015249-01A (03040712)</td>
<td>F&amp;A: 0</td>
<td></td>
</tr>
</tbody>
</table>
Sambamurti, Kumar  
Physiology and Neuroscience  
Effects of Cholinergic Drugs on APP Metabolism  
Sponsor: Axonvx Corp.  
Award: (04010704)  
Direct: $135,000  
F&A: 33,750

Sahin, Steven  
Principal Investigator  
Medicine  
Effect of Roflumilast on Exacerbation Rate in Patients with Chronic Obstructive Pulmonary Disease: A 52 Week, Multi-Center, Double-Blind Study with 500 mcg Roflumilast Once Daily Versus Placebo  
Sponsor: Atrana Pharma  
Award: BY217/M2-111 (04051805)  
Direct: $90,291  
F&A: 22,573

Effects of Cholinergic Drugs on APP Metabolism  
Sponsor: Axonvx Corp.  
Award: (04010704)  
Direct: $135,000  
F&A: 33,750

Rubinchik, Semyon  
Co-Investigator  
Microbiology & Immunology  
Viral Vector Core Facility  
Pt: NÖRRIS, JAMES S.  
Sponsor: NIH/NCI  
Award: 5 R24 CA088163-04 (03121014)  
Budget Dates: 1/1/2001-6/30/2005  
Direct: $135,000  
F&A: 58,050

Rowland, Melisa  
Psychiatry & Behavioral Sciences  
Manualized MST/CRA for Treatment of SUDS in Youth  
Sponsor: Amer. Acad. of Child Psychiatry  
Award: 02052208  
Budget Dates: 7/1/2003 - 6/30/2004  
Direct: $137,500  
F&A: 0

Persistent Adeno-EBV Vectors for Gene Therapy  
Pt: DONG, JIANYUN  
Sponsor: NIH/NIDDK  
Award: 5 R01 DK057997-03 (03040106)  
Budget Dates: 7/1/2001-6/30/2005  
Direct: $135,000  
F&A: 58,050

Sambamurti, Kumar  
Principal Investigator  
Physiology and Neuroscience  
Effects of Cholinergic Drugs on APP Metabolism  
Sponsor: Axonvx Corp.  
Award: (04010704)  
Direct: $135,000  
F&A: 33,750
### College of Medicine

**Physiology and Neuroscience**

**Role of Alzheimer's APP in Retinal Degeneration**
- **Principal Investigator:** Sambamurti, Kumar
- **Sponsor:** Amer. Health Assistance Fdn.
- **Budget Dates:** 4/1/2004 - 3/31/2005
- **Direct:** $50,000
- **F&A:** 0

**Residual Funds**
- **Sponsor:** Mayo Clinic
- **Budget Dates:** 1/1/2003 - 12/31/2004
- **Direct:** $78,061
- **F&A:** 0

**Mechanisms of Neurotrophin-Impaired Cognition in Aging**
- **Co-Investigator:** Santos, Alberto
- **Sponsor:** NIH/NIA
- **Budget Dates:** 9/29/1991-8/31/2008
- **Award:** 2 R01 AG010755-10A1 (03081202)
- **Direct:** $218,250
- **F&A:** 0

**Psychiatry & Behavioral Sciences**

**Schizophrenia Liability Genes Among African Americans**
- **Principal Investigator:** Saul, J.
- **Sponsor:** NIH/NIMH
- **Budget Dates:** 9/1/1999 - 2/29/2004
- **Direct:** $438,155
- **F&A:** 89,240

**Understanding & Eliminating Health Disparities in Blacks - Investigator Development Core C**
- **Co-PI or Project Leader:** Santos, Alberto
- **Sponsor:** AHCPR/AHRQ
- **Budget Dates:** 9/21/2000-8/31/2005
- **Direct:** $54,375
- **F&A:** 23,381

**SC Cooperative for Healthy Aging in Minority Populations - Investigator Development Core D**
- **Sponsor:** NIH/NIA
- **Budget Dates:** 9/30/2002-8/31/2007
- **Direct:** $132,086
- **F&A:** 60,760

**Prospective Assessment after Pediatric Cardiac Ablation**
- **Sponsor:** UCSF Stanford Health Care
- **Budget Dates:** 3/1/1999 - 2/29/2004
- **Direct:** $13,264
- **F&A:** 3,051

**2004 ACCF/Pfizer Visiting Professorship in Cardiovascular Medicine**
- **Sponsor:** Pfizer, Inc.
- **Budget Dates:** 5/1/2004 - 4/30/2005
- **Direct:** $13,264
- **F&A:** 0

**Randomized Clinical Trials for Pediatric Heart Disease**
- **Sponsor:** NIH/NHLBI
- **Budget Dates:** 9/1/2003 - 8/31/2004
- **Direct:** $394,514
- **F&A:** 55,806

**Multidisciplinary Research in Developmental Cardiology**
- **Sponsor:** NIH/NHLBI
- **Budget Dates:** 7/1/2001 - 6/30/2004
- **Direct:** $227,178
- **F&A:** 17,368

**South Carolina Birth Defects Surveillance and Prevention Program**
- **Co-PI or Project Leader:** Saul, J.
- **Sponsor:** Greenwood Genetic Center
- **Budget Dates:** 10/1/2003-9/30/2004
- **Direct:** $6,849
- **F&A:** 3,151

**Mechanisms of Myocardial Radiofrequency Scar Expansion**
- **Co-Investigator:** Saul, J.
- **Sponsor:** NIH/NHLBI
- **Budget Dates:** 7/1/2001-6/30/2005
- **Direct:** $175,000
- **F&A:** 75,250

**Psychiatry & Behavioral Sciences**

**Service Systems Models IDE Program**
- **Principal Investigator:** Saunders, Benjamin
- **Sponsor:** SAMHSA/CMHS
- **Budget Dates:** 9/30/2003 - 9/29/2004
- **Direct:** $469,197
- **F&A:** 130,659

---

Annual Report for Research FY04
Saunders, Benjamin
Principal Investigator

**Psychiatry & Behavioral Sciences**  
Navy Family Study, Comparison Component  

- **Sponsor:** Wellesley Coll.  
- **Budget Dates:** 9/28/2003 - 9/27/2004  
- **Direct:** $251,597  
- **F&A:** $65,415  

Co-Co-Investigator

**Child Violence, Adult Victimization, Injury and Health**  

- **PI:** KILPATRICK, DEAN G.  
- **Sponsor:** CDC  
- **Budget Dates:** 9/30/2001-9/29/2005  
- **Direct:** $208,426  
- **F&A:** $89,623  

Schaffer, Frederick
Principal Investigator

**Pediatrics**  
A Randomized, Double-Blind, Clinical Study of Continuous Nebulization of Levalbuterol, in Comparison to Racemic-Albuterol, in a Cohort of Pediatric Patients with Status Asthmatics  

- **Sponsor:** Sepracor, Inc.  
- **Budget Dates:** 4/1/2004 - 4/30/2005  
- **Direct:** $80,880  
- **F&A:** $20,220  

Schey, Kevin
Principal Investigator

**Cell & Molecular Pharmacology**  
The Role of Lens MIP in Aging and Cataractogenesis  

- **Sponsor:** NIH/NEI  
- **Budget Dates:** 5/1/2004 - 4/30/2005  
- **Direct:** $150,000  
- **F&A:** $64,500  

 Schmidt, Michael
Principal Investigator

**Microbiology & Immunology**  
Management of the Nuclear Energy Research Advisory Committee (NERAC)  

- **Sponsor:** SCUREF  
- **Budget Dates:** 11/1/2000 - 9/30/2005  
- **Direct:** $120,087  
- **F&A:** $16,155
Schmidt, Michael  
Principal Investigator  

**Microbiology & Immunology**  
Radiochemistry Education Award Program (REAP)  
Sponsor: SCUREF  
Award: DC-FC09-00SR22184 (04062202)  
Budget Dates: 5/1/2004 - 9/30/2005  
Direct: $7,269  
F&A: 1,761

Navy Nuclear Propulsion Graduate Fellowship Program  
Sponsor: SCUREF  
Award: NEID-005 (01061512)  
Budget Dates: 6/1/2001 - 9/30/2005  
Direct: $709,022  
F&A: 1,795

*Administer and Manage the Nuclear Engineering/Health Physics Fellowship and Scholarship Program*  
Sponsor: SCUREF  
Award: NEID-001 (01050803)  
Budget Dates: 11/1/2000 - 9/30/2005  
Direct: $630,393  
F&A: 37,149

Schmiedt, Richard  
Principal Investigator  

**Otolaryngology**  
Physiological Studies of Age-Related Hearing Loss  
Sponsor: NIH/NIA  
Award: 5 R01 AG014748-07 (04012803)  
Direct: $175,000  
F&A: 80,500

Inner Ear Ion Transport Mechanisms  
Pt: SCHULTE, BRADLEY A.  
Sponsor: NIH/NIDCD  
Award: 5 R01 DC000713-14 (04013009)  
Direct: $227,500  
F&A: 97,825

Experimental and Clinical Studies of Presbyacusis  
Pt: MILLS, JOHN H.  
Sponsor: NIH/NIDCD  
Award: 5 P50 DC000422-17 (03042903)  
Budget Dates: 7/1/1987-6/30/2007  
Direct: $1,060,058  
F&A: 487,627

Schoenwald, Sonja  
Principal Investigator  

**Psychiatry & Behavioral Sciences**  
Linking Science and Practice to Improve Youth Mental Health Care: II Evidenced-based Practice in Clinics and Systems  
Sponsor: Univ. of California, Los Angeles  
Award: 0875 G EF272 (04032604)  
Budget Dates: 10/1/2003 - 8/31/2004  
Direct: $10,000  
F&A: 0

Testing EBP and Organization Effects in Rural Appalachia  
Sponsor: Univ. of Tennessee  
Award: OR4175-001.01 (02101401)  
Budget Dates: 7/1/2003 - 6/30/2004  
Direct: $173,468  
F&A: 79,796

School as Context for Mental Health: Interdisciplinary Network  
Sponsor: Univ. of Illinois at Chicago  
Award: 1 R21 MH067361-01 (02040907)  
Budget Dates: 9/20/2002 - 8/31/2005  
Direct: $15,960  
F&A: 7,342

Schulte, Bradley  
Principal Investigator  

**Pathology & Laboratory Medicine**  
Inner Ear Ion Transport Mechanisms  
Sponsor: NIH/NIDCD  
Award: 5 R01 DC000713-14 (04013009)  
Direct: $227,500  
F&A: 97,825

Interaction of Age-Related and Noise-Induced Hearing Loss  
Sponsor: Univ. of South Alabama  
Award: 7 R01 AG015705-06 (03031901)  
Direct: $64,499  
F&A: 29,670

**Orthopedic Surgery**  
A Prospective, Consecutive Series, Clinical Evaluation of Primary Hip Replacement Utilizing Exeter Femoral Stems (with Orthinox Femoral Heads) for Cemented Indications in Combinations with Cementless Trident Hemispherical Acetabular Shell and Crossfire  
Sponsor: Stryker Howmedica Osteonics  
Award: (03031901)  
Budget Dates: 7/1/2003 - 1/1/2009  
Direct: $54,696  
F&A: 13,674
<table>
<thead>
<tr>
<th>Name</th>
<th>Department</th>
<th>Role</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct Award</th>
<th>F&amp;A Award</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schweinfest, Clifford</td>
<td>Medicine</td>
<td>Principal Investigator</td>
<td>Elucidation of a DRA Signaling Pathway in Colon Cancer</td>
<td>NIH/NCI</td>
<td>4/1/2004 - 3/31/2005</td>
<td>$90,000</td>
<td>41,400</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Models of DRA Growth Suppression in Colon Cancer</td>
<td>NIH/NCI</td>
<td>7/1/2003 - 6/30/2004</td>
<td>$178,000</td>
<td>81,880</td>
</tr>
<tr>
<td>Seamans, Jeremy</td>
<td>Physiology and Neuroscience</td>
<td>Principal Investigator</td>
<td>Dopamine &amp; Ach Regulation of Inhibition in PFC</td>
<td>NIH/NIMH</td>
<td>2/1/2004 - 1/31/2005</td>
<td>$150,000</td>
<td>69,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Fast and Slow Dopamine Signaling in Prefrontal Cortex</td>
<td>NIH/NIMH</td>
<td>8/1/2003 - 7/31/2004</td>
<td>$175,000</td>
<td>80,500</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cellular Investigation of Neural Circuits Involved in Schizophrenia</td>
<td>NARSAD</td>
<td>7/1/2003 - 6/30/2004</td>
<td>$30,000</td>
<td>0</td>
</tr>
<tr>
<td>Sedmera, David</td>
<td>Cell Biology &amp; Anatomy</td>
<td>Co-PI or Project Leader</td>
<td>SC COBRE for Cardiovascular Disease: Project 6 - Strategies for Prenatal Repair of Hypoplastic Myocardium</td>
<td>NIH/NCRR</td>
<td>9/30/2001-6/30/2006</td>
<td>$100,000</td>
<td>43,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Myocyte Proliferation in the Embryonic Chick Heart</td>
<td>NIH/NHLBI</td>
<td>7/1/1993-2/28/2008</td>
<td>$200,000</td>
<td>92,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Co-Investigator</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>See, Ronald</td>
<td>Physiology and Neuroscience</td>
<td>Principal Investigator</td>
<td>Basolateral Amygdala - A Substrate for Relapse</td>
<td>NIH/NIDA</td>
<td>8/1/2003-4/30/2008</td>
<td>$150,000</td>
<td>69,000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Co-PI or Project Leader</td>
<td>The Neurobiology of Addiction Research Center Animal Core B</td>
<td>NIH/NIDA</td>
<td>9/30/2002-6/30/2007</td>
<td>$115,037</td>
<td>52,917</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ORWH: SCOR on Sex and Gender Factors Affecting Women's Health: Project 1 - Sex Differences in an Animal Model Relapse</td>
<td>NIH/NIDA</td>
<td>9/30/2002-6/30/2007</td>
<td>$115,037</td>
<td>52,917</td>
</tr>
<tr>
<td>Selassie, Anbesaw</td>
<td>Biostatistics, Bioinformatics &amp; Epidemiology</td>
<td>Principal Investigator</td>
<td>SC Traumatic Brain Injury (TBI) Surveillance Program</td>
<td>SC-DHEC</td>
<td>9/15/2003 - 7/31/2004</td>
<td>$38,033</td>
<td>9,889</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>South Carolina Epidemiological Studies of Epilepsy and Seizure Disorder</td>
<td>AAMC</td>
<td>10/1/2003 - 9/30/2004</td>
<td>$239,657</td>
<td>67,409</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>The South Carolina Traumatic Brain Injury Registry</td>
<td>CDC</td>
<td>8/1/2003 - 7/31/2004</td>
<td>$586,674</td>
<td>125,628</td>
</tr>
<tr>
<td>College of Medicine</td>
<td>Psychiatry &amp; Behavioral Sciences</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>----------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sheidow, Ashli</td>
<td>Development of Outpatient MST for Dually Diagnosed Youth</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct: 75,000</td>
<td>F&amp;A: 34,500</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mentored Patient-Oriented Research Career Development Award</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Award: 1 K23 DA015658-01A (02102501)</td>
<td>Project Dates: 9/30/2003 - 6/30/2008</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Direct: 110,960</td>
<td>F&amp;A: 8,877</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Shen, Zhijun</th>
<th>Pathology &amp; Laboratory Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shen, Zhijun</td>
<td>Ion Transport Mechanisms in Type I Fibrocytes</td>
</tr>
<tr>
<td>Sponsor: NIH/NIDCD</td>
<td>Project Dates: 8/1/2003 - 7/31/2005</td>
</tr>
<tr>
<td>Award: 5 R03 DC005148-03 (03052313)</td>
<td>Project Dates: 8/1/2001 - 7/31/2005</td>
</tr>
<tr>
<td>Direct: 50,000</td>
<td>F&amp;A: 21,500</td>
</tr>
<tr>
<td>Inner Ear Ion Transport Mechanisms</td>
<td></td>
</tr>
<tr>
<td>PI: SCHULTE, BRADLEY A.</td>
<td>Sponsor: NIH/NIDCD</td>
</tr>
<tr>
<td>Award: 5 R01 DC000713-14 (04013009)</td>
<td>Project Dates: 8/1/1999-3/31/2001</td>
</tr>
<tr>
<td>Direct: 227,500</td>
<td>F&amp;A: 97,825</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Shirali, Girish</th>
<th>Pediatrics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shirali, Girish</td>
<td>South Carolina Birth Defects Surveillance and Prevention Program</td>
</tr>
<tr>
<td>Sponsor: Greenwood Genetic Center</td>
<td>Project Dates: 10/1/2003 - 9/30/2004</td>
</tr>
<tr>
<td>Direct: 39,726</td>
<td>F&amp;A: 18,274</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Silver, Richard</th>
<th>Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Silver, Richard</td>
<td>NIAMS Clinical Research Center for Rheumatoid Disease</td>
</tr>
<tr>
<td>Award: 5 P60 AR049459-02 (04020403)</td>
<td>Project Dates: 4/15/2003 - 3/31/2008</td>
</tr>
<tr>
<td>Direct: 855,775</td>
<td>F&amp;A: 321,995</td>
</tr>
<tr>
<td>Pfizer Visiting Professor-Dr. John Harley</td>
<td></td>
</tr>
<tr>
<td>Award: (04012303)</td>
<td>Project Dates: 4/1/2004 - 6/30/2005</td>
</tr>
<tr>
<td>Direct: 7,500</td>
<td>F&amp;A: 0</td>
</tr>
<tr>
<td>NIAMS Clinical Research Center for Rheumatoid Disease-Minority Supplement</td>
<td></td>
</tr>
<tr>
<td>Award: 3 P60 AR049459-01S (03111301)</td>
<td>Project Dates: 1/1/2004 - 6/30/2005</td>
</tr>
<tr>
<td>Direct: 57,450</td>
<td>F&amp;A: 26,427</td>
</tr>
<tr>
<td>Build-2: A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety and Tolerability of Bosetan in Patients with Interstitial Lung Disease Associated with Systemic Sclerosis</td>
<td></td>
</tr>
<tr>
<td>Direct: 68,000</td>
<td>F&amp;A: 17,000</td>
</tr>
<tr>
<td>Scleroderma Lung Study</td>
<td></td>
</tr>
<tr>
<td>Sponsor: NIH/NHLBI</td>
<td>Project Dates: 7/1/2003 - 6/30/2005</td>
</tr>
<tr>
<td>Award: 5 U01 HL060750-05 (03042901)</td>
<td>Project Dates: 8/10/1999 - 6/30/2005</td>
</tr>
<tr>
<td>Direct: 50,488</td>
<td>F&amp;A: 19,820</td>
</tr>
<tr>
<td>Co-Investigator</td>
<td>The Role of Thrombin and Its Receptor on Myofibroblast Differentiation in Scleroderma Lung Fibrosis</td>
</tr>
<tr>
<td>PI: BRADLEY, ANNA LUDWICKA</td>
<td>Sponsor: Scleroderma Fdn.</td>
</tr>
<tr>
<td>Award: (02091305)</td>
<td>Project Dates: 1/1/2003-12/31/2004</td>
</tr>
<tr>
<td>Direct: 69,444</td>
<td>F&amp;A: 5,556</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Silvestri, Gerard</th>
<th>Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Silvestri, Gerard</td>
<td>Emphasis Medical Endobronchial Valve for Emphysema Palliation Trial (VENT)</td>
</tr>
<tr>
<td>Sponsor: Emphasis Medical, Inc.</td>
<td>Project Dates: 10/10/2003 - 10/10/2008</td>
</tr>
<tr>
<td>Award: 630-0001-F (03072801)</td>
<td>Project Dates: 10/10/2003 - 10/10/2008</td>
</tr>
<tr>
<td>Direct: 332,600</td>
<td>F&amp;A: 79,900</td>
</tr>
<tr>
<td>Improving Physician Skill at Providing End-of-Life Care</td>
<td></td>
</tr>
<tr>
<td>Award: 698400 (01062709)</td>
<td>Project Dates: 5/1/2002 - 4/30/2004</td>
</tr>
<tr>
<td>Direct: 207,415</td>
<td>F&amp;A: 89,189</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Singh, Avtar</th>
<th>Pathology &amp; Laboratory Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td>Singh, Avtar</td>
<td>Globoid Cell Leukodystrophy</td>
</tr>
<tr>
<td>Award: 5 R01 NS040810-04 (04021201)</td>
<td>Project Dates: 4/12/2001 - 5/31/2006</td>
</tr>
<tr>
<td>Direct: 250,000</td>
<td>F&amp;A: 107,500</td>
</tr>
<tr>
<td>Project Title</td>
<td>Sponsor</td>
</tr>
<tr>
<td>------------------------------------------------------------------------------</td>
<td>-----------------------------</td>
</tr>
<tr>
<td>Simvastatin and Interferon B Therapy for Multiple Sclerosis</td>
<td>Myelin Project Fdn.</td>
</tr>
<tr>
<td>Fatty Acid Oxidation in X-Linked Adrenoleukodystrophy</td>
<td>NIH/NINDS</td>
</tr>
<tr>
<td>Peroxisomal Function in Renal Ischemia</td>
<td>Dialysis Clinics, Inc.</td>
</tr>
<tr>
<td>Semiparametric Bayesian Survival Analysis</td>
<td>NIH/NCI</td>
</tr>
<tr>
<td>Oncology Center: Biostatistic Project</td>
<td>DOE</td>
</tr>
<tr>
<td>Phase III Trial of Selenium and Prostate Cancer Prevention</td>
<td>Univ. of Arizona</td>
</tr>
<tr>
<td>PSA Screening and US Prostate Cancer Trends</td>
<td>Fred Hutchinson Cancer Center</td>
</tr>
<tr>
<td>DOD Phase VI: Project 19 -Geographical Determinants of Prostate Cancer (PrCA) Progression in South Carolina</td>
<td>Geo-Centers/DOD</td>
</tr>
<tr>
<td>South Carolina COBRE for Oral Health: Core B - Biostatistics Core</td>
<td>NIDCR</td>
</tr>
<tr>
<td>Oral Health Research Infrastructure Planning at MUSC</td>
<td>Organ Recovery Systems</td>
</tr>
<tr>
<td>Axonal Nerve Regeneration</td>
<td>Organ Recovery Systems</td>
</tr>
</tbody>
</table>
### College of Medicine

**Smith, Alison**  
**Principal Investigator**

#### Comparative Medicine

**In-Vitro Presentation and Viability Assessment of Rat Embryonic Metanephroi**  
**Sponsor:** Organ Recovery Systems  
**Award:** (03080101)  
**Project Dates:** 1/1/2004 - 12/31/2004  
**F&A:** $1,370

**Preservation of Myocardial Tissue Engineered Constructs**  
**Sponsor:** Organ Recovery Systems  
**Award:** (02112702)  
**Project Dates:** 9/1/2003 - 5/31/2005  
**F&A:** $5,886

**Organ Preservation Using Molecular Ice Control**  
**Sponsor:** Organ Recovery Systems  
**Award:** 1 R43 DK64488-01 (00720511)  
**Project Dates:** 9/1/2003 - 6/30/2004  
**F&A:** $2,681

#### Psychiatry & Behavioral Sciences

**Measurement and Impact of Maternal Support Following Child Sexual Abuse**  
**Sponsor:** DHHS/Children's Bureau  
**Award:** 90CA1689/03 (03031702)  
**Project Dates:** 9/30/2003 - 9/29/2004  
**F&A:** $50,732

**Service Systems Models IDE Program**  
**Pt:** SAUNDERS, BENJAMIN E.  
**Sponsor:** SAMHSA/CMHS  
**Award:** 1 UD1 SM56070-01 (03080609)  
**Project Dates:** 9/30/2003 - 9/29/2004  
**F&A:** $130,659

**Management for Healthy Aging in Minority Populations**  
**Pt:** TILLEY, BARBARA  
**Sponsor:** NIH/NIA  
**Award:** 5 P30 AG021677-02 (03071007)  
**Project Dates:** 9/30/2003 - 9/29/2004  
**F&A:** $161,960

**Child and Adult Trauma Victims: A Training Program**  
**Pt:** KILPATRICK, DEAN G.  
**Sponsor:** NIH/NIMH  
**Award:** 2 T32 MH018869-16 (02050903)  
**Project Dates:** 1/1/2004 - 12/31/2005  
**F&A:** $15,190

**Navy Family Study, Comparison Component**  
**Pt:** SAUNDERS, BENJAMIN E.  
**Sponsor:** Wellesley Coll.  
**Award:** N00140-01-C-N662 (01091004)  
**Project Dates:** 9/28/2001 - 9/30/2006  
**F&A:** $65,415

### Smith, Daniel  
**Principal Investigator**

#### Psychiatry & Behavioral Sciences

**Service Systems Models IDE Program**  
**Pt:** SAUNDERS, BENJAMIN E.  
**Sponsor:** SAMHSA/CMHS  
**Award:** 1 UD1 SM56070-01 (03080609)  
**Project Dates:** 9/30/2003 - 9/29/2004  
**F&A:** $130,659

**Management for Healthy Aging in Minority Populations**  
**Pt:** TILLEY, BARBARA  
**Sponsor:** NIH/NIA  
**Award:** 5 P30 AG021677-02 (03071007)  
**Project Dates:** 9/30/2003 - 9/29/2004  
**F&A:** $161,960

#### Medicine

**Long-Term Bosentan Open-Label Extension of RAPIDS-2 Study in Systemic Sclerosis Patients with Ischemic Digital Ulcers**  
**Sponsor:** Actelion Pharmaceuticals  
**Award:** PROTOCOL#AC-052-331 RAPIDS 2 (03092401)  
**Project Dates:** 9/28/2001-9/30/2006  
**F&A:** $251,597

**Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)**  
**Sponsor:** Univ. of Alabama  
**Award:** 04021205 (04062111)  
**Project Dates:** 5/27/2004 - 12/31/2005  
**F&A:** $19,775

**Clinical Screening Protocol on Clinical Status of Scleroderma Patients for Potential Clinical Trials**  
**Sponsor:** Genzyme Corp.  
**Award:** CAT192-003-03 (04012302)  
**Project Dates:** 5/27/2004 - 12/31/2005  
**F&A:** $4,944

**Autoimmune Biomarkers Collaborative Network-Amendment 1**  
**Sponsor:** Univ. of Alabama  
**Award:** N01-AR-1-2256 (UAB#) (03102103)  
**Project Dates:** 9/30/2003 - 9/29/2004  
**F&A:** $6,464

**A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Effect of Bosentan on Healing and Prevention of Ischemic Digital Ulcers in Patients with Systemic Sclerosis**  
**Sponsor:** Actelion Pharmaceuticals  
**Award:** AC-052-331 RAPIDS 2 (03092401)  
**Project Dates:** 9/30/2003 - 9/29/2004  
**F&A:** $21,099

**CLEAR Registry**  
**Sponsor:** Univ. of Alabama, Birmingham  
**Award:** 04021205 (00060609)  
**Project Dates:** 5/27/2004 - 12/31/2005  
**F&A:** $77,555
**Smith, Edwin**  
Co-PI or Project Leader  

**Medicine**  
NIAMS Clinical Research Center for Rheumatoid Disease-Pt. Res. Core  
Pl: SILVER, RICHARD M.  
Sponsor: NIH/NIAMS  
Award: 5 P60 AR049459-02 (04020403-03)  
Direct: $132,466  
F&A: 60,934

**Scleroderma Lung Study**  
Pl: SILVER, RICHARD M.  
Sponsor: NIH/NHLBI  
Project Dates: 8/10/1999-6/30/2005  
Award: 5 U01 HL060750-05 (03042901)  
Direct: $50,488  
F&A: 19,820

**Smolka, Adam**  
Principal Investigator  

**Medicine**  
Surrogate Biomarkers of Micrometastatic Gastric Cancer  
Sponsor: NIH/NCI  
Direct: $50,000  
F&A: 19,820

**Solomon, Kerry**  
Principal Investigator  

**Ophthalmology**  
Rebamipide Ophthalmic Suspension in the Treatment of Dry Eye: A Multi-Center, Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, 52 Week Study  
Sponsor: PPD Development  
Budget Dates: 6/15/2004 - 6/14/2005  
Direct: $24,400  
F&A: 6,100

**Paroxetine Treatment in Outpatients with Comorbid PTSD and Substance Dependence**  
Sponsor: GlaxoSmithKline  
Budget Dates: 10/1/2002 - 7/31/2005  
Direct: $8,960  
F&A: 2,240

**Sonne, Susan**  
Principal Investigator  

**Psychiatry & Behavioral Sciences**  
A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of GABITRIL, at Dosages up to 16 mg/day, in Adults with Chronic, Post-Traumatic Stress Disorder  
Sponsor: Cephalon, Inc.  
Direct: $48,275  
F&A: 12,069

**A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of GABITRIL at Dosages up to 16mg/day in the Treatment of Chronic Post-Traumatic Stress Disorder in Adults**  
Sponsor: Cephalon, Inc.  
Budget Dates: 10/1/2002 - 7/31/2005  
Direct: $8,960  
F&A: 2,240

**Southeastern Node of the Clinical Trials Network**  
Pl: BRADY, KATHLEEN T.  
Sponsor: NIH/NIDA  
Project Dates: 9/30/2000-8/31/2005  
Award: 5 U10 DA013727-04 (03062618)  
Direct: $1,307,975  
F&A: 392,075
**Obstetrics/Gynecology**

**The Validation of the Menstrual Pictogram Against the Alkaline Hematin Method in Measuring Menstrual Blood Loss in Women with Uterine Leiomyomata**

- **Sponsor:** Tap Pharmaceuticals, Inc.
- **Budget Dates:** 5/1/2004 - 4/30/2005
- **Direct:** $37,800

**An Open-Label, Randomized, Comparator-Controlled Study of the Contraceptive Efficacy of Norethindrone Acetate, 1 mg/Ethinyl Estradiol 20 mcg Oral Tablets Administered for 24 days of a 28-day Cycle**

- **Sponsor:** Galen Holdings PLC
- **Budget Dates:** 1/16/2004 - 1/31/2006
- **Direct:** $9,000

- **Award:** PROTOCOL #03903 (04041501)
- **Project Dates:** 1/16/2004 - 1/31/2006

**Assessment of the Clinical Performance of SYSCAN3 ELISA and CANDIA5 as Aids in the Diagnosis of Vulvovaginal Candidiasis**

- **Sponsor:** Rockeby Biomed Corp.
- **Budget Dates:** 11/13/2003 - 12/31/2004
- **Direct:** $8,000

- **Award:** (03120407)
- **Project Dates:** 11/13/2003 - 12/31/2004

**A Multi-Center, Double-Blind, Parallel-Group Study Comparing the Bioequivalence of Atrix Laboratories, Inc. Generic Formulation of Metronidazole Vaginal Gel, 0.75% and MetroGelVaginal**

- **Sponsor:** SFBC, Charlotte
- **Budget Dates:** 8/18/2003 - 1/1/2005
- **Direct:** $32,450

- **Award:** ATRIX-112 (03061208)
- **Project Dates:** 8/18/2003 - 1/1/2005

**A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy and Safety of an Intravaginal Ring Delivering Metronidazole in the Treatment of Bacterial Vaginosis**

- **Sponsor:** Warner Chilcott, Inc.
- **Budget Dates:** 8/12/2002 - 4/30/2004
- **Direct:** $7,259

- **Award:** PR 01301.0 (02100205)
- **Project Dates:** 8/12/2002 - 4/30/2004

**Inhaled NO for the Prevention of Chronic Lung Disease**

- **Sponsor:** Univ. of Colorado
- **Budget Dates:** 9/1/2003 - 8/31/2004
- **Direct:** $36,644

- **Award:** (02100205)
- **Project Dates:** 9/1/2000 - 8/31/2004

**Post-Transcription Regulation of Human bcl-2 Expression**

- **Sponsor:** NIH/NCI
- **Budget Dates:** 7/1/2003 - 6/30/2004
- **Direct:** $142,500

- **Award:** 5 R01 CA087553-02 (03043004)
- **Project Dates:** 7/1/2002 - 6/30/2006

**A Multi-Center, Pilot Study to Evaluate the Efficacy of Adenoscan R (Adenosine) as a Pharmacologic Stress Agent to Assess Coronary Artery Disease by Myocardial Perfusion Using Contrast Enhanced MRI in Comparison to Conventional X-Ray Angiography**

- **Sponsor:** Fujisawa Healthcare, Inc.
- **Budget Dates:** 1/26/2004 - 1/1/2005
- **Direct:** $70,000

- **Award:** AD-03001 (03121801)
- **Project Dates:** 1/26/2004 - 1/1/2005

**A Prospectively Randomized, Phase III, Multi-Center, Controlled Trial to Evaluate the Safety and Efficacy of Zevalin TM Therapeutic Regiman Plus Rituxan Compared with Rituxan Alone in Patients with Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma**

- **Sponsor:** Idec Pharmaceuticals Corp.
- **Budget Dates:** 7/30/2003 - 7/31/2007
- **Direct:** $192,000

- **Award:** 106-10 (03070204)
- **Project Dates:** 7/30/2003 - 7/31/2007

**A Phase IIIb, Open-Label, Non-Randomized, Multi-Center Trial to Assess the Ability of DMP 115 Contrast Enhanced Ultrasound Imaging to Correctly Detect and Characterize Liver or Kidney Pathology**

- **Pt:** ACKERMAN, SUSAN
- **Sponsor:** Bristol Myers Squibb
- **Budget Dates:** 1/31/2004-1/31/2005
- **Direct:** $10,200

- **Award:** PROTOCOL DMP115-305 (04012102)
- **Project Dates:** 1/31/2004-1/31/2005

**A Phase III, Open-Label, Multi-Center Trial to Compare the Diagnostic Accuracy for Definity (R)-Enhanced Ultrasound Imaging Versus Contrast-Enhanced Computed Tomography (CT) for Characterization of Liver Lesions**

- **Pt:** ACKERMAN, SUSAN
- **Sponsor:** Bristol Myers Squibb
- **Budget Dates:** 2/6/2004-1/31/2005
- **Direct:** $37,860

- **Award:** DMP 115-306 (04012101)
- **Project Dates:** 2/6/2004-1/31/2005
Spicer, Samuel  
Co-Investigator  

**Pathology & Laboratory Medicine**  

*Inner Ear Ion Transport Mechanisms*  
Pt: SCHULTE, BRADLEY A.  
Sponsor: NIH/NIDCD  
Award: 5 R01 DC000713-14 (04013009)  
Direct: $227,500  
F&A: 97,825

*Experimental and Clinical Studies of Presbyacusis*  
Pt: MILLS, JOHN H.  
Sponsor: NIH/NIDCD  
Project Dates: 7/1/1987-6/30/2007  
Award: 5 P50 DC000422-17 (03042903)  
F&A: 487,627

Spinale, Francis  
Principal Investigator  

**Surgery**  

*Selective Endothelin-A Receptor Inhibition Following Cardiac Surgery: A Safety Study*  
Sponsor: Encysive, LP  
Budget Dates: 5/1/2004 - 10/31/2004  
Direct: $101,192  
F&A: 25,298

*Collagenase Inhibition in Heart Failure*  
Pt: SCHULTE, BRADLEY A.  
Sponsor: NIH/NHLBI  
Award: 5 R01 HL059165-07 (03112603)  
F&A: 96,750

*Protection of Myocyte Function After Cardioplegia*  
Pt: SCHULTE, BRADLEY A.  
Sponsor: NIH/NHLBI  
Award: 5 R01 HL056603-07 (03093009)  
F&A: 96,750

*The Influence of Pre-Operative Use of HMG-CoA Reductase Inhibitors in Cardiac Surgery: An 8 Year Retrospective Study*  
Pt: SCHULTE, BRADLEY A.  
Sponsor: Merck  
Budget Dates: 2/1/2003 - 2/1/2005  
Direct: $30,760  
F&A: 7,690

*Endothelin Receptors and the Progression to Heart Failure*  
Pt: SCHULTE, BRADLEY A.  
Sponsor: NIH/NHLBI  
Award: 2 R01 HL057952-05A (03022503)  
F&A: 69,000

*Double-Blind, Multi-Center Study of the Safety and Efficacy of Parecoxib/Valdecoxib and Placebo/Valdecoxib to Placebo for Treatment of Post-Surgical Pain in Patients Who Have Coronary Bypass Graft via Median Sternotomy*  
Sponsor: Pharmacia  
Budget Dates: 12/17/2002 - 1/1/2005  
Direct: $300  
F&A: 75

Spratt, Eve  
Principal Investigator  

**Pediatrics**  

*HALOS: Program Development Connecting Faith Communities with Abused and Neglected Victims*  
Pt: COOPER, IV, GEORGE  
Sponsor: NIH/NHLBI  
Project Dates: 8/1/1993-7/31/2008  
Award: 2 P01 HL048788-11 (03012709-07)  
F&A: 74,658

*Neurodevelopmental Biology of Neglected Children*  
Pt: COOPER, IV, GEORGE  
Sponsor: NIH/NIMH  
Project Dates: 8/1/1993-7/31/2008  
Award: 5 R01 HL048788-11 (03012709-07)  
F&A: 643,827

*Promoting Happy and Healthy Youth*  
Pt: COOPER, IV, GEORGE  
Sponsor: HRSA  
Project Dates: 7/1/2003 - 6/30/2004  
Award: 1 R01 HL075488-01 (03012704)  
F&A: 103,500

*An fMRI Study of Healthy Mothers Hearing Infant Cries*  
Pt: LORBERBAUM, JEFFREY  
Sponsor: NIH/NINDS  
Project Dates: 9/1/2000-8/31/2005  
Award: 5 R01 NS40259-03 (02072501)  
F&A: 13,800
<table>
<thead>
<tr>
<th>Faculty Activity by College</th>
<th>Medical University of South Carolina</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>College of Medicine</strong></td>
<td><strong>FERNANDES</strong></td>
</tr>
<tr>
<td><strong>Spruill, Ida</strong></td>
<td>Co-Investigator</td>
</tr>
<tr>
<td><strong>Medicine</strong></td>
<td><strong>Lupus Educational and Awareness Outreach Program</strong></td>
</tr>
<tr>
<td>Pt: FERNANDES, JYOTIKA K.</td>
<td>Sponsor: DHHS</td>
</tr>
<tr>
<td></td>
<td>F&amp;A: 2,308</td>
</tr>
<tr>
<td><strong>Spyropoulos, Demetri</strong></td>
<td>Co-Investigator</td>
</tr>
<tr>
<td><strong>Cell Biology &amp; Anatomy</strong></td>
<td><strong>Models of DRA Growth Suppression in Colon Cancer</strong></td>
</tr>
<tr>
<td>Pt: SCHWEINFEST, CLIFFORD</td>
<td>Sponsor: NIH/NCI</td>
</tr>
<tr>
<td>Project Dates: 7/1/2003-6/30/2007</td>
<td>Award: 1 R01 CA095172-01A2 (02102401)</td>
</tr>
<tr>
<td></td>
<td>F&amp;A: 81,880</td>
</tr>
<tr>
<td><strong>Steed, Lisa</strong></td>
<td>Principal Investigator</td>
</tr>
<tr>
<td><strong>Pathology &amp; Laboratory Medicine</strong></td>
<td><strong>ICU Surveillance Study: Incidence of Multiresistant Gram Negative Bacilli in ICU-2003</strong></td>
</tr>
<tr>
<td>Award: (03060505)</td>
<td>Project Dates: 7/1/2003 - 6/30/2004</td>
</tr>
<tr>
<td></td>
<td>Direct: $2,500</td>
</tr>
<tr>
<td></td>
<td>F&amp;A: 625</td>
</tr>
<tr>
<td><strong>Steyer, Terrence</strong></td>
<td>Principal Investigator</td>
</tr>
<tr>
<td><strong>Family Medicine</strong></td>
<td><strong>Leadership Seminar Series for Primary Care Residents and Faculty in Medicine and Dentistry</strong></td>
</tr>
<tr>
<td>Award: (02100208)</td>
<td>Project Dates: 10/1/2002 - 9/30/2007</td>
</tr>
<tr>
<td></td>
<td>Direct: $36,697</td>
</tr>
<tr>
<td></td>
<td>F&amp;A: 2,935</td>
</tr>
<tr>
<td></td>
<td><strong>Academic Administrative Units in Primary Care</strong></td>
</tr>
<tr>
<td>Pt: HUESTON, WILLIAM</td>
<td>Sponsor: HRSA/BHP/Medicine</td>
</tr>
<tr>
<td>Project Dates: 9/1/2000-8/31/2006</td>
<td>Award: 8 D54 HP00023-04 (02122002)</td>
</tr>
<tr>
<td></td>
<td>F&amp;A: 12,160</td>
</tr>
<tr>
<td><strong>Impact of Direct to Consumer Pharmaceutical Marketing</strong></td>
<td></td>
</tr>
<tr>
<td>Pt: BRADFORD, W. DAVID</td>
<td>Sponsor: AHCPR/AHRQ</td>
</tr>
<tr>
<td>Project Dates: 7/7/2003-6/30/2005</td>
<td>Award: 1 R01 HS011326-01A2 (02062806)</td>
</tr>
<tr>
<td></td>
<td>F&amp;A: 83,850</td>
</tr>
<tr>
<td><strong>Strange, Charlie</strong></td>
<td>Principal Investigator</td>
</tr>
<tr>
<td><strong>Medicine</strong></td>
<td><strong>Phase II: Comparative, Pharmacokinetic and Pharmacodynamic Study of Epoetin Alfa (Procrit) in Anemic Critically Ill Patients Randomized to One of Six Dose Regimens for 15 Days</strong></td>
</tr>
<tr>
<td></td>
<td>F&amp;A: 5,824</td>
</tr>
<tr>
<td><strong>FPH02 (STRIDE-11): A Phase III, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Sitaxsentan Sodium Treatment with an Open-Label Bosentan Arm in Patients with Pulmonary Arterial Hypertension</strong></td>
<td></td>
</tr>
<tr>
<td>Sponsor: Cycle Solutions</td>
<td>Budget Dates: 12/30/2003 - 12/1/2005</td>
</tr>
<tr>
<td>Award: FPH02 (STRIDE-11) (03120406)</td>
<td>Project Dates: 12/30/2003 - 12/1/2005</td>
</tr>
<tr>
<td></td>
<td>F&amp;A: 17,276</td>
</tr>
<tr>
<td><strong>FPH 02X: An Open-Label Study to Evaluate the Long-Term Safety of Sitaxsentan Sodium Treatment with a Bosentan Arm in Patients with Pulmonary Arterial Hypertension</strong></td>
<td></td>
</tr>
<tr>
<td>Sponsor: Cycle Solutions</td>
<td>Budget Dates: 12/30/2003 - 12/31/2005</td>
</tr>
<tr>
<td>Award: FPH 02X (03120405)</td>
<td>Project Dates: 12/30/2003 - 12/31/2005</td>
</tr>
<tr>
<td></td>
<td>F&amp;A: 23,776</td>
</tr>
<tr>
<td><strong>FPH 03: A Long-Term, Open Label Study to Evaluate the Safety of Sitaxsentan Sodium Treatment in Patients with Pulmonary Arterial Hypertension Who Have Failed Bosentan Therapy</strong></td>
<td></td>
</tr>
<tr>
<td>Award: FPH 03 (03120404)</td>
<td>Project Dates: 12/30/2003 - 11/30/2006</td>
</tr>
<tr>
<td></td>
<td>F&amp;A: 26,112</td>
</tr>
<tr>
<td><strong>FPH 06: A Double-Blind, Safety and Efficacy Study of Sitaxsentan Sodium Treatment in Patients with Pulmonary Arterial Hypertension</strong></td>
<td></td>
</tr>
<tr>
<td>Award: FPH 06 (03120403)</td>
<td>Project Dates: 8/1/2003 - 7/31/2004</td>
</tr>
<tr>
<td></td>
<td>Direct: $45,104</td>
</tr>
<tr>
<td></td>
<td>F&amp;A: 11,276</td>
</tr>
<tr>
<td><strong>Alpha-1 Foundation Registry</strong></td>
<td></td>
</tr>
<tr>
<td>Award: (03081201)</td>
<td>Project Dates: 7/1/2003 - 7/31/2004</td>
</tr>
<tr>
<td></td>
<td>Direct: $197,519</td>
</tr>
<tr>
<td></td>
<td>F&amp;A: 0</td>
</tr>
<tr>
<td><strong>Genetic Modifiers of Alpha-1 Antitrypsin Deficiency</strong></td>
<td></td>
</tr>
<tr>
<td>Award: (03072301)</td>
<td>Project Dates: 8/1/2003 - 7/31/2004</td>
</tr>
<tr>
<td></td>
<td>Direct: $10,000</td>
</tr>
<tr>
<td></td>
<td>F&amp;A: 0</td>
</tr>
<tr>
<td><strong>Emphasis Medical Endobronchial Valve for Emphysema PalliationN Trial (VENT)</strong></td>
<td></td>
</tr>
<tr>
<td>Pt: SILVESTRI, GERARD A.</td>
<td>Sponsor: Emphasis Medical, Inc.</td>
</tr>
<tr>
<td>Project Dates: 10/10/2003-10/10/2008 Award: 630-0001-F (03072801-01)</td>
<td>Direct: $332,600</td>
</tr>
<tr>
<td></td>
<td>F&amp;A: 79,900</td>
</tr>
<tr>
<td><strong>Medical University of South Carolina Faculty Activity by College</strong></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td></td>
</tr>
<tr>
<td><strong>SILVER</strong></td>
<td><strong>College of Medicine</strong></td>
</tr>
<tr>
<td><strong>Strange, Charlie</strong></td>
<td>Co-Investigator</td>
</tr>
<tr>
<td><strong>Build-2: A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety and Tolerance of Bosetan in Patients with Interstitial Lung Disease Associated with Systemic Sclerosis</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PI:</strong> SILVER, RICHARD M.</td>
<td><strong>Sponsor:</strong> Actelion Pharmaceuticals</td>
</tr>
<tr>
<td><strong>Project Dates:</strong> 8/6/2003-5/31/2005</td>
<td><strong>Award:</strong> AC-052-330 (03060601)</td>
</tr>
<tr>
<td><strong>Direct:</strong> $68,000</td>
<td><strong>F&amp;A:</strong> 17,000</td>
</tr>
<tr>
<td><strong>Experimental and Clinical Studies of Presbyacusis</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PI:</strong> MILLS, JOHN H.</td>
<td><strong>Sponsor:</strong> NIH/NIDCD</td>
</tr>
<tr>
<td><strong>Project Dates:</strong> 7/1/1987-6/30/2007</td>
<td><strong>Award:</strong> 5 P50 DC00422-17 (03042903)</td>
</tr>
<tr>
<td><strong>Direct:</strong> $1,060,058</td>
<td><strong>F&amp;A:</strong> 487,627</td>
</tr>
<tr>
<td><strong>Co-Investigator</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Stuart, Robert</strong></td>
<td>Principal Investigator</td>
</tr>
<tr>
<td><strong>PI:</strong> SPICER, KENNETH M.</td>
<td><strong>Sponsor:</strong> Idec Pharmaceuticals Corp.</td>
</tr>
<tr>
<td><strong>Project Dates:</strong> 7/30/2003-7/31/2007</td>
<td><strong>Budget Dates:</strong> 6/7/2004 - 12/31/2006</td>
</tr>
<tr>
<td><strong>Direct:</strong> $192,000</td>
<td><strong>Award:</strong> 106-10 (03070204)</td>
</tr>
<tr>
<td><strong>F&amp;A:</strong> 32,240</td>
<td></td>
</tr>
<tr>
<td><strong>Co-Investigator</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Swenson, Cynthia</strong></td>
<td>Principal Investigator</td>
</tr>
<tr>
<td><strong>MST Model with a Child Maltreatment</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PI:</strong> SPICER, KENNETH M.</td>
<td><strong>Sponsor:</strong> Idec Pharmaceuticals Corp.</td>
</tr>
<tr>
<td><strong>Project Dates:</strong> 7/30/2003-7/31/2007</td>
<td><strong>Budget Dates:</strong> 6/7/2004 - 12/31/2006</td>
</tr>
<tr>
<td><strong>Direct:</strong> $192,000</td>
<td><strong>Award:</strong> 106-10 (03070204)</td>
</tr>
<tr>
<td><strong>F&amp;A:</strong> 32,240</td>
<td></td>
</tr>
<tr>
<td><strong>Community-Based Treatment for Child Physical Abuse</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PI:</strong> MILLS, JOHN H.</td>
<td><strong>Sponsor:</strong> NIH/NIMH</td>
</tr>
<tr>
<td><strong>Project Dates:</strong> 7/30/2003-7/31/2007</td>
<td><strong>Budget Dates:</strong> 4/1/2000 - 3/31/2005</td>
</tr>
<tr>
<td><strong>Direct:</strong> $188,500</td>
<td><strong>Award:</strong> 5 R01 MH060663-05 (04012603)</td>
</tr>
<tr>
<td><strong>F&amp;A:</strong> 49,010</td>
<td></td>
</tr>
<tr>
<td><strong>Obstetrics/Gynecology</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Study of Duloxetine HCl in Women of Different Demographic Characteristics and Co-Morbidities with Stress Urinary Incontinence: Evaluation of Efficacy and Safety</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PI:</strong> MILLS, JOHN H.</td>
<td><strong>Sponsor:</strong> Omni Care</td>
</tr>
<tr>
<td><strong>Project Dates:</strong> 7/30/2003-7/31/2007</td>
<td><strong>Budget Dates:</strong> 2/2/2004 - 1/31/2006</td>
</tr>
<tr>
<td><strong>Direct:</strong> $27,440</td>
<td><strong>Award:</strong> PROTOCOL FIJ-US-SBC (04012710)</td>
</tr>
<tr>
<td><strong>F&amp;A:</strong> 0</td>
<td></td>
</tr>
<tr>
<td><strong>Proposal to Institute and Validate an Observed Structured Assessment of Technical Skills (OSATS) for Obstetrics and Gynecology Residents</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PI:</strong> MILLS, JOHN H.</td>
<td><strong>Sponsor:</strong> Apgo Medical Education Fdn.</td>
</tr>
<tr>
<td><strong>Project Dates:</strong> 7/30/2003-7/31/2007</td>
<td><strong>Budget Dates:</strong> 7/1/2003 - 6/30/2004</td>
</tr>
<tr>
<td><strong>Direct:</strong> $15,000</td>
<td><strong>Award:</strong> (02100107)</td>
</tr>
<tr>
<td><strong>F&amp;A:</strong> 0</td>
<td></td>
</tr>
<tr>
<td><strong>Comparative Medicine</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Developing BSL3 Animal Facilities at MUSC</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PI:</strong> MILLS, JOHN H.</td>
<td><strong>Sponsor:</strong> NIH/NCRR</td>
</tr>
<tr>
<td><strong>Project Dates:</strong> 7/30/2003-7/31/2007</td>
<td><strong>Budget Dates:</strong> 6/1/2004 - 5/31/2005</td>
</tr>
<tr>
<td><strong>Direct:</strong> $631,352</td>
<td><strong>Award:</strong> 1 G20 RR019721-01 (03062001)</td>
</tr>
<tr>
<td><strong>F&amp;A:</strong> 0</td>
<td></td>
</tr>
<tr>
<td><strong>Vitrification for Tissue Engineered Blood Vessels</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PI:</strong> MILLS, JOHN H.</td>
<td><strong>Sponsor:</strong> Organ Recovery Systems</td>
</tr>
<tr>
<td><strong>Project Dates:</strong> 7/30/2003-7/31/2007</td>
<td><strong>Budget Dates:</strong> 2/1/2004 - 1/31/2006</td>
</tr>
<tr>
<td><strong>Direct:</strong> $55,724</td>
<td><strong>Award:</strong> 2 R44 HL066688-02 (03040103)</td>
</tr>
<tr>
<td><strong>F&amp;A:</strong> 25,633</td>
<td></td>
</tr>
<tr>
<td><strong>Feasibility of Hypothermic Liver Perfusion</strong></td>
<td></td>
</tr>
<tr>
<td><strong>PI:</strong> MILLS, JOHN H.</td>
<td><strong>Sponsor:</strong> Organ Recovery Systems</td>
</tr>
<tr>
<td><strong>Project Dates:</strong> 7/30/2003-7/31/2007</td>
<td><strong>Budget Dates:</strong> 2/1/2004 - 8/1/2004</td>
</tr>
<tr>
<td><strong>Direct:</strong> $13,322</td>
<td><strong>Award:</strong> 1 R43 DK066985-01 (03040102)</td>
</tr>
<tr>
<td><strong>F&amp;A:</strong> 6,128</td>
<td></td>
</tr>
<tr>
<td>College of Medicine</td>
<td>Comparative Medicine</td>
</tr>
<tr>
<td>---------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td><strong>Pancreas Transporter Development and Feasibility Testing</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Sponsor:</strong> Organ Recovery Systems</td>
<td><strong>Budget Dates:</strong> 9/10/2003 - 8/31/2004</td>
</tr>
<tr>
<td><strong>Award:</strong> (02112703)</td>
<td><strong>Project Dates:</strong> 1/10/2003 - 8/31/2004</td>
</tr>
<tr>
<td><strong>Direct:</strong> $17,996</td>
<td><strong>F&amp;A:</strong> 8,278</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Biochemistry &amp; Molecular Biology</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SC COBRE in Lipidomics and Pathobiology</strong></td>
</tr>
<tr>
<td><strong>Principal Investigator:</strong> Swindle, M.</td>
</tr>
<tr>
<td><strong>Sponsor:</strong> NIH/NCRR</td>
</tr>
<tr>
<td><strong>Award:</strong> 5 P20 RR017677-02 (03071704)</td>
</tr>
<tr>
<td><strong>Direct:</strong> $1,457,324</td>
</tr>
<tr>
<td><strong>Direct:</strong> $1,457,324</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Studies on B2-Adrenergic Receptor mRNA Binding Protein</strong></td>
</tr>
<tr>
<td><strong>Sponsor:</strong> NIH/NCRR</td>
</tr>
<tr>
<td><strong>Award:</strong> 1 P01 CA97132-01A1 (01100808)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Psychiatry &amp; Behavioral Sciences</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Alcohol Research Center-Treatment and Implications-Shared Scientific Resource Core</strong></td>
</tr>
<tr>
<td><strong>Principal Investigator:</strong> Szumlinski, Karen</td>
</tr>
<tr>
<td><strong>Sponsor:</strong> Scripps Research Inst.</td>
</tr>
<tr>
<td><strong>Award:</strong> 5-7239/5 U01 AA0135 (03070303)</td>
</tr>
<tr>
<td><strong>Direct:</strong> $1,457,324</td>
</tr>
<tr>
<td><strong>Direct:</strong> $1,457,324</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MRU 2002-002 - A Double-Blind, Randomized, Dose Escalating, Efficacy and Safety Study of Implitapide at Daily Doses of 10mg, 15mg, 20mg, 25mg, 30mg and 40mg Compared with Placebo Patients with Heterozygous Familial Hypercholesterolemia (heFH) on Maximal</strong></td>
</tr>
<tr>
<td><strong>Sponsor:</strong> PPD Development</td>
</tr>
<tr>
<td><strong>Award:</strong> MRLI 2002-002 (04071603)</td>
</tr>
</tbody>
</table>
ThOMAS

**Medical University of South Carolina Faculty Activity by College**

**College of Medicine**

**THOMAS, James**  
Principal Investigator

**Medicine**

- **The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients with Intermittent Claudication-A Matrix Design**  
  Sponsor: Kos Pharmaceuticals, Inc.  
  Award: MA-03-010401 (04012114)  
  Budget Dates: 1/21/2004 - 2/1/2005  
  Direct: $69,350  
  F&A: 17,337

- **A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Study of Rosuvastatin (Crestor) 20 mg in the Primary Prevention of Cardiovascular Events among Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of C-Reactive Protein**  
  Sponsor: AstraZeneca  
  Award: 4522US/0011 (03072802)  
  Direct: $75,600  
  F&A: 18,900

- **18 Week, Open Label, Cross-Over Study Design Comparing Atorvastatin to Simvastatin in Study Subjects with Type IIa and IIb Hypercholesterolemia and Small LDL Cholesterol Particles**  
  Sponsor: Pfizer, Inc.  
  Award: (00061904)  
  Direct: $69,350  
  F&A: 17,337

**Psychiatry & Behavioral Sciences**

- **Paroxetine for Social Anxiety Disorder and Alcoholism**  
  PI: RANDALL, CARRIE L.  
  Sponsor: NIH/NIAAA  
  Award: 5 R01 AA013379-03 (04010706)  
  Direct: $258,475  
  F&A: 111,144

- **Training in Comorbidity of Alcoholism and Mental Illness**  
  PI: BOOK, SARAH  
  Sponsor: NIH/NIAAA  
  Award: 1 K23 AA014430-01 (03062616)  
  Direct: $148,529  
  F&A: 11,356

**Cell Biology & Anatomy**

- **Myocyte Proliferation in the Embryonic Chick Heart**  
  Sponsor: NIH/NHLBI  
  Award: 2 R01 HL050582-10A (03030704)  
  Direct: $200,000  
  F&A: 92,000

**Obstetrics/Gynecology**

- **A Multi-Center, Double-Blind, Parallel-Group Study Comparing the Bioequivalence of Atrix Laboratories, Inc. Generic Formulation of Metronidazole Vaginal Gel, 0.75% and MetroGelVaginal**  
  PI: SOPER, DAVID  
  Sponsor: SFBC, Charlotte  
  Award: ATRIX-112 (03061208)  
  Budget Dates: 8/18/2003-1/1/2005  
  Direct: $32,450  
  F&A: 8,113

**Biostatistics, Bioinformatics & Epidemiology**

- **t-PA Stroke Trial**  
  Sponsor: Kai, Inc.  
  Award: KA1-2051-S1/N01-NS (04040202)  
  Direct: $40,697  
  F&A: 17,500

- **Research Supplement for Underrepresented Minorities - SC Cooperative for Healthy Aging in Minority Populations**  
  Sponsor: NIH/NIA  
  Award: 3 P30 AG021677-02S (04022401)  
  Direct: $24,452  
  F&A: 11,248

- **SC Cooperative for Healthy Aging in Minority Populations**  
  Sponsor: NIH/NIA  
  Award: 3 P30 AG021677-02S (03090905)  
  Direct: $20,000  
  F&A: 9,200

- **Understanding & Eliminating Health Disparities in Blacks**  
  Sponsor: AHCPR/AHRQ  
  Award: 5 P01 HS010871-04 (03071008)  
  Direct: $1,583,666  
  F&A: 574,732

- **SC Cooperative for Healthy Aging in Minority Populations**  
  Sponsor: NIH/NIA  
  Award: 5 P30 AG021677-02 (03071007)  
  Direct: $410,013  
  F&A: 161,960

---

**Thomas, Suzanne**  
Co-Investigator

**Psychiatry & Behavioral Sciences**

- **The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients with Intermittent Claudication-A Matrix Design**  
  Sponsor: Kos Pharmaceuticals, Inc.  
  Award: MA-03-010401 (04012114)  
  Budget Dates: 1/21/2004 - 2/1/2005  
  Direct: $69,350  
  F&A: 17,337

**Thompson, Robert**  
Principal Investigator

- **Myocyte Proliferation in the Embryonic Chick Heart**  
  Sponsor: NIH/NHLBI  
  Award: 2 R01 HL050582-10A (03030704)  
  Direct: $200,000  
  F&A: 92,000

**Thurman, Andrea**  
Co-Investigator

**Biostatistics, Bioinformatics & Epidemiology**

- **t-PA Stroke Trial**  
  Sponsor: Kai, Inc.  
  Award: KA1-2051-S1/N01-NS (04040202)  
  Direct: $40,697  
  F&A: 17,500

---

**Tilley, Barbara**  
Principal Investigator

**Biostatistics, Bioinformatics & Epidemiology**

- **Research Supplement for Underrepresented Minorities - SC Cooperative for Healthy Aging in Minority Populations**  
  Sponsor: NIH/NIA  
  Award: 3 P30 AG021677-02S (04022401)  
  Direct: $24,452  
  F&A: 11,248

- **SC Cooperative for Healthy Aging in Minority Populations**  
  Sponsor: NIH/NIA  
  Award: 3 P30 AG021677-02S (03090905)  
  Direct: $20,000  
  F&A: 9,200

- **Understanding & Eliminating Health Disparities in Blacks**  
  Sponsor: AHCPR/AHRQ  
  Award: 5 P01 HS010871-04 (03071008)  
  Direct: $1,583,666  
  F&A: 574,732

- **SC Cooperative for Healthy Aging in Minority Populations**  
  Sponsor: NIH/NIA  
  Award: 5 P30 AG021677-02 (03071007)  
  Direct: $410,013  
  F&A: 161,960

---

**Annual Report for Research FY04**  

117
Faculty Activity by College

Medical University of South Carolina

Tilley, Barbara
Principal Investigator

Biostatistics, Bioinformatics & Epidemiology
SC Cooperative for Healthy Aging In Minority Populations
- **Sponsor:** NIH/NIA
- **Budget Dates:** 9/30/2003 - 8/31/2004
- **Direct:** $99,714
- **Award:** 3 P30 AG021677-02S (03070704)
- **Project Dates:** 9/30/2002 - 8/31/2007
- **F&A:** 11,500

Parkinson's Disease Clinical Trial: Statistical Center
- **Sponsor:** NIH/NINDS
- **Budget Dates:** 8/1/2003 - 7/31/2004
- **Direct:** $265,225
- **Award:** 5 U01 NS043127-03 (03060207)
- **Project Dates:** 9/30/2001 - 7/31/2006
- **F&A:** 114,047

NIAMS Clinical Research Center for Rheumatoid Disease-Meth-Core
- **Pl.:** SILVER, RICHARD M.
- **Sponsor:** NIH/NIAMS
- **Direct:** $137,437
- **Award:** 5 P60 AR049459-02 (04020401)
- **Project Dates:** 9/30/2002 - 8/31/2007
- **F&A:** 63,221

Human Serum Albumin Therapy for Stroke
- **Pl.:** PALESCH, YUKO
- **Sponsor:** Univ. of Miami
- **Direct:** $25,703
- **Award:** 5 R01 NS40406-03 (03051401)
- **Project Dates:** 8/15/2001 - 7/31/2004
- **F&A:** 1,623

Tomlinson, Stephen
Principal Investigator

Microbiology & Immunology
Interaction Between CD59 and Its Complement Ligands
- **Sponsor:** NIH/NIAID
- **Budget Dates:** 5/1/2004 - 4/30/2005
- **Direct:** $189,224
- **Award:** 5 R01 AI047386-04 (04022701)
- **Project Dates:** 6/1/2001 - 4/30/2006
- **F&A:** 81,366

The Component System as a Therapeutic Target for Lupus
- **Sponsor:** Arthritis Fdn.
- **Budget Dates:** 3/1/2004 - 2/28/2005
- **Direct:** $230,232
- **Award:** 5 R01 AI034451-09 (03082302)
- **Project Dates:** 7/1/2004 - 2/28/2006
- **F&A:** 18,419

Targeted Complement Inhibitors
- **Sponsor:** NIH/NIAID
- **Budget Dates:** 7/1/2003 - 6/30/2005
- **Direct:** $225,000
- **Award:** 5 R01 AI034451-09 (03082801)
- **Project Dates:** 7/1/2003 - 6/30/2005
- **F&A:** 96,750

Complement Inhibitors and Immunotherapy
- **Sponsor:** NIH/NCI
- **Budget Dates:** 9/25/2003 - 12/31/2004
- **Direct:** $171,839
- **Award:** 7 R01 CA082867-06 (03060905)
- **Project Dates:** 9/25/2003 - 12/31/2004
- **F&A:** 79,046

Co-PI or Project Leader
DOD Phase VI: Project 1.0 - Translational Research and Cancer Prevention and Control and Risk Factor Identification
- **Pl.:** REED, CAROLYN E.
- **Sponsor:** Geo-Centers/DOD
- **Direct:** $51,250
- **Award:** GC-3532-03-42153CM (03080712)
- **Project Dates:** 9/2/2003 - 8/28/2005
- **F&A:** 23,575

Toole, Bryan
Principal Investigator

Cell Biology & Anatomy
Tumor Cell-Stromal Interactions in Cancer
- **Sponsor:** NIH/NCI
- **Budget Dates:** 6/1/2004 - 5/31/2005
- **Direct:** $247,775
- **Award:** 5 R01 CA079866-06 (04033104)
- **Project Dates:** 7/1/2003 - 5/31/2005
- **F&A:** 72,710

Tumor Cell-Stromal Interactions in Cancer
- **Sponsor:** NIH/NCI
- **Budget Dates:** 7/1/2003 - 5/31/2004
- **Direct:** $220,001
- **Award:** 7 R01 CA079866-06 (03061001)
- **Project Dates:** 6/15/2000 - 5/31/2005
- **F&A:** 75,918

Perturbation of Hyaluronan Function in Cancer
- **Sponsor:** NIH/NCI
- **Budget Dates:** 9/25/2003 - 12/31/2004
- **Direct:** $171,839
- **Award:** 7 R01 CA082867-06 (03060905)
- **Project Dates:** 9/25/2003 - 12/31/2004
- **F&A:** 79,046

Tourkina, Elena
Principal Investigator

Medicine
Caveolin-1 in Scleroderma Lung Disease
- **Sponsor:** Scleroderma Fdn.
- **Budget Dates:** 1/5/2004 - 12/31/2004
- **Direct:** $69,444
- **Award:** 010/04 (03091203)
- **Project Dates:** 1/5/2004 - 12/31/2005
- **F&A:** 5,556
**TREMONT College of Medicine**

**Principal Investigator**

**Tremont, Ivo**

**Neurology**

**Phase III, Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to Gliadel Wafer with Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence**

- **Sponsor:** Neopharm, Inc.  
  **Budget Dates:** 6/11/2004 - 12/31/2006  
  **Direct:** $512,722

- **Neurology**

  **A Phase III, Randomized, Open-Label Study of IV Edotecarin vs. Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients with Glioblastoma Multiforme That Has Progressed/Recurred after Alkylator-Based (Neo) Adjuvant Chemotherapy**

  - **Sponsor:** Pharmacia  
    **Budget Dates:** 8/6/2003 - 9/17/2007  
    **Direct:** $34,400

**Co-Investigator**

**Triplett, Leah**

**Leah Triplett Rheumatology Fellowship**

- **Sponsor:** Thomas Mem. Hosp.  
  **Budget Dates:** 7/1/2003 - 6/30/2005  
  **Direct:** $105,000

**Trojanowska, Maria**

**Medicine**

**TGF-Beta Receptor Signaling in Scleroderma**

- **Sponsor:** NIH/NIAMS  
  **Budget Dates:** 5/21/2004-12/31/2007  
  **Direct:** $676,664

**Co-PI or Project Leader**

**Trusk, Thompson**

**Cardiac Valvuoseptal Morphogenesis-Core B: Molecular Morphology Core**

- **Sponsor:** NIH/NHLBI  
  **Budget Dates:** 4/15/2003-3/31/2008  
  **Direct:** $134,930

**Tumminello, Paola**

**Neurology**

**Betaseron vs Avonex in the Treatment of Relapsing Remitting Multiple Sclerosis (ABOVE)**

- **Sponsor:** Amer. Heart Assoc./Mid-Atlantic  
  **Budget Dates:** 7/15/2003-12/31/2006  
  **Direct:** $199,122

**Co-Investigator**

**Turner, Justin**

**Medicine**

**Signal Transduction Pathways That Regulate GPCR-Dependent and -Independent Activation of Na+/H+ Exchange**

- **Sponsor:**  
  **Budget Dates:** 7/1/2003 - 6/30/2004  
  **Direct:** $18,200

**Turner, Robert**

**Neurology**

**South Carolina Epidemiological Studies of Epilepsy and Seizure Disorder**

- **Sponsor:** AAMC  
  **Budget Dates:** 7/1/2003 - 6/30/2004  
  **Direct:** $239,657

---

**Annual Report for Research FY04**  
119
Faculty Activity by College

Medical University of South Carolina

College of Medicine

Turner, Robert
Co-Investigator

Neurology
The South Carolina Traumatic Brain Injury Registry
Pt: SELASSIE, ANBESAW  Sponsor: CDC  Award: U17/CCU421926-02 (03041802)  Direct: $586,674  F&A: 125,628
Project Dates: 8/1/2002-7/31/2005

Tyor, William
Principal Investigator

Neurology
HAART in SCID Mice with HIV Encephalitis
Award: 5 R01 MH062697-04 (03080803)  Project Dates: 9/30/2000 - 8/31/2005
Betaseron vs Avonex in the Treatment of Relapsing Remitting Multiple Sclerosis (ABOVE)

Calpain Activation of T Cells in Demyelinating Disease
Award: 5 R01 NS041088-04 (03102701)  F&A: 96,750

Uflacker, Renan
Principal Investigator

Radiology
Effects of the Injection of DEAC-Glucosamine in High Flow Vessels
Evaluation of the Ziver Vascular Stent in the Iliac Arteries
Award: PROTOCOL # 02-513 (04021903)  Project Dates: 3/1/2004 - 3/1/2005
Obliteration of the Aneurysmal Sac in Abdominal Aortic Aneurysm in an Animal Model
Award: (02021202)  Project Dates: 5/2/2002 - 6/30/2004
A Study of the GORE Biliary Endoprosthesis for Relief of Biliary Obstruction Caused by Malignant Biliary Strictures: Continued Access
Award: (01062007)  Project Dates: 6/19/2001 - 6/30/2002

Upadhyaya, Himanshu
Principal Investigator

Psychiatry & Behavioral Sciences
Combined Pharmaco/Behavior Therapy in Adolescent Smokers
Award: 1 R01 DA017460-01 (03041101)  Project Dates: 9/30/2003 - 6/30/2008
ORWH: SCOR on Sex and Gender Factors Affecting Women's Health: Project 3 - Gender Menstrual Cycle and Smoking Cue Reactivity
Pt: BRADY, KATHLEEN T.  Sponsor: NIH/NIDA  Direct: $93,390  F&A: 42,959
Award: 5 P50 DA016511-02 (03050502-04)  Project Dates: 9/30/2002-6/30/2007
Southeastern Node of the Clinical Trials Network
Pt: BRADY, KATHLEEN T.  Sponsor: NIH/NIDA  Direct: $1,307,975  F&A: 392,075
Award: 5 U10 DA130724-01 (03062618)  Project Dates: 9/30/2000-8/31/2005
ORWH: SCOR on Sex and Gender Factors Affecting Women's Health
Pt: BRADY, KATHLEEN T.  Sponsor: NIH/NIDA  Direct: $579,460  F&A: 266,552
Award: 5 P50 DA016511-02 (03050502)  Project Dates: 9/30/2002-6/30/2007
A Multi-Center, 10-Week, Randomized, Double-Blind Study of Sertraline and Placebo in Children and Adolescents with Post Traumatic Stress Disorder (PTSD)
Pt: DEAS, DEBORAH  Sponsor: Pfizer, Inc.  Direct: $8,000  F&A: 2,000
Award: A051061 (02101402)  Project Dates: 11/1/2002-10/31/2004

Van Bakel, Adrian
Principal Investigator

Medicine
A Multi-Center, Controlled Trial of the Orqis Medical Cancion - Cardiac Recovery System (CRS) for the Use in Treatment of Acute Decompensated Heart Failure in a Chronic Heart Failure Population Requiring Hospitalization and Intravenous Pharmacologic Inte
Sponsor: Orqis Medical  Budget Dates: 8/1/2003 - 12/31/2006  Direct: $48,000  F&A: 12,000
### VEATCH

#### Psychiatry & Behavioral Sciences

**Repeated Ethanol Withdrawals: Disruption in Sleep Architecture**  
Principal Investigator: Veatch, Lynn  
Sponsor: VAMC Merit Award  
Direct: $127,964  
Award: 04063025  
F&A: 0

#### Radiology

**Increasing the Computational Power and Speed in Advanced Neuroimaging**  
Principal Investigator: Vincent, Diana  
Sponsor: Intel Corp.  
Direct: $30,000  
Award: 04011203  
F&A: 0

### Virella, Gabriel

#### Microbiology & Immunology

**Research and Development**  
Principal Investigator: Virella, Gabriel  
Sponsor: VAMC  
Direct: $6,940  
Award: 534-D3597 (04032201)  
F&A: 0

**Immune Mechanisms of Micro/Macrovacular Disease in Type 1 Diabetes**  
Co-Investigator: Arterial Compression of the Ventro-Lateral Medulla  
Sponsor: NIH/NHLBI  
Direct: $127,056  
Award: 5 K23 HL067993-03 (04020301)  
F&A: 0

**Markers and Mechanisms of Vascular Disease in Diabetes**  
Co-Investigator: Markers and Mechanisms of Vascular Disease in Diabetes  
Sponsor: NIH/NHLBI  
Budget Dates: 9/30/1996-8/31/2005  
Direct: $1,402,342  
Award: 5 P01 HL055782-08 (03071705)  
Project Dates: 9/30/1996-8/31/2005  
F&A: 0

### Virella-Lowell, Isabel

#### Pediatrics

**AAT as Anti-Inflammatory Gene Therapy for Cystic Fibrosis**  
Principal Investigator: Virella-Lowell, Isabel  
Sponsor: Cystic Fibrosis Fdn.  
Budget Dates: 8/15/2003 - 12/31/2005  
Direct: $172,414  
Award: VIRELL01A0 (03100804)  
Project Dates: 8/15/2003 - 12/31/2005  
F&A: 0

### Voelkel-Johnson, Christina

#### Microbiology & Immunology

**TRAIL-Induced Apoptosis in Prostate Cancer**  
Principal Investigator: Voelkel-Johnson, Christina  
Sponsor: NIH/NCI  
Direct: $157,499  
Award: 1 R01 CA102218-01A  
F&A: 0

**Apoptosis in Colon Cancer Cells**  
Co-Investigator: Apoptosis in Colon Cancer Cells  
Sponsor: Univ. of South Carolina  
Direct: $75,000  
Award: 1 P20 RR17698-01 (02112102)  
F&A: 0

**Sphingolipids in Cancer Therapy and Angiogenesis**  
Co-Investigator: Sphingolipids in Cancer Therapy and Angiogenesis  
Sponsor: NIH/NCI  
Budget Dates: 8/1/2003-7/31/2008  
Direct: $715,167  
Award: 1 P01 CA97132-01A1 (01100808)  
Project Dates: 8/1/2003-7/31/2008  
F&A: 0

### Voit, Eberhard

#### Biostatistics, Bioinformatics & Epidemiology

**Training of Toolmakers for Biomedical Informatics**  
Principal Investigator: Voit, Eberhard  
Sponsor: NIH/NLM  
Budget Dates: 7/1/2003 - 6/30/2004  
Direct: $314,858  
Award: 5 T15 LM007438-02 (03100804)  
Project Dates: 7/1/2003 - 6/30/2004  
F&A: 0

### Vroman, David

#### Ophthalmology

**Rebamipide Ophthalmic Suspension in the Treatment of Dry Eye: A Multi-Center, Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, 52 Week Study**  
Co-PI or Project Leader: Rebamipide Ophthalmic Suspension in the Treatment of Dry Eye: A Multi-Center, Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, 52 Week Study  
Sponsor: PPD Development  
Budget Dates: 6/15/2004-6/14/2005  
Direct: $50,351  
Award: 37E-03-202 (04031516-01)  
Project Dates: 6/15/2004-6/14/2005  
F&A: 0
**OPHTHALMOLOGY**

**Evaluation of Functional Performance and Patient Satisfaction for the ACRYSOF RESTOR OIL (Alcon) Versus the ACRYSOF MA60BM (Alcon) and the ARRAY SA40N (AMO)**

Pl: SOLOMON, KERRY D.  
Sponsor: Alcon, Inc.  
Direct: $59,120  
F&A: $14,780

**Clinical Study of the ACRYSOF Multifocal Intraocular Lens**

Pl: SOLOMON, KERRY D.  
Sponsor: Alcon, Inc.  
Direct: $17,285  
F&A: $3,975

**PEDIATRICS**

**Evaluation of Vitamin D Requirements During Pregnancy**

Pl: HOLLIS, BRUCE W.  
Sponsor: NIH/NICHD  
Direct: $382,526  
Project Dates: 9/1/2003-7/31/2008  
Award: 1 R01 HD043921-01 (02053004)  
F&A: $155,995

**PSYCHIATRY & BEHAVIORAL SCIENCES**

**ORWH: SCOR on Sex and Gender Factors Affecting Women's Health**

Pl: BRADY, KATHLEEN T.  
Sponsor: NIH/NIDA  
Direct: $579,460  
Project Dates: 9/30/2002-6/30/2007  
Award: 5 P50 DA016511-02 (03050502)  
F&A: $266,552

**NEUROLOGY**

**Betaseron vs Avonex in the Treatment of Relapsing Remitting Multiple Sclerosis (ABOVE)**

Pl: TYOR, WILLIAM R.  
Sponsor: Berlex Laboratories  
Direct: $199,122  
Award: 307245 (03051902)  
F&A: $49,781

**MEDICINE**

**A Study to Further Assess the Efficacy of Bowel Preparation with the Use of a Pre-Packed Diet/Bowel Prep Kit Versus Usual and Customary Bowel Preparation for Colonoscopy**

Pl: DELEGGE, MARK  
Sponsor: Ezem, Inc.  
Direct: $1,540  
Project Dates: 3/1/2001-6/30/2003  
Award: EZEM-01-001 (01042603)  
F&A: $354

**CELL & MOLECULAR PHARMACOLOGY**

**Flavonoid Bioavailability in Humans-Cellular Studies**

Pl: SOLOMON, KERRY D.  
Sponsor: NIH/NIGMS  
Direct: $166,750  
Award: 5 R01 GM062317-04 (04010503)  
F&A: $71,703

**Inactivation of CYP1A1 by Flavones - Lung Cancer Prevention**

Pl: SOLOMON, KERRY D.  
Sponsor: Amer. Inst. for Cancer Research  
Direct: $98,899  
Award: GC-3532-03-42153CM (03080703-18)  
F&A: $25,711

**FUNCTIONAL GENOMIC APPROACH TO SIGNAL TRANSDUCTION AND INNATE IMMUNITY IN SHRIMP**

Pl: SOLOMON, KERRY D.  
Sponsor: NSF  
Budget Dates: 8/15/2003 - 8/31/2004  
Direct: $107,143  
Project Dates: 8/15/2003 - 8/31/2004  
Award: MCB-0315393 (03021801)  
F&A: $27,857

**MUSC's Activities in Support of the Charleston Health and Risk Assessment (HERA) of Bottlenose Dolphin Populations Project: Task 4 - Toxico-Genomics**

Pl: PEDEN-ADAMS, MARGIE  
Sponsor: NOAA  
Direct: $29,724  
Award: WC133C04CN0012 (04021801-04)  
F&A: $7,728
<table>
<thead>
<tr>
<th>Name</th>
<th>College</th>
<th>Department</th>
<th>Role</th>
<th>Project Title</th>
<th>PI</th>
<th>Sponsor</th>
<th>Direct</th>
<th>Award</th>
<th>F&amp;A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Warr, Gregory</td>
<td>PEDEN-ADAMS College of Medicine</td>
<td>Biochemistry &amp; Molecular Biology</td>
<td>Co-Investigator</td>
<td>MUSC’s Activities in Support of the Charleston Health and Risk Assessment (HERA) of Bottlenose Dolphin Populations</td>
<td>PEDEN-ADAMS, MARGIE</td>
<td>NOAA</td>
<td>$282,880</td>
<td>WC133C04CN0012 (04021801)</td>
<td>62,820</td>
</tr>
<tr>
<td>Wasef, Sherif</td>
<td></td>
<td>Medicine</td>
<td>Co-Investigator</td>
<td>Substituting Lantus (Insulin Glargine [RDNA Origin] Injection) for a Thiazolidinedione vs a Third Oral Agent as Add-On Therapy in Patients Failing a Thiazolidinedione and Sulfonylurea or Glucophage (Metformin) Combination</td>
<td>HERMAYER, KATHIE</td>
<td>Aventis Pharmaceutical, Inc.</td>
<td>$57,400</td>
<td>HEO 901/4022 (03111903)</td>
<td>14,350</td>
</tr>
<tr>
<td>Watson, Dennis</td>
<td></td>
<td>Pathology &amp; Laboratory Medicine</td>
<td>Principal Investigator</td>
<td>The Role of Thromboxane A2 in Bladder Cancer</td>
<td>REED, CAROLYN E.</td>
<td>NIH/NCI</td>
<td>$90,000</td>
<td>1 R21 CA106570-01 (03060304)</td>
<td>41,400</td>
</tr>
<tr>
<td>Watson, Patricia</td>
<td></td>
<td>Pathology &amp; Laboratory Medicine</td>
<td>Co-Pl or Project Leader</td>
<td>Role of an Epithelial Ets Factor in Breast Cancer</td>
<td>TROJANOWSKA, MARIA E.</td>
<td>NIH/NIAMS</td>
<td>$222,500</td>
<td>1 R01 CA102297-01 (02100204)</td>
<td>102,350</td>
</tr>
<tr>
<td>Watson, Patricia</td>
<td></td>
<td>Medicine</td>
<td>Co-Investigator</td>
<td>Role of a Novel Oncogene in Mesothelioma</td>
<td>BOYLAN, ALICE</td>
<td>NIH/NIEHS</td>
<td>$166,250</td>
<td>5 R01 ES011323-02 (04040105)</td>
<td>76,475</td>
</tr>
<tr>
<td>Wei, Ling</td>
<td></td>
<td>Pathology &amp; Laboratory Medicine</td>
<td>Principal Investigator</td>
<td>Function Restoration by ES Cell Implant after Ischemia</td>
<td>BOYLAN, ALICE</td>
<td>NIH/NINDS</td>
<td>$213,750</td>
<td>5 R01 NS045155-02 (04040801)</td>
<td>98,325</td>
</tr>
<tr>
<td>Welsh, Cynthia</td>
<td></td>
<td>Pathology &amp; Laboratory Medicine</td>
<td>Co-Investigator</td>
<td>Neural Plasticity/Vascular Remodeling after Ministroke</td>
<td>RAY, SWAPAN</td>
<td>NIH/NCI</td>
<td>$351,450</td>
<td>1 R01 CA091460-01A1 (03041602)</td>
<td>70,289</td>
</tr>
<tr>
<td>Wessels, Arno</td>
<td></td>
<td>Cell Biology &amp; Anatomy</td>
<td>Co-PI or Project Leader</td>
<td>Patterning by Invasive Mesenchyme in the Embryonic Heart: Core B - Imaging Core</td>
<td>GOURDIE, ROBERT</td>
<td>NIH/NICHD</td>
<td>$150,000</td>
<td>1 R01 CA091460-01A1 (03041602)</td>
<td>69,000</td>
</tr>
</tbody>
</table>
College of Medicine

Wessels, Arno  
Co-PI or Project Leader

Cell Biology & Anatomy  
Cardiac Valvuloseptal Morphogenesis-Project 2: Myocardialization and Epicardialization of Cushion Tissue  
Pt: MARKWALD, ROGER R.  Sponsor: NIH/NHLBI  Direct: $195,484  

Willner, Ira  
Co-Investigator

Medicine  
A Comparison of the Safety and Efficacy of Two Doses of Peg-Interferon Alfa-2b (PEG-Intro: 1.5 ug/kg vs. 3.0 up/kg) in Combination with Ribavirin (Rebetol) for Treatment of Chronic Hepatitis C Patients  
Pt: REUBEN, ADRIAN  Sponsor: Schering-Plough Corp.  Direct: $6,960  
Project Dates: 4/1/2002-4/30/2005  Award: (02040317)  F&A: 1,740

Wilson, Frederick  
Principal Investigator

Medicine  
A Phase III, Multi-National, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, 26 Week Study to Assess the Safety and Efficacy of the Humanise Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed at weeks 0,2,4 then 4-weekly to Week 24), in th 

Co-Investigator

Medicine  
A Phase III, Multi-National, Multi-Center, Open-Label, 52 Week, Safety Study to Assess the Safety of Chronic Therapy with the Humanise Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed 4-weekly to 48 week), in the Treatment of Patients with Active Crohn' s  

A Phase III, Multi-National, Multi-Center, Open Label, 52 Week, Safety Study to Assess the Safety of Re-Exposure after a Variable Interval and Subsequent Chronic Therapy with the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc (dosed at weeks 0,2 and 4  

A Study to Further Assess the Efficacy of Bowel Preparation with the Use of a Pre-Packed Diet/Bowel Prep Kit Versus Usual and Customary Bowel Preparation for Colonoscopy  
Pt: DELEGGE, MARK  Sponsor: Ezem, Inc.  Direct: $1,540  

Wilson, M.  
Principal Investigator

Ophthalmology  
Research to Prevent Blindness  
Sponsor: Research to Prevent Blindness  
Budget Dates: 1/1/2004 - 12/31/2004  Direct: $110,000  
Award: (98071702)  Project Dates: 1/1/1999 - 12/31/2004  F&A: 0

Wilson, Peter  
Principal Investigator

Medicine  
Improvement in Estimation of CHD Risk  
Sponsor: Donald W. Reynolds Fdn.  
Budget Dates: 7/1/2003 - 6/30/2004  Direct: $185,935  
Award: (03112502)  Project Dates: 7/1/2003 - 6/30/2007  F&A: 19,371

Inflammatory Markers and Improving CHD Risk Assessment  
Sponsor: NIH/NHLBI  
Budget Dates: 9/19/2003 - 8/31/2004  Direct: $100,000  
Award: 1 R01 HL073272-01 (03090402)  Project Dates: 9/19/2003 - 8/31/2005  F&A: 39,100

Wolff, Daynna  
Co-Investigator

Pathology & Laboratory Medicine  
Experimental and Clinical Studies of Presbyacusis  
Pt: MILLS, JOHN H.  Sponsor: NIH/NIDCD  
Budget Dates: 7/1/1987-6/30/2007  Direct: $1,060,058  
Award: 5 P50 DC000422-17 (03042902)  Project Dates: 7/1/1987-6/30/2007  F&A: 487,627

Woodley, Cheryl  
Principal Investigator

Dean's Office  
Molecular and Pathobiology Studies to Identify the Causative Agent of Juvenile Oyster Disease  
Sponsor: SC Sea Grant Consortium  
Award: NA86RG0052.AM.11 (03101601)  Project Dates: 10/1/2001 - 9/30/2004  F&A: 0

Woodward, John  
Principal Investigator

Physiology & Neuroscience  
Neural Actions of Toluene  
Sponsor: NIH/NIDA  
## Woodward, John
### Physiology and Neuroscience
#### Training in Alcohol Research
- **Sponsor:** NIH/NIAAA
- **Budget Dates:** 4/1/2004 - 3/31/2005
- **Direct:** $265,582

#### Ethanol Sensitivity of Native and Cloned NMDA Receptors
- **Sponsor:** NIH/NIAAA
- **Budget Dates:** 4/1/2004 - 3/31/2005
- **Direct:** $137,500

#### Ethanol Sensitivity - Native/ Recombinant NMDA Receptors
- **Sponsor:** NIH/NIAAA
- **Budget Dates:** 8/1/2003 - 7/31/2004
- **Direct:** $136,958

### Biostatistics, Bioinformatics & Epidemiology
#### The Influence of Pre-Operative Use of HMG-CoA Reductase Inhibitors in Cardiac Surgery: An 8 Year Retrospective Study
- **Sponsor:** Merck
- **Budget Dates:** 2/1/2003-2/1/2005
- **Direct:** $30,760

### Pathology & Laboratory Medicine
#### Short-Term Training for Minority Students
- **Sponsor:** NIH/NHLBI
- **Budget Dates:** 5/1/2004 - 4/30/2005
- **Direct:** $100,576

### Medicine
#### Novel AT1a Receptor Interaction Partners
- **Sponsor:** NIH/NIDDK
- **Budget Dates:** 1/1/2004 - 12/31/2004
- **Direct:** $89,397

#### Vitamin D Differentiation-Inducing Anti-Tumor Reactivity
- **Sponsor:** VAMC Merit Award
- **Budget Dates:** 7/1/2003 - 6/30/2004
- **Direct:** $135,000

#### Contribution of Vasculogenesis to Tumor Vascularization
- **Sponsor:** NIH/NCI
- **Budget Dates:** 5/1/2004 - 4/30/2005
- **Direct:** $157,500

Woolson, Robert
### Biostatistics, Bioinformatics & Epidemiology
#### ORWH: SCOR on Sex and Gender Factors Affecting Women's Health
- **Sponsor:** NIH/NIDA
- **Budget Dates:** 9/30/2000-8/31/2005
- **Direct:** $225,000

### Pathology & Laboratory Medicine
#### Combined Pharmaco/Behavior Therapy in Adolescent Smokers
- **Sponsor:** NIH/NIDA
- **Budget Dates:** 9/30/2003-6/30/2007
- **Direct:** $225,000

### Medicine
#### Contribution of Vasculogenesis to Tumor Vascularization
- **Sponsor:** NIH/NCI
- **Budget Dates:** 7/1/2003 - 6/30/2004
- **Direct:** $157,500

Young, M.
### Physiology and Neuroscience
#### Ethanol and ERK/PKB Signaling in Brain
- **Sponsor:** NIH/NIAAA
- **Budget Dates:** 12/1/1996-4/30/2008
- **Direct:** $225,000

### Pathology & Laboratory Medicine
#### Contribution of Vasculogenesis to Tumor Vascularization
- **Sponsor:** NIH/NCI
- **Budget Dates:** 7/1/2003 - 6/30/2004
- **Direct:** $157,500

### Medicine
#### Vitamin D Differentiation-Inducing Anti-Tumor Reactivity
- **Sponsor:** VAMC Merit Award
- **Budget Dates:** 7/1/2003 - 6/30/2004
- **Direct:** $135,000

### Pathology & Laboratory Medicine
#### Protein-Protein Interactions among the Vaccinia Virus Late Transcription Factors
- **Sponsor:** SC EPSCOR
- **Budget Dates:** 5/16/2003 - 6/30/2004
- **Direct:** $44,360

### Biostatistics, Bioinformatics & Epidemiology
#### Southeastern Node of the Clinical Trials Network
- **Sponsor:** NIH/NIDA
- **Budget Dates:** 9/30/2000-8/31/2005
- **Direct:** $136,958

### Medicine
#### Contribution of Vasculogenesis to Tumor Vascularization
- **Sponsor:** NIH/NCI
- **Budget Dates:** 1/16/2004 - 4/30/2005
- **Direct:** $157,500

### Pathology & Laboratory Medicine
#### Short-Term Training for Minority Students
- **Sponsor:** NIH/NHLBI
- **Budget Dates:** 5/30/1992 - 4/30/2008
- **Direct:** $100,576

### Medicine
#### Novel AT1a Receptor Interaction Partners
- **Sponsor:** NIH/NIDDK
- **Budget Dates:** 5/1/2004 - 4/30/2005
- **Direct:** $89,397

### Biostatistics, Bioinformatics & Epidemiology
#### Pro-Inflammatory Cytokine Induction in Response to Hepatic Injury: A Mouse Model
- **Sponsor:** Merck
- **Budget Dates:** 2/1/2003-2/1/2005
- **Direct:** $30,760

### Pathology & Laboratory Medicine
#### Short-Term Training for Minority Students
- **Sponsor:** NIH/NHLBI
- **Budget Dates:** 5/1/2004 - 4/30/2005
- **Direct:** $100,576
<table>
<thead>
<tr>
<th>College of Medicine</th>
<th>Medicine</th>
<th>Blocking Angiogenesis by Targeting PP-2A Pathways</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sponsor</td>
<td>NIH/NCI</td>
</tr>
<tr>
<td></td>
<td>Award</td>
<td>1 R01 CA097813-01A (03041003)</td>
</tr>
<tr>
<td></td>
<td>Project Dates</td>
<td>7/1/2003 - 6/30/2004</td>
</tr>
<tr>
<td></td>
<td>Direct</td>
<td>$222,500</td>
</tr>
<tr>
<td></td>
<td>F&amp;A</td>
<td>52,528</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>College of Medicine</th>
<th>Medicine</th>
<th>The Role of Cholesterol in Development</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sponsor</td>
<td>NIH/NHLBI</td>
</tr>
<tr>
<td></td>
<td>Award</td>
<td>5 R01 HL068660-02 (03050205)</td>
</tr>
<tr>
<td></td>
<td>Project Dates</td>
<td>7/1/2003 - 6/30/2008</td>
</tr>
<tr>
<td></td>
<td>Direct</td>
<td>$250,000</td>
</tr>
<tr>
<td></td>
<td>F&amp;A</td>
<td>104,810</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Biostatistics, Bioinformatics &amp; Epidemiology</th>
<th>Tobacco Prevention/Cessation Education: Medical Students</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor</td>
<td>NIH/NCI</td>
</tr>
<tr>
<td>Award</td>
<td>5 R01 HL068660-02 (03050205)</td>
</tr>
<tr>
<td>Project Dates</td>
<td>7/1/2003 - 6/30/2008</td>
</tr>
<tr>
<td>Direct</td>
<td>$20,262</td>
</tr>
<tr>
<td>F&amp;A</td>
<td>1,621</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Biostatistics, Bioinformatics &amp; Epidemiology</th>
<th>Understanding &amp; Eliminating Health Disparities in Blacks - Project 3: An Exploration of Racial Differences in End-of-Life Care Preferences Among Cancer and CHF Patients in South Carolina</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor</td>
<td>AHCPR/AHRQ</td>
</tr>
<tr>
<td>Award</td>
<td>5 P01 HS010871-04 (03071008-06)</td>
</tr>
<tr>
<td>Project Dates</td>
<td>7/26/2002 - 6/30/2007</td>
</tr>
<tr>
<td>Direct</td>
<td>$300,659</td>
</tr>
<tr>
<td>F&amp;A</td>
<td>129,281</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Biostatistics, Bioinformatics &amp; Epidemiology</th>
<th>Racial and Ethnic Approaches to Community Health (REACH)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor</td>
<td>CDC</td>
</tr>
<tr>
<td>Award</td>
<td>U50/CCU22184-02 (02073102)</td>
</tr>
<tr>
<td>Direct</td>
<td>$818,523</td>
</tr>
<tr>
<td>F&amp;A</td>
<td>198,925</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Biostatistics, Bioinformatics &amp; Epidemiology</th>
<th>Oncology Center: Bioinformatic Project: A Post-Genomic Systems Approach to Revealing Determinants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor</td>
<td>DOE</td>
</tr>
<tr>
<td>Award</td>
<td>DE FG02-01ER63121 (02012909-06)</td>
</tr>
<tr>
<td>Project Dates</td>
<td>7/1/2001-9/30/2004</td>
</tr>
<tr>
<td>Direct</td>
<td>$200,000</td>
</tr>
<tr>
<td>F&amp;A</td>
<td>86,000</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pathology &amp; Laboratory Medicine</th>
<th>D609-A Novel Cytoprotectant and Selective Anti-Tumor Agent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor</td>
<td>NIH/NCI</td>
</tr>
<tr>
<td>Award</td>
<td>1 R01 CA102558-01A (03062701)</td>
</tr>
<tr>
<td>Direct</td>
<td>$184,500</td>
</tr>
<tr>
<td>F&amp;A</td>
<td>84,677</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Biostatistics, Bioinformatics &amp; Epidemiology</th>
<th>D609-A Novel Cytoprotectant and Selective Anti-Tumor Agent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor</td>
<td>Charlotte Geyer Fdn.</td>
</tr>
<tr>
<td>Award</td>
<td>(03052909)</td>
</tr>
<tr>
<td>Project Dates</td>
<td>8/1/2003 - 7/31/2004</td>
</tr>
<tr>
<td>Direct</td>
<td>$86,234</td>
</tr>
<tr>
<td>F&amp;A</td>
<td>8,623</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Biostatistics, Bioinformatics &amp; Epidemiology</th>
<th>DOD Phase VI: Project 12 - Translational Research and Cancer Prevention and Control and Risk Factor Identification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor</td>
<td>Geo-Centers/DOD</td>
</tr>
<tr>
<td>Award</td>
<td>GC-3532-03-42153CM (03080703-14)</td>
</tr>
<tr>
<td>Direct</td>
<td>$25,685</td>
</tr>
<tr>
<td>F&amp;A</td>
<td>11,815</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Candesartan Cilexetil in Heart Failure - Assessment of Reduction in Mortality and Morbidity (CHARM) (SH-AHS-0003) (SH-AHS-0007)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor</td>
<td>Astra Pharmaceuticals, L.P.</td>
</tr>
<tr>
<td>Award</td>
<td>(99060802)</td>
</tr>
<tr>
<td>Project Dates</td>
<td>4/1/1999 - 12/31/2004</td>
</tr>
<tr>
<td>Direct</td>
<td>$4,065</td>
</tr>
<tr>
<td>F&amp;A</td>
<td>935</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medicine</th>
<th>Stiffness in Hypertrophy - Role of the Cardiac Cytoskeleton</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor</td>
<td>VAMC Merit Award</td>
</tr>
<tr>
<td>Award</td>
<td>(04063027)</td>
</tr>
<tr>
<td>Direct</td>
<td>$135,000</td>
</tr>
<tr>
<td>F&amp;A</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medicine</th>
<th>A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of a 200mg Oral Dose of PG-116800 Given as the Sodium Salt (PG-530742) Twice Daily for 90 Days to Patients Following Acute Myocardial Infarction, with Post-Treatment Follo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor</td>
<td>Procter and Gamble</td>
</tr>
<tr>
<td>Award</td>
<td>2002135 (03060306)</td>
</tr>
<tr>
<td>Project Dates</td>
<td>8/25/2003 - 12/31/2005</td>
</tr>
<tr>
<td>Direct</td>
<td>$54,976</td>
</tr>
<tr>
<td>F&amp;A</td>
<td>13,740</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medicine</th>
<th>A CHF Trial Investigating Outcomes of Exercise Training</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sponsor</td>
<td>Duke Clinical Research Institute</td>
</tr>
<tr>
<td>Award</td>
<td>1 U01 HL63747 01A2 (03032704)</td>
</tr>
<tr>
<td>Project Dates</td>
<td>4/1/2003 - 12/31/2009</td>
</tr>
<tr>
<td>Direct</td>
<td>$239,400</td>
</tr>
<tr>
<td>F&amp;A</td>
<td>59,850</td>
</tr>
</tbody>
</table>
Zile, Michael  
Co-PI or Project Leader

**Medicine**

**Load-Induced Cardiac Hypertrophy in the Adult Mammal - Project 6: Diastolic Heart Failure: Defining Cardiocyte Mechanisms**
- **PI:** COOPER, IV, GEORGE
- **Sponsor:** NIH/NHLBI
- **Direct:** $161,541
- **Award:** 2 P01 HL048788-11 (03012709-11)
- **F&A:** 74,309
- **Project Dates:** 8/1/1993-7/31/2008

**Load-Induced Cardiac Hypertrophy in the Adult Mammal - Core C: Animal Model Core**
- **PI:** COOPER, IV, GEORGE
- **Sponsor:** NIH/NHLBI
- **Direct:** $134,786
- **Award:** 2 P01 HL048788-11 (03012709-03)
- **F&A:** 62,002
- **Project Dates:** 8/1/1993-7/31/2008

**Cardiovascular Proteomics Center - Project 1: Application of Proteomic Analysis to Cardiovascular Research in Diastolic Heart Failure**
- **PI:** KNAPP, DANIEL R.
- **Sponsor:** NIH/NHLBI
- **Direct:** $121,011
- **Award:** N01-HV-281-81-000 (02030610-24)
- **F&A:** 55,665
- **Project Dates:** 9/30/2002-9/29/2009

**Matrix Metalloproteinase Dysregulation in Diastolic Heart Failure**
- **PI:** AHMED, S. HINAN
- **Sponsor:** Heart Failure Soc. Of Amer.
- **Direct:** $65,000
- **Award:** (03013116)
- **F&A:** 0
- **Project Dates:** 7/1/2003-6/30/2004

**Load-Induced Cardiac Hypertrophy in the Adult Mammal**
- **PI:** COOPER, IV, GEORGE
- **Sponsor:** NIH/NHLBI
- **Direct:** $1,400,000
- **Award:** 2 P01 HL048788-11 (03012709)
- **F&A:** 643,827
- **Project Dates:** 8/1/1993-7/31/2008
<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct Cost</th>
<th>F&amp;A Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barbosa, Gail</td>
<td>Principal Investigator</td>
<td>Web-Based Learning, A Response to the Shortage of Baccalaureate and Advanced Practice Nurses in South Carolina</td>
<td>Duke Endowment</td>
<td>7/1/2003 - 6/30/2004</td>
<td>$200,000</td>
<td>0</td>
</tr>
<tr>
<td>Edlund, Barbara</td>
<td>Principal Investigator</td>
<td>Madre y Nino (Mother and Child)</td>
<td>The Community Fdn.</td>
<td>11/18/2002 - 11/17/2004</td>
<td>$10,000</td>
<td>0</td>
</tr>
<tr>
<td>Francis-Baldesari, Catherine</td>
<td>Principal Investigator</td>
<td>Racial and Ethnic Approaches to Community Health (REACH)</td>
<td>CDC</td>
<td>9/30/2003 - 9/29/2004</td>
<td>$818,523</td>
<td>198,925</td>
</tr>
<tr>
<td>Kelechi, Teresia</td>
<td>Principal Investigator</td>
<td>Skin Temperature and Perfusion in Venous Disease</td>
<td>NIH/NINR</td>
<td>9/30/2003 - 9/29/2005</td>
<td>$100,000</td>
<td>39,986</td>
</tr>
<tr>
<td>Laken, Marilyn</td>
<td>Principal Investigator</td>
<td>Community-Based Participatory Prevention Research: Health-e-AME Faith Based Physical Activity Initiative</td>
<td>CDC</td>
<td>9/30/2002 - 9/29/2005</td>
<td>$379,359</td>
<td>44,350</td>
</tr>
<tr>
<td>Leuner, Jean</td>
<td>Principal Investigator</td>
<td>Basic Nurse Education and Practice Program</td>
<td>HRSA/BHP/Nursing</td>
<td>7/1/2003 - 6/30/2004</td>
<td>$302,989</td>
<td>24,239</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Advanced Education Nursing Traineeships Program</td>
<td>HRSA/BHP/Nursing</td>
<td>7/1/2003 - 6/30/2004</td>
<td>$65,717</td>
<td>0</td>
</tr>
<tr>
<td>Name</td>
<td>Position</td>
<td>Title</td>
<td>Sponsor</td>
<td>Budget Dates</td>
<td>Direct</td>
<td>Award</td>
</tr>
<tr>
<td>---------------------</td>
<td>---------------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------</td>
<td>--------------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>Leuner, Jean</td>
<td>Principal Investigator</td>
<td>Basic Nurse Education and Practice Program - Cost Share MUHA</td>
<td>MUSC Hospital Authority</td>
<td>7/1/2002 - 6/30/2004</td>
<td>$200,000</td>
<td>(01113009)</td>
</tr>
<tr>
<td></td>
<td>Co-Investigator</td>
<td>Combined Pharmaco/Behavior Therapy in Adolescent Smokers</td>
<td>NIH/NIDA</td>
<td>9/30/2003-6/30/2008</td>
<td>$225,000</td>
<td>1 R01 DA017460-01 (03041101)</td>
</tr>
<tr>
<td>Michel, Yvonne</td>
<td>Principal Investigator</td>
<td>South Carolina Statewide Systemic Initiative National Science Foundation</td>
<td>SC Dept. of Education</td>
<td>7/1/2001 - 8/30/2003</td>
<td>$14,464</td>
<td>04 GA 306-01 (03091501)</td>
</tr>
<tr>
<td>Nickerson, Brenda</td>
<td>Principal Investigator</td>
<td>Mathematics Science Partnership</td>
<td>SC Dept. of Education</td>
<td>9/1/2003 - 8/30/2004</td>
<td>$23,596</td>
<td>04 MS 306 (03090903)</td>
</tr>
<tr>
<td>Stuart, Gail</td>
<td>Co-Investigator</td>
<td>Fellowship in Health Services Research</td>
<td>AHCPR/AHRQ</td>
<td>7/1/2003-6/30/2008</td>
<td>$124,722</td>
<td>1 T32 HS013851-01 (02083005)</td>
</tr>
<tr>
<td>Williamson, Deborah</td>
<td>Principal Investigator</td>
<td>Improving the Longevity and Quality of Life for Women: A Breast Cancer Screening Project</td>
<td>Susan G. Komen Fdn.</td>
<td>4/1/2004 - 3/31/2005</td>
<td>$24,424</td>
<td>(03120205)</td>
</tr>
</tbody>
</table>
College of Pharmacy

Arrington, David  
Pharmaceutical Sciences  
Identification of a Novel Mitochondrial Calpain  
Sponsor: NIH/NIEHS  
Award: F30 ES013083-01 (03081101)  
Direct: $32,219  
F&A: 0  

Bain, Amy  
Pharmaceutical Sciences  
Design and Development of a Novel Inhibitor of the HIV Protease  
Sponsor: Amer. Fdn. for Pharmaceutical Educ.  
Award: 03080702  
Direct: $5,000  
F&A: 0  

Beeson, Craig  
Pharmaceutical Sciences  
Synthesis of Cleavable Linkers for P01 CA4991  
Sponsor: Fred Hutchison Cancer Center  
Award: NCI 5 P01 CA044991- (04070803)  
Budget Dates: 5/1/2000 - 4/30/2005  
Project Dates: 5/1/2000 - 4/30/2005  
Direct: $43,599  
F&A: 20,055  

Chumney, Elinor  
Pharmacy  
Pharmaceutical Economics Model of Kaletra and Atzanavir  
Pt: SIMPSON, KIT  
Sponsor: Abbott Labs  
Award: 03080110-01  
Project Dates: 8/1/2003-12/31/2004  
Direct: $70,800  
F&A: 17,700  

Dix, Thomas  
Pharmaceutical Sciences  
Sponsored Research  
Sponsor: Argolyn Bioscience, Inc.  
Award: 03092308  
Budget Dates: 10/1/2003 - 9/30/2004  
Project Dates: 10/1/2003 - 9/30/2004  
Direct: $75,000  
F&A: 11,250  

Non-Natural Amino Acids in Peptide Drug Design  
Sponsor: Argolyn Bioscience, Inc.  
Award: 02040309  
Budget Dates: 11/1/2002 - 8/31/2003  
Project Dates: 11/1/2002 - 8/31/2003  
Direct: $49,960  
F&A: 0  

PKC-Related Proteins in Lung Fibrosis  
Pt: HOFFMAN, STANLEY  
Sponsor: NIH/NHLBI  
Award: R01 HL073718-01 (02091904)  
Direct: $250,000  
F&A: 115,000  

Hadden, Matthew  
Pharmaceutical Sciences  
Development of Bioactive Peptides as Drug Candidates  
Sponsor: Amer. Fdn. for Pharmaceutical Educ.  
Award: 02073104  
Direct: $6,000  
F&A: 0  

Hall, Philip  
Pharmaceutical Sciences  
Identifying Predictive Factors of Response to Recombinant Erythropoietin in Chemotherapy-Induced Anemia  
Sponsor: Ortho Biotech  
Award: 03052105  
Budget Dates: 7/1/2003 - 6/30/2005  
Project Dates: 7/1/2003 - 6/30/2005  
Direct: $20,000  
F&A: 5,000  

Targeting Protein Synthesis in AML  
Sponsor: Wake Forest Univ.  
Award: R01 CA90263 (03032103)  
Direct: $9,589  
F&A: 4,411  

Diphtheria Fusion Protein Therapy of AML  
Sponsor: Wake Forest Univ.  
Award: R01 CA76178 (03032102)  
Budget Dates: 1/1/2004 - 12/31/2004  
Project Dates: 1/1/2004 - 12/31/2004  
Direct: $10,431  
F&A: 4,798
<table>
<thead>
<tr>
<th>Name</th>
<th>College</th>
<th>Project Title</th>
<th>PI</th>
<th>Sponsor</th>
<th>Budget Dates</th>
<th>Direct</th>
<th>F&amp;A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Markowitz, John</td>
<td>Pharmaceutical Sciences</td>
<td>Pharmacokinetics of Olanzapine after Oral Administration of Standard Tablet Versus Normal and Sublingual Administration of Orally Disintegrating Tablets (Zyprexa-Zydis) in Healthy Adults</td>
<td>PI: STEED, LISA L.</td>
<td>Merck</td>
<td>2/1/2004 - 11/30/2004</td>
<td>$75,850</td>
<td>18,962</td>
</tr>
<tr>
<td>Mazyck, Pamela</td>
<td>Pharmacy Practice</td>
<td>Understanding &amp; Eliminating Health Disparities in Blacks - Project 4: Improving Care for High Risk Minority Patients with Chronic Illnesses by Using Pharmacist Consultations to Follow Up on Missed Prescription Refills</td>
<td>PI: TILLEY, BARBARA</td>
<td>AHCPR/AHRQ</td>
<td>9/30/2002-8/31/2005</td>
<td>$143,086</td>
<td>61,527</td>
</tr>
<tr>
<td>Meier, Guy</td>
<td>Pharmaceutical Sciences</td>
<td>D609-A Novel Cytoprotectant and Selective Anti-Tumor Agent</td>
<td>PI: ZHOU, DAOHONG</td>
<td>NIH/NCI</td>
<td>4/1/2004-3/31/2008</td>
<td>$184,500</td>
<td>84,677</td>
</tr>
<tr>
<td>Patrick, Kennerly</td>
<td>Pharmaceutical Sciences</td>
<td>Methylphenidate-Ethanol Interaction in ADHD and Coabuse</td>
<td>PI: PATRICK, KENNERLY S.</td>
<td>NIH/NIDA</td>
<td>9/30/2003-8/31/2004</td>
<td>$175,000</td>
<td>80,500</td>
</tr>
<tr>
<td>Robert, Sophie</td>
<td>Pharmacy</td>
<td>A Double-Blind, Eight-Week, Placebo and Risperidone Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of SR142801 in the Treatment of Patients with Schizophrenia or Schizoaffective Disorder</td>
<td>PI: HAMNER, MARK B.</td>
<td>Sanofi Synthelabo, Inc.</td>
<td>2/24/2004-2/8/2005</td>
<td>$198,416</td>
<td>22,104</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A Multi-Center, Open Label, Flexible-Dose, Parallel-Group Evaluation of the Cataractogenic Potential of Quetiapine Fumarate (SEROQUEL tm) and Risperidone (RISPERDAL tm) in the Long-Term Treatment of Patients with Schizophrenia and Schizoaffective Disorder</td>
<td>PI: HAMNER, MARK B.</td>
<td>AstraGerm</td>
<td>1/30/2004-1/29/2006</td>
<td>$234,640</td>
<td>58,860</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A Multi-Center, Randomized, Parallel-Group, Double Blind, Phase III Comparison of the Efficacy and Safety of Quetiapine Fumarate (oral tablets 400 mg daily in divided doses) to Placebo when Used as Adjunct to Mood Stabilizers (Lithium or Divalproex) in t</td>
<td>PI: HAMNER, MARK B.</td>
<td>AstraGerm</td>
<td>2/2/2004-1/29/2006</td>
<td>$199,841</td>
<td>49,960</td>
</tr>
</tbody>
</table>
Schnellmann, Rick

Principal Investigator

**Pharmaceutical Sciences**

**Uptake and Cellular Effects of 2'-MOE Modified Phosphorothioate Oligonucleotides in Primary Cultures of Rabbit Renal Proximal Tubular Cells**

Sponsor: Isis Pharmaceuticals, Inc.  
Direct: $36,000

**Novel PLA2 in Oxidant-Induced Renal Cell Oncosis**

Sponsor: NIH/NIDDK  
Direct: $269,792

Co-PI or Project Leader

**Identification of a Novel Mitochondrial Calpain**

PI: ARRINGTON, DAVID  
Sponsor: NIH/NIEHS  
Direct: $32,219

Simpson, Kit

Principal Investigator

**Pharmacy Practice**

**Pharmacoeconomic Model of Kaletra and Atzanavir**

Sponsor: Abbott Labs  
Budget Dates: 8/1/2003 - 12/31/2004  
Direct: $70,800

**Targeting Acute HIV: Cost Effectiveness Modeling**

Sponsor: Univ. of North Carolina  
Budget Dates: 9/19/2003 - 6/30/2004  
Direct: $17,123

**Understanding & Eliminating Health Disparities in Blacks - Project 2: Economic Access to Antiretroviral (ARV) Prescription Drugs and Adherence to ARV Guidelines for African American Medicaid Enrollees with HIV-Disease in South Carolina**

PI: TILLEY, BARBARA  
Sponsor: AHCPR/AHRQ  
Budget Dates: 9/21/2000-8/31/2005  
Direct: $115,565

**Health Benefit and Economic Impact of Hemofiltration in High-Risk Patients Undergoing Cardiac Catheterization**

PI: SPENCER, ANNE  
Sponsor: Gambro Renal Products, Inc.  
Budget Dates: 5/1/2004-10/31/2004  
Direct: $16,008

**SC Cooperative for Healthy Aging in Minority Populations**

PI: TILLEY, BARBARA  
Sponsor: NIH/NIA  
Direct: $410,013

**Southeastern Node of the Clinical Trials Network**

PI: BRADY, KATHLEEN T.  
Sponsor: NIH/NIDA  
Budget Dates: 9/30/2000-8/31/2005  
Direct: $1,307,975

**Fellowship in Health Services Research**

PI: DARDEN, PAUL M.  
Sponsor: AHCPR/AHRQ  
Budget Dates: 7/1/2003-6/30/2008  
Direct: $124,722

Sweat, Douglas

Co-PI or Project Leader

**Environmental Biosciences Program: EnvTox-Sweet-Action of TCE**

PI: MOHR, JR., LAWRENCE C.  
Sponsor: DOE  
Direct: $84,407

Spencer, Anne

Principal Investigator

**Public Health Practice**

**Health Benefit and Economic Impact of Hemofiltration in High-Risk Patients Undergoing Cardiac Catheterization**

PI: SPENCER, ANNE  
Sponsor: Gambro Renal Products, Inc.  
Budget Dates: 5/1/2004-10/31/2004  
Direct: $16,008

**Co-Investigator**

**Health Benefit and Economic Impact of Hemofiltration in High-Risk Patients Undergoing Cardiac Catheterization**

PI: SPENCER, ANNE  
Sponsor: Gambro Renal Products, Inc.  
Budget Dates: 5/1/2004-10/31/2004  
Direct: $16,008

**Understanding & Eliminating Health Disparities in Blacks - Project 2: Economic Access to Antiretroviral (ARV) Prescription Drugs and Adherence to ARV Guidelines for African American Medicaid Enrollees with HIV-Disease in South Carolina**

PI: TILLEY, BARBARA  
Sponsor: AHCPR/AHRQ  
Budget Dates: 9/21/2000-8/31/2005  
Direct: $115,565

**South Carolina Cooperative for Healthy Aging in Minority Populations**

PI: TILLEY, BARBARA  
Sponsor: NIH/NIA  
Direct: $410,013

**Southeastern Node of the Clinical Trials Network**

PI: BRADY, KATHLEEN T.  
Sponsor: NIH/NIDA  
Budget Dates: 9/30/2000-8/31/2005  
Direct: $1,307,975

**Fellowship in Health Services Research**

PI: DARDEN, PAUL M.  
Sponsor: AHCPR/AHRQ  
Budget Dates: 7/1/2003-6/30/2008  
Direct: $124,722

**Co-Investigator**

**Understanding & Eliminating Health Disparities in Blacks - Project 2: Economic Access to Antiretroviral (ARV) Prescription Drugs and Adherence to ARV Guidelines for African American Medicaid Enrollees with HIV-Disease in South Carolina**

PI: TILLEY, BARBARA  
Sponsor: AHCPR/AHRQ  
Budget Dates: 9/21/2000-8/31/2005  
Direct: $115,565

**Southern Regional Cooperative for Healthy Aging in Minority Populations**

PI: TILLEY, BARBARA  
Sponsor: NIH/NIA  
Direct: $410,013

**Southeastern Node of the Clinical Trials Network**

PI: BRADY, KATHLEEN T.  
Sponsor: NIH/NIDA  
Budget Dates: 9/30/2000-8/31/2005  
Direct: $1,307,975

**Fellowship in Health Services Research**

PI: DARDEN, PAUL M.  
Sponsor: AHCPR/AHRQ  
Budget Dates: 7/1/2003-6/30/2008  
Direct: $124,722

**Co-Investigator**

**Understanding & Eliminating Health Disparities in Blacks - Project 2: Economic Access to Antiretroviral (ARV) Prescription Drugs and Adherence to ARV Guidelines for African American Medicaid Enrollees with HIV-Disease in South Carolina**

PI: TILLEY, BARBARA  
Sponsor: AHCPR/AHRQ  
Budget Dates: 9/21/2000-8/31/2005  
Direct: $115,565

**Southern Regional Cooperative for Healthy Aging in Minority Populations**

PI: TILLEY, BARBARA  
Sponsor: NIH/NIA  
Direct: $410,013

**Southeastern Node of the Clinical Trials Network**

PI: BRADY, KATHLEEN T.  
Sponsor: NIH/NIDA  
Budget Dates: 9/30/2000-8/31/2005  
Direct: $1,307,975

**Fellowship in Health Services Research**

PI: DARDEN, PAUL M.  
Sponsor: AHCPR/AHRQ  
Budget Dates: 7/1/2003-6/30/2008  
Direct: $124,722
**UBER, Lynne**  
**Pharmacy Practice**  
**The Utility of C2 Cyclosporine Monitoring in Cardiac Transplantation: A Cardiac Transplant Research Database**  
*PI: UBER, WALT*  
*Sponsor: Univ. of Alabama, Birmingham*  
*Direct: $7,120*  
*Project Dates: 7/15/2003-12/31/2005*  
*Award: (03051901)*  
*F&A: 1,780*

---

**UBER, Walt**  
**Pharmacy Practice**  
**The Utility of C2 Cyclosporine Monitoring in Cardiac Transplantation: A Cardiac Transplant Research Database**  
*Sponsor: Univ. of Alabama, Birmingham*  
*Budget Dates: 7/15/2003 - 12/31/2005*  
*Direct: $7,120*  
*Award: (03051901)*  
*F&A: 1,780*

---

**White, Roger**  
**Pharmaceutical Sciences**  
**Role of Surfactant Protein B in Innate Airway Defense**  
*PI: BAATZ, JOHN*  
*Sponsor: NIH/NHLBI*  
*Direct: $200,000*  
*Project Dates: 7/1/2001-6/30/2005*  
*Award: 5 R01 HL066066-03 (03042905)*  
*F&A: 85,088*

---

**Wright, Gary**  
**Pharmaceutical Sciences**  
**Prolyl Hydroxylase Oxygen-Sensing in Heart**  
*Sponsor: NIH/NIEHS*  
*Direct: $100,000*  
*Award: 1 K22 ES012261-01 (04040802)*  
*F&A: 8,000*

---

**Young, Vicki**  
**Pharmacy Practice**  
**Understanding & Eliminating Health Disparities in Blacks - Pilot Study 2: Pain Management of Elderly African American Patients with Cancer in the Community Setting**  
*PI: TILLEY, BARBARA*  
*Sponsor: AHCPR/AHRQ*  
*Direct: $56,099*  
*Project Dates: 9/21/2000-8/31/2005*  
*Award: 5 P01 HS010871-04 (03071008-09)*  
*F&A: 24,123*

---

**Yu, Shan**  
**Pharmaceutical Sciences**  
**Membrane-Delimited Modulation of Non-NMDA Receptors by Metabotropic Glutamate Receptors**  
*Sponsor: NSF*  
*Budget Dates: 7/1/2003 - 4/30/2004*  
*Direct: $13,123*  
*Award: IBN-9817151 (02121905)*  
*F&A: 6,037*

---

**Chloride Channel Modulation and Neuronal Apoptosis**  
*Sponsor: NIH/NINDS*  
*Budget Dates: 7/1/2003 - 6/30/2005*  
*Direct: $131,849*  
*Award: 7 R21 NS042236-03 (02110701)*  
*Project Dates: 8/1/2001 - 6/30/2005*  
*F&A: 60,651*

---

**Potassium Channel Modulation in Apoptosis and Effects of Potassium Channel Blockers on Ischemic Cell Death**  
*Sponsor: Amer. Heart Assoc.*  
*Budget Dates: 1/1/2003 - 12/31/2003*  
*Direct: $182,000*  
*Award: 0170064N (02103106)*  
*Project Dates: 11/1/2002 - 12/31/2004*  
*F&A: 18,000*

---

**Co-PI or Project Leader**  
**Neuroprotective Effect of Merck Compounds In Ischemic Stroke Rats**  
*PI: WEI, LING*  
*Sponsor: Merck*  
*Direct: $351,450*  
*Project Dates: 1/1/2004-12/31/2004*  
*Award: (04010502-01)*  
*F&A: 70,289*

---

**Function Restoration by ES Cell Implant after Ischemia**  
*PI: WEI, LING*  
*Sponsor: NIH/NINDS*  
*Direct: $213,750*  
*Project Dates: 5/15/2003-4/30/2007*  
*Award: 5 R01 NS045155-02 (04040801)*  
*F&A: 98,325*
### Center Affiliated Awards

**Center For Health Care Research**

#### Medicine

**Egede, Leonard**  
**Collaborative Management of Diabetes in Blacks**  
**Sponsor:** AHCPR/AHRQ  
**Award:** (03022508) 5 K08 HS011418-03  
**Direct:** $117,250  
**Budget Dates:** 07/01/03 - 06/30/04  
**F & A:** $9,380  
**Project Dates:** 07/01/01 - 06/30/06

#### Health Professions

**Forti, Esther**  
**Geriatric Oral Health Education Project**  
**Sponsor:** HRSA  
**Award:** (03071102) 3 D31HP70148-03-01  
**Direct:** $100,000  
**Budget Dates:** 09/01/03 - 06/30/04  
**F & A:** $8,000  
**Project Dates:** 07/01/01 - 06/30/06

#### Ophthalmology

**Rohrer, Baerbel**  
**Transgenic Rod Development and Function**  
**Sponsor:** NIH/NEI  
**Award:** (02030509) 1 R03 EY013728-01A1  
**Direct:** $100,000  
**Budget Dates:** 07/01/03 - 06/30/04  
**F & A:** $35,225  
**Project Dates:** 07/01/03 - 06/30/06

#### Physiology

**Granholm, Ann-Charlotte**  
**Mechanisms of Neurotrophin-Impaired Cognition in Aging**  
**Sponsor:** NIH/NIA  
**Award:** (03081202) 2 R01 AG010755-10A1  
**Direct:** $218,250  
**Budget Dates:** 09/03/03 - 08/31/04  
**F & A:** $89,240  
**Project Dates:** 09/29/01 - 06/31/08

**Pharmacological Correlates of Aging and Brain Cell Grafts**  
**Sponsor:** Univ. of South Florida  
**Award:** (03100103) 6155-032-LO-B  
**Direct:** $110,562  
**Budget Dates:** 07/01/03 - 06/30/04  
**F & A:** $47,542  
**Project Dates:** 07/01/01 - 06/30/04

**Effects of Lipopolysaccharide Injections on BDNF and GDNF Partial Knockout Animals**  
**Sponsor:** Margot Anderson Brain Restoration Fun  
**Award:** (04032401)  
**Direct:** $20,000  
**Budget Dates:** 04/01/04 - 03/31/05  
**F & A:** $0  
**Project Dates:** 04/01/04 - 03/31/05

**Kindy, Mark**  
**Oxidized Lipoproteins in Neurodegeneration**  
**Sponsor:** NIH/NINDS  
**Award:** (03070102) 5 R01 NS039588-04  
**Direct:** $200,000  
**Budget Dates:** 09/01/03 - 08/31/04  
**F & A:** $92,000  
**Project Dates:** 11/01/02 - 08/31/05

**Neprilysin and Abeta-Degradation in Alzheimer's Disease**  
**Sponsor:** NIH/NIA  
**Award:** (03100101) 5 R01 AG019323-03  
**Direct:** $186,000  
**Budget Dates:** 12/01/03 - 11/30/04  
**F & A:** $39,560  
**Project Dates:** 02/01/02 - 11/30/05

**Sambamurti, Kumar**  
**Residual Funds**  
**Sponsor:** Mayo Clinic  
**Award:** (03011702)  
**Direct:** $78,061  
**Budget Dates:** 01/01/03 - 12/31/04  
**F & A:** $0  
**Project Dates:** 01/01/03 - 12/31/04

**Role of Alzheimer's APP in Retinal Degeneration**  
**Sponsor:** Amer. Health Assistance Fdn.  
**Award:** (03102205) M-2004-027  
**Direct:** $50,000  
**Budget Dates:** 04/01/04 - 03/31/05  
**F & A:** $0  
**Project Dates:** 04/01/04 - 05/31/06
<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Sponsor</th>
<th>Direct Amount</th>
<th>F&amp;A Amount</th>
<th>Budget Dates</th>
<th>Project Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sambamurti, Kumar</td>
<td>Effects of Cholinergic Drugs on APP Metabolism</td>
<td>Axonix Corp.</td>
<td>$135,000</td>
<td>$33,750</td>
<td>12/25/03 - 12/25/04</td>
<td>12/25/03 - 12/25/04</td>
</tr>
<tr>
<td>Castell, Donald</td>
<td>MII to Characterize Reflux in Barrett's Esophagus</td>
<td>NIH/NIDDK</td>
<td>$100,000</td>
<td>$41,400</td>
<td>06/01/04 - 04/30/05</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Extension of SWAL-QOL for Use in Esophageal Dysphagia</td>
<td>VAMC</td>
<td>$27,543</td>
<td>$0</td>
<td>07/01/03 - 03/31/05</td>
<td></td>
</tr>
<tr>
<td></td>
<td>A Multi-Center, Open-Label Trial to Evaluate the Safety of OSB-IR 40 mg in Patients</td>
<td>TKL Research</td>
<td>$32,000</td>
<td>$8,000</td>
<td>11/01/03 - 03/31/05</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Comparison of Clinical Innovations CI Catheter with Solid State Catheters for Validation</td>
<td>Clinical Innovations</td>
<td>$33,700</td>
<td>$8,425</td>
<td>03/01/04 - 12/31/04</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Use of Combined Multi-Channel Intraluminal Impedance to Evaluate the Effects of Prokinetic Agents on Esophageal Function and Gastroesophageal Reflux</td>
<td>Pfizer, Inc.</td>
<td>$130,554</td>
<td>$32,638</td>
<td>06/01/04 - 05/31/05</td>
<td></td>
</tr>
<tr>
<td>Cotton, Peter</td>
<td>Boston Scientific Fellowship IV</td>
<td>Boston Scientific Corp.</td>
<td>$46,296</td>
<td>$3,704</td>
<td>08/01/03 - 12/31/04</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Multi-Center, Prospective, Randomized, Controlled Trial of the Nitinol Zilver Expandable Endoprosthesis in the Palliation of Extrabiliary Malignant Biliary Obstruction (MOZART!)</td>
<td>Wilson Cook</td>
<td>$6,000</td>
<td>$1,500</td>
<td>10/17/03 - 10/31/04</td>
<td></td>
</tr>
<tr>
<td>Delegge, Mark</td>
<td>A Study to Further Assess the Efficacy of Bowel Preparation with the Use of a Pre-Packed Diet/Bowel Prep Kit Versus Usual and Customary Bowel Preparation for Colonoscopy</td>
<td>Ezem, Inc.</td>
<td>$1,540</td>
<td>$354</td>
<td>03/01/01 - 06/30/03</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Endoscopic Implantation of Enteryx for the Treatment of Symptomatic Gastroesophageal Reflux Disease</td>
<td>Boston Scientific Corp.</td>
<td>$32,304</td>
<td>$8,076</td>
<td>08/01/03 - 12/31/07</td>
<td></td>
</tr>
<tr>
<td>Hawes, Robert</td>
<td>Study of the NDO Surgical Plication System for the Treatment of Symptomatic Gastroesophageal Reflux Disease</td>
<td>NDO Surgical, Inc.</td>
<td>$32,175</td>
<td>$9,652</td>
<td>07/23/01 - 02/01/03</td>
<td></td>
</tr>
<tr>
<td></td>
<td>North American Pancreatitis Study 2 (NAPS2)</td>
<td>Univ. of Pittsburgh</td>
<td>$5,993</td>
<td>$2,757</td>
<td>07/01/03 - 04/30/05</td>
<td></td>
</tr>
<tr>
<td>Hoffman, Brenda</td>
<td>A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study of the Efficacy and Safety of OPC-6535 Tablets in the Treatment of Subjects with Active Ulcerative Colitis</td>
<td>Otsuka Medical Research Inst.</td>
<td>$37,904</td>
<td>$9,476</td>
<td>03/28/03 - 04/30/05</td>
<td></td>
</tr>
</tbody>
</table>
Hoffman, Brenda

**Molecular Detection of Pancreatic Cancer in Patients with Chronic Focal Pancreatitis Using Real-Time RT-PCR and EUS with FNA**
- **Sponsor:** Amer. Soc. for GI Endoscopy
- **Award:** (03100701)
- **Direct:** $10,000
- **F & A:** $0

**A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, 52-Week, Dose Comparison Study of the Efficacy and Safety of 25mg QD and 50mg QD of OPC 6535 Oral Tablets and 800mg BID of Asacol in the Maintenance of Remission in Ulcerative Colitis**
- **Sponsor:** Otsuka Medical Research Inst.
- **Award:** (04041502) 197-02-220
- **F & A:** $14,250

**Antegren under Protocol ELN 100226-CD307**
- **Sponsor:** Elan Pharmaceuticals
- **Award:** (04041505) ELN 100226-CD307
- **F & A:** $10,746

Wilson, Frederick

**A Phase III, Multi-National, Multi-Center, Open Label, 52 Week, Safety Study to Assess the Safety of Re-Exposure after a Variable Interval and Subsequent Chronic Therapy with the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc (dosed at weeks 0,2 and 4 then 4-weekly to Week 48), in the Treatment of Patients with Active Crohn’s Disease Who Have Previously Been Withdrawn from Studies CDP870-031 or CDP870-032 Due to an Exacerbation of Crohn’s Disease**
- **Sponsor:** Icon Clinical Research, Inc.
- **Award:** (04012202) CDP870-034
- **F & A:** $11,481

**A Phase III, Multi-National, Multi-Center, Open-Label, 52 Week, Safety Study to Assess the Safety of Chronic Therapy with the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed 4-weekly to 48 week), in the Treatment of Patients with Active Crohn’s Disease Who Have Previously Completed Studies CDP870-031 or CDP870-032**
- **Sponsor:** Icon Clinical Research, Inc.
- **Award:** (04012203) CDP870-033
- **F & A:** $6,357

**A Phase III, Multi-National, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, 26 Week Study to Assess the Safety and Efficacy of the Humanised Anti-TNF PEG Conjugate, CDP870 400 mg sc, (Dosed at weeks 0,2,4 then 4-weekly to Week 24), in the Treatment of Patients with Active Crohn’s Disease**
- **Sponsor:** Icon Clinical Research, Inc.
- **Award:** (04012204) CDP870-031
- **F & A:** $11,481

Del Poeta, Maurizio

**Roles for Inositol Phosphoryl Ceramide Synthase 1 (IPC1) in Fungal-Host Interaction**
- **Sponsor:** Burroughs Wellcome Fdn.
- **Award:** (01103103) 1003642
- **Direct:** $80,000
- **F & A:** $0

**Role of Ipc1 in Fungal Pathogenesis**
- **Sponsor:** NIH/NIAD
- **Award:** (02022714) 1 R21 AI051924-01A1
- **Direct:** $225,000
- **F & A:** $86,480

Hannun, Yusuf

**Sphingolipids in Cancer Therapy and Angiogenesis**
- **Sponsor:** NIH/NCI
- **Award:** (01100808) 1 P01 CA97132-01A1
- **Direct:** $715,167
- **F & A:** $318,811

**Mitochondrial Sphingolipids in Apoptosis**
- **Sponsor:** Univ. of North Carolina
- **Award:** (02092305) 5 P01 DK59340-02
- **Direct:** $111,971
- **F & A:** $48,148

**Development of Chemical and Structural Biology**
- **Sponsor:** SC Research Authority
- **Award:** (03091003) 0005
- **Direct:** $1,403
- **F & A:** $0
Ogretmen, Besim  
**Regulation of Telomerase By Ceramide in Lung Cancer**  
**Sponsor:** NIH/NCI  
**Award:** (04011404) 5 R01 CA088932-03  
**Direct:** $174,620  
**F & A:** $76,050  
**Budget Dates:** 04/01/04 - 03/31/05  
**Project Dates:** 04/01/04 - 03/31/07

Spicer, Eleanor  
**Post-Transcription Regulation of Human bcl-2 Expression**  
**Sponsor:** NIH/NCI  
**Award:** (03043004) 5 R01 CA087553-02  
**Direct:** $142,500  
**F & A:** $65,550  
**Budget Dates:** 07/01/03 - 06/30/04  
**Project Dates:** 07/01/02 - 06/30/06

**Cell Biology & Anatomy**

Hsu, Tien  
**Regulation of Nitric Oxide and Catecholamine Signaling in Drosophila Tracheal Development: New Angiogenic Models**  
**Sponsor:** Univ. of Alabama  
**Award:** (02031905) 5 R21 CA099021-02  
**Direct:** $30,000  
**F & A:** $13,800  
**Budget Dates:** 02/07/03 - 01/31/05  
**Project Dates:** 02/07/03 - 01/31/05

**Clinical Services**

Holladay, E.  
**HPV DNA Sequencing for Paraffin-Embedded Cervical Tissue Specimens, (Amendment to Protocol #6)**  
**Sponsor:** Ventana Medical Systems  
**Award:** (04030814)  
**Direct:** $2,920  
**F & A:** $730  
**Budget Dates:** 02/01/04 - 12/31/04  
**Project Dates:** 02/01/04 - 12/31/04

**Dean's Office - COM**

Reed, Carolyn  
**Institutional Research Grant**  
**Sponsor:** Amer. Cancer Soc.  
**Award:** (02100801) IRG-97-219-05  
**Direct:** $181,500  
**F & A:** $0  
**Budget Dates:** 07/01/03 - 12/31/06  
**Project Dates:** 02/01/04 - 12/31/04

**Medicine**

Awgulewitsch, Alexander  
**Roles of Hox Genes in Skin and Hair Follicle Development**  
**Sponsor:** NIH/NIAMS  
**Award:** (03060202) 5 R01 AR047204-04  
**Direct:** $188,000  
**F & A:** $80,840  
**Budget Dates:** 08/01/03 - 07/31/05  
**Project Dates:** 08/01/03 - 07/31/05

Boylan, Alice  
**Role of a Novel Oncogene in Mesothelioma**  
**Sponsor:** NIH/NIAMS  
**Award:** (02112103) 1 R01 ES011323-01A2  
**Direct:** $166,250  
**F & A:** $76,475  
**Budget Dates:** 09/01/03 - 05/31/04  
**Project Dates:** 09/01/03 - 05/31/08

**Role of a Novel Oncogene in Mesothelioma**  
**Sponsor:** NIH/NIAMS  
**Award:** (04040105) 5 R01 ES011323-02  
**Direct:** $166,250  
**F & A:** $76,475  
**Budget Dates:** 06/01/04 - 05/31/05  
**Project Dates:** 09/01/03 - 05/31/08

Brescia, Frank  
**A 2x2 Factorial, Randomized, Phase III Study of Intermittent Oral Cephalosphine in Combination with Intravenous Oxaliplatin (Q3W) (Xelox) with/without Intravenous Bevacizumab (Q3W) vs Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin PCL#N 016966C**  
**Sponsor:** Hoffman-Laroche, Inc.  
**Award:** (04070113) N016966C  
**Direct:** $165,690  
**F & A:** $41,423  
**Budget Dates:** 06/11/04 - 11/30/06  
**Project Dates:** 06/11/04 - 11/30/06
Hollings Cancer Center

**Chaudhary, Uzair**

- **A Phase II/III, Multi-Center, Randomized, Double-Blind Study of Docetaxel Plus DN-101 or Placebo in Androgen Independent Prostate Cancer (AIPC)**
  - **Sponsor:** Novacea
  - **Award:** (03103007) DN101-002
  - **Direct:** $46,810
  - **Budget Dates:** 10/10/03 - 10/10/04
  - **Project Dates:** 10/10/03 - 10/10/05

- **Phase I Trial of Epirubicin and Taxotere in Patients with Metastatic Androgen Independent Prostate Cancer**
  - **Sponsor:** Aventis Pharmaceutical, Inc.
  - **Direct:** $84,260
  - **Budget Dates:** 04/01/04 - 04/01/05
  - **Award:** (04042101) GPC SAT3-03-01
  - **F & A:** $21,065
  - **Project Dates:** 04/01/04 - 04/01/05

- **A Multi-Center, Multi-National, Double-Blind, Randomized, Phase III Study of Satraplatin Plus Prednisone or Placebo Plus Prednisone in Patients with Hormone Refractory Prostate Cancer Previously Treated with One Cycotox Chemotherapy Regimen**
  - **Sponsor:** GPC Biotech
  - **Direct:** $35,020
  - **Budget Dates:** 05/11/04 - 03/01/06
  - **Award:** (04050401) GPC SAT3-03-01
  - **F & A:** $8,755
  - **Project Dates:** 05/11/04 - 03/01/06

- **A Phase I Study of Concurrent Docetaxel with Radiation Therapy and Hormonal Therapy for Clinically Localized High Risk Prostate Cancer**
  - **Sponsor:** Aventis Pharmaceutical, Inc.
  - **Direct:** $84,260
  - **Budget Dates:** 04/01/04 - 04/01/05
  - **Award:** (04060702) IIT16159
  - **F & A:** $21,065
  - **Project Dates:** 04/01/04 - 04/01/05

**Frei-Lahr, Debra**

- **A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer**
  - **Sponsor:** Amgen
  - **Direct:** $113,210
  - **Budget Dates:** 05/01/04 - 05/01/06
  - **Award:** (04070210) 20010103
  - **F & A:** $28,303
  - **Project Dates:** 05/01/04 - 05/01/06

**Green, Mark**

- **Randomized Trial of Pivanex Plus Docetaxel or Docetaxel Monotherapy in Patients with Chemotherapy Resistant Advanced Non-Small Cell Carcinoma of the Lung (NSCLC)**
  - **Sponsor:** Titan Pharmaceuticals, Inc.
  - **Direct:** $28,680
  - **Budget Dates:** 12/15/03 - 12/31/06
  - **Award:** (03080801) TTN 286.3020
  - **F & A:** $16,900
  - **Project Dates:** 12/15/03 - 12/31/06

**Kneuper-Hall, Rayna**

- **A Randomized, Open-Label, Phase III Study of RPR109881 IV Every 3 Weeks Versus Capecitabine (Xeloda) Tablets Twice Daily for 2 Weeks in 3-Week Cycles in Patients with Metastatic Breast Cancer Progressing after Taxanes and Anthracycline Therapy**
  - **Sponsor:** Aventis Pharmaceutical, Inc.
  - **Direct:** $37,316
  - **Budget Dates:** 03/31/04 - 02/01/06
  - **Award:** (04033103) XRP9881B-3001
  - **F & A:** $9,329
  - **Project Dates:** 03/31/04 - 02/01/06

- **A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral CCI-779 Administered in Combination with Letrozole vs Letrozole Alone as First Line Hormonal Therapy in Postmenopausal Women with Locally Advanced or Metastatic Breast Cancer**
  - **Sponsor:** Wyeth, Inc.
  - **Direct:** $422,370
  - **Budget Dates:** 02/22/04 - 04/01/05
  - **Award:** (04062105) 3066A1-303-WW
  - **F & A:** $35,593
  - **Project Dates:** 02/22/04 - 04/01/05

- **An Randomized, Open-Label Study Comparing Treatment with Either Pegylated Liposomal Doxorubicin or Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer in Women 65 Years or Older**
  - **Sponsor:** Ortho Biotech
  - **Direct:** $33,910
  - **Budget Dates:** 05/01/04 - 05/01/05
  - **Award:** (04062106) DO03-21-022
  - **F & A:** $8,478
  - **Project Dates:** 05/01/04 - 05/01/05
### Hollings Cancer Center

**Kraft, Andrew**
- **Hollings Cancer Center Planning Grant**
  - **Sponsor:** NIH/NCI  
  - **Direct:** $59,499  
  - **Budget Dates:** 08/24/01 - 07/31/05  
  - **F & A:** $25,584  
  - **Project Dates:** 08/24/01 - 07/31/05

**Stuart, Robert**
  - **Sponsor:** Celgene Corp.  
  - **Direct:** $18,470  
  - **Budget Dates:** 06/07/04 - 12/31/06  
  - **Award:** (04062104) CC-513-MM-012  
  - **F & A:** $4,618  
  - **Project Dates:** 06/07/04 - 12/31/06

**Microbiology & Immunology**

**Tomlinson, Stephen**
- **Complement Inhibitors and Immunotherapy**
  - **Sponsor:** NIH/NCI
  - **Direct:** $90,000
  - **Budget Dates:** 04/01/04 - 03/31/05
  - **Award:** (03012404) 1 R21 CA104579-01
  - **F & A:** $41,400
  - **Project Dates:** 04/01/04 - 03/31/06

- **Interaction Between CD59 and its Complement Ligands**
  - **Sponsor:** NIH/NIAID
  - **Direct:** $189,224
  - **Budget Dates:** 05/01/04 - 04/30/05
  - **Award:** (04022701) 5 R01 AI047386-04
  - **F & A:** $81,366
  - **Project Dates:** 05/01/04 - 04/30/06

**Voelkel-Johnson, Christina**
- **TRAIL-Induced Apoptosis in Prostate Cancer**
  - **Sponsor:** NIH/NCI
  - **Direct:** $157,499
  - **Budget Dates:** 04/01/04 - 02/28/05
  - **Award:** (03062621) 1 R01 CA102218-01A1
  - **F & A:** $72,450
  - **Project Dates:** 04/01/04 - 02/28/09

**Neurological Surgery**

**Patel, Sunil**
- **Phase V GliSite Radiation Therapy System (RTS) Registry Protocol for the Treatment of Resectable Malignant Brain Tumors**
  - **Sponsor:** Proxima Therapeutics
  - **Direct:** $42,700
  - **Budget Dates:** 06/01/03 - 06/01/13
  - **Award:** (03060215)
  - **F & A:** $10,675
  - **Project Dates:** 06/01/03 - 06/01/13

**Neurology**

**Tremont, Ivo**
- **Phase III, Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to Gliadel Wafer with Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence**
  - **Sponsor:** Neopharm, Inc.
  - **Direct:** $512,722
  - **Budget Dates:** 06/11/04 - 12/31/06
  - **Award:** (04060302)
  - **F & A:** $128,181
  - **Project Dates:** 06/11/04 - 12/31/06

**Nursing**

**Nickerson, Brenda**
- **Mammography Screening to Reduce Breast Cancer Mortality Through Early Detection and Referral for Treatment of Disease**
  - **Sponsor:** Susan G. Komen Fdn.
  - **Direct:** $1,950
  - **Budget Dates:** 05/01/03 - 04/01/04
  - **Award:** (04010701)
  - **F & A:** $0
  - **Project Dates:** 05/01/03 - 04/01/04

**Obstetrics/Gynecology**

**Kohler, Matthew**
- **A Multi-Center, Randomized, Phase III, Comparative Study to Compare the Efficacy and Safety of Taxotere/Carboplatin Combination Therapy Versus Sequential Therapy with Taxotere then Carboplatin as Second-Line Treatment of Patients with Relapsed, Platinum-Sensitive Ovarian Cancer**
  - **Sponsor:** PPD Development
  - **Direct:** $39,600
  - **Budget Dates:** 12/22/03 - 12/01/06
  - **Award:** (03122203) DUMC 03
  - **F & A:** $9,900
  - **Project Dates:** 12/22/03 - 12/01/06
Pathology & Laboratory Medicine

Watson, Dennis  X Role of an Epithelial Ets Factor in Breast Cancer  
Sponsor: NIH/NCI  
Award: (02100204) 1 R01 CA102297-01  
Direct: $222,500  
Budget Dates: 07/01/03 - 06/30/04  
F & A: $102,350  
Project Dates: 07/01/03 - 06/30/08

Pediatrics

Barredo, Julio  X Molecular Correlates of Methotrexate in Childhood ALL  
Sponsor: Wayne State Univ.  
Award: (03041601) Y-373555  
Direct: $18,412  
Budget Dates: 01/01/04 - 12/31/04  
F & A: $8,470  
Project Dates: 01/01/03 - 12/31/08

Pharmaceutical Sciences

Hall, Philip  X Diphtheria Fusion Protein Therapy of AML  
Sponsor: Wake Forest Univ.  
Award: (03032102) R01 CA76178  
Direct: $10,431  
Budget Dates: 01/01/04 - 12/31/04  
F & A: $4,798  
Project Dates: 01/01/03 - 12/31/06

Radiation Oncology

Gattoni-Celli, Sebastiano  X South Carolina Prostate Cancer Telehealth Program - Phase III  
Sponsor: Inst. For Cancer Prevention  
Award: (04012704)  
Direct: $12,787  
Budget Dates: 09/01/03 - 08/31/04  
F & A: $5,882  
Project Dates: 09/01/03 - 08/31/04

Surgery

Cole, David  X In Vivo Effector Cell Response to Peptide Vaccination  
Sponsor: NIH/NCI  
Award: (03042801) 5 R01 CA083672-03  
Direct: $157,500  
Budget Dates: 07/01/03 - 06/30/04  
F & A: $67,725  
Project Dates: 07/01/03 - 06/30/04

Reed, Carolyn  X Institutional Research Grant: Role of FA2H in Aberrant Glycolipid Microdomain Formation  
Sponsor: Amer. Cancer Soc.  
Award: (02100801) IRG-97-219-05  
Direct: $58,500  
Budget Dates: 11/01/03 - 10/31/04  
F & A: $0  
Project Dates: 11/01/03 - 10/31/04

X Oncology Center: Utilization of Digital Mammography in HCC Breast Screening, Diagnosis, Treatment and Research  
Sponsor: DOE  
Award: (03051401) DE-FG02-01ER63121  
Direct: $759,803  
Budget Dates: 07/01/03 - 06/30/04  
F & A: $50,510  
Project Dates: 07/03/03 - 08/31/05

X Health Care Facilities and Other Construction  
Sponsor: HRSA  
Award: (03051604) 4 C76HF00155-01-02  
Direct: $3,442,479  
Budget Dates: 07/01/03 - 12/31/05  
F & A: $0  
Project Dates: 09/01/03 - 12/31/05

X Hollings Cancer Center Planning Grant  
Sponsor: NIH/NCI  
Award: (03060206) 5 P20 CA093282-03  
Direct: $181,480  
Budget Dates: 08/01/03 - 07/31/04  
F & A: $78,036  
Project Dates: 08/24/01 - 07/31/04

X DOD Phase VI: Translational Research and Cancer Prevention and Control and Risk Factor Identification  
Sponsor: Geo-Centers/DOD  
Award: (03080709) GC-3532-03-42153CM  
Direct: $1,339,062  
Budget Dates: 09/01/03 - 08/31/05  
F & A: $461,345  
Project Dates: 09/01/03 - 08/31/05
**Marine Biomedicine And Environmental Sciences**

### Biochemistry & Molecular Biology

**Gross, Paul**

- **Analysis of a New and Potentially Multi-Functional Antimicrobial Peptide Family Identified in the Pacific White Shrimp, Litopenaeus Vannamei**
  - **Sponsor:** USDA
  - **Direct:** $86,501
  - **Budget Dates:** 01/01/04 - 12/31/05
  - **F & A:** $18,499
  - **Project Dates:** 01/01/04 - 12/31/05

**Identification and Functional Characterization of Toll-Like Family of Pathogen Receptors from the Pacific White Shrimp Litopenaeus Vannamei**
  - **Sponsor:** USDA
  - **Direct:** $41,479
  - **Budget Dates:** 01/15/04 - 01/14/05
  - **F & A:** $0
  - **Project Dates:** 01/15/04 - 01/14/05

**Research Experiences for Undergraduates (REU) Supplement to Shrimp Immunity: Genetic and Functional Studies of Diversity in an Antimicrobial Peptide**
  - **Sponsor:** NSF
  - **Direct:** $121,194
  - **Budget Dates:** 03/01/04 - 02/28/05
  - **F & A:** $52,113
  - **Project Dates:** 03/01/04 - 02/28/05

**Development of cDNA Microarrays for Analysis of Environmental Stressors and Disease in Local Populations of White Shrimp, Litopenaeus - Third Year Renewal for SC Sea Grant Project # R/MT-S**
  - **Sponsor:** SC Sea Grant Consortium
  - **Direct:** $59,600
  - **Budget Dates:** 03/01/04 - 02/28/05
  - **F & A:** $0
  - **Project Dates:** 03/01/04 - 02/28/05

**Warr, Gregory**

- **Functional Genomic Approach to Signal Transduction and Innate Immunity in Shrimp**
  - **Sponsor:** NSF
  - **Direct:** $107,143
  - **Budget Dates:** 08/15/03 - 08/31/04
  - **F & A:** $27,857
  - **Project Dates:** 08/15/03 - 08/31/04

**Duck Antibody Genes: Unusual Organization Expression**
  - **Sponsor:** NIH/NIAID
  - **Direct:** $125,000
  - **Budget Dates:** 06/01/99 - 11/30/07
  - **F & A:** $32,500
  - **Project Dates:** 06/01/99 - 11/30/07

**IgH Enhancer Function in an Ectothermic Vertebrate**
  - **Sponsor:** NIH/NIGMS
  - **Direct:** $166,750
  - **Budget Dates:** 03/01/04 - 02/28/05
  - **F & A:** $71,703
  - **Project Dates:** 03/01/04 - 02/28/05

### Cell Biology & Anatomy

**Lacy, Eric**

- **Hollings Visiting Scholar Award**
  - **Sponsor:** Jardon and Howard Tech.
  - **Direct:** $99,950
  - **Budget Dates:** 05/01/04 - 04/30/05
  - **F & A:** $9,495
  - **Project Dates:** 05/01/04 - 04/30/05

**Morris, Pamela**

- **Environmental Assessment of Bunker C Crude Oil Leaking from the USS Arizona**
  - **Sponsor:** Natl. Park Service
  - **Direct:** $21,739
  - **Budget Dates:** 08/25/03 - 12/31/04
  - **F & A:** $3,261
  - **Project Dates:** 08/25/03 - 12/31/04

### Dean's Office - COM

**Woodley, Cheryl**

- **Molecular and Pathobiology Studies to Identify the Causative Agent of Juvenile Oyster Disease**
  - **Sponsor:** SC Sea Grant Consortium
  - **Direct:** $62,022
  - **Budget Dates:** 10/01/03 - 09/30/04
  - **F & A:** $0
  - **Project Dates:** 10/01/03 - 09/30/04
**Pediatrics**

Peden-Adams, Margie  
**MUSC's Activities in Support of the Charleston Health and Risk Assessment (HERA) of Bottlenose Dolphin Populations**  
**Sponsor:** NOAA  
**Award:** (04021801) WC133C04CN0012  
**Direct:** $282,880  
**F & A:** $62,820  
**Budget Dates:** 03/29/04 - 03/28/05  
**Project Dates:** 03/29/04 - 03/28/05

**Neuroscience Institute**

**Medicine**

Obeid, Lina  
**Supplement to P20 RR17677: Development of NMR Spectroscopy**  
**Sponsor:** NIH/NCRR  
**Award:** (03030701) 3 P20 RR17677-02S1  
**Direct:** $500,000  
**F & A:** $0  
**Budget Dates:** 09/01/03 - 06/30/04  
**Project Dates:** 09/26/03 - 06/30/04

**Ophthalmology**

Rohrer, Baerbel  
**Rod Neurodegenerative and Protective Genes**  
**Sponsor:** NIH/NEI  
**Award:** (03042501) 5 R01 EY013520-03  
**Direct:** $586,662  
**F & A:** $75,250  
**Budget Dates:** 08/01/03 - 07/31/04  
**Project Dates:** 08/01/03 - 07/31/04

**Pathology & Laboratory Medicine**

Wei, Ling  
**Neuroprotective Effect of Merck Compounds In Ischemic Stroke Rats**  
**Sponsor:** Merck  
**Award:** (04010502)  
**Direct:** $351,450  
**F & A:** $70,289  
**Budget Dates:** 01/01/04 - 12/31/04  
**Project Dates:** 01/01/04 - 12/31/04

**Physiology**

Chandler, L.  
**Ethanol and Glutamate Receptor Regulation of Dendritic Spine Dynamics**  
**Sponsor:** Alcoholic Bev. Medical Research Fnd.  
**Award:** (02083010)  
**Direct:** $34,609  
**F & A:** $5,191  
**Budget Dates:** 01/01/04 - 12/31/04  
**Project Dates:** 01/01/04 - 12/31/04

Chaptiaux, Nicolas  
**The Role of Nicotinic Receptors Activation in Behavioral Sensitization to Cocaine**  
**Sponsor:** Philip Morris, Inc.  
**Award:** (03010709)  
**Direct:** $40,000  
**F & A:** $3,200  
**Budget Dates:** 01/01/04 - 12/31/04  
**Project Dates:** 01/01/04 - 12/31/04

Granholm, Ann-Charlotte  
**Trophic Support of Ventral Mesencephalic Grafts**  
**Sponsor:** DOD/US Army  
**Award:** (00121501) DAMD17-99-1-9480  
**Direct:** $171,441  
**F & A:** $49,510  
**Budget Dates:** 05/01/04 - 06/30/05  
**Project Dates:** 05/01/04 - 06/30/05

Gregory, Mary  
**Prefrontal Glutamate and Working Memory**  
**Sponsor:** NIH/NIMH  
**Award:** (03040711) 1 F30 MH070194-01  
**Direct:** $24,517  
**F & A:** $0  
**Budget Dates:** 09/30/03 - 09/29/04  
**Project Dates:** 09/30/03 - 06/29/07

Kalivas, Peter  
**Neurobiology of Addiction Research Center (NARC)**  
**Sponsor:** NIH/NIDA  
**Award:** (02102215) 1 P50 DA015369-01A1  
**Direct:** $895,481  
**F & A:** $380,975  
**Budget Dates:** 08/01/03 - 04/30/04  
**Project Dates:** 08/01/03 - 04/30/08

**Glutamate and Craving for Cocaine**  
**Sponsor:** NIH/NIDA  
**Award:** (04010504) 5 R01 DA012513-05  
**Direct:** $144,798  
**F & A:** $62,263  
**Budget Dates:** 02/01/04 - 01/31/05  
**Project Dates:** 02/10/00 - 01/31/05
<table>
<thead>
<tr>
<th>Name</th>
<th>Project Title</th>
<th>Sponsor</th>
<th>Direct</th>
<th>Budget Dates</th>
<th>F &amp; A</th>
<th>Project Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kalivas, Peter</td>
<td>Cocaine Opioids and Drug Abuse</td>
<td>NIH/NIDA</td>
<td>$175,000</td>
<td>06/01/04 - 05/31/05</td>
<td>$75,250</td>
<td>12/01/04 - 05/31/05</td>
</tr>
<tr>
<td>McFarland, Krista</td>
<td>Stress-Induced Reinstatement of Cocaine-Seeking Behavior</td>
<td>NIH/NIDA</td>
<td>$175,000</td>
<td>04/10/04 - 03/31/05</td>
<td>$57,500</td>
<td>04/10/04 - 03/31/05</td>
</tr>
<tr>
<td>McGinty, Jacqueline</td>
<td>Telencephalic Opioid Neurons: Psychostimulant Effects</td>
<td>NIH/NIDA</td>
<td>$200,000</td>
<td>06/01/04 - 05/31/05</td>
<td>$86,000</td>
<td>05/01/88 - 05/31/06</td>
</tr>
<tr>
<td>Seamans, Jeremy</td>
<td>Fast and Slow Dopamine Signaling in Prefrontal Cortex</td>
<td>NIH/NIMH</td>
<td>$175,000</td>
<td>08/01/03 - 07/31/04</td>
<td>$80,500</td>
<td>08/01/02 - 07/31/07</td>
</tr>
<tr>
<td>See, Ronald</td>
<td>Basolateral Amygdala - A Substrate for Relapse</td>
<td>NIH/NIDA</td>
<td>$150,000</td>
<td>06/01/04 - 05/31/05</td>
<td>$69,000</td>
<td>04/10/97 - 05/31/07</td>
</tr>
<tr>
<td>Tempel, George</td>
<td>GK-12 Lowcountry Science Partners for Inquiry Teaching and Learning</td>
<td>NSF</td>
<td>$520,061</td>
<td>06/01/03 - 05/31/05</td>
<td>$3,294</td>
<td>06/01/02 - 05/31/06</td>
</tr>
<tr>
<td>Becker, Howard</td>
<td>Ethanol Dependence and Stress Effects on Ethanol Drinking</td>
<td>NIH/NIAAA</td>
<td>$164,755</td>
<td>03/01/04 - 02/28/05</td>
<td>$75,787</td>
<td>03/01/03 - 02/28/07</td>
</tr>
<tr>
<td>Brady, Kathleen</td>
<td>ORWH: SCOR on Sex and Gender Factors Affecting Women's Health</td>
<td>NIH/NIDA</td>
<td>$579,460</td>
<td>07/01/03 - 06/30/04</td>
<td>$266,552</td>
<td>09/30/02 - 06/30/07</td>
</tr>
<tr>
<td>Name</td>
<td>Title</td>
<td>Sponsor</td>
<td>Direct Costs</td>
<td>F &amp; A Costs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------</td>
<td>--------------</td>
<td>-------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthur, J</td>
<td>Proteomics Core Facility</td>
<td>Dialysis Clinics, Inc.</td>
<td>$322,665</td>
<td>$0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(01082804)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carter, R</td>
<td>ALS Creatine Study</td>
<td>Carolinas Healthcare</td>
<td>$38,144</td>
<td>$19,385</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(03031102) 30282</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dix, T</td>
<td>Non-Natural Amino Acids in Peptide Drug Design</td>
<td>Argolyn Bioscience, Inc.</td>
<td>$49,960</td>
<td>$0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(02040309)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dong, J</td>
<td>Development of an HIV Drug Resistance Test; 2) Further Development</td>
<td>GenPhar, Inc.</td>
<td>$218,237</td>
<td>$44,862</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>of a Method for Treating Tumors Using FAS-L and TRAIL</td>
<td>(02110804)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Induced Apoptosis; 3) Collection of Data from Small Animals</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Regarding GenPhar's Pending Patent on Genetic Vaccines; and 4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Assist with the Testing of Vaccines in Mice</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaplan, A</td>
<td>Konishi-MUSC Institute for Inflammation Research</td>
<td>Nippon Zoki Pharmaceuticals</td>
<td>$293,209</td>
<td>$563,791</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(99062101)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kozel, F</td>
<td>A Systemic Plan of Studies Geared to Reducing to Practice the Ability</td>
<td>Cephos Corp.</td>
<td>$152,451</td>
<td>$38,113</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Use FMRI to Detect Deception within Cooperative Healthy Adults</td>
<td>(03111701)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kusumam, J</td>
<td>Effects of Neurotropin on Gene Expression in Leukocytes of Allergic</td>
<td>Nippon Zoki Pharmaceuticals</td>
<td>$70,000</td>
<td>$0</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rhinitis Patients</td>
<td>(04060404)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>London, L</td>
<td>Effect of Protein Based Therapeutics on Reovirus 1/L Induced ARDS</td>
<td>Eli Lilly</td>
<td>$194,892</td>
<td>$89,650</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(02011109)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>